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Abstract	
	
Isoform-specific	Ras	expression	and	signalling.	Anna	Urszula	Newlaczyl		
Ras	 proteins	 are	 GTPases	 that	 are	molecular	 central	 hubs	 for	 propagation	 of	intracellular	 signals	 that	 are	 involved	 in	 diverse	 processes,	 including	 cell	differentiation	and	proliferation.	The	 four	main	Ras	 isoforms,	HRas,	NRas	and	the	 two	 KRas	 splice	 variants,	 KRasA	 and	 KRasB,	 are	 highly	 homologous		and	 conserved	 proto-oncogenes	 that	 constitute	 a	 paradigm	 of	 cellular	transformation.	While	all	RAS	genes	are	commonly	mutated	in	human	cancers,	different	 isoforms	 couple	 to	 distinct	 tumours	 and	 the	 mutations	 in	 KRAS	constitute	the	majority	(~86%)	of	all	RAS	mutations.	Intriguingly,	KRasB	is	the	only	Ras	isoform	essential	for	normal	embryonic	growth	in	the	mouse.		
Such	 discrepancy	 of	 Ras	 isoform	 contribution	 to	 different	 cancers	 and	 the	uniquely	 essential	 role	 of	 KRasB	 in	 normal	 development	 may	 stem	 from	 the	distinct	 spatiotemporal	 expression	 of	 Ras	 isoforms	 and	 their	 differential	coupling	 to	 downstream	 effectors.	 However,	 to	 date	 there	 has	 been	 no	comprehensive	 quantitative	 comparison	 of	 Ras	 isoform	 expression	 across	various	 tissues	 throughout	 development.	 Moreover,	 there	 are	 no	 studies	 that	compared	Ras	isoform-specific	signalling	in	an	endogenous	context.	Therefore,	this	 thesis	 aims	 to	 provide	 the	 first	 complete	map	 of	 Ras	 isoform	 expression	during	 development	 and	 the	 first	 comparison	 of	 endogenous	 Ras	 isoform-specific	signalling.	
In	 the	 first	 part	 of	 this	 work,	 quantitative	 real-time	 RT-PCR	 was	 used	 to	measure	 Ras	 isoform	 transcript	 levels	 in	mouse	 embryonic	 stem	 cells	 (ESCs)	and	 in	 a	 panel	 of	 embryonic,	 postnatal	 and	 adult	 mouse	 tissues.	 KRasB	 was	found	to	be	the	most	highly	expressed	isoform,	whereas	KRasA	was	shown	to	be	the	most	dynamically	 regulated.	Transcript	 copy	number	does	not	necessarily	
	 III	
correlate	 with	 protein	 copy	 number;	 therefore,	 protein	 standard	 absolute	quantitation	 mass	 spectrometry	 was	 used	 to	 accurately	 measure	 tissue	 Ras	protein	 levels.	 In	 contrast	 to	 the	 qRT-PCR	 data	 where	 KRasB	 was	 5-10-fold	higher	expressed	than	any	of	the	other	isoforms,	protein	abundance	levels	were	found	to	be	similar	for	the	Ras	isoforms.	The	mechanistic	basis	for	this	and	the	implications	for	models	of	isoform-specific	Ras	association	with	specific	cancers	are	discussed.	
In	 the	 second	 part	 of	 this	 thesis,	 isogenic	 SW48	 human	 colorectal	 cancer	 cell	lines	identical	except	for	the	presence	of	an	activating	G12V	mutation	in	each	of	the	 three	RAS	 gene	 loci	were	utilised	 to	 study	endogenous	Ras	 signalling.	The	results	 revealed	 isoform-specific	 coupling	 to	 canonical	 Ras	 effector	 pathways	for	 example,	 HRas	 was	 the	 most	 potent	 activator	 of	 downstream	 MAPK	 and	PI3K	 pathways.	 These	 data	 represent	 the	 basis	 for	 planned	 network	 biology	studies	to	model	Ras	isoform-specific	signalling.	
Together,	 this	study	provides	 the	 first	most	complete	approaches	 for	studying	baseline	Ras	 isoform	expression	and	signalling	 in	an	endogenous	context.	The	results	 guide	 our	 understanding	 of	 Ras	 isoform-specific	 network	 biology,	coupling	to	distinct	human	cancers	and	involvement	in	normal	development.	
	
	
	
	
	
	
	
	
	 IV	
Table	of	Contents		Title	Page		 		I	Abstract		 	II	Table	of	Contents		 	 IV	List	of	Figures		 IX	List	of	Tables		 XIII	Abbreviations		 		XV	Acknowledgements		 XVIII		
Chapter	1	 Introduction		 	 	 	 	 	 	 1	1.1	 	 Importance	of	Ras	in	normal	tissues		 	 	 	 1	1.1.1	 	 Ras	superfamily	of	GTPases		 	 	 	 	 1	1.1.2	 	 Ras	subfamily		 	 	 	 	 4	1.1.3		 	 Cellular	dynamics	and	signalling	differences	between	Ras	isoforms		 	 	 	 	 10	1.1.3.1		 	 Ras	signalling	pathways		 	 	 	 	 10	1.1.3.1.1		 Upstream	activators	of	Ras		 	 	 	 	 10	1.1.3.1.2		 Downstream	Ras	effectors		 	 	 	 	 13	1.1.3.2	 	 Ras	trafficking	and	posttranslational	modifications		 	 16	1.1.4		 	 Ras	function	in	development		 	 	 	 19	1.1.4.1	 	 Functions	of	Ras	isoforms	in	self-renewal	and	differentiation		 19	1.1.4.2		 	 Mouse	models	to	study	Ras	during	development		 	 19	1.1.4.2.1		 Normal	mouse	development		 	 	 	 19	1.1.4.2.2		 Ras	mouse	models	 	 	 	 	 24	1.2		 	 Ras	in	pathogenesis		 	 	 	 	 24	1.2.1		 	 Ras	in	developmental	disorders		 	 	 	 24	1.2.2		 	 Ras	in	cancer		 	 	 	 	 25	1.3		 	 Aims	of	this	study		 	 	 	 	 28	
	 V	
Chapter	2	 Materials	and	Methods		 30	2.1	 	 Materials		 	 	 	 	 	 30	2.2	 	 Cell	lines		 	 	 	 	 	 30	2.2.1		 	 SW48	Ras	isogenic	cell	lines		 	 	 	 30	2.2.2	 	 STO	mouse	fibroblasts		 	 	 	 	 31	2.2.3		 	 R1	mouse	Embryonic	Stem	Cells	(mESCs)		 	 	 31	2.3		 	 Routine	cell	culture		 	 	 	 	 31	2.3.1	 	 Routine	SW48	Ras	isogenic	cell	lines	culture		 	 31	2.3.2	 	 Embryonic	stem	cell	culture		 	 	 	 33	2.3.2.1	 	 Plate	coating	protocols		 	 	 	 	 33	2.3.2.2	 	 STO	culture	as	a	feeder	layer		 	 	 	 33	2.3.2.3	 	 Routine	ESCs	culture		 	 	 	 	 35	2.3.3	 	 Cell	freezing	protocols		 	 	 	 	 35	2.3.4	 	 Cell	thawing	protocols		 	 	 	 	 37	2.3.5	 	 Cell	counting		 	 	 	 	 37	2.3.6	 	 Separation	of	R1	ESCs	from	STO	feeder	layer		 	 	 38	2.4	 	 Suspension	differentiation	protocols		 	 	 38	2.5		 Phenotypic	assays		 39	2.5.1	 	 Microscopy		 	 	 	 	 	 39	2.5.2	 Cell	viability	assay		 39	2.5.3	 Growth	factor	and	inhibitor	assays		 40	2.6		 Preparation	of	murine	tissues		 41	2.6.1	 Organ	dissection	and	tissue	harvesting		 41	2.6.2		 Tissue	homogenisation		 42	2.7		 Molecular	Biology		 42	2.7.1		 Agarose	gel	electrophoresis		 42	2.7.2	 Gel	extraction	of	DNA	fragments		 43	2.7.3		 TOPO	cloning		 43	2.7.4	 Bacterial	transformation		 44	2.7.5	 Glycerol	stock		 45	2.7.6	 Plasmid	preparation	(miniprep)		 45	2.7.7	 Restriction	digestion		 45	2.7.8		 RNA	extraction	and	purification		 46	
	 VI	
2.7.9	 Reverse	transcription	(RT)		 48	2.7.10	 PCR	primers		 48	2.7.11	 Polymerase	Chain	Reaction	(PCR)		 50	2.7.12	 Quantitative	Reverse	Transcription-Polymerase	Chain	Reaction	(qRT-PCR)		 52	2.8	 Protein	Biochemistry		 54	2.8.1	 Cell	lysis	and	harvesting		 54	2.8.2		 Protein	purification		 55	2.8.3	 	 BCA	protein	assay		 	 	 	 	 55	2.8.4	 	 Sodium	dodecyl	sulfate-polyacrylamide	gel	electrophoresis	(SDS-PAGE)		 	 	 	 	 	 56	2.8.5	 	 Western	Blotting		 	 	 	 	 57	2.9	 	 Proteomics		 	 	 	 	 	 60	2.9.1	 	 Ras	standards		 	 	 	 	 60	2.9.2	 	 In-gel	digest	protocol		 	 61	2.9.3	 	 Mass	spectrometry		 	 	 	 	 63	2.10	 	 Bioinformatics	and	statistical	analysis		 	 	 63	
	
Chapter	3	 Establishing	Reagents	for	qRT-PCR	 64	3.1	 	 Introduction		 	 	 	 	 64	3.1.1	 	 qRT-PCR	as	a	method	for	accurate	quantification	of	transcript	abundance		 	 	 	 	 	 64	3.1.2	 	 Considerations	for	the	design	and	optimisation			 	 of	qRT-PCR				 	 	 	 	 66	3.1.2.1	 	 Primer	design		 	 	 	 	 66	3.1.2.2	 Annealing	temperature		 	 	 	 67	3.1.2.3		 Primer	efficiency		 68	3.1.2.4		 	 Quantification	of	qRT-PCR		 	 	 	 69	3.1.2.5		 Selection	of	reference	genes	for	relative	quantitation		 in	qRT-PCR		 	 	 	 	 	 70	3.2	 Results		 	 	 	 	 	 72	3.2.1	 	 Primer	design		 	 	 	 	 72	
	 VII	
3.2.2	 Optimisation	of	qRT-PCR		 	 	 	 79	3.2.2.1	 	 Generation	of	plasmids		 	 	 	 79	3.2.2.2		 	 Annealing	temperature	optimisation		 	 	 82	3.2.2.3		 	 Primer	specificity		 	 	 	 	 84	3.2.2.4			 	 Primer	efficiency		 	 	 	 	 85	3.2.2.5	 	 Quantification	of	qRT-PCR	results		 	 	 87	3.2.2.6	 Reference	genes	for	relative	quantitation	in	qRT-PCR		 89	3.3	 Summary	and	conclusions		 	 	 	 93	
Chapter	4	 Ras	isoform	expression	in	mouse	embryonic	stem	cells		 94	4.1	 	 Introduction		 	 	 	 	 94	4.1.1	 Embryonic	stem	cells	(ESCs)	and	embryoid	body	(EB)	model	of	early	embryogenesis			 	 	 	 94	4.1.2	 	 Functions	of	Ras	isoforms	in	ESCs		 	 	 98	4.2	 Results		 	 	 	 	 	 99	4.2.1	 	 Establishing	ESC	culture	protocols		 	 	 99	4.2.2	 	 Quality	control	of	RNA	from	ESCs		 	 	 102	4.2.3	 	 Ras	isoform	transcript	expression	in	undifferentiated		 	 R1	mESC		 	 	 	 	 104	4.2.4	 	 Ras	isoform	transcript	expression	in	differentiating			 R1	mESCs		 	 	 	 	 	 107	4.3		 	 Discussion		 	 	 	 	 	 111	
Chapter	5	 Ras	isoform	expression	in	mouse	tissues	during		
development		 116	5.1	 Introduction		 	 	 	 	 116	5.1.1	 Ras	isoform-specific	mutation	frequency	and	role	in		development		 	 	 	 	 116	5.1.2	 Ras	isoform-specific	abundance	in	normal	tissues		 118	5.2		 Results		 	 	 	 	 	 120	5.2.1	 Expression	studies	using	a	mouse	model		 	 120	5.2.2	 Extraction	and	quality	control	of	RNA	from	mouse	tissues		 121	
	 VIII	
5.2.3	 Absolute	transcript	copy	number	of	Ras	isoforms	in	mouse		adult	tissues	and	during	development		 	 	 125	5.2.4		 Absolute	abundance	of	Ras	isoform	proteins	in	mouse	adult	tissues		 	 	 	 	 	 134	5.3	 Discussion		 	 	 	 	 	 137	5.3.1		 Comparison	with	previous	studies		 	 	 139	5.3.2		 Dynamic	KRasA	expression		 	 	 	 142	5.3.3	 Correlation	between	Ras	isoform	expression	and	cancer		 143	5.3.4	 Transcript	versus	protein	abundance		 	 	 145	
Chapter	6	 Isoform-specific	Ras	isoform	signalling		 148	6.1	 Introduction		 	 	 	 148	6.2	 Results		 	 	 	 	 152	6.2.1	 Cell	growth	kinetics	of	SW48	isogenic	cell	lines		 152	6.2.2	 Differential	activation	of	PI3K	and	MAPK	pathways		 154	6.2.3	 Isoform-specific	Ras	networks		 	 161	6.2.3.1	 Stimulation	of	Ras	upstream	signalling		 	 161	6.2.3.2	 Inhibition	of	Ras	downstream	signalling		 166	6.2.3.3						 Optimisation	of	Raf	inhibition	in	Ras	isogenic	cell	lines		 172	6.3		 Discussion		 	 	 	 	 177	
Chapter	7	 Conclusions	and	Perspectives		 184	
Bibliography		 189	
Appendix		 	 234		
	
	
	
	
	
	 IX	
List	of	Figures	Fig.	1.1	 GTPase	cycle	in	Ras	proteins.			 	 	 	 1	Fig.	1.2	 Phylogenetic	tree	of	the	extended	Ras	family	members	in	Mus	
musculus	(house	mouse)	based	on	protein	sequence	similarity.		3	Fig.	1.3	 Key	milestones	in	Ras	research.			 	 	 5	Fig.	1.4		 Ras	domain	structure.			 	 	 	 7	 	Fig.	1.5	 Ras	isoform	conservation	across	species.				 	 9	Fig.	1.6		 Conservation	of	mRNA	protein	coding	sequences	of	KRasA	isoform	between	human	and	mouse.			 	 	 10	Fig.	1.7		 Ras	signalling	pathways.				 	 	 	 15	Fig.	1.8	 Ras	isoform	post-translational	modifications	and	subcellular	localisations.				 	 	 	 	 17	Fig.	1.9		 Mutation	pattern	for	Ras	isoforms	across	all	human	cancers.		 27	Fig.	2.1		 Schematic	illustrations	of	cell	culture	conditions	for	undifferentiated	and	differentiating	R1	mouse	embryonic		stem	cells	ESCs.		 	 	 	 	 36	Fig.	3.1		 ERas	sequence	and	position	of	qRT-PCR	primers.		 75	Fig.	3.2		 HRas	sequence	and	position	of	qRT-PCR	primers.		 76	Fig.	3.3		 KRas	sequence	and	position	of	qRT-PCR	primers.		 77	Fig.	3.4	 NRas	sequence	and	position	of	qRT-PCR	primers.		 78	Fig.	3.5		 Generation	of	mouse	isoform-specific	Ras	fragments	for	subcloning	into	pCR4-TOPO	plasmid.		 	 	 81	Fig.	3.6		 Optimising	annealing	temperature	(Ta)	for	Ras	isoform		primers.			 	 	 	 	 	 83	Fig.	3.7		 Ras	isoform	primer	specificity.		 	 	 85	Fig.	3.8		 Mouse	Ras	isoform	primer	amplification	efficiencies.		 86	Fig.	3.9		 Ta	optimisation	and	primer	specificity	for	mouse	POL2RE	primers.		 	 	 	 	 	 90	Fig.	3.10		 POL2RE	primer	amplification	efficiency.		 	 91	Fig.	3.11		 Generation	of	mouse	POL2RE	reference	gene	fragment	for	subsequent	subcloning	into	pCR4-TOPO	plasmid.		 92	
	 X	
Fig.	4.1		 Morphological	changes	of	embryoid	bodies	(EBs)	during	differentiation	of	mouse	embryonic	stem	cells	(ESCs).		 97	Fig.	4.2		 Separation	of	undifferentiated	R1	embryonic	stem	cells		(ESCs)	from	STO	feeder	layer	cells	for	cell	harvesting.		 100	Fig.	4.3		 Morphology	of	mouse	embryoid	bodies	(EB)	during	differentiation.		 	 	 	 	 101	Fig.	4.4		 Assessment	of	RNA	quality	by	agarose	gel	electrophoresis		of	mouse	R1	ESCs	samples.		 	 	 	 103	Fig.	4.5		 Ras	isoform	transcript	abundance	in	undifferentiated		R1	ESCs.		 	 	 	 	 	 106	Fig.	4.6		 Ras	isoform	transcript	expression	during	endoderm	and	mesoderm	differentiation	of	mouse	ESCs.		 	 108	Fig.	4.7	 Ras	isoform	expression	during	mesoderm	differentiation		of	mouse	ESCs.		 	 	 	 	 110	Fig.	4.8		 Percentage	contribution	and	total	Ras	isoform	transcript	expression	in	undifferentiated	and	differentiating		mouse	ESCs.		 	 	 	 	 112	Fig.	5.1		 Developmental	time	points	at	which	mouse	tissues	were	harvested	for	analysis	of	Ras	abundance.		 	 122	Fig.	5.2		 Assessment	of	RNA	quality	by	agarose	gel	electrophoresis		of	mouse	tissues:	intestine,	stomach,	liver	and	kidneys,	throughout	development.		 	 	 	 123	Fig.	5.3		 Assessment	of	RNA	quality	by	agarose	gel	electrophoresis		of	mouse	tissues:	heart,	limb/muscle,	brain	and	lungs,		throughout	development.		 	 	 	 124	Fig.	5.4		 Ras	isoform	transcript	expression	in	adult	mouse	tissues.		 126	Fig.	5.5		 Ras	isoform	transcript	expression	throughout	mouse	development	in	intestine,	stomach,	liver	and	kidney.		 128	Fig.	5.6		 Ras	isoform	transcript	expression	throughout	mouse	development	in	heart,	muscle,	brain	and	lung.		 	 129	Fig.	5.7		 Statistical	significance	of	Ras	isoform	transcript	expression		data	obtained	by	qRT-PCR	throughout	normal	mouse	development.	 	 	 	 	 130	
	 XI	
Fig.	5.8		 Heat	map	representing	relative	total	Ras	(panRas)		transcript	expression	throughout	mouse	development		across	different	tissue	types.		 	 	 	 132	Fig.	5.9		 Heat	maps	representing	relative	Ras	isoform	transcript	expression	throughout	mouse	development	across		different	tissue	types.		 	 	 	 133	Fig.	5.10		 Assessment	of	protein	quality	of	Ras	standards	labelled		with	heavy	arginine	(Arg10)	and	lysine	(Lys8)	for		proteomics	by	gel	electrophoresis.		 	 	 134	Fig.	5.11	 Ras	isoform	protein	levels	in	adult	mouse	tissues.		 136	Fig.	5.12		 Protein	and	transcript	levels	of	Ras	isoforms	in	normal	adult	mouse	tissues.		 	 	 	 	 138	Fig.	5.13		 Ras	isoform	abundance	in	10	different	tissue	types	across		a	range	of	studies	compared	to	Ras	isoform-specific		mutation	frequency	in	human	cancers	derived	from	the	corresponding	tissues	of	origin.		 	 	 140	Fig.	6.1		 A	schematic	representation	of	Ras-dependent	signalling		network	measured	by	effector-specific	inhibitors	and		receptor	agonists.		 	 	 	 	 151	Fig.	6.2		 Optimisation	of	seeding	density	of	SW48	parental	cell	line		for	cell	viability	assay.		 	 	 	 153	Fig.	6.3		 Cell	growth	differences	between	Ras	isogenic	cell	lines		measured	by	cell	viability	assay.		 	 	 153	Fig.	6.4		 Ras	isoform	protein	levels	in	SW48	isogenic	cell	lines.		 155	Fig.	6.5		 Activation	of	downstream	PI3K	signalling	pathway	in		Ras	isogenic	SW48	cell	lines	depending	on	stimulation		with	different	concentrations	of	EGF.		 	 	 157	Fig.	6.6		 Activation	of	downstream	MAPK	signalling	pathway	in		Ras	isogenic	SW48	cell	lines	depending	on	stimulation		with	different	concentrations	of	EGF.		 	 	 158	Fig.	6.7		 Activation	of	MAPK	and	PI3K	pathways	in	Ras	isoform		SW48	isogenic	cell	lines	by	EGF	stimulation.		 	 159	
	 XII	
Fig.	6.8		 Differential	response	to	EGF	in	Ras	isoform	SW48		isogenic	cell	lines.		 	 	 	 	 160	Fig.	6.9		 Phosphorylation	status	of	EGFR	in	SW48	Ras	isogenic		cell	lines.		 	 	 	 	 	 162	Fig.	6.10		 Phosphorylation	status	of	Met	receptor	in	SW48	Ras		isogenic	cell	lines.		 	 	 	 	 163	Fig.	6.11		 Phosphorylation	status	of	IGFR1β	in	SW48	Ras	isogenic		cell	lines.		 	 	 	 	 	 164	Fig.	6.12		 Differential	expression	of	cell	membrane	receptors	in		SW48	isogenic	cell	lines.		 	 	 	 165	Fig.	6.13		 Inhibition	of	PI3K	in	SW48	Ras	isogenic	cell	lines		with	different	LY294002	concentrations.		 	 167	Fig.	6.14	 Inhibition	of	MEK1/2	in	SW48	Ras	isogenic	cell	lines		with	different	AZD6244	concentrations.		 	 168	Fig.	6.15		 Inhibition	of	mTOR	in	SW48	Ras	isogenic	cell	lines	with		different	Rapamycin	concentrations.		 	 	 170	Fig.	6.16		 Inhibition	of	Raf	in	SW48	Ras	isogenic	cell	lines	with		different	Sorafenib	concentrations.		 	 	 171	Fig.	6.17		 Inhibition	of	Raf	in	SW48	parental	cell	line	with	Sorafenib		for	16	hours.		 	 	 	 	 173	Fig.	6.18		 Inhibition	of	Raf	with	Sorafenib	for	16	hours	in	SW48	Ras		isogenic	cell	lines	and	apoptotic	effect.		 	 	 174	Fig.	6.19		 Micrographs	of	SW48	Ras	isogenic	cell	lines	treated	with		Raf	inhibitor	Sorafenib.		 	 	 	 175	Fig.	A3.1		 pCR4-TOPO-mHRas	plasmid.		 	 	 	 234	Fig.	A3.2		 pCR4-TOPO-mNRas	plasmid.		 	 	 	 235	Fig.	A4.1		 Plasmid	standard	curves	used	in	qRT-PCR	for	endoderm		and	mesoderm	differentiation	of	mouse	embryonic	stem		cells	(ESCs).			 	 	 	 	 236	Fig.	A4.2		 Plasmid	standard	curves	used	in	qRT-PCR	for	mesoderm	differentiation	of	mouse	embryonic	stem	cells	(ESCs).		 237	Fig.	A5.1		 Ras	isoform	standard	curves	used	for	the	qRT-PCR	data		from	mouse	tissues.		 	 	 	 	 238	
	 XIII	
List	of	Tables	Table	1.1		 Main	functional	and	cellular	differences	between	the	four		main	Ras	isoforms.			 	 	 	 	 11	Table	2.1		 A	list	of	cell	lines	used	in	this	study	and	splitting	densities.			 32	Table	2.2		 Standard	seeding	densities	for	SW48	Ras	isogenic	cell	lines.		 32	Table	2.3		 A	list	of	cell	culture	media	used	for	the	culture	of	STO	feeder		layer	and	embryonic	stem	cells	(ESC).		 34	Table	2.4		 Inhibitors	used	in	this	study	with	the	corresponding	cellular	targets	and	IC50	values.			 41	Table	2.5		 TOPO-cloning	reaction	mixture.		 44	Table	2.6		 Restriction	digest	reaction	mixture.		 46	Table	2.7		 List	of	restriction	enzymes	used	for	restriction	digestion.			 46		Table	2.8		 Reverse	transcription	buffer	mixture.		 	 48	Table	2.9		 Primer	sequences	used	for	end-point	PCR	and	quantitative		real	time	(qRT)	PCR.		 49	Table	2.10		 Sequencing	primers.		 49	Table	2.11		 PfuUltra	Hotstart	DNA	Polymerase	reaction	mixtures	for		end-point	PCR.				 50	Table	2.12		 PfuUltra	Hotstart	DNA	polymerase	protocol.		 51	Table	2.13		 Taq	DNA	Polymerase	reaction	mixtures	for	end-point	PCR.		 51	Table	2.14		 Taq	DNA	polymerase	protocol.		 51	Table	2.15		 qRT-PCR	reaction	mixture.		 52	Table	2.16		 qRT-PCR	protocol.		 53	Table	2.17		 5-fold	dilution	series	of	KRasB	plasmid	standard	curve	with	corresponding	concentrations	and	copy	numbers	per	qPCR	reaction.		 	 54	Table	2.18		 Recipes	for	10%	resolving	and	4%	stacking	gel	solutions		for	SDS-PAGE.		 57	Table	2.19		 Primary	antibody	list	for	Western	blotting.		 59	Table	2.20		 Secondary	antibody	list	for	Western	blotting.		 60	Table	3.1		 Properties	of	Ras	isoform	and	reference	gene	primer	pairs.		 74	Table	3.2		 Properties	of	HRas	cloning	primers.		 80	
	 XIV	
Table	3.3		 5-fold	dilution	series	of	mouse	Ras	isoform	plasmid		standards.		 88	Table	3.4		 5-fold	dilution	series	of	mouse	POL2RE	plasmid	standards		 92	Table	4.1		 Ras	isoform	and	reference	gene	RNA	polymerase	II		(POL2RE)	transcript	levels	in	undifferentiated	mouse		R1	ESCs.		 105	Table	7.1		 The	main	changes	in	the	understanding	of	Ras	isoform		cellular	and	functional	differences	after	the	study	of	this		thesis.	 187	Table	A5.1		 Ras	isoform	protein	abundance	in	adult	mouse	tissues.		 239																								
	 XV	
Abbreviations	∆G	–	Gibbs	free	energy		A	–	adenine	aa	–	amino	acid	ATP	–	adenosine	triphosphate	BM	–	basement	membrane	bp	–	base	pair	C	–	cysteine	cDNA	–	complementary	DNA	CDS	–	coding	DNA	sequence		cds	–	coding	sequence	DEPC	–	diethyl	pyrocarbonate		DMEM	–	Dulbecco’s	modified	eagle	medium	DNA	–	deoxyribonucleic	acid	dsDNA	–	double	stranded	DNA	DTT	–	dithiothreitol		E	–	embryonic	day	%E	–	percent	efficiency	EB	–	embryoid	body	EDTA	–	ethylenediaminetetraacetic	acid	EGF	–	epidermal	growth	factor	EGFR	–	EGF	receptor	ER	–	endoplasmic	reticulum	ERK	–	extracellular	signal-regulated	kinase	ESC	–	embryonic	stem	cells	FBS	–	foetal	bovine	serum	fg	–	femtogram	G	–	guanine	GDP	–	guanosine	diphosphate	GTP	–	guanosine	triphosphate	hESC	–	human	embryonic	stem	cells	HGF	–	hepatocyte	growth	factor	
	 XVI	
HVR	–	hypervariable	region	IAA	–	iodoacetamide		IGF	–	insulin-like	growth	factor	IGFR	–	IGF	receptor	IMDM	–	Iscove’s	modified	Dulbecco’s	medium	ITS	–	insulin	transferrin	selenium	KI	–	knock-in	KO	–	knock-out	LIF	–	leukemia	inhibitory	factor	MDA	–	modular	response	analysis	MEK	–	mitogen-activated	protein	kinase	kinase	mESC	–	mouse	embryonic	stem	cells	mg	–	milligram	min	–	minute/minutes	mRNA	–	messenger	RNA	MTG	–	monothioglycerol		ng	–	nanogram	nt	–	nucleotide	P	–	postnatal	day	PBS	–	phosphate	buffer	saline	PCR	–	polymerase	chain	reaction	PDGF	–	platelet-derived	growth	factor	PDGFR	–	PDGF	receptor	pg	–	picogram	PI3K	–	phosphoinositide	3-kinase	PM	–	plasma	membrane	POL2RE	–	RNA	polymerase	II,	polypeptide	E	qRT-PCR	–	quantitative	reverse	transcription	PCR	RNA	–	ribonucleic	acid	rRNA	–	ribosomal	RNA	RTK	–	receptor	tyrosine	kinase	SD	–	standard	deviation	SDS-PAGE	–	sodium	dodecyl	sulfate	polyacrylamide	
	 XVII	
SEM	–	standard	error	of	the	mean	siRNA	–	small	interfering	RNA	ssDNA	–	single	stranded	DNA	T	–	thymine	Ta	–	annealing	temperature	TFA	–	trifluoroacetic	acid		Tm	–	melting	temperature	UTR	–	untranslated	region		wt	–	wild	type	µg	–	microgram				
			
	
	
	
	
	
	
	
	
	
	
	 XVIII	
Acknowledgements	
	
“It	always	seems	impossible	until	it’s	done.”	
	 	 	 -	Nelson	Mandela	
	First	 of	 all,	 I	 would	 like	 to	 thank	my	 supervisors	 Prof	 Ian	 Prior	 and	 Dr	 Judy	Coulson	 for	 their	 continuous	 support,	 guidance	 and	 invaluable	 remarks,	 and	especially	for	sharing	their	experience	and	optimism.			Many	thanks	go	to	my	PhD	mentors	Prof	Alan	Morgan,	Prof	Chris	Sanderson	and	Dr	Tobias	Zech,	for	their	support	and	encouragement.	I	would	like	to	thank	Prof	Sylvié	 Urbe	 and	 Prof	 Michael	 Clague	 for	 their	 discussions	 during	 laboratory	meetings	and	beyond.	I	am	much	obliged	to	Dr	Craig	Mageean	for	his	help	with	mass	spectrometry	and	Dr	Fiona	Hood	for	her	help	with	SW48	cell	line	culture.	A	big	thank	you	to	all	past	and	present	members	of	our	lab:	Dr	Yvonne	Tang,	Dr	Claire	 Heride	 (for	 her	 help	 with	 microscopy),	 Dr	 Amos	 Liang,	 Dr	 Emma	Rusiłowicz,	 Dr	 Ewan	 MacDonald,	 Dr	 Han	 Liu,	 Dr	 Jia	 Lih	 Wong,	 Dr	 Monica	Faronato,	Dr	Yasminka	Omerovic,	Dr	Dora	Pedroso,	Dr	Veronica	Aran,	Dr	Maria	Hernandez-Valladares,	Rebecca	Eccles,	Dr	Monika	Chojnowska,	Dr	Viktor	Malec,	Alice	Howarth,	Alison	Beckett,	Dr	Simon	Oliver	(for	providing	NRasG12V	SW48	cell	line),	Arnold	Salvais,	Dr	Jenna	Kenyani,	Sarah	Darling,	Matthew	Concannon,	Zohra	Butt	(for	her	help	with	statistical	analysis),	Dr	Andrew	Fielding,	Dr	Joseph	Sacco,	Carolyn	Levene	and	Michelle	Nelson,	not	only	 for	your	help	around	 the	lab,	but	also	for	being	very	good	friends	and	colleagues.		A	big	thank	you	to	Dr	Patricia	Murray	and	her	lab	members,	Dr	Aleksandra	Rak-Raszewska,	Dr	Virginie	Mournetas,	Dr	 Sofia	 Pereira	 and	Dr	Arthur	Taylor,	 for	providing	 mouse	 embryonic	 stem	 cells	 and	 training	 in	 SC	 culture.	 A	 special	thank	you	goes	to	Dr	Bettina	Wilm	for	her	invaluable	help	in	mouse	dissections.	I	would	like	to	thank	the	employees	of	APEX	building	for	their	assistance	with	animal	work	and	Prof	Mark	Caddick	and	Jean	Wood	for	providing	PowerLyzer	
	 XIX	
for	tissues	homogenisation.	Many	thanks	go	to	Dr	Pryank	Patel	for	his	help	with	data	 analysis	 and	 Dr	 Rosalind	 Jenkins	 for	 processing	 mass	 spectrometry	samples.	I	would	like	to	express	my	gratitude	to	the	Wellcome	Trust	for	funding	this	project	[092791/Z/10/Z].		I	 would	 also	 like	 to	 thank	 my	 boyfriend	 Dominik,	 who	 has	 always	 been	 a	constant	 support	 for	me.	 Lastly,	 this	work	would	 not	 be	 possible	without	 the	love	and	never-ending	care	of	my	Parents	throughout	my	education.	For	them	I	want	 to	dedicate	my	 thesis	and	 there	are	no	words	 to	describe	how	grateful	 I	am	to	have	them.						
			
	
	 1	
Chapter	1	
Introduction	
	
1.1	 	 Importance	of	Ras	in	normal	tissues	
1.1.1		 	 	 Ras	superfamily	of	GTPases		Ras	proteins	are	part	of	a	 superfamily	of	 small	GTPases,	which	comprise	over	100	 molecules,	 sized	 20	 to	 25	 kDa	 (Colicelli,	 2004,	 Karnoub	 and	 Weinberg,	2008,	Rojas	et	al.,	2012).	The	superfamily	is	divided,	among	the	others,	into	Ras,	Rab,	Ran,	Rho	and	Arf	 families,	which	all	 share	a	 common	 intrinsic	 guanosine	triphosphate	 (GTP)	 hydrolysis	mechanism	 (Fig	 1.1)	 and	 are	 highly	 conserved	across	different	species.				
	
	
Fig.	 1.1	GTPase	 cycle	 in	Ras	proteins.	Members	of	Ras	superfamily	of	small	GTPases	share	a	common	mechanism	for	binding	and	hydrolysis	of	GTP.	As	an	example,	Ras	 is	 illustrated	 in	 the	 inactive,	GDP-bound	state	on	 the	 left,	and	 its	activated	form	bound	to	GTP	is	shown	on	the	right.	The	exchange	of	GDP	to	GTP	is	 facilitated	with	 a	 guanosine	 exchange	 factor	 (GEF),	which	 then	 results	 in	 a	conformational	 change	 in	 Ras	 and	 binding	 of	 downstream	 effectors.	 The	intrinsic	 GTPase	 activity	 of	 Ras	 is	 enhanced	 via	 a	 GTPase	 activating	 protein	(GAP),	 which	 leads	 to	 GTP	 hydrolysis	 and	 return	 of	 Ras	 to	 its	 inactive	conformation.		
RAS$$
GDP$
GEF$
GTP$ GDP$
GAP$
PO42)$ Eﬀector$
RAS$
GTP$
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The	 GTPase	 cycle	 switches	 Ras	 proteins	 between	 active	 GTP	 (guanosine	triphosphate)-bound	 and	 inactive	 GDP	 (guanosine	 diphosphate)-bound	 states.	Upon	 extracellular	 stimulation	 by	 growth	 factors	 (Campisi	 et	 al.,	 1984)	 or	cytokines	(Emanoil-Ravier	et	al.,	1985,	Samid	et	al.,	1985),	guanine	nucleotide-exchange	factors	(GEFs)	(e.g.	son	of	sevenless	–	SOS)	promote	the	exchange	of	GDP	 for	 GTP	 in	 the	 Ras	 nucleotide	 binding	 pocket.	 This	 brings	 about	conformational	 changes	 of	 switch	 I	 and	 II	 regions	 of	 Ras	 that	 result	 in	 the	formation	of	an	 interface	for	downstream	effector	proteins	(Fig.	1)	(Hall	et	al.,	2002,	Karnoub	and	Weinberg,	2008,	Shima	et	al.,	2010,	Vetter	and	Wittinghofer,	2001,	Wittinghofer	and	Herrmann,	1995).	The	signals	transduced	are	involved	in	 a	 plethora	 of	 cellular	 processes,	 including	 proliferation	 and	 differentiation	(Crespo	and	Leon,	2000,	Traverse	et	al.,	1992).	While	intrinsic	GTPase	activity	of	Ras	 is	 relatively	 weak	 (Gibbs	 et	 al.,	 1984,	 Manne	 et	 al.,	 1985,	 McGrath	 et	 al.,	1984,	Sweet	et	al.,	1984),	a	myriad	of	GTPase	activating	proteins	(GAPs),	such	as	EIF5,	 NF1	 or	 RasGAP	 (Boguski	 and	 McCormick,	 1993,	 Bos	 et	 al.,	 2007,	Pamonsinlapatham	et	al.,	2009)	facilitate	hydrolysis	of	GTP	and,	hence,	 lead	to	the	inactivation	of	Ras	(Trahey	and	McCormick,	1987).		The	Ras	family	of	GTPases	is	further	subdivided	into	subfamilies,	including	Rit,	Rap,	Ral,	MRas,	RRas	and	Ras,	on	the	basis	of	their	protein	sequence	similarity	(Fig.	 1.2)	 (Crespo	 and	 Leon,	 2000,	 Karnoub	 and	Weinberg,	 2008).	 The	 family	also	includes	ERas,	which	was	discovered	in	mouse	embryonic	stem	cells	(ESCs)	(Takahashi	et	al.,	2003)	and	 is	more	distantly	related	to	the	other	subfamilies.	There	is	evidence	that	the	functional	protein	of	ERas	is	not	expressed	in	normal	human	 tissues	 (Kameda	 and	 Thomson,	 2005),	 although	 it	 could	 be	 found	 in	human	 gastric	 cancer	 (Yashiro	 et	 al.,	 2009).	 The	 extended	 Ras	 family	 also	encompasses	 proteins	 with	 lower	 sequence	 homology	 than	 ERas,	 including	Rheb,	 Rem	 and	 RasD	 (Fig.	 1.2).	 The	 study	 of	 this	 thesis	 focuses	 on	 the	 Ras	subfamily,	but	also	on	ERas	in	mouse	ESCs.				 		
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Fig.	 1.2	 Phylogenetic	 tree	 of	 the	 extended	 Ras	 family	 members	 in	Mus	
musculus	 (house	 mouse)	 based	 on	 protein	 sequence	 similarity.	 The	dendrogram	was	generated	using	VECTOR	NTI	Advance	(v11.5.2)	and	includes	ERas,	 which	 is	 expressed	 only	 in	 undifferentiated	 embryonic	 stem	 cells	(Takahashi	et	al.,	2003).		
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1.1.2	 	 	 Ras	subfamily	The	key	members	of	Ras	 subfamily	of	 small	GTPases	are	highly	 related	HRAS,	KRAS	and	NRAS,	and	all	play	crucial	 role	 in	human	carcinogenesis.	Since	 their	discovery	 in	 viral	 sequences	 and	 their	 cellular	 counterparts,	 substantial	research	has	focused	on	biochemical	properties	and	delineation	of	function	and	signalling	of	 these	Ras	 isoforms	(Cox	and	Der,	2010,	Malumbres	and	Barbacid,	2003).	 Essential	 discoveries	 in	 this	 field	 are	 summarised	 in	 Fig.	 1.3	 and	 are	described	in	detail	in	this	and	further	sections.			The	founding	studies	that	paved	the	way	into	extensive	Ras	research	took	place	in	 the	 1960s,	 when	 for	 the	 first	 time	 oncogenic	 Harvey	 and	 Kirsten	 murine	sarcoma	 viruses	 (Ha-MSV	 and	 Ki-MSV)	 were	 isolated	 by	 two	 independent	groups	 and	 were	 named	 after	 their	 discoverers	 (Harvey,	 1964,	 Kirsten	 and	Mayer,	1967).	In	early	1970s,	the	Ha-MSV	and	Ki-MSV	genomes	were	found	to	contain	normal	rat	gene	sequences	that	 lead	to	transforming	properties	of	 the	viruses	 (Scolnick	 and	 Parks,	 1974,	 Scolnick	 et	 al.,	 1973).	 Further	 work	ascertained	that	these	viral	ras	genes,	named	for	causing	rat	sarcomas,	produce	21	 kDa	 protein	 products	 (p21)	 (Shih	 et	 al.,	 1979),	 which	 bind	 guanine	nucleotides	 (Scolnick	 et	 al.,	 1979)	 and	 localise	 to	 the	plasma	membrane	 (PM)	(Willingham	et	al.,	1980).	The	cellular	homologues	of	the	viral	genes	were	soon	discovered	 in	 rat	 and	human	genomes,	 as	well	 as	 in	 other	 vertebrate	 species,	including	mouse	and	chicken	(Chang	et	al.,	1982b,	DeFeo	et	al.,	1981,	Ellis	et	al.,	1982,	Ellis	et	al.,	1981).			The	 protein	 products	 of	 cellular	 ras	 genes	 were	 also	 identified	 in	 vertebrate	cells	(Langbeheim	et	al.,	1980)	and	were	shown	to	associate	with	GDP	and	GTP	and	 attach	 to	 the	 PM,	 similarly	 to	 their	 viral	 equivalents	 (Papageorge	 et	 al.,	1982).	Notably,	high	levels	of	normal	cellular	Ras	proteins	were	shown	to	elicit	oncogenic	 transformation	 (Chang	 et	 al.,	 1982a),	 which	 required	 a	 GTP-bound	state	of	Ras	(Gibbs	et	al.,	1984,	Scolnick	et	al.,	1979).	Transforming	activation	of	endogenous	ras	was	also	found	to	be	due	to	single	point	mutations,	which	were	also	present	in	the	viral	ras	(Capon	et	al.,	1983,	Reddy	et	al.,	1982,	Tabin	et	al.,	1982,	Taparowsky	et	al.,	1982).	
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Activated	Ras	oncogenes	have	since	been	found	in	numerous	human	cancer	cell	lines	 and	 human	 tumours	 (Der	 et	 al.,	 1982,	 Parada	 et	 al.,	 1982,	 Santos	 et	 al.,	1984,	Santos	et	al.,	1982,	Cox	et	al.,	2014,	Feig	et	al.,	1984,	Prior	et	al.,	2012).	The	 genes	 were	 labelled	 HRAS	 and	 KRAS,	 and	 the	 corresponding	 protein	products	 HRas	 and	 KRas.	 The	 third	 ras	 gene	 was	 discovered	 in	 human	neuroblastoma	 and	 leukaemia	 cell	 lines	 and	 was	 termed	 NRAS,	 for	
neuroblastoma-ras	 (Hall	 et	 al.,	 1983,	Murray	et	 al.,	 1983,	 Shimizu	et	 al.,	 1983,	Taparowsky	et	al.,	1983).			Remarkably,	KRAS	gene	expresses	two	alternative	splice	variants	–	KRas-4A	(or	KRasA)	 and	KRas-4B	 (KRasB),	which	differ	 only	 in	 their	 fourth	 terminal	 exon	(Capon	et	al.,	1983,	McGrath	et	al.,	1983).	All	Ras	isoforms,	HRas,	NRas	and	the	two	KRas	splice	variants,	are	highly	homologous	and	comprise	189	residues,	or	188	for	KRasB.	The	sequence	similarity	is	around	82-90%	among	the	isoforms	and	 all	 proteins	 are	 identical	 in	 the	 first	 164	 residues,	 which	 contain	 the	 G	domain	responsible	for	binding	and	hydrolysis	of	guanine	nucleotides	(Fig.	1.4).					The	G	domain	 is	highly	 conserved	not	only	 across	 the	main	Ras	 isoforms,	but	also	across	Ras	superfamily	members	and	heterotrimeric	G	proteins	(Vetter	and	Wittinghofer,	2001).	 It	 is	 around	20	kDa	and	contains	a	 six-stranded	β-	 sheet,	five	α-helices	and	ten	interconnecting	loops.	The	three-dimensional	structure	of	Ras	proteins	was	solved	by	X-ray	crystallography	and	it	provided	detail	on	the	differences	 between	GTP-	 and	GDP-bound	 states	 of	 Ras	 and	 on	 their	mutants	(Brunger	et	al.,	1990,	Krengel	et	al.,	1990,	Milburn	et	al.,	1990,	Pai	et	al.,	1989,	Schlichting	et	al.,	1990,	Tong	et	al.,	1989).			The	G	domain	consists	of	five	conserved	motifs	placed	on	the	loop	regions	that	take	 part	 in	 nucleotide	 binding	 and	 GTP	 hydrolysis	 (Fig.	 1.4)	 (Vetter	 and	Wittinghofer,	 2001,	Karnoub	and	Weinberg,	 2008).	The	nucleotide	base	binds	mainly	 to	 the	 N/TKxD	motif,	 whereas	 the	 β,	 γ-phosphates	 interacts	 with	 the	phosphate-binding	loop	(P-loop)	that	comprises	the	GxxxxGKS/T	motif	(Saraste	et	al.,	1990).			The			guanine			binding			specificity		arises			from			the			side			of			the		
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conserved	aspartate	 residue	 situated	 in	 the	DxxG	motif	 and	 the	main	 chain	of	the	alanine	(Ala146)	residue	from	the	SAK	motif.		The	 G	 domain	 also	 contains	 two	 so-called	 “switch	 regions”	 that	 change	conformation	 upon	 GTP	 binding	 and	 take	 part	 in	 interactions	 of	 Ras	with	 its	upstream	regulators,	such	as	GAPs	and	GEFs,	as	well	as	downstream	targets	by	exposing	effector	binding	domain	(Milburn	et	al.,	1990,	Schlichting	et	al.,	1990,	Vetter	and	Wittinghofer,	2001).	In	the	GTP-bound	state,	the	γ-phosphate	forms	two	hydrogen	bonds	with	the	threonine	(Thr35,	which	also	binds	Mg2+)	residue	in	 switch	 I	 (amino	 acids	 30-38)	 and	with	 glycine	 (Gly60)	 residue	 in	 switch	 II	region	(amino	acids	60-76)	(Cox	and	Der,	2010).	Following	GTP	hydrolysis,	the	two	switch	regions	go	back	to	the	relaxed	GDP-bound	conformation.		Ras	 proteins	 are	 highly	 conserved	 across	 different	 species,	 as	 depicted	 in	 Fig.	1.5,	which	 compares	 all	 three	main	Ras	 protein	 sequences	 and	 their	 isoforms	based	 on	 protein	 sequences	 from	 model	 organisms	 representing	 major	eukaryotic	kingdoms	and	phyla.	Although	there	are	no	direct	homologs	of	Ras	in	plant	genomes,	the	flowering	plant	Arabidopsis	thaliana,	as	shown	in	the	figure,	expresses	a	Ras-related	RABD2A	protein,	which	 is	related	more	to	RAB	family	member	RAB1A	(part	of	Ras	superfamily).	However,	homologous	Ras	proteins	have	 been	 studied	 in	 species	 such	 as	 amoeba	 Dictyostelium	 discoideum	(Reymond	 et	 al.,	 1984),	 yeast	 Saccharomyces	 cerevisiae	 (Dhar	 et	 al.,	 1984,	Powers	et	al.,	1984),	nematode	Caenorhabditis	elegans	 (Beitel	et	al.,	1990,	Han	and	 Sternberg,	 1990),	 arthropods,	 such	 as	 common	 fruit	 fly	 Drosophila	
melanogaster	 (Neuman-Silberberg	 et	 al.,	 1984),	 amphibians	 such	 as	 African	clawed	frog	Xenopus	laevis	(Andeol	et	al.,	1990,	Baum	and	Bebernitz,	1990)	and	zebrafish	Danio	rerio	(Cheng	et	al.,	1997,	Liu	et	al.,	2008).		Mouse	 and	 human	 Ras	 proteins	 are	 highly	 related	 with	 97-100%	 identity,	depending	on	the	isoform.	Similarly,	their	mRNA	sequence	is	highly	conserved,	showing	88-95%	identity.	Fig.	1.6	depicts	mRNA	coding	sequence	alignment	for	KRASA,	 which	 shows	 the	 highest	 sequence	 homology	 between	 mouse	 and	human.		
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Fig.	1.5	Ras	 isoform	conservation	across	species.	Phylogenetic	tree	of	main	Ras	 subfamily	 members	 and	 their	 isoforms	 in	 model	 organisms	 and	 human	(Saccharomyces	 cerevisiae,	 Dictyostelium	 discoideum,	 Caenorhabditis	 elegans,	
Drosophila	melanogaster,	 Xenopus	 laevis,	 Danio	 rerio,	Mus	musculus	 and	Homo	
sapiens),	based	on	protein	sequence	similarity.	In	plants	(Arabidopsis	thaliana),	the	most	 closely	 related	protein	 to	Ras	 is	RABD2A	 (homologue	of	RAB	 family	member	RAB1A).	The	dendrogram	was	generated	using	VECTOR	NTI	Advance	(v11.5.2).				
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Fig.	1.6	Conservation	of	mRNA	protein	coding	sequences	of	KRasA	isoform	
between	human	and	mouse.	Alignment	of	mRNA	coding	sequence	for	KRasA	in	 human	 (H)	 and	 mouse	 (M)	 show	 high	 identity	 (95%)	 between	 the	 two	species.	Numbers	on	the	right	indicate	nucleotide	number	in	mRNA	sequence.	
	
	
1.1.3		 	 Cellular	dynamics	and	signalling	differences	between	
Ras	isoforms	Although	 highly	 conserved	 in	 mRNA	 and	 protein	 sequence,	 Ras	 isoforms	 are	non-redundant	 in	 their	 cellular	 functions.	 Table	 1.1	 summarises	 the	 main	functional	differences	between	the	four	main	Ras	isoforms	that	are	discussed	in	the	next	sections.		
	
1.1.3.1		 	 	 Ras	signalling	pathways	
1.1.3.1.1	 	 Upstream	activators	of	Ras	Ras	 proteins	 are	molecular	 central	 hubs,	 on	which	 a	 plethora	 of	 intracellular	signals			converge			and		diverge		(Fig		1.8).		Epidermal			growth			factor			receptor	
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Table	1.1	Main	functional	and	cellular	differences	between	the	four	main	
Ras	isoforms.	For	references	please	refer	to	text.	PM	–	plasma	membrane;	ESCs	–	embryonic	stem	cells,	IL-3	–	interleukin-3,	CSF-1	–	colony-stimulating	factor	1,	EGF	–	epidermal	growth	factor,	AML	–	acute	myelogenous	leukaemia,	HNSCC	–	neck	squamous	cell	carcinoma	
Property	
Ras	isoform	
HRas	 KRasB	 KRasA	 NRas	
PM	
attachment	
Farnesylation	+	double	palmitoylation	 Farnesylation	+	polybasic	lysine	stretch		 Farnesylation	+	monopalmitoyl-ation	 Farnesylation	+	monopalmitoyl-ation	
Upstream	
activators	
Ras-GRF1,	Sos1	strongest	 RasGRP2,	Sos1	weakest,	calmodulin,		 RasGRP2,	Sos1	medium	preferential:	IL-3,	CSF-1	and	EGF	 	
MAPK/PI3K	
association	
Weakest	activator	of	Raf-1	 Best	activator	of	Raf-1	 Second-best	activator	of	Raf-1	 Weak	activator	of	Raf-1	Better	activator	of	PI3K	 Better	activator	of	Rac	 Better	activator	of	PI3K	
Downstream	
effectors	
NF-κB	 RASSF2	 	
Intracellular	
localisation	
and	signalling		
Golgi	stacks;	ER;	endosomes;	lipid	rafts	and	bulk	membrane	of	PM	
Bulk	membrane	of	PM	 PM	 Noncaveolar	lipid	rafts	of	PM,	trans	Golgi,	ER	
mRNA	
expression	
Lowly	abundant	 Highly	abundant,	ubiquitous	 Not	ubiquitous,	minor	KRas	isoform	 Moderately	abundant	
Protein	
expression	
Lowly	abundant	 Highly	abundant;	impaired	translation	 Lowly	abundant	 Moderately	abundant	
Function	in	
development	
Dispensable	for	mouse	development;	supports	differentiation	and	growth	arrest		
Essential	for	mouse	development;	specific	for	cardiovascular	homeostasis;		
Dispensable	for	mouse	development;		 Dispensable	for	mouse	development	
supports	proliferation	and	self-renewal	
Involvement	
in	congenital	
disorders	
Costello	and	Noonan	syndromes		 Noonan	syndrome	
Function	in	
cancer	
3%	of	Ras	mutations,	prevalent	in	HNSCC,	bladder	cancer	
86%	of	Ras	mutations,	prevalent	in	pancreatic	and	lung	cancers,	multiple	myeloma,	endometrial,	stomach	and	colorectal	cancers		
11%	of	Ras	mutations,	prevalent	in	melanoma,	AML,	thyroid	cancer	
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(EGFR)	 was	 the	 first	 receptor	 discovered	 responsible	 for	 conveying	 signals	upstream	of	Ras	(Kamata	and	Feramisco,	1984).	Stimulation	of	EGFR,	as	well	as	another	 receptor	 tyrosine	kinase	 (RTK)	platelet-derived	growth	 factor	 (PDGF)	receptor	(PDGFR)	by	receptor-specific	ligands	was	shown	to	augment	activated	Ras	 (GTP-bound)	 (Gibbs	 et	 al.,	 1990,	 Satoh	 et	 al.,	 1990a,	 Satoh	 et	 al.,	 1990b).	Further	work	determined	 that	Grb2	 is	an	adaptor	protein	 that	 links	upstream	RTKs	with	Ras	(Lowenstein	et	al.,	1992)	through	its	association	with	GEF	Sos1	(Buday	and	Downward,	1993,	Chardin	et	al.,	1993,	Egan	et	al.,	1993,	Gale	et	al.,	1993,	Li	et	al.,	1993,	Olivier	et	al.,	1993,	Quilliam	et	al.,	1994,	Rozakis-Adcock	et	al.,	 1993,	 Simon	 et	 al.,	 1993).	 Further	 research	 demonstrated	 that	Grb2	 could	connect	Ras	with	other	adaptors,	such	as	Shc,	leading	to	association	of	Ras	with	many	 different	 RTKs	 (Giubellino	 et	 al.,	 2008,	 Margolis	 and	 Skolnik,	 1994,	Yonezawa	et	al.,	1994).		Subsequent	work	 showed	 that	 Ras	 proteins	 can	 be	 stimulated	 by	 a	 variety	 of	upstream	 receptors,	 including	 G	 protein-coupled	 receptors	 (GPCR),	 such	 as	bradykinin	 B2	 or	 adrenergic	 receptors	 via	 activation	 of	 phospholipase	 C	 β	(PLCβ)	(Blaukat	et	al.,	2000,	Della	Rocca	et	al.,	1997,	Dikic	et	al.,	1996,	Dorsam	and	Gutkind,	2007),	and	integrin	receptors	(Schlaepfer	et	al.,	1994,	Yoon	et	al.,	2006).	Nonetheless,	the	level	of	activation	by	upstream	signalling	is	not	uniform	among	Ras	 isoforms.	Ras-GRF1,	a	GEF,	activates	 in	vivo	HRas,	but	not	KRas	or	NRas	(Jones	and	Jackson,	1998,	Matallanas	et	al.,	2003).	In	contrast,	RasGRP2,	a	GEF	that	is	stimulated	by	calcium	and	diacylgrycerol	(DAG),	activates	only	NRas	and	KRas	(Clyde-Smith	et	al.,	2000).	Sos1,	 in	 turn,	activates	Ras	 isoforms	with	the	 following	 efficiency:	 HRas	 >	 NRas	 >	 KRas	 (Jaumot	 et	 al.,	 2002).	 Further	differences	 between	 Ras	 isoform	 coupling	 and	 activation	 include	 preferential	binding	of	calmodulin	to	KRas,	which	inhibits	downstream	ERK1/2	(Villalonga	et	 al.,	 2001),	 covalent	 binding	 of	 the	 cyclopentenone	 15-deoxy-delta	 12,14-prostaglandin	 J2	 to	HRas,	which	 leads	 to	 cell	 proliferation	 (Oliva	 et	 al.,	 2003)	and	 preferential	 activation	 of	 KRasB	 by	 the	 growth	 factors	 interleukin-3,	colony-stimulating	factor	1	and	epidermal	growth	factor	(EGF)	(Ehrhardt	et	al.,	2004).		
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1.1.3.1.2	 	 Downstream	Ras	effectors		The	canonical	signalling	pathways	that	diverge	from	activated	Ras	are	mitogen-activated	 protein	 kinase	 (MAPK)	 and	 phosphoinositide	 3-kinase	 (PI3K)	pathways	 (Fig.	 1.7).	 The	 first	 identified	 mammalian	 Ras	 effector	 was	 the	serine/threonine	protein	kinase	Raf	(Van	Aelst	et	al.,	1993,	Warne	et	al.,	1993,	Zhang	et	al.,	1993),	which	was	known	to	activate	downstream	MAPK	kinase	1	and	2	(MEK1	and	MEK2),	as	well	as	MAPK,	also	known	as	extracellular	signal-regulated	kinase	1	and	2	(ERK1	and	ERK2)	(Dent	et	al.,	1992,	Howe	et	al.,	1992,	Kyriakis	et	al.,	1992,	Moodie	et	al.,	1993).	In	this	way,	the	prototypical	Ras-Raf-MEK-ERK	pathway	(MAPK	cascade)	was	delineated	and	it	was	ascertained	that	homologous	pathways	 are	 present	 in	 a	 range	 of	 species	 (Dickson	 et	 al.,	 1992,	Masuda	et	al.,	1995,	Han	et	al.,	1993).	To	propagate	signals	down	the	pathway,	the	 effectors	 utilise	 activating	 phosphorylation	 events	 on	 their	 downstream	targets.	In	mammals,	the	pathway	is	essential	for	a	myriad	of	cellular	functions,	including	 proliferation,	 differentiation	 and	 gene	 expression	 (Chang	 and	Karin,	2001,	Imajo	et	al.,	2006,	Nishida	and	Gotoh,	1993,	Pearson	et	al.,	2001).			The	second	Ras	effector	to	be	discovered	was	PI3K,	a	lipid	kinase	that	consists	of	 the	 p110	 catalytic	 and	 p85	 regulatory	 subunits	 (Rodriguez-Viciana	 et	 al.,	1994,	 Rodriguez-Viciana	 et	 al.,	 1996,	 Sjolander	 et	 al.,	 1991).	 Activated	 PI3K	generates	 phosphatidylinositol-3,4,5-triphosphate	 (PIP3),	 which	 acts	 as	 a	second	messenger	 and	 translocates	protein	 kinase	B	 (PKB,	 also	 called	Akt)	 to	the	 PM	 (Scheid	 and	 Woodgett,	 2001).	 Akt,	 in	 turn,	 is	 phosphorylated	 and	activated	 by	 phosphoinositide	 dependent	 kinase	 1	 (PDK1).	 Akt	 regulates	 a	range	of	downstream	effectors,	such	as	mammalian	target	of	rapamycin	(mTOR)	and	glycogen	synthase	kinase-3	(GSK-3),	which	are	key	for	regulating	cell	cycle,	cell	proliferation	and	survival	(Cross	et	al.,	1995,	Nave	et	al.,	1999,	Osaki	et	al.,	2004,	Sekulic	et	al.,	2000).		Importantly,	 each	 Ras	 effector	 possesses	 a	 Ras	 binding	 domain	 (RBD),	 which	allows	them	to	specifically	associate	with	activated	GTP-bound	Ras	through	its	effector	domain	(Spaargaren	and	Bischoff,	1994,	Vojtek	et	al.,	1993).	Apart	from	
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Raf	 and	 PI3K,	 Ras	 propagates	 signals	 to	 a	 plethora	 of	 other	 downstream	effectors.	 RalGDS	 (ral	 GDP	 dissociation	 stimulator),	 a	 GEF	 for	 Ras-related	proteins	(RalA	and	RalB),	is	the	third	main	downstream	target	of	Ras	(Hinoi	et	al.,	1996,	Kikuchi	and	Williams,	1996,	Urano	et	al.,	1996).	 It	 interacts	with	Ras	via	 its	 Ras	 association	 (RA)	 domain	 (Hofer	 et	 al.,	 1994,	 Kikuchi	 et	 al.,	 1994,	Spaargaren	 and	 Bischoff,	 1994)	 and	 transmits	 signals	 to	 downstream	phospholipase	D	(PLD)	and	Ral-interacting	protein	1(RIP1),	to	name	a	few,	that	are	 responsible	 for	 cell	migration,	 actin	 organisation,	 as	well	 as	 regulation	 of	endocytosis	and	exocytosis	(Cantor	et	al.,	1995,	Feig,	2003,	Jullien-Flores	et	al.,	1995,	Luo	et	al.,	1998,	Rosse	et	al.,	2006).		The	 remaining	 Ras	 effectors	 include	 Rac-specific	 GEF	 –	 T	 lymphoma	 invasion	and	metastasis	protein	1	(Tiam1)	(Lambert	et	al.,	2002),	which	takes	part	in	cell	migration	(Yamauchi	et	al.,	2005a,	Yamauchi	et	al.,	2005b),	PLCε	(Kelley	et	al.,	2001,	Lopez	et	al.,	2001,	Song	et	al.,	2002),	which	is	involved	in	cell	growth	and	differentiation	 (Wu	et	 al.,	 2003,	Yun	et	 al.,	 2008)	and	RAS	association	domain	family	 proteins	 (e.g.	 Rassf1)	 (Tommasi	 et	 al.,	 2002,	 Vos	 et	 al.,	 2003b)	 that	control	 apoptosis	 (Allen	 et	 al.,	 2007,	 Eckfeld	 et	 al.,	 2004,	 Khokhlatchev	 et	 al.,	2002,	Vos	et	al.,	2000,	Vos	et	al.,	2003a).	Nonetheless,	different	Ras	isoforms	differ	in	their	quantitative	ability	to	activate	downstream	 effectors.	 KRas	 recruits	 Raf-1	 more	 efficiently	 to	 the	 plasma	membrane	and	is	its	more	potent	activator	than	HRas,	which,	in	turn,	is	a	better	activator	of	PI3K	(Yan	et	al.,	1998).	Yet,	recent	work	has	shown	that	Ras	alone	cannot	activate	PI3K,	but	for	this	it	requires	stimulation	by	GFs	(Mendoza	et	al.,	2011,	 Toettcher	 et	 al.,	 2013).	 Moreover,	 all	 four	 Ras	 isoforms	 differ	 in	 their	abilities	to	activate	Raf-1,	with	the	following	order:	KRasB	>	KRasA	>>>	NRas	>	HRas	(Voice	et	al.,	1999).	The	extent	of	G	domain	reorientation	towards	the	PM	is	 thought	 to	 affect	 such	 preferential	 coupling	 of	 isoforms	 to	 downstream	effectors	(Abankwa	et	al.,	2010,	Abankwa	et	al.,	2008).		The	activation	of	the	Rac	pathway	by	oncogenic	KRasG12V	is	2-fold	greater	than	that	by	HRasG12V,	which	is	demonstrated	by	higher	surface	area	of	membrane	
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ruffles,	higher	number	of	pinocytic	vesicles,	enhanced	cell	migration	in	a	wound	healing	assay	and	Pak-binding	activity	of	Rac,	which	 is	a	measure	of	activated	Rac	 (Walsh	 and	 Bar-Sagi,	 2001).	 There	 are	 also	 several	 Ras	 isoform-specific	effectors,	which	include	pro-apoptotic	RASSF2	–	a	KRas-specific	effector	(Vos	et	al.,	2003a)	–	and	downstream	NF-κB,	which	is	preferentially	activated	by	HRas	(Millan	 et	 al.,	 2003).	As	 a	 result,	 differential	 effector	 coupling	 of	Ras	 isoforms	leads	 to	 isoform-specific	 signalling,	differences	 in	 transforming	potency	and	 it	affects	cell	motility	and	induction	of	apoptosis.		
 
 
	
	
Fig.	 1.7	 Ras	 signalling	 pathways.	 A	 growth	 factor	 (GF)	 binds	 and	 activates	receptor	 tyrosine	 kinase	 (RTK),	 which	 then	 propagates	 the	 signal	 through	adapter	 proteins	 and	 guanosine	 exchange	 factors	 (GEFs)	 (not	 shown)	 to	 a	membrane-bound	Ras.	As	a	central	signalling	hub,	Ras	disseminates	activating	signals	 to	 a	 plethora	 of	 downstream	 effectors,	 which	 stimulate	 signalling	cascades	 involved	 in	 all	 major	 cellular	 processes,	 including	 cell	 cycle	 and	survival.	
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1.1.3.2	 	 	 Ras	trafficking	and	posttranslational	modifications	
	Effector	 binding	 and	 growth	 factor	 activation	 differences	 may	 stem	 from	distinct	 plasma	 membrane	 and	 cellular	 localisations	 of	 Ras	 isoforms.	 Ras	proteins	 traffic	 to	 the	 plasma	 membrane	 via	 alternative	 pathways	 due	 to	differential	 lipid	 post-translational	 modifications	 that	 are	 necessary	 for	membrane	 association	 (Apolloni	 et	 al.,	 2000,	 Hancock	 et	 al.,	 1990).	 These	distinct	modifications	 result	 from	amino	 acid	 differences	 at	 the	 hypervariable	region	(HVR)	located	at	the	C-terminal	region	(Fig.	1.8).			In	 the	 cytosol,	 the	 cysteine	 residue	 of	 the	 CAAX	 motif	 of	 all	 Ras	 isoforms	 is	targeted	 for	 the	 addition	 of	 a	 farnesyl	 moiety	 by	 the	 farnesyl	 transferase	enzyme	 (Hancock	 et	 al.,	 1989,	 Lowy	 and	 Willumsen,	 1989).	 Subsequent	proteolysis	and	methylation	of	the	C-terminus	take	place	on	the	ER	(Casey	et	al.,	1989,	 Hancock	 et	 al.,	 1989).	 Farnesylated	 KRasB	 is	 directly	 transported	 into	high-buoyant	density	domains	in	the	PM,	which	contain	activated	receptors	and	GEFs	 (Ehrhardt	 et	 al.,	 2004).	 Such	 location	 may	 privilege	 KRasB	 for	 better	activation	 by	 GFs	 compared	 to	 other	 Ras	 isoforms.	 Ras	 requires	 a	 second	membrane-targeting	 signal,	which	 for	 KRasB	 comprises	 an	 intrinsic	 polybasic	stretch	 of	 six	 lysine	 residues	 (Hancock	 et	 al.,	 1990).	 For	 the	 other	 isoforms,	KRasA,	 HRas	 and	 NRas,	 the	 second	 signal	 involves	 palmitoylation	 of	 cysteine	residues	and	this	lipid	modification	directs	trafficking	to	the	PM	via	the	exocytic	pathway	(Apolloni	et	al.,	2000,	Choy	et	al.,	1999,	Laude	and	Prior,	2008,	Rocks	et	al.,	2005).	HRas	is	palmitoylated	on	two	cysteine	residues,	whereas	KRasA	and	NRas	 are	 monopalmitoylated	 (Roy	 et	 al.,	 2005).	 The	 continuous	de/repalmitoylation	cycle	allows	dynamic	shuttling	of	Ras	between	the	PM	and	the	Golgi	(Lorentzen	et	al.,	2010).		Interestingly,	 Ras	 isoforms	 also	 differ	 in	 segregation	 to	 distinct	 plasma	membrane	microdomains.	HRas	resides	in	caveolar	and	noncaveolar	lipid	rafts	and	in	the	bulk	membrane,	whereas	KRas	is	only	found	in	the	latter	(Prior	and	Hancock,	 2001,	 Prior	 et	 al.,	 2003).	 All	 three	 Ras	 isoforms	 are	 dynamically	associating	with	distinct	 signalling	nanoclusters;	whilst	HRas	 leaves	 lipid	rafts	when	 activated,	 NRas	 travels	 in	 the	 opposite	 direction	 (Omerovic	 and	 Prior,	2009).	
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Until	 recently,	 it	 has	 been	 postulated	 that	 Ras	 activation	 and	 Ras-dependent	signalling	originates	exclusively	 from	 the	PM	(Quilliam	et	al.,	1995).	However,	latest	 research	 provides	 evidence	 for	 Ras	 signalling	 from	 distinct	 subcellular	compartments:	the	ER,	the	Golgi	complex	and	the	endosomes	(Fig.	1.8)	(Chiu	et	al.,	 2002,	 Perez	 de	 Castro	 et	 al.,	 2004,	 Roy	 et	 al.,	 2002).	 Constitutively	 active	HRas	has	been	shown	to	recruit	RBD	of	Raf-1	on	the	PM,	the	Golgi	and	the	ER,	and	 constitutively	 active	 NRas	 –	 on	 the	 PM	 and	 the	 Golgi	 (Chiu	 et	 al.,	 2002,	Philips,	2005).	Another	study	has	demonstrated	that	HRas	dynamically	shuttles	from	the	PM	to	the	recycling	endosomes,	where	it	also	binds	to	the	downstream	RBD	 of	 Raf-1	 (Gomez	 and	 Daniotti,	 2005).	 Oncogenic	 H-Ras,	 when	 artificially	anchored	 to	 the	 ER,	 activates	 ERK,	 c-Jun	 N-terminal	 kinase	 (JNK)	 and	 PI3K.	However,	when	tethered	to	the	Golgi,	H-RasG12V	may	activate	ERK	or	RalGDS	(Matallanas	et	al.,	2006).	While	HRas	is	evenly	distributed	on	the	Golgi,	NRas	is	present	mainly	on	the	cis	Golgi	sub-compartment	(Lynch	et	al.,	2015).	RasGRP1,	a	Ras	GEF,	has	been	shown	to	specifically	activate	Ras	on	the	Golgi	(Caloca	et	al.,	2003).	 On	 the	 other	 hand,	 endogenous	 NRas	 is	 selectively	 activated	 by	endothelial	 nitric	 oxide	 synthase	 (eNOS)	 on	 the	 Golgi	 in	 response	 to	 antigen	stimulation	of	T	cells	(Ibiza	et	al.,	2008).			The	 different	 Ras	 subcellular	 localisations	 can	 be	 also	 affected	 by	 various	factors:	 the	 deubiquitinating	 enzyme	USP17	disrupts	NRas	 localisation	 on	 the	PM,	 but	 not	 on	 the	 Golgi	 or	 ER	 (de	 la	 Vega	 et	 al.,	 2010),	 BRaf	 inhibitors	specifically	enhance	nanoclustering	of	KRas	and	NRas	on	the	PM	and	decrease	PI3K	 signalling	 (Cho	 et	 al.,	 2012),	 whereas	 high	 intracellular	 oxygen	 leads	 to	accumulation	of	HRas	on	the	Golgi	and	PM	(Kim	et	al.,	2015).		What	is	more,	Ras	isoforms	 can	 also	 localise	 to	 the	 mitochondria	 and	 the	 nucleus.	 KRas	 that	 is	anchored	 to	 the	 plasma	 membrane	 can	 induce	 transformation,	 while	 KRas	associated	with	Bcl-Xl	on	the	mitochondria	can	induce	apoptosis	(Bivona	et	al.,	2006).	 Both	 KRas	 and	 NRas	 have	 also	 been	 shown	 to	 regulate	 normal	mitochondrial	 biology	 (Wolfman	 et	 al.,	 2006).	 Moreover,	 transcriptional	profiling	 of	 compartment-specific	 Ras	 signalling	 revealed	 distinct	 gene	signatures	(Agudo-Ibanez	et	al.,	2007).	Yet,	other	studies	argue	that	endogenous	activation	 of	Ras	 could	 only	 be	 visualised	 at	 the	PM	 (Augsten	 et	 al.,	 2006).	 In	light	of	these	discrepancies	between	results,	the	possibility	of	Ras	activation	at	
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different	subcellular	compartments	and	the	possibility	of	differential	activation	of	Ras	isoforms	and	diverse	signalling	outcomes	remain	to	be	resolved.		
		
1.1.4		 	 	 Ras	function	in	development	
	
1.1.4.1	 	 	 Functions	of	Ras	isoforms	in	self-renewal	and	
differentiation	
	Various	 in	 vitro	 studies	 utilised	 exogenous	 Ras	 to	 study	 isoform-dependent	signalling	 in	a	context	of	 cellular	differentiation	and	self-renewal	of	 stem	cells	(SCs).	Distinct	Ras	 isoforms	have	been	shown	 to	differentially	engage	 in	 these	developmental	processes	(discussed	in	section	4.1.2).	In	general,	activated	HRas	was	 associated	 with	 differentiation	 and	 growth	 arrest	 (Quinlan	 et	 al.,	 2008,	Quinlan	 and	 Settleman,	 2008,	 Yoshida-Koide	 et	 al.,	 2004),	 whereas	 KRas	supported	proliferation	and	self-renewal	of	SCs	(Luo	et	al.,	2007,	Quinlan	et	al.,	2008,	Quinlan	and	Settleman,	2008).	On	the	other	hand,	the	Ras	isoform	ERas,	which	 is	 expressed	 only	 in	 mouse	 embryonic	 SCs	 (ESCs),	 was	 shown	 to	contribute	 to	 oncogenic	 properties	 of	 undifferentiated	 cells	 (Kameda	 and	Thomson,	 2005,	 Takahashi	 et	 al.,	 2003).	 Such	 disparity	 in	Ras	 involvement	 in	cellular	 processes	 may	 be	 a	 reflection	 of	 Ras	 isoform-specific	 coupling	 to	downstream	 effectors,	 intracellular	 localisation	 or	 Ras	 expression	 levels	(Castellano	and	Santos,	2011).		
	
1.1.4.2		 	 Mouse	models	to	study	Ras	during	development		
	
1.1.4.2.1	 Normal	mouse	development	
	Mouse	models	are	often	utilised	to	study	cellular	signalling	at	different	stages	of	development	by	gene	knock-in	(KI)	or	knock	out	(KO)	techniques.	However,	to	appreciate	the	phenotypic	outcomes	of	such	models,	 it	 is	 imperative	to	clearly	understand	 the	 physiological	 changes	 that	 take	 place	 during	 normal	 mouse	development.	The	following	paragraphs	describe	prenatal	and	postnatal	mouse	development	with	particular	emphasis	on	the	major	organs	that	were	examined	in	this	study	–	brain,	intestine,	stomach,	liver,	skeletal	muscle,	heart,	kidney	and	lung.	
	 20	
Around	 4	 days	 post-conception	 (E4.5),	 the	mouse	 embryo	 is	 a	 blastocyst	 and	begins	 implantation,	 i.e.	 adhering	 to	 the	 uterine	 wall	 (Theiler,	 1989).	 At	embryonic	 day	 6	 (E6),	 differentiation	 of	 embryonic	 and	 extraembryonic	endoderm	and	ectoderm	begins,	while	mesoderm	starts	to	form	around	E7.	At	E7.5	 the	neural	 plate	 is	more	distinct	 and	 the	head	process	 starts	 to	 develop.	Mouse	 organogenesis	 begins	 at	 E8,	 during	 which	 the	 gut	 pocket,	 pronephric	duct	and	cardiac	crescent	appear	and	the	brain	plate	rapidly	develops	(Theiler,	1989,	Davidson,	2008,	Mitiku	and	Baker,	2007,	Kaufman,	1992).	Also,	 the	 first	somite	 pairs	 appear,	 which	 are	 lumps	 of	 mesenchymal	 cells	 derived	 from	paraxial	mesoderm	 of	 segmented	 animals	 and	 subsequently	 differentiate	 into	vertebrae,	 ribs,	 skeletal	 muscle	 and	 the	 dermis	 (Tam,	 1981,	 Gilbert,	 2010).	Mouse	 embryos	 reach	 over	 60	 pairs	 of	 somites	 at	 E15	 (up	 to	 65	 pairs)	(Kaufman,	1992,	Tam,	1981).		At	E8.5	the	mouse	embryo	rotates	resulting	in	a	major	change	in	shape	(Theiler,	1989).	The	first	organ	buds	start	to	form	from	the	foregut	and	hindgut	around	E9–10.5	and	give	rise	to	lung,	liver,	stomach,	pancreas	and	intestine	(Crawford	et	 al.,	 2010,	 Maeda	 et	 al.,	 2007,	 Wells	 and	 Melton,	 1999).	 By	 E9,	 the	 heart	sustains	primitive	circulation	with	regular	heartbeat,	while	both	the	ventricular	and	 atrial	 chambers	 are	 being	 developed	 (Savolainen	 et	 al.,	 2009,	 Theiler,	1989).	 Proper	 kidney	 development	 starts	 at	 E10.5	 with	 the	 formation	 of	 the	uretic	bud	from	the	pronephric	duct	(Davidson,	2008).	By	the	same	time,	brain	development	has	substantially	advanced	(Gilbert,	2010,	Kaufman,	1992,	Theiler,	1989).	 The	 neural	 tube	 closed	 completely	 as	 the	 neural	 folds	 joined	 together	and	 the	 cranial	 blood	 vessels	 rapidly	 developed.	 Differentiating	 neural	 crest	gave	 rise	 to	 peripheral	 nervous	 system	 ganglia.	 The	 hindbrain	 portion	 of	 the	brain,	which	 later	 develops	 into	 the	 pons,	medulla	 oblongata	 and	 cerebellum,	enlarged	substantially.	Cranial	motor	nuclei	and	inferior	olivary	nucleus,	which	are	 involved	 in	 motor	 control,	 show	 peak	 in	 neurogenesis	 at	 E9	 and	 E10,	respectively	 (Finlay	 et	 al.,	 1995).	 By	 E11	 mouse	 sex	 cannot	 be	 determined	(Theiler,	1989).		At	E11.5	 the	 limb	buds	 start	 to	differentiate,	while	 the	 arterial	 system	 is	now	more	mature	(Kaufman,	1992,	Theiler,	1989).	The	heart	is	still	developing	–	the	
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atrium	is	almost	partitioned,	but	the	ventricle	remains	unpaired	and	the	aorta	is	differentiating.	The	liver	shows	hematopoietic	foci	and,	together	with	stomach,	it	enlarged	substantially	as	compared	to	E10.5	(Theiler,	1989).	In	the	lung,	the	branching	 of	 the	major	 bronchi	 takes	 place	 (Metzger	 et	 al.,	 2008,	Warburton,	2008).	 At	 this	 stage,	 kidney	 development	 progresses	 with	 the	 formation	 of	metanephros	as	a	 result	of	branching	of	 the	uretic	bud	 (Davidson,	2008).	The	brain	has	grown	and	matured	 substantially	 and	 the	 forebrain	part,	which	will	form	 the	 thalamus	 and	hypothalamus,	 is	more	distinct	 (Gilbert,	 2010,	Theiler,	1989).	The	embryo	is	around	6-7	mm	long	and	has	now	43-48	pairs	of	somites	(Kaufman,	1992,	Theiler,	1989).			At	 E12	 the	 mouse	 embryo	 has	 the	 first	 signs	 of	 developing	 fingers	 (Theiler,	1989).	The	aorta	and	the	pulmonary	artery	are	formed	through	the	division	of	an	arterial	trunk	(Gilbert,	2010,	Theiler,	1989).	The	rudiments	of	the	tongue	and	teeth	 start	 to	 develop	 and	 the	 lung	 buds	 have	 now	 tertiary	 bronchi.	 The	epithelium	of	the	stomach	shows	regional	differentiation,	while	the	liver	starts	producing	 megakaryocytes,	 which	 are	 responsible	 for	 the	 production	 of	platelets.	At	this	stage	sexual	differentiation	may	be	apparent	(Theiler,	1989).	In	the	 brain,	 the	 pineal	 gland	 starts	 to	 form,	 while	 the	 lens	 of	 the	 eye	 is	differentiating.		By	E13	the	length	of	the	embryo	is	around	9-11	mm	and	the	outer	ear	is	rapidly	developing	 (Theiler,	 1989).	 In	 the	 heart,	 the	 valves	 have	 formed,	while	 in	 the	lungs,	 the	 branching	 of	 the	 bronchi	 has	 advanced.	 The	 liver	 development	progresses	 substantially	and	both	hepatocytes	and	biliary	epithelial	 cells	 start	to	differentiate	(Zorn,	2008).	By	E13.5	the	liver	is	divided	into	four	main	lobes	(Crawford	 et	 al.,	 2010).	 The	 kidneys	 also	 rapidly	 develop,	 while	 sexual	differentiation	begins	(Theiler,	1989).	In	the	brain,	the	development	of	choroid	plexus,	which	produces	cerebrospinal	fluid,	is	complete	(Gilbert,	2010,	Theiler,	1989).			By	E15	the	mouse	embryo	is	around	11.5-14	mm	and	the	toes	of	its	hindlimbs	are	well	separated	(Theiler,	1989).	The	final	prenatal	circulation,	as	well	as	the	
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shape	 of	 the	 heart	 are	 established.	 The	 four	main	 heart	 valves	 are	 developed	and	the	ventricles	are	separated	(Gilbert,	2010,	Theiler,	1989).	In	the	small	and	large	intestine,	the	villi	and	the	crypts	are	forming,	respectively	(Theiler,	1989).	The	 two	 parts	 of	 the	 stomach	 –	 the	 glandular	 and	 nonglandular	 –	 can	 be	distinguished.	 In	 the	 developing	 lung,	 the	 major	 bronchi	 subsequently	 form	secondary	and	tertiary	branches	that	proliferate	until	E16	(Metzger	et	al.,	2008,	Warburton,	 2008).	 This	 process	 is	 accompanied	 by	 innervation	 and	vasculogenesis	 (Maeda	 et	 al.,	 2007).	 In	 the	 forebrain,	 the	 primary	 cortex	 is	formed	and	the	cranial	nerves,	as	well	as	ganglia	are	more	distinct.		By	E16	the	embryo’s	heart	achieved	the	definitive	prenatal	configuration,	apart	form	 the	 coronary	 artery	 and	atrioventricular	 valve	 leaflets	 (Savolainen	et	 al.,	2009,	 Theiler,	 1989).	 The	 intestinal	 tract	 is	 still	 developing	 –	 the	 villi	 of	 the	small	 intestine,	 the	 crypts	 of	 the	 large	 intestine	 and	 the	 epithelium	 of	 the	stomach	are	forming	and	rapidly	growing	(Theiler,	1989).	The	liver	achieved	its	final	 external	 appearance	 and	 is	 increasing	 the	 production	 of	 blood	 cells.	 The	glomeruli	 of	 the	 kidney	 are	 being	 formed,	 but	 the	 nephrons	 are	 still	 not	developed	 (Theiler,	 1989).	 In	 the	 foetal	 brain,	 the	 pituitary	 and	 pineal	 glands	are	still	differentiating	and	the	primary	cerebral	cortex	is	expanding.		At	E17	mouse	foetus	is	around	16.5-20	mm,	its	eyelids	are	fused	and	the	skin	is	thickened	 (Theiler,	 1989).	 At	 this	 stage,	 the	 major	 changes	 include	 the	developing	 epithelium	 in	 the	 aveolar	 ducts	 of	 the	 lungs.	 By	 E17.5	 pulmonary	acinus	becomes	organised	and	the	respiratory	epithelium	starts	to	differentiate,	which	 will	 continue	 until	 around	 postnatal	 day	 5	 (P5)	 (Maeda	 et	 al.,	 2007).	Between	 E17	 and	 birth,	 the	 intrahepatic	 bile	 ducts	 are	 forming	 in	 the	 liver,	while	hepatocytes	become	more	epithelial	and	mature	(Zorn,	2008).			Around	E18	the	mouse	measures	between	18-23	mm	and	has	long	whiskers.	By	this	time,	 large	alveolar	ducts	and	primitive	alveoli	markedly	developed	in	the	lungs	(Theiler,	1989).	The	liver	is	still	the	site	of	haemopoiesis	and	the	stomach	is	subdivided	into	two	parts:	glandular,	which	contains	gastric	glands,	and	non-glandular,	which	 stores	 and	digests	 the	 food	 (Kararli,	 1995).	 In	 the	 brain,	 the	
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pineal	and	pituitary	glands	and	the	olfactory	 lobe	are	now	developed	(Theiler,	1989).		At	birth	(postnatal	day	0	–	P0),	the	newborn	mouse	measures	around	23-27	mm	and	 its	eyes	and	ears	are	closed.	By	 this	 time,	histological	development	 is	 still	ongoing	 and	 the	 neonates	 are	 considered	 histologically	 immature	 (Theiler,	1989).	 In	 the	 heart,	 the	 foramen	 ovale,	 which	 is	 a	 foetal	 cardiac	 shunt	 that	allows	the	blood	to	flow	from	the	right	to	the	left	atrium,	is	no	longer	functional	(Gilbert,	2010,	Theiler,	1989).	The	 liver	 is	 still	 the	 site	of	haemopoiesis,	while	the	stomach	starts	active	enzyme	secretion	to	aid	in	the	digestion	of	milk.	The	kidneys	 are	 growing	 in	 size	 and	more	 ossification	 centres	 are	 present	 in	 the	vertebral	column.		During	postnatal	period,	the	mouse	grows	in	size	and	fully	matures	at	least	until	P30	(Holder	and	Blaustein,	2014,	Theiler,	1989).	Postnatal	development	of	the	lungs	is	demonstrated	by	the	formation	and	growth	of	alveoli	and	maturation	of	the	 vasculature	 until	 P28	 (Maeda	 et	 al.,	 2007).	 For	 the	 liver,	 its	 size	 rapidly	increases	until	P21	and	the	final	remodelling	of	the	bile	duct	and	organisation	of	hepatocytes	 takes	 place	 (Crawford	 et	 al.,	 2010).	 In	 the	 brain,	 some	 major	changes	 in	 the	 formation	of	 layer	V	 in	 the	 cerebral	 cortex	 and	 in	 the	whisker	sensory	 area	 occur	 until	 P5.	 Also	 by	 the	 same	 time,	 the	 internal	 ear	 is	 still	differentiating,	but	the	ears	open	and	a	fine	fur	appears	(Theiler,	1989).		By	P10,	more	ossification	centres	are	present	in	the	bone	and	by	P15	both	ears	and	eyes	are	 open	 and	 fully	 developed.	Weaning	 starts	 around	 P20	 and	may	 continue	until	P30	(Curley	et	al.,	2009).	By	this	time,	mice	should	show	firs	signs	of	sexual	maturation	 –	 for	 CD1	 mice,	 vaginal	 opening	 occurs	 approximately	 at	 P30	(Holder	and	Blaustein,	2014).	The	 first	oestrus	cycle	occurs	around	7-20	days	after	 the	 vaginal	 opening	 (Holder	 and	 Blaustein,	 2014)	 and	 the	 first	 mating	when	the	mouse	is	around	2-3	months	old	(Theiler,	1989).					
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1.1.4.2.2	 Ras	mouse	models	
 Several	 mouse	 models	 demonstrated	 that	 only	 KRasB	 is	 essential	 for	 mouse	embryo	development	(discussed	in	section	5.1.1)	(Koera	et	al.,	1997,	Johnson	et	al.,	1997,	Plowman	et	al.,	2003,	Umanoff	et	al.,	1995,	Esteban	et	al.,	2001).	KRASB	KO	 mice	 had	 increased	 embryonic	 lethality	 due	 to	 anaemia,	 liver	 defects,	 thin	heart	 ventricular	 walls	 and	 increased	 motoneuron	 cell	 death.	 However,	subsequent	studies	demonstrated	that	replacement	of	KRas	with	HRas,	which	was	knocked	 into	 the	 KRAS	 locus,	 resulted	 in	 normal	 embryonic	 development,	 but	induced	 dilated	 cardiomyopathy	 during	 adulthood	 (Potenza	 et	 al.,	 2005).	 This	suggests	 that	 HRas	 could	 functionally	 replace	 KRas	 during	 early	 development,	when	its	expression	pattern	in	mouse	tissues	mimics	that	of	KRas.	However,	HRas	may	 not	 compensate	 for	 KRas-specific	 function	 in	 adult	 cardiovascular	homeostasis.	 Yet,	 the	 ability	 of	HRas	 to	 substitute	 KRas	 in	 certain	 physiological	context	 could	 mean	 that	 Ras	 isoforms	 share	 many	 cellular	 functions	 and	 the	isoform-specific	differences	in	signalling	are	the	result	of	disparity	in	timing	of	their	 gene	 expression	 and	 in	 tissue/lineage-specific	 expression	 pattern	(Castellano	and	Santos,	2011).		To	 date,	 only	 a	 few	 studies	 have	 provided	 semi-quantitative	 data	 on	 Ras	expression	across	different	tissues	and	developmental	stages	in	the	mouse	and	human	(further	discussed	in	section	5.1.2)	(Leon	et	al.,	1987,	Pells	et	al.,	1997,	Plowman	 et	 al.,	 2006,	 Plowman	 et	 al.,	 2003).	 More	 work	 is	 needed	 to	quantitatively	 measure	 Ras	 abundance,	 which	 will	 inform	 models	 of	 the	mechanistic	basis	of	Ras	isoform	functional	overlap.	
		
1.2		 	 	 Ras	in	pathogenesis		
	
1.2.1		 	 	 Ras	in	developmental	disorders	
	The	 role	 of	 isoform-specific	 function	 in	 early	 development	 could	 be	 better	understood	 by	 studying	 rasopathies	 –	 distinct	 congenital	 disorders	 caused	 by	germline	 mutations	 in	 RAS	 genes	 or	 in	 other	 components	 of	 Ras	 signalling	pathways	(Denayer	et	al.,	2008,	Schubbert	et	al.,	2006,	Tartaglia	and	Gelb,	2010,	
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Tidyman	and	Rauen,	2008,	Tidyman	and	Rauen,	2009).	Rasopathies	share	many	phenotypic	 features	 and	 are	 collectively	 referred	 to	 as	 neuro-cardio-faciocutaneous	 (NCFC)	 developmental	 syndromes,	 characterised	 by	 mental	retardation,	developmental	delay,	cardiomyopathies,	as	well	as	musculoskeletal	and	craniofacial	abnormalities.			Costello	 syndrome	 (CS)	 is	 a	 rare	 autosomal	 dominant	 disease	 predominantly	caused	by	germline	HRAS	mutations,	especially	G12S	(Aoki	et	al.,	2008,	Rauen,	2007,	 Tidyman	 and	 Rauen,	 2009).	 Patients	 with	 CS	 are	 predisposed	 to	developing	 tumours,	 such	 as	 bladder	 carcinoma	 or	 ganglioneuroblastoma	(Roberts	et	al.,	2006a).	Noonan	syndrome	(NS),	 in	 turn,	 is	a	common	disorder	(1/2000	births)	 caused	by	 various	 germline	mutations	 in	 the	MAPK	pathway,	where	 Ras	mutations,	 especially	 in	KRAS,	 constitute	 less	 than	 2%	 of	 all	 cases	(Cirstea	 et	 al.,	 2010,	 Roberts	 et	 al.,	 2007,	 Tartaglia	 and	 Gelb,	 2010).	 NS	 is	characterised	 by	 webbed	 neck	 and	 rotated	 ears	 and	 cancer	 is	 uncommon	 in	patients,	 but	 some	 can	 develop	 acute	 lymphoblastic	 leukaemia.	 Scarce	 RAS	mutations	 have	 also	 been	 reported	 in	 cardio-facio-cutaneous	 syndrome	 and	autoimmune	lymphoproliferative	syndrome	(Oliveira	et	al.,	2007,	Tidyman	and	Rauen,	2008). 	
RAS	 mutations	 involved	 in	 NCFC	 syndromes	 affect	 various	 codons	 and	 are	usually	 milder	 than	 those	 found	 in	 cancers	 (Fernandez-Medarde	 and	 Santos,	2011,	 Schubbert	 et	 al.,	 2006,	 Seeburg	 et	 al.,	 1984).	 Mouse	models	 have	 been	developed	 for	many	 of	 these	mutations,	which	 allows	 investigating	molecular	mechanisms	that	lead	to	distinct	phenotypic	changes	in	NCFC	syndromes.			
	
1.2.2		 	 	 Ras	in	cancer	
	Ras	proteins	constitute	a	paradigm	of	cellular	transformation	by	being	some	of	the	 most	 commonly	 mutated	 proto-oncogenes	 in	 human	 cancer	 (Cox	 et	 al.,	2014,	Forbes	et	al.,	2015,	Prior	et	al.,	2012).	Although	HRas,	NRas	and	both	KRas	splice	variants	share	high	sequence	homology	and	many	cellular	functions,	each	
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isoform	presents	 a	distinct	 spectrum	of	mutations	 (Fig.	1.9),	 as	well	 as	 shows	unique	pattern	of	coupling	to	different	cancer	types	(discussed	in	section	5.1.1).			The	most	common	Ras	mutations	found	in	cancers	affect	residues	G12,	G13	and	Q61	 in	 the	 protein	 sequence,	 all	 of	 which	 are	 part	 of	 the	 Ras	 active	 site	 for		intrinsic	GTP	hydrolysis	(Franken	et	al.,	1993,	Gremer	et	al.,	2008,	Krengel	et	al.,	1990,	Pai	et	al.,	1990).	While	HRas	shows	equal	mutation	frequency	of	all	three	codons,	 KRas	 is	most	 often	mutated	 at	 residue	 G12	 and	NRas	 at	 residue	Q61	(Fig.	 1.9)	 (Forbes	 et	 al.,	 2015).	The	 extensively	 studied	G12V	mutation,	which	substitutes	the	glycine	residue	into	a	more	bulky	valine	residue	at	position	12,	is	the	 second	most	 common	Ras	mutation	 across	 all	 human	 cancers	 (over	20%)	and	is	most	prevalent	 in	KRas	(23%	of	all	KRas	mutations,	Fig.	1.9)	(Forbes	et	al.,	 2015,	 Prior	 et	 al.,	 2012).	 	 The	 mutation	 decreases	 the	 intrinsic	 GTPase	activity	 of	 Ras	 to	 around	 10%	 of	 that	 of	 the	 wild	 type,	 as	 well	 reduces	 the	affinity	 of	 GAPs	 (Al-Mulla	 et	 al.,	 1999,	 John	 et	 al.,	 1988).	 This	 causes	 a	constitutively	 active	 GTP-bound	 state	 and	 activation	 of	 Ras,	 resulting	 in	increased	propagation	of	the	signal	to	downstream	effectors.		KRas	mutations	 comprise	 around	 86%	of	 all	 Ras	mutations	 in	 human	 cancer,	while	 HRas	 mutations	 are	 uncommon	 and	 constitute	 around	 3%	 of	 all	 Ras	mutations	 (Forbes	et	 al.,	 2015).	The	disparity	 in	mutation	 frequency,	 residues	that	are	mutated	and	 the	affected	 tissues	of	 cancer	origin	across	Ras	 isoforms	may	 arise	 from	 differences	 in	 isoform	 subcellular	 location	 and	 coupling	 to	downstream	effectors	(Chiu	et	al.,	2002,	Perez	de	Castro	et	al.,	2004,	Roy	et	al.,	2002,	Voice	et	al.,	1999,	Yan	et	al.,	1998).	A	recent	study	also	suggested	that	the	high	mutation	frequency	of	KRas	could	be	the	result	of	 its	 lower	expression	at	protein	level	due	to	the	presence	of	rare	codons	in	its	sequence	(Lampson	et	al.,	2013).	 Strikingly,	 lower	 expression	 of	 a	 Ras	 oncogene	 is	 linked	 to	 cellular	proliferation,	 whereas	 higher	 expression	 leads	 to	 a	 senescent	 phenotype	(Collado	and	Serrano,	2010,	Sarkisian	et	al.,	2007).	This	correlation	means	that	KRas	mutations	may	accumulate	more	readily	due	to	less	cellular	senescence.			
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Fig.	1.9	Mutation	pattern	for	Ras	isoforms	across	all	human	cancers.	HRas,	KRas	 and	 NRas	 mutations	 not	 only	 couple	 to	 different	 cancers,	 but	 also	 the	distribution	 of	 their	 different	mutations	 across	 human	 tumour	 samples	 is	 not	uniform.	 The	 predominant	 mutation	 site	 for	 KRas	 is	 G12	 (82%	 of	 all	 KRas	mutations),	while	for	NRas	it	is	Q61	(61%	of	NRas	mutations).	HRas	mutations	are	 equally	 distributed	 among	 G12,	 G13	 and	 Q61	 residues.	 Among	 all	 Ras	mutations,	 the	 G12	 residue	 is	 the	most	 frequently	mutated.	 The	 data	 used	 to	generate	mutation	distribution	pies	is	based	on	COSMIC	database	(v72)	(Forbes	et	al.,	2015).			
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There	 has	 been	 little	 progress	 in	 the	 development	 of	 anti-Ras	 therapies.	Farnesyltransferase	 inhibitors	 (FTIs)	 that	 target	 post-translational	farnesylation	 of	 Ras	 proteins	 and	 therefore	 their	 membrane	 recruitment,	proved	 largely	unsuccessful	due	 to	alternative	geranylgeranylation	of	Ras	and	off-target	effects	 (Zhu	et	al.,	2003).	 So	 far	 little	advancement	 in	 targeting	Ras-driven	cancers	was	achieved	by	using	anti-Ras	ribozymes	(Kijima	et	al.,	2004)	and	small	interfering	RNA	(siRNA)	(Fleming	et	al.,	2005).	A	recently	developed	treatment	against	activated	Ras	shows	a	more	specific	and	promising	approach	by	 allosterically	 targeting	 KRas	 G12C	 mutation,	 often	 found	 in	 lung	 tumours	(non-small	cell	lung	carcinoma	–	NSCLC)	(Fiala	et	al.,	2013,	Ostrem	et	al.,	2013).	The	inhibitor	disrupts	the	conformational	state	of	Ras	and	blocks	the	interaction	with	downstream	Raf	 effector.	Nevertheless,	 this	 approach	 still	 awaits	 further	validation	 in	vitro	and	 future	clinical	 trials.	More	research	 into	key	differences	between	Ras	mutations,	as	well	as	Ras	isoform-dependent	signalling	is	needed	to	elucidate	specific	mechanisms	as	targets	for	possible	Ras-targeted	therapies.	
		
1.3		 	 Aims	of	this	study		While	 there	 has	 been	 substantial	 research	 into	 Ras	 function	 in	 pathological	context	 of	 cancer,	 still	 little	 is	 known	 about	 Ras	 isoform-specific	 biological	functions	 in	 normal	 non-cancerous	 tissues	 and	during	 development.	 Research	into	normal	physiological	processes	and	endogenous	levels	of	expression	of	Ras	isoforms	 could	 lead	 into	 clues	 in	 answering	 questions	 about	 KRasB	predominance	 in	 the	 regulation	 of	 normal	 mouse	 development	 and	 the	prevalence	 of	 KRas-driven	 tumours.	 Yet,	 there	 is	 no	 single	 study	 that	 would	provide	a	comprehensive	quantitative	method	for	measuring	expression	levels	across	 all	 Ras	 isoforms	 and	 across	 various	 tissue	 types	 throughout	development.	Based	on	this,	the	following	hypothesis	can	be	formulated:		Hypothesis	 1:	 The	 expression	 levels	 can	 explain	 Ras	 isoform	 functional	 non-redundancy	during	development.		
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To	 test	 this	 hypothesis,	 one	 of	 the	 aims	 of	 this	 study	 is	 to	 use	 a	 quantitative	method	 that	 would	 measure	 the	 absolute	 number	 of	 transcripts	 (absolute	quantification)	 of	 all	 Ras	 isoforms	 across	 a	 range	 of	 normal	 mouse	 tissues	throughout	development.	The	early	developmental	 stages	will	be	measured	 in	mouse	ESCs.	This	study	will	provide	the	first	most	complete	comparison	of	the	spatiotemporal	distribution	of	Ras	isoform	expression	in	absolute	copy	number.		Another	aspect	of	Ras	biology,	which	is	not	fully	understood,	is	the	preferential	coupling	of	Ras	 isoforms	 to	 their	downstream	effectors.	 Importantly,	previous	work	 did	 not	 provide	 a	 comprehensive	 analysis	 of	 all	 Ras	 isoforms	 in	 an	endogenous	context	and,	hence	I	would	like	to	test	the	following	hypothesis:		Hypothesis	2:	Endogenous	Ras	isoforms	signal	differently	from	each	other.		Thus,	 the	next	objective	of	 this	project	 is	 to	compare	the	endogenous	 levels	of	Ras	isoform-specific	pathway	activation	using	isogenic	cell	lines.	This	model	will	provide	 the	 first	 comprehensive	 comparison	 of	 Ras	 isoform-dependent	signalling	at	endogenous	levels.			In	summary,	this	project	is	divided	into	three	main	research	areas,	in	which	I:		 1. develop	a	method	for	absolute	quantification	(non	semi-quantitative)	for	measuring	Ras	 isoform	transcript	 levels	based	on	real	 time	polymerase	chain	reaction	(RT-PCR)	(Chapter	3);		 2. measure	and	compare	Ras	isoform	transcript	abundance	in	mouse	ESCs	(Chapter	 4)	 and	 across	 different	 mouse	 tissues	 throughout	 normal	development	by	qRT-PCR	method	developed	earlier	and	also	at	protein	level	by	mass	spectrometry	(MS)	(Chapter	5);		 3. quantitatively	 measure	 Ras	 isoform	 downstream	 signalling	 in	 an	endogenous	 context	 using	 isogenic	 cell	 lines	 and	 Western	 blotting	(Chapter	6).	
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Chapter	2	
Materials	and	Methods	
	
2.1	 	 	 Materials	All	 tissue	 culture	 plasticware	 was	 from	 Corning	 (Corning	 B.V.	 Life	 Sciences,	Fogostraat	12,	1060	LJ	Amsterdam,	 the	Netherlands),	unless	otherwise	stated.	Mouse-specific	 Ras	 plasmids	 (pCR4-TOPO-ERas	 (IMAGE	 ID:	 8734026),	 pCR-Blunt	 II-TOPO-KRas-4A	 (IMAGE	 ID:	 40052024)	 and	 pCMV-SPORT6-KRas4B	(IMAGE	ID:	3158212))	were	purchased	from	Source	BioScience	(William	James	house,	Cowley	Road,	Cambridge,	CB4	0WU,	UK).		
All	chemicals	were	ordered	 from	Sigma	(Sigma-Aldrich	Company	Ltd.,	The	Old	Brickyard,	 New	 Road,	 Gillingham,	 Dorset,	 SP8	 4XT),	 unless	 otherwise	 stated.	Absolute	ethanol	and	methanol	were	obtained	from	the	Chemistry	Department,	University	of	Liverpool.	
In	 this	 work	 the	 following	 laboratory	 equipment	 was	 used:	 benchtop	microcentrifuges:	#022621807,	5417R,	Eppendorf	AG;	#13-100-676,	 accuSpin	Micro	17R,	Fisher	Scientific	and	#5453	000.011,	MiniSpin	plus,	Eppendorf	AG;	Jouan	CR4i	 centrifuge,	Thermo	Electron	Corporation;	 tissue	 culture	 centrifuge	#5804	 000.013,	 5804,	 Eppendorf	 AG;	 thermomixer	 compact,	 Eppendorf	 AG;	microplate	reader	Multiskan	Spectrum	no.	1500,	Thermo	Lab	Systems.	
	
2.2	 	 													Cell	lines	
2.2.1		 	 	 SW48	Ras	isogenic	cell	lines	
The	 SW48	 cell	 line	 was	 originally	 derived	 from	 Duke’s	 type	 C,	 grade	 IV,	colorectal	adenocarcinoma	from	an	82-year-old	female	by	A.	Leibovitz	at	Scott	and	 White	 Clinic,	 Temple,	 Texas,	 USA	 (Leibovitz	 et	 al.,	 1976).	 For	 this	 study	parental	(wild	type	Ras),	HRasG12V	and	KRasG12V	SW48	cell	 lines	(#HD	103-034	 and	 HD	 103-007)	 were	 purchased	 from	 Horizon	 Discovery	 (7100	
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Cambridge	 Research	 Park,	 Waterbeach,	 Cambridge,	 CB25	 9TL,	 UK),	 whereas	NRasG12V	 SW48	 cell	 line	 was	made	 in	 house	 by	 Dr	 Simon	 Oliver	 using	 AAV	technology	(Vasileva	and	Jessberger,	2005),	at	 the	University	of	Liverpool,	UK.	In	all	Ras	isoform	isogenic	cell	lines,	only	one	allele	was	targeted.	
	
2.2.2	 	 	 STO	mouse	fibroblasts			The	 STO	 cell	 line	 was	 originally	 derived	 from	 a	 continuous	 cell	 line	 of	 SIM	(Sandos	 Inbred	Mice)	mouse	embryonic	 fibroblasts	by	A.	Bernstein	at	Ontario	Cancer	Institute,	Toronto,	Canada	(Martin	and	Evans,	1975).	For	this	study	the	cell	line	was	kindly	provided	by	Dr	Patricia	Murray,	University	of	Liverpool,	UK.	
	
	
2.2.3		 	 	 R1	mouse	Embryonic	Stem	Cells	(mESCs)		The	R1	cell	 line	was	originally	derived	 from	 inner	cell	mass	of	a	3.5	day	male	blastocyst	by	crossing	two	mouse	129	substrains	(129S1/SvlmJ	and	129X1/SvJ)	in	1991	by	Andras	Nagy	in	Toronto,	Canada	(Nagy	et	al.,	1993).	For	this	study	the	cell	line	was	kindly	provided	by	Dr	Patricia	Murray,	University	of	Liverpool,	UK.	
 	
2.3		 	 Routine	cell	culture		As	a	part	of	routine	cell	culture,	all	cell	lines	were	verified	by	STR	(short	tandem	repeat)	DNA	profiling	and	were	regularly	 tested	 for	mycoplasma.	All	 cell	 lines	were	cultured	at	37˚C	in	a	humidified	5%	(v/v)	CO2	atmosphere.		
	
	
2.3.1	 	 Routine	SW48	Ras	isogenic	cell	lines	culture		SW48	 cell	 lines	 were	 routinely	 cultured	 in	 McCoy’s	 medium	 (#S6600-021,	Gibco)	 containing	10%	(v/v)	Foetal	Bovine	Serum	(FBS)	 (#10270-106,	Gibco)	and	 1%	 (v/v)	 Penicillin/Streptomycin	 (stock	 10,000	 U/ml	 Pen,	 10,000	 µg/ml	
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Strep,	29.2	mg/ml	L-Glutamine,	#10378-016,	Gibco)	on	10	cm	dishes	and	were	passaged	 after	 achieving	 80%	 confluence.	 First,	 cells	 were	washed	 once	with	0.01M	(1	x)	Phosphate	Buffered	Saline	(PBS)	(#P5493)	and	then	incubated	in	1	ml	of	0.05%	(1	x)	trypsin-EDTA	(#15400-054,	Gibco)	at	37˚C	for	5-10	mins.	The	trypsin	reaction	was	stopped	by	adding	4	ml	of	10%	FBS	McCoy’s	medium	and	cells	were	 typically	 split	 1	 in	3	 to	1	 in	5	 (Table	2.1)	 into	 another	10	 cm	dish.	Typical	seeding	densities,	depending	on	the	plate	used,	are	summarised	in	Table	2.2			
Table	2.1	A	list	of	cell	lines	used	in	this	study	and	splitting	densities.			
Cell	line	 Splitting	ratio	SW48	parental	 1	in	5	SW48	HRasG12V	 1	in	4	SW48	KRasG12V	 1	in	4	SW48	NRasG12V	 1	in	3	STO	mouse	fibroblasts	 1	in	3	R1	mouse	embryonic	stem	cells	 1	in	3			
Table	2.2	Standard	seeding	densities	for	SW48	Ras	isogenic	cell	lines.		
SW48	cell	line	 10	cm	dish	 6-well	plate	 24-well	plate	
Parental	 2.3	x	106	cells	 4.0	x	105	cells/well	 3.5	x	105	cells/well	
HRasG12V	 2.3	x	106	cells	 4.0	x	105	cells/well	 3.5	x	105	cells/well	
KRasG12V	 3.0	x	106	cells	 5.3	x	105	cells/well	 4.64	x	105	cells/well	
NRasG12V	 3.0	x	106	cells	 5.3	x	105	cells/well	 4.64	x	105	cells/well	
RIPA	buffer	(V)	 300	µl	 100	µl	per	well	 20-40	µl	per	well	
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2.3.2	 	 Embryonic	stem	cell	culture				
2.3.2.1	 	 Plate	coating	protocols		To	allow	cell	attachment	of	STOs	and	ESCs,	cell	culture	dishes	were	first	coated	with	sterile	0.1%	(w/v)	gelatin	by	incubation	at	room	temperature	for	10	mins.	7	 ml	 or	 2	 ml	 of	 gelatin	 solution	 was	 added	 to	 10	 cm	 or	 3.5	 cm	 dishes,	respectively.	 Gelatin	 solution	 was	 then	 aspirated	 and	 dishes	 were	 washed	 3	times	for	5	mins	with	warm	1	x	PBS.			For	 the	 suspension	 differentiation	 protocol,	 3.5	 cm	 non-adherent	 petri	 dishes	(Sarsted)	 were	 treated	 with	 2	 ml	 of	 0.01%	 (w/v)	 Pluronic	 F-127	 (#P6867,	Invitrogen)	 in	1	x	PBS	 for	at	 least	15	mins	and	 then	washed	3	 times	with	1	x	PBS.	
 
2.3.2.2	 	 STO	culture	as	a	feeder	layer		STOs	 were	 routinely	 cultured	 in	 Dulbecco’s	 Modified	 Eagle	 medium	 (DMEM)	high	 glucose	 (2500	 mg/L,	 #D6546)	 containing	 10%	 FBS,	 1%	 L-Glutamine	(#25030-081,	Gibco),	0.1	mM	Non	Essential	Amino	Acids	(NEAA)	(#11140-050,	Gibco),	 1%	 Penicillin/	 Streptomycin	 and	 0.01%	 (5	 µM)	 β-mercaptoethanol	(stock	50	mM,	#31350-010	Gibco),	hereafter	referred	to	as	STO	medium	(Table	2.3),	on	gelatin-coated	10	cm	dishes.	When	cells	were	about	90%	confluent,	50	µl	 of	 2	 mg/ml	 mitomycin	 C	 (20	 µg/ml,	 #M4287)	 was	 added	 to	 5	 ml	 of	 STO	medium	 to	 stop	 cell	 proliferation.	 Cells	 were	 washed	 twice	 in	 1	 x	 PBS	 and	incubated	in	5	ml	of	1	x	trypsin	for	5	mins	at	37˚C.	7	ml	of	10%	FBS	DMEM	(stop	medium)	was	added	to	the	cells	to	stop	trypsinisation.	Cells	were	centrifuged	at	200	x	g	 for	3	mins,	 the	medium	was	aspirated	and	12	ml	of	STO	medium	was	added	and	mixed	with	the	cells.	1	ml	of	cells	was	added	to	each	of	the	twelve	3.5	cm	dishes	already	containing	1	ml	of	STO	medium.	STO	cells	were	then	ready	to	be	used	as	a	feeder	layer	for	mESC	culture.				
	 34		
	 35	
2.3.2.3	 	 Routine	ESCs	culture		R1	embryonic	stem	cells	were	cultured	on	a	feeder	layer	of	STOs	(2.3.2.2)	on	3.5	cm	 cell	 culture	 dishes	 using	 the	 following	 protocol	 (Fig.	 2.1	 A,	 derived	 from	(Xiong	et	al.,	1998)).	Cells	were	grown	in	filtered	R1	ESC	medium	(DMEM	high	glucose	 (#D6546)	 containing	 15%	 FBS,	 1%	 L-glutamine,	 0.1	 mM	 NEAA,	 1%	Penicillin/Streptomycin,	 0.01%	 (5	 µM)	 β-mercaptoethanol	 and	 260	 U/ml	leukemia	 inhibitory	 factor	 (LIF)	 (107	 U/ml	 #ESG1107,	 lot	 #JBC1872217,	Chemicon,	 Millipore))	 (Table	 2.3)	 and	 split	 when	 they	 were	 around	 90%	confluent.	 Cells	 were	 trypsinised	 and	 after	 centrifugation	 the	 medium	 was	aspirated	and	 the	cells	were	re-suspended	 in	3	ml	of	R1	ESC	medium.	1	ml	of	cells	was	transferred	to	each	of	the	3	gelatinised	3.5	cm	dishes	with	STO	feeder	layer,	which	already	contained	1	ml	of	R1	ESC	medium.			
2.3.3	 	 Cell	freezing	protocols				To	 freeze	SW48	cell	 lines,	cells	grown	in	75	cm2	 flasks	that	were	at	 least	80%	confluent	were	 first	washed	once	with	1	x	PBS	and	 incubated	 in	1.5	ml	of	1	x	trypsin/EDTA	for	5-10	mins	at	37˚C.	 	8.5	ml	of	10%	FBS	McCoy’s	medium	was	added	to	stop	the	reaction	and	the	cells	were	centrifuged	at	200	x	g	for	5	mins.	The	 medium	 was	 aspirated	 and	 4	 ml	 of	 freezing	 medium	 (50%	 FBS,	 45%	McCoy’s	 medium,	 5%	 dimethyl	 sulfoxide	 (DMSO	 #sc-358801,	 Santa	 Cruz	Biotechnology))	was	added	to	the	cells	and	mixed	gently.	1	ml	of	the	cells	was	then	transferred	into	cryovials	(#BR114840).	To	 freeze	R1	ESCs,	 cells	 grown	on	a	 feeder	 layer	on	3.5	 cm	gelatinised	dishes	that	were	at	least	90%	confluent	were	washed	twice	with	1	x	PBS	and	incubated	in	 1.5	ml	 of	 1	 x	 trypsin/EDTA	 for	 3-5	mins	 at	 37˚C.	 To	 terminate	 the	 trypsin	reaction,	 2	ml	 of	 stop	medium	was	 added	 to	 the	dish	 and	 the	 cells	were	 then	transferred	 to	 15	ml	 Falcon	 tubes	 already	 containing	 2	ml	 stop	medium.	 The	cells	were	centrifuged	at	200	x	g	for	3	mins	and	the	medium	was	aspirated.	The	cells	 were	 re-suspended	 in	 3	 ml	 of	 RecoveryTM	 Cell	 Culture	 Freezing		
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Fig.	 2.1	 Schematic	 illustrations	 of	 cell	 culture	 conditions	 for	
undifferentiated	and	differentiating	R1	mouse	embryonic	stem	cells	ESCs.	
A	 Undifferentiated	 ESCs	 culture	 on	 STO	 feeder	 layer.	 STO	 mouse	 fibroblasts	were	cultured	on	a	gelatin-coated	dish	and,	when	confluent,	 their	growth	was	inhibited	with	mitomycin	C.	R1	ESCs	were	 then	seeded	onto	STO	 feeder	 layer.			
B	Separation	of	ESCs	from	feeder	layer	for	embryoid	body	(EB)	differentiation	protocol.	ESCs	cultured	on	STO	feeder	layer	were	passaged	onto	gelatinised	dish	in	R1	medium	several	times	to	deplete	STOs	(1).	ESCs	were	passaged	in	R1/EB	medium	to	deplete	the	remaining	STOs	(2).	ESCs	were	seeded	onto	Pluronic	F-127-coated	Petri	dish	in	EB	medium	to	initiate	cell	differentiation	(3).		
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Medium	 (#12648-010,	 Gibco)	 and	 1	 ml	 transferred	 into	 individual	 cryovials	(#BR114840).	
	Cryovials	 for	 all	 cell	 lines	 were	 placed	 into	 a	 freezing	 chamber	 containing	isopropanol	and	left	in	-80˚C	freezer	overnight	to	allow	slow	freezing	by	1˚C	per	hour.	The	next	day,	cells	were	transferred	into	a	 liquid	nitrogen	tank	for	 long-term	storage.		
2.3.4	 	 Cell	thawing	protocols			All	cell	 lines	were	first	thawed	in	a	water	bath	at	37˚C.	SW48	Ras	isogenic	cell	lines	 were	 gently	 mixed	 by	 pipetting	 and	 then	 transferred	 to	 25	 cm2	 flasks	containing	9	ml	of	10%	FBS	McCoy	medium.	Once	thawed,	1	ml	of	stop	medium	was	 added.	 Cells	 were	 gently	 mixed,	 transferred	 to	 15	 ml	 Falcon	 tubes	containing	 3	ml	 stop	medium	 and	 centrifuged	 at	 200	 x	 g	 for	 3	mins	 and	 the	medium	 was	 aspirated.	 For	 STO	 cells,	 10	 ml	 of	 STO	 medium	 was	 added	 for	subsequent	routine	cell	culture	on	10	cm	gelatinised	tissue	culture	dishes.	For	R1	mESCs,	2	ml	of	R1	ESC	medium	was	added,	mixed	and	pipetted	gently	onto	3.5	cm	tissue	culture	dish	with	STO	feeder	layer,	from	which	STO	medium	was	aspirated.	
	
	
2.3.5	 	 Cell	counting			Cells	 were	 trypsinised	 and	 transferred	 to	 15	 ml	 Falcon	 tubes.	 10	 µl	 of	 cell	suspension	 was	 pipetted	 onto	 a	 Hausser	 Scientific	 haemocytometer	 and	 cells	were	 observed	 under	 the	 microscope	 (Leica	 DM	 IL	 Microsystems	 Type	 090-135.001)	using	10	x	objective	lens.	Viable	cells	that	appeared	round	and	healthy	were	counted	in	four	squares	and	the	average	number	of	cells	was	multiplied	by	a	chamber	factor	of	104,	which	gave	the	cell	number	per	1	ml	of	cell	suspension.	The	required	number	of	cells	was	then	calculated	and	diluted	in	the	appropriate	amount	of	medium	for	seeding.		
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2.3.6	 	 Separation	of	R1	ESCs	from	STO	feeder	layer		To	extract	RNA	and	protein	from	undifferentiated	R1	ESCs,	these	cells	had	to	be	first	 separated	 from	 the	 STO	 feeder	 layer.	 In	 order	 to	 do	 this,	 cells	were	 first	trypsinised	as	described	before	 (section	2.3.2.3).	After	 the	centrifugation	step,	the	medium	was	 aspirated	 and	 the	 cells	were	 re-suspended	 in	5ml	 of	R1	ESC	medium,	and	then	transferred	onto	gelatinised	10	cm	dishes	containing	5	ml	of	R1	ESC	medium.	The	dish	was	left	at	37˚C	for	at	least	20	mins	to	allow	STOs	to	attach	to	the	plate.	As	the	rate	of	attachment	to	the	gelatinised	plate	is	faster	for	STOs	than	R1	ESCs,	separation	of	the	two	cell	lines	was	possible.	The	cells	were	observed	under	the	microscope	to	see	whether	STO	attachment	to	the	plate	was	complete.	10	ml	of	the	R1	ESCs	suspension	in	the	medium	was	then	transferred	to	a	Falcon	 tube	and	centrifuged	at	200	x	g	 for	3	mins.	Cells	were	 then	either	counted	 using	 a	 haemocytometer	 (section	 2.3.5)	 and	 split	 onto	 a	 gelatinised	dish	 for	 imaging,	 or	 re-suspended	 in	 RNA	 lysis	 buffer	 for	 RNA	 and	 protein	extraction	(section	2.7.8	and	2.8.2).		 	 	 	 	 	 	
	
2.4	 	 Suspension	differentiation	protocols		R1	mESCs	were	grown	in	suspension	to	form	embryoid	bodies	(EB)	as	a	model	to	 study	 cell	 differentiation,	 according	 to	 an	 established	 protocol	 (Fig.	 2.1	 B,	derived	from	(Murray	and	Edgar,	2000,	Rak-Raszewska	et	al.,	2012)).	First,	cells	were	cultured	on	an	STO	 feeder	 layer	on	3.5	cm	dishes	 in	R1	ESC	medium,	as	described	in	section	2.3.2.3,	and	then	passaged	several	times	onto	gelatinised	6	cm	dishes	without	the	feeder	 layer	 in	5	ml	of	R1	ESC	medium	to	deplete	STOs	from	 the	 culture.	When	 cells	were	90%	confluent,	 they	were	 split	 1	 in	6	onto	gelatinised	6	cm	dishes	(Thermo	Scientific,	NuncTM)	in	5	ml	of	R1	ESC	medium	for	endoderm	differentiation	or	in	5	ml	of	MESO	ESC/EB	medium	(10%	FBS,	1%	L-glutamine,	 1%	 Penicillin/Streptomycin,	 0.15%	 monothioglycerol	 (MTG,	100mM	stock,	#M6145),	 1,000	U/ml	 LIF	 in	 IMDM	 (#13390,	 Iscove’s	modified	Dulbecco’s	 medium))	 for	 mesoderm	 differentiation	 (ESC/EB	 medium,	 Table	2.3).	 When	 the	 cells	 achieved	 90%	 confluence,	 they	 were	 trypsinised	 and	counted	for	seeding	on	Pluronic	F-127-coated	dishes	(section	2.3.2.1).		
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For	endoderm	differentiation,	50,000	cell/ml	were	seeded	onto	the	Pluronic	F-127-treated	dishes	 in	2	ml	of	ENDO	EB	medium	(R1	ESC	medium	without	LIF,	Table	2.3).	For	mesoderm	differentiation,	30,000	cells/ml	were	seeded	onto	the	dishes	in	2	ml	of	MESO	EB	medium	(15%	FBS,	1%	L-glutamine,	0.45%	MTG,	1%	ITS	 (insulin	 transferrin	 selenium,	 #25-800-CI,	 Mediatech),	 1%	 Penicillin/	Streptomycin,	 0.1%	 ascorbic	 acid	 (500mM	 stock)	 in	 IMDM,	 Table	 2.3).	 The	embryoid	bodies	that	started	to	form	were	cultured	for	a	maximum	of	20	days	and	the	EB	media	were	changed	every	2	days.				
2.5		 								Phenotypic	assays		
2.5.1	 	 Microscopy		To	take	bright-field	images,	SW48	cells	were	placed	in	a	chamber	at	37	˚C	and	viewed	 under	 Nikon	 Ti-E	 microscope	 using	 a	 20	 x	 objective	 lens.	 STOs,	undifferentiated	 R1	 ESCs	 and	 embryoid	 bodies	 were	 viewed	 under	 a	 Leica	DFC420C	microscope	using	10	x	 and	20	x	objective	 lenses	 to	 take	bright-field	images.	
	
	
2.5.2		 	 	 Cell	viability	assay		CellTiter-Glo®	Luminescent	 Cell	 Viability	Assay	 (#G7571,	 Promega)	was	used	according	to	manufacturer’s	instructions	to	measure	cell	viability	by	quantifying	the	 amount	of	ATP	produced	by	metabolically	 active	 cells.	 SW48	Ras	 isogenic	cell	lines	were	seeded	in	5	technical	replicates	at	specified	densities	(250-5000	cells/well)	onto	96-well	plates	and	cultured	in	10%	FBS	McCoy’s	medium	for	1-5	 days.	 As	 a	 control	 for	 background	 luminescence,	 5	wells	 contained	medium	only.	Before	the	assay,	cells	were	taken	out	of	the	incubator	and	equilibrated	at	room	 temperature	 for	 30	 mins.	 100	 µl	 of	 CellTiter-Glo®	 Reagent	 (CellTiter-Glo®	Buffer	mixed	with	CellTiter-Glo®	Substrate)	was	then	added	per	well	and	the	 plate	 was	 shaken	 at	 250	 rpm	 on	 an	 orbital	 plate	 shaker	 (Rotamax	 120,	Heidolph)	 for	 2	 mins	 to	 induce	 cell	 lysis	 and	 left	 at	 room	 temperature	 for	 a	
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further	 10	 mins	 away	 from	 the	 light	 to	 stabilise	 the	 luminescent	 signal.	Luminescence	 was	 recorded	 using	 a	 GloMAX®-Multi+	 Microplate	 Multimode	Reader	with	 Instinct®	 software	 (Promega)	with	 integration	 time	 of	 1	 sec	 per	well.	 The	 background	 luminescence	 of	 control	 wells	 with	 media	 only	 was	subtracted	from	the	raw	data.		
	
	
	
2.5.3		 	 	 Growth	factor	and	inhibitor	assays		SW48	 cell	 lines	 were	 seeded	 on	 10	 cm	 dishes	 or	 6-	 or	 24-well	 plates	 using	appropriate	 seeding	 densities	 (Table	 2.2).	 Once	 cells	 achieved	 70-80%	confluence	 (after	 1-3	 days),	 they	 were	 serum-starved	 for	 24	 hours	 (0%	 FBS	media)	and	treated	with	varying	concentrations	of	inhibitors	or	with	DMSO	as	a	control	for	the	indicated	length	of	time	(1	hour	up	to	16	hours).	The	following	inhibitors	were	used	 in	 this	study	(Table	2.4):	AZD6244	(selumetinib)	(#6061	43-52-6/S1008,	Selleck,	Lot	#S100823),	Sorafenib	(#S-8502,	LC	Labs;	Lot	#BSF-106),	LY294002	(#BML-ST420-0005,	Enzo	Life	Sciences),	Rapamycin	(#S1039,	Selleck,	Lot	#S103908)	and	AZ628	(#4836,	Tocris).	Following	serum-starvation,	cells	were	stimulated	with	specific	growth	factors	or	20%	FBS	in	media	that	also	contained	the	 inhibitor,	where	appropriate,	at	37˚C	typically	 for	either	5	or	20	mins.	 The	 following	 growth	 factors	were	 used	 at	 varying	 concentrations:	 EGF	(#AF-100-15,	 Preprotech),	 HGF	 (#100-39,	 Preprotech,	 Lot	 #0410S201-3)	 and	IGF-1	 (#100-11,	 Preprotech,	 Lot	 #11201).	 After	 stimulation,	 cells	 were	 lysed	(section	2.8.1)	or	visualised	(section	2.5.1).		
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Table	2.4	Inhibitors	used	in	this	study	with	the	corresponding	cellular	
targets	and	IC50	values.		
	
Inhibitor	 Target	 IC50	 Reference	AZD6244	 MEK1	ERK1/2	 14	nM	10	nM	 (Garon	et	al.,	2010,	Huynh	et	al.,	2007)	
Sorafenib	 c-Raf-1	BRAF	(wt)	BRAFV600E	
6	nM	22	nM	38	nM	 (Wilhelm	et	al.,	2004)	LY294002	 PI(3)K	Pim-1	kinase	 1.4	uM	4.0	uM	 (Mena	et	al.,	2014,	Wu	et	al.,	2014)	Rapamycin	 mTOR	 ~0.1	nM	 (Edwards	and	Wandless,	2007)	
	
	
2.6		 			 	 Preparation	of	murine	tissues		
2.6.1	 		 	 Organ	dissection	and	tissue	harvesting	Adult	CD1	mice	(Charles	River)	were	sacrificed	by	increasing	CO2	concentration	in	CO2	chamber	and	by	cervical	dislocation	as	stated	in	Schedule	1	procedure	of	Home	Office	Regulations.	Mouse	embryos	were	dissected	from	time-mated	mice	at	 embryonic	 days	 (E)	 11.5,	 13.5	 and	 16.5.	 First,	 the	 uterine	 horns	 were	removed	from	mothers	at	room	temperature	and	then	placed	in	ice	cold	1x	PBS	(Invitrogen).	 Next,	 embryos	 were	 removed	 from	 extraembryonic	 membranes	and	decapitated	according	to	Schedule	1	procedure	of	Home	Office	Regulations.	Organs	 were	 dissected	 using	 a	 stereoscopic	 microscope	 (Leica	 MZ6)	 starting	from	the	 limbs/skeletal	muscle,	 the	heart	and	 the	 lungs,	 followed	by	 the	 liver,	stomach,	intestine,	kidney	rudiments/kidney	and	finally	the	brain.	Neonates	at	postnatal	 days	 (P)	 0,	 5,	 10,	 15,	 20,	 25	 and	 30,	 as	 well	 as	 adult	 mice,	 were	sacrificed	and	dissected	accordingly.	Dissected	organs	and	tissues	were	placed	in	1.5	ml	microcentrifuge	tubes	(#3621,	CostarTM),	 immediately	snap-frozen	in	liquid	nitrogen	and	stored	at	-80	˚C	before	tissue	homogenisation.	
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2.6.2		 	 	 Tissue	homogenisation	Frozen	mouse	 tissues	were	placed	 in	1.5	ml	microcentrifuge	 tubes	on	dry	 ice.	Small	pieces	of	 tissue	were	cut	with	a	curved	surgical	blade	(Sterile	Blade	No.	12,	 Swann-Morton),	 transferred	 to	 pre-weighed	 2	 ml	 tubes	 (#UC-13119-500,	Cambio)	 containing	 6	 x	 2.8	 mm	 ceramic	 beads	 (#13114-325,	 Cambio)	 and	weighed	 on	milligram	 digital	 balance	 (AVI14C	 Adventurer®	 Pro,	 OHAUS).	 For	RNA	 extraction,	 300	 µl	 of	 RNA	 Lysis	 Buffer	 (#17215,	 Lot	 #582484,	 Norgen	Biotek	 Corp;	 XI-0718	 Geneflow)	 containing	 1%	 (v/v)	 β-mercaptoethanol	 was	added	 per	 10	 mg	 of	 tissue	 and	 the	 tissues	 were	 homogenised	 using	 a	PowerLyzer®	24	 (#13155,	MO	BIO	Laboratories)	 using	 the	 following	protocol	(based	on	manufacturer’s	recommended	settings	for	RNA	isolation	from	animal	tissues):	 3,500	 rpm	 (~5.7	m/sec),	 2	 x	 45	 sec.,	 30	 sec.	 dwell	 time.	 For	 protein	extraction,	 100	 µl	 of	 RIPA	 buffer	 (10	mM	 TrisHCl	 pH	 7.5,	 150	mM	 NaCl,	 1%	(w/v)	 Triton-X,	 0.1%	 (w/v)	 SDS,	 1%	 (w/v)	 sodium	 deoxycalate)	 containing	mammalian	 Protease	 Inhibitor	 Cocktail	 (#P8340)	 was	 used	 per	 10	 mg	 of	tissues.	 The	 lysates	 were	 transferred	 to	 RNase-free	 microcentrifuge	 tubes	(#3621,	Costar)	 and	 centrifuged	 for	2	minutes	at	18,000	x	g	 to	pellet	 any	 cell	debris.	 600	 µl	 of	 the	 supernatant	 was	 transferred	 to	 fresh	 microcentrifuge	tubes,	snap	frozen	in	liquid	nitrogen	and	stored	at	-80˚C	before	RNA	and	protein	extraction	(section	2.7.8	and	2.8.2).	
	
2.7		 	 	 Molecular	Biology	
2.7.1		 Agarose	gel	electrophoresis	Agarose	 gel	 electrophoresis	 was	 run	 to	 check	 the	 size	 of	 DNA	 products	amplified	 in	 PCR	 reactions	 (section	 2.7.11)	 and	 restriction	 digests	 (section	2.7.7),	and	to	check	the	quality	of	RNA	samples	(section	2.7.8).	1.2	–	2%	agarose	gels	 were	 made	 by	 boiling	 agarose	 powder	 (#161-3101EDU,	 Bio-Rad)	 in	 1	 x	TBE	 (Tris/Borate/EDTA)	 buffer	 (89	 mM	 Tris-borate,	 2	 mM	 EDTA,	 pH	 8.3,	#T3913)	 and	 adding	 ethidium	 bromide	 to	 a	 final	 concentration	 of	 0.5	 µg/ml.	Gels	were	set	in	gel	tanks	(Bio-Rad)	and	1	x	TBE	running	buffer	was	added.	The	DNA	or	RNA	samples	were	prepared	 in	1	x	sample	buffer	 (0.5%	w/v	glycerol,	
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0.01	mM	EDTA,	0.004%	bromophenol	blue)	 and	electrophoresed	at	120	V	 for	1.5	–	2	hours,	along	with	HyperLadder	IV	(#BIO-33029,	Bioline),	HyperLadder	VI	(#BIO-33033,	Bioline)	or	MassRuler	(#SM0403,	Life	Technologies)	molecular	weight	markers.	DNA	and	RNA	bands	were	visualised	by	ultraviolet	light	using	GeneFlash	 gel	 documentation	 system	 (Syngene).	 For	 RNA	 samples,	 all	 buffers	and	 solutions	 were	 made	 in	 nuclease-free	 water	 treated	 with	 diethyl	pyrocarbonate	(DEPC)	and	all	equipment	was	treated	with	RNaseZAP	(#R2020)	before	use.		
	
2.7.2	 Gel	extraction	of	DNA	fragments	Following	agarose	gel	electrophoresis,	appropriate	DNA	fragments	were	excised	and	weighed	on	a	milligram	digital	balance	(AVI14C	AdventureTM	Pro,	OHAUS).	DNA	was	extracted	using	QIAquick	gel	extraction	kit	 (#28704,	QIAGEN)	and	a	microcentrifuge,	 according	 to	manufacturer’s	 instructions.	Briefly,	 one	volume	of	 agarose	 gel	 was	 dissolved	 in	 3	 volumes	 of	 Buffer	 QG	 at	 50°C,	 and	 one	 gel	volume	of	isopropanol	was	added	and	mixed.	The	sample	was	then	added	onto	the	QIAquick	column	and	centrifuged	for	1	min	at	10,000	x	g	to	bind	DNA.	The	column	was	washed	with	0.75	ml	Buffer	PE	and	the	extracted	DNA	was	eluted	in	a	 final	 volume	 of	 30	 µl	 of	 Elution	 Buffer	 (10	 mM	 Tris-Cl,	 pH	 8.5).	 DNA	concentrations	 were	 determined	 using	 a	 NanoDrop	 Spectrophotometer	 ND-1000	(Thermo	Scientific)	based	on	absorbance	at	a	wavelength	of	260	nm.	The	eluted	DNA	fragments	were	subsequently	used	for	subcloning	(section	2.7.3)	or	were	 sent	 for	 sequencing	 to	 DNA	 Sequencing	 &	 Services	 (MRC	PPU	MSI/WTB/JBC	 Complex,	 College	 of	 Life	 Sciences,	 University	 of	 Dundee,	Dundee,	Scotland,	DD1	5EH,	UK).	
	
2.7.3		 TOPO	cloning	Gel-purified	 DNA	 fragments	 were	 subcloned	 into	 pCR4®Blunt-TOPO	 vector	using	TOPO	technology	(Invitrogen).	A	typical	TOPO	ligation	mixture	is	detailed	in	Table	2.5.	The	reaction	was	 left	at	 room	temperature	 (RT)	 for	15	mins	and	then	put	on	ice	just	before	bacterial	transformation	(secton	2.7.4).	
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Table	2.5	TOPO-cloning	reaction	mixture.		
Reagent	 Volume	pCR4®Blunt-TOPO	vector	(10	ng/µl)	 1	µl	Salt	solution	(200	mM	NaCl,	10	mM	MgCl2)	 1	µl	Extracted	PCR	product	(~10	ng)	 4	µl	Total	 6	µl	
		
2.7.4	 	 	 Bacterial	transformation	50	 µl	 of	 TOP10	 chemically	 competent	E.	 coli	 cells	 (#C4040,	 Invitrogen)	 were	thawed	on	 ice	 and	briefly	 spun	down	 to	 collect	 the	 cells	 at	 the	 bottom	of	 the	tube.	6	µl	of	TOPO	ligation	reaction	(section	2.7.3)	was	added	to	the	cells,	which	were	then	left	on	ice	for	20	mins.	To	transform	the	cells,	the	bacteria	were	heat-shocked	at	42˚C	 for	60	sec	and	 then	 left	on	 ice	 for	about	2	minutes.	200	µl	of	Lysogeny	 broth	 (LB)	 (1%	 (w/v)	 tryptone,	 0.5%	 (w/v)	 yeast	 extract,	 170	mM	NaCl)	was	added	to	the	cells,	which	were	then	incubated	at	37˚C	for	50-60	mins	in	a	thermoshaker	at	180	rpm.	After	incubation,	the	cell	suspension	was	spread	onto	 LB/agar	 plates	 with	 appropriate	 antibiotic	 (100	 µg/ml	 Ampicillin	 or	 50	µg/ml	Kanamycin),	which	were	left	to	dry	for	about	10	mins	and	then	inverted	and	incubated	at	37˚C	overnight.	
The	next	day	single	bacterial	colonies	were	picked	and	inoculated	into	5-8	ml	LB	with	 the	 appropriate	 antibiotic.	 The	 bacterial	 cultures	 were	 grown	 overnight	and	 the	 following	day	 the	DNA	was	purified	by	QIAGEN	MiniPrep	Kit	 (section	2.7.6).		
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2.7.5	 	 	 Glycerol	stock	To	make	glycerol	stocks,	800	µl	of	overnight	bacterial	culture,	which	was	grown	from	a	single	bacterial	colony,	was	gently	mixed	with	200	µl	of	sterile	glycerol	and	left	on	ice	for	30mins.	Glycerol	stocks	were	then	stored	at	-80˚C.	
	
2.7.6	 	 	 Plasmid	preparation	(miniprep)	5	ml	 of	 overnight	 LB	 culture	 from	 a	 single	 bacterial	 colony	was	 pelleted	 and	used	 for	 plasmid	 preparation	 using	 QIAprep	 Spin	 Miniprep	 Kit	 (#27104,	QIAGEN)	 and	 a	 microcentrifuge	 according	 to	 manufacturer’s	 instructions.	Briefly,	the	bacterial	pellet	was	resuspended	in	250	µl	Buffer	P1	and	mixed	first	with	250	µl	Buffer	P2	and	then	with	350	µl	Buffer	N3	in	a	microcentrifuge	tube.	The	sample	was	centrifuged	for	10	min	at	17,900	x	g	and	the	supernatant	was	transferred	onto	QIAprep	spin	column	and	centrifuged	for	1	min	to	bind	DNA.	The	column	was	washed	with	0.75	ml	Buffer	PE	and	the	purified	plasmid	DNA	was	eluted	in	a	final	volume	of	40	µl	of	Elution	Buffer	(10	mM	Tris-Cl,	pH	8.5).	DNA	 concentration	 was	 checked	 using	 a	 NanoDrop,	 as	 described	 in	 section	2.7.2.	
	
2.7.7	 Restriction	digestion		Restriction	 digests	 were	 set	 up	 to	 screen	 for	 correct	 inserts	 of	 TOPO	 cloning	(section	2.7.3)	and	to	make	linearised	plasmid	standards	for	qRT-PCR	(section	2.7.12).	 Typically,	 1-2	 µg	 of	 plasmid	 DNA	 was	 used	 per	 restriction	 digest	reaction	 and	 an	 appropriate	 restriction	 enzyme	was	 chosen	 together	with	 its	incubation	 buffer	 (NEB,	 New	 England	 Biolabs,	 	75-77	 Knowl	 Piece,	 	Wilbury	Way,		Hitchin,		Herts	SG4	0TY).	A	typical	restriction	digest	reaction	is	shown	in	Table	2.6	and	all	restriction	enzymes	used	in	this	study	are	listed	in	Table	2.7.	The	restriction	digestion	reactions	were	incubated	at	37˚C	for	2	hours	and	the	digest	products	were	analysed	on	1.2%	agarose	gels.	
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Table	2.6	Restriction	digest	reaction	mixture.		
Reagent	 Volume/amount	Restriction	enzyme	 1	µl	10	x	NEB	buffer	 2	µl	10	x	BSA	(if	required)	 2	µl	DNA	 1-2	µg	(~15	µl)	water	 up	to	20	µl	Total	 20	µl	
	
Table	2.7	List	of	restriction	enzymes	used	for	restriction	digestion.		
Restriction	enzyme	 NEB	buffer	used	
BglII	 NEB3	
EcoRI	 NEB4	
NcoI	 NEB3	
XcmI	 NEB2	
XhoI	 NEB3	+	BSA	
		
2.7.8		 	 	 RNA	extraction	and	purification	Total	 RNA	 was	 extracted	 from	 tissues	 or	 cell	 lysates	 using	 an	 RNA/Protein	Purification	Kit	in	a	96-well	format	(#37900,	Norgen;	Geneflow	code:	P4-0085,	cat	 #582782)	 or	 columns	 (#23000,	 Norgen;	 Geneflow	 lot	 no	 #581790),	 by	 a	centrifugation	procedure	according	to	the	manufacturer’s	instructions.	In	short,	the	protocol	was	as	 follows:	600	µl	of	 tissue	 lysate	(section	2.6.2)	or	350	µl	of	cultured	cell	lysate	was	combined	with	an	equal	volume	of	70%	ethanol	or	with	150	µl	of	isopropanol	(#I9516),	respectively,	and	vortexed	for	10	seconds.	Next,	this	mix	was	applied	onto	 the	 column,	600	µl	 at	 a	 time,	 and	 centrifuged	 for	1	min	at	14,000	x	g.	The	flow-through	was	retained	for	protein	extraction.	400	µl	of	 Nucleic	 Acid	Wash	 Solution	was	 applied	 per	 column	 and	 centrifuged	 for	 1	
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min.	 To	 eliminate	 genomic	 DNA	 contamination,	 100	 µl	 of	 Enzyme	 Incubation	Buffer	(40	mM	Tris-HCl,	pH	8.0,	10	mM	MgSO4,	1	mM	CaCl2)	mix	containing	25	U	of	 DNase	 I	 (RQ1	 RNase-Free	 DNase	 #M6101,	 Promega)	 was	 added	 to	 the	column	and	centrifuged	for	1	min.	To	ensure	maximum	DNA	removal	and	RNA	yield,	the	flow	through	was	re-applied	to	the	column	and	incubated	at	RT	for	15	mins	before	washing	the	column	with	400	µl	of	Nucleic	Acid	Wash	Solution	and	drying	 for	 2	mins	 at	 14,000	 x	 g.	 	 The	 column	was	 placed	 into	 a	 fresh	 1.7	ml	elution	 tube	 and	 RNA	 was	 eluted	 by	 adding	 50	 µl	 of	 Nucleic	 Acid	 Elution	Solution	and	centrifuging	for	2	mins	at	200	x	g,	followed	by	1	min	at	14,000	x	g.	The	columns	were	retained	for	the	protein	purification	step	(section	2.8.2)	and	eluted	RNA	was	stored	at	-80˚C.		
For	the	96-well	format,	300	µl	of	tissue	lysate	(section	2.6.2)	was	combined	with	120	 µl	 of	 isopropanol,	 mixed	 and	 applied	 onto	 the	 well.	 The	 plate	 was	centrifuged	 for	 2	 mins	 at	 3,000	 x	 g	 and	 the	 flow	 through	 was	 retained	 for	protein	 purification	 (section	 2.8.2).	 400	 µl	 of	Nucleic	Acid	Wash	 Solution	was	applied	per	well	and	centrifuged	for	2	mins.	75	µl	of	RQ1	DNase	Reaction	Buffer	mix	containing	18.75	U	of	DNase	 I	was	added	per	well,	centrifuged	 for	30	sec,	pipetted	back	onto	the	wells	and	incubated	for	15	mins.	The	wells	were	washed	twice	with	400	µl	of	Nucleic	Acid	Wash	Solution	and	dried	for	5	mins	at	3,000	x	g.	 	The	96-well	filter	plate	was	placed	on	top	of	the	Elution	Plate	and	RNA	was	eluted	by	adding	75	µl	 of	Nucleic	Acid	Elution	Solution	and	 centrifuging	 for	2	mins.	at	3,000	x	g.	The	96-well	filter	plate	was	retained	for	protein	purification	and	RNA	was	stored	at	-80˚C.	
RNA	 integrity	 was	 assessed	 by	 running	 agarose	 gel	 electrophoresis	 (section	2.7.1).	 The	presence	of	 two	distinct	 bands	of	 28S	 and	18S	 rRNA	 subunits	 and	lack	 of	 smears	 indicated	 intact	 RNA.	 RNA	 concentration	 was	 determined	 by	measuring	 absorbance	 at	 260nm	 using	 a	 NonaDrop,	 as	 described	 for	 DNA	 in	section	2.7.2.	In	addition,	RNA	quality	was	determined	from	the	260nm/280nm	and	and	260nm/280nm	ratios,	which	respectively	indicate	protein	or	chemical	contamination.	
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2.7.9	 	 	 Reverse	transcription	(RT)	Extracted	mRNA	was	reverse	transcribed.	Either	0.5	µg	or	1	µg	of	RNA	was	used	as	 a	 template	 for	 cDNA	 synthesis	 and	 in	 a	 parallel	 “-RT”	 control	 reaction,	 to	which	 no	 reverse	 transcriptase	 enzyme	 was	 added.	 The	 volume	 of	 RNA	 was	adjusted	 to	 10	 µl	with	 nuclease-free	water	 (#W4502)	 and	 1	 µl	 of	 Oligo(dT)15	Primer	 (500	 µg/ml,	 #C1101,	 Promega)	 was	 added,	 which	 hybridises	 to	 the	poly(A)	tail	of	mRNA.	The	reaction	mixture	was	incubated	at	70˚C	for	5	minutes,	then	snap-cooled	on	ice	and	8	µl	of	the	RT	buffer	mixture	(Table	2.8)	was	added.	The	 reactions	were	 incubated	 at	 37˚C	whilst	 adding	 1	 µl	 of	M-MuLV	 Reverse	Transcriptase	 (200U,	 #EPO451,	 Thermo	 Fisher	 Scientific).	 No	 reverse	transcriptase	 was	 added	 to	 the	 negative	 “-RT”	 tubes.	 All	 reactions	 were	incubated	at	42˚C	for	1	hour	and	then	at	70˚C	for	10	mins	to	heat	inactivate	the	reverse	 transcriptase.	 cDNA	and	 “-RT”	 samples	were	 snap-cooled	 on	 ice	 for	 5	mins,	diluted	5	x	with	80	µl	of	nuclease-free	water	to	the	final	volume	of	100	µl	and	stored	at	-20˚C.	
	
Table	2.8	Reverse	transcription	buffer	mixture.	
	 5	x	Reverse	Transcription	Buffer	(MBI-Fermentas)		 4	µl	PCR	Nucleotide	Mix,	10mM	(#C1145,	Promega)	 2	µl	RNasin(R)	Plus	RNase	Inhibitor	(#N2615,	Promega)	 0.5	µl	Nuclease-free	deionised	water	 1.5	µl	Total	volume	 8	µl					
2.7.10		 	 PCR	primers	Primer	 sequences	 were	 individually	 designed	 to	 amplify	 the	 different	 Ras	isoform	transcripts	(Chapter	3)	and	were	ordered	from	Eurofins	MWG	Operon	in	an	amount	of	0.025	µmol.	Primers	were	dissolved	in	nuclease-free	water	up	to	 a	 stock	 concentration	 of	 100	 µM	 and	 stored	 at	 -20˚C.	 For	 working	concentrations,	primers	were	 further	diluted	to	20	µM	or	10	µM.	Details	of	all	
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PCR	primer	sequences	used	in	this	study	are	shown	in	Table	2.9.	The	amplified	PCR	products	were	sequence	verified	 in	both	directions	by	DNA	Sequencing	&	Services	(Dundee)	using	M13	primers	(Table	2.10).	
	
Table	2.9	Primer	sequences	used	for	end-point	PCR	and	quantitative	real	
time	(qRT)	PCR.		 Primer	pair	name	 Primer	sequences	 Amplicon	size	ERas	 F:	5’	GGTCAGATCCGCCTACTGCC	3’	 230	bp	R:	5’	CACCACCACTGCCTTGTACTCG	3’	HRas	 F:	5’	GCTGTAGAAGCTATGACAGAATAC	3’	 188	bp	R:	5’	GCTGTGTCTAAGATGTCCAGTAG	3’	KRas-4A	 F:	5’	AGATGTGCCTATGGTCCTGGTAG	3’	 184	bp	R:	5’	CAATCTGTACTGTCGGATCTCTCTC	3’	KRas-4B	 F:	5’	GATGTGCCTATGGTCCTGGTAG	3’	 142	bp	R:	5’	CATCGTCAACACCCTGTCTTG	3’	NRas	 F:	5’	CAAGGACAGTTGACACAAAGC	3’	 213	bp	R:	5’	TGTCTTACTACATCAGCACACAG	3’	POL2RE	 F:	5’	CCGGAAGCTTACCATGGAAC	3’	 278	bp	R:	5’	TGTCTGTCTGAGGTAAGTGC	3’	18SrRNA	 F:	5’	TTGACGGAAGGGCACCACCAG	3’	 131	bp	R:	5’	GCACCACCACCCACGGAATCG	3’	
	
	
Table	2.10	Sequencing	primers.	
	
Target	 Primer	name		 Primer	Sequences	pCR4-TOPO		 M13	 F:	5’	CTGGCCGTCTTTTAC	3’	R:	5’	CAGGAAACAGCTATGAC	3’	
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2.7.11	 Polymerase	Chain	Reaction	(PCR)	End-point	 PCR	 (Mullis	 et	 al.,	 1986)	 was	 used	 to	 amplify	 DNA	 fragments	 for	subcloning	 into	 TOPO	 vectors	 and	 to	 check	 for	 correct	 insertion	 of	 a	 DNA	fragment	 into	 a	 vector,	 as	 well	 as	 to	 test	 primer	 specificity	 and	 optimise	 the	annealing	temperatures	for	primer	pairs	to	be	used	in	RT-PCR.	For	subcloning	(section	 2.7.3),	 DNA	 was	 amplified	 using	 PfuUltra	 Hotstart	 Polymerase	(#600390,	Strategene)	and	a	typical	reaction	mixture	and	reaction	protocols	are	shown	 in	Table	2.11	and	Table	2.12,	 respectively.	For	all	 other	PCR	reactions,	Taq	 DNA	 polymerase	 (#BIO-21040,	 Bioline)	was	 used	with	 a	 typical	 reaction	mixture	detailed	in	Table	2.13	and	PCR	protocol	in	Table	2.14.	All	PCR	reactions	were	performed	in	0.5	ml	PCR	tubes	(#I1405-8200,	StarLab)	on	a	PCR	Express	Thermal	Cycler	(Px2,	Thermo	Hybaid).	
	
	
	
Table	2.11	PfuUltra	Hotstart	DNA	Polymerase	reaction	mixtures	 for	end-
point	PCR.				
	
Reagents	 Volume	cDNA	 4	µl	Forward	Primer		(20µM)	 0.625	µl	Reverse	Primer	(20µM)	 0.625	µl	PfuUltra	HF	Reaction	Buffer	(10X)	 5	µl	PfuUltra	HS	DNA	Polymerase	(2.5U/µl)	 1	µl	dNTPs		(100mM)	 0.5	µl	Water	 38.25	µl	Total	Volume		 50	µl	
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Table	2.12	PfuUltra	Hotstart	DNA	polymerase	protocol.		
	 Step	 No.	of	cycles	 Temperature	 Time	Duration	Initial	denaturation	 1	 95˚C	 5	min	Denaturation	 40	 95˚C	 45	sec	Annealing	 Tm/gradient	 45	sec	Extension	 68˚C	 45	sec	Final	extension	 1	 68˚C	 10	min	
	
	
	
	
Table	2.13	Taq	DNA	Polymerase	reaction	mixtures	for	end-point	PCR.		
	
Reagents	 Volume	cDNA	 2	µl	Forward	Primer		(10µM)	 1.5	µl	Reverse	Primer	(10µM)	 1.5	µl	Hostart	Taq	Mastermix	 15	µl	Water	 10	µl	Total	Volume		 30	µl	
	
	
	
Table	2.14	Taq	DNA	polymerase	protocol.		 Step	 No.	of	cycles	 Temperature	 Time	Duration	Initial	denaturation	 1	 95˚C	 5	min	Denaturation	 35-40	 94˚C	 30	sec	Annealing	 60-62˚C	 30	sec	Extension	 72˚C	 30	sec	Final	extension	 1	 72˚C	 5	min	
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2.7.12	 Quantitative	Reverse	Transcription-Polymerase	Chain	
Reaction	(qRT-PCR)	Real	 time	 qRT-PCR	 (Higuchi	 et	 al.,	 1992)	 was	 used	 to	 measure	 the	 absolute	levels	of	Ras	isoform	transcripts	in	RNA	extracted	from	mouse	embryonic	stem	cells	and	mouse	tissues.	First,	cDNA	(section	2.7.1)	was	diluted	1:4	in	nuclease-free	 water,	 from	 which	 4	 µl	 was	 used	 in	 10	 µl	 reaction	 in	 96-well	 plates	(#HSS9601,	 Bio-Rad).	 The	 protocol	 was	 based	 on	 the	 manufacturer’s	instructions	 for	 the	 SYBR®	Green	qPCR	kit	 (Bio-Rad),	 and	 is	 detailed	 in	Table	2.15.	The	PCR	primers	were	designed	in-house	(as	described	in	Chapter	3),	and	are	listed	in	Table	2.8.		
	
Table	2.15	qRT-PCR	reaction	mixture.	
cDNA	 4	µl	2	x	SYBR	Mastermix	 5	µl	Nuclease-free	deionised	water	 0.7	µl	Forward	Primer	10µM	 0.15	µl	Reverse	Primer	10µM	 0.15	µl	Total	volume	per	well	 10	µl	
	
	
PCR	products	were	amplified	using	a	CFX	ConnectTM	Real-Time	PCR	Detection	System	(Bio-Rad)	and	a	protocol	based	on	the	manufacturer’s	instructions	that	are	detailed	in	Table	2.16.	
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Table	2.16	qRT-PCR	protocol.	
Step	
No.	of	
Cycles	
Temperature	 Time	Duration	
Initial	denaturation	 1	 95˚C	 3	mins	Denaturation	 40	 94˚C	 30	sec.	Annealing	 62˚C	 30	sec.	Extension	 72˚C	 30	sec.	Melting	curve	 41	 55˚C	to	95˚C	 30	sec.	for	every	0.5	˚C		
	
Fluorescence	 was	 measured	 in	 real	 time	 after	 each	 extension	 step	 of	 the	 40	cycles.	To	be	able	to	compare	between	different	qPCR	plates,	cDNA	synthesised	from	 RNA	 of	 undifferentiated	 R1	 mESCs	 was	 used	 as	 an	 on-plate	 internal	control.	 Standard	 curves	 based	 on	 a	 5-fold	 dilution	 series	 of	 linearised	 Ras	isoform-specific	 plasmids	 (section	 2.7.7)	 were	 used	 to	 calculate	 the	 absolute	transcript	copy	numbers	 in	 the	mRNA	of	 interest.	An	example	of	 the	standard	curve	concentrations	and	corresponding	copy	numbers	for	the	KRasB	plasmid	is	shown	in	Table	2.17.	Each	sample	was	analysed	in	duplicate	or	triplicate	(as	on-plate	technical	repeats).	To	calculate	statistical	significance,	at	least	3	biological	replicates	experiments	were	analysed.		
As	a	standard	quality	control	measure,	melt	curves	(run	after	qRT-PCR	protocol	in	0.5˚C	 increments)	were	assessed	for	evidence	of	primer-dimer	formation	or	non-specific	 amplicons.	 Furthermore,	 to	 control	 for	 non-specific	 PCR	 product	formation	(e.g.	from	genomic	DNA),	negative	“-RT”	controls	(section	2.7.9)	and	water	blanks	were	run	alongside	qPCR	reactions	with	cDNA.	
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Table	 2.17	 5-fold	 dilution	 series	 of	 KRasB	 plasmid	 standard	 curve	 with	
corresponding	concentrations	and	copy	numbers	per	qPCR	reaction.		
	
Standard	
no	
Concentration	 4µl	per	well	
contains	
Copy	
number	1	 0.2	ng/ul	 0.8ng	 1.2	x	108	2	 0.04	ng/ul	 0.16ng	 2.4	x	107	3	 8	pg/ul	 32pg	 48	x	105	4	 1.6	pg/ul	 6.4pg	 9.6	x	105	5	 0.32	pg/ul	 1.28pg	 1.92	x	105	6	 64	fg/ul	 256fg	 3.84	x	104	7	 12.8	fg/ul	 51.2fg	 7,680	8	 2.56	fg/ul	 10.24fg	 1,536	9	 0.512	fg/ul	 2.048fg	 307.2		10	 0.1024	fg/ul	 0.4096fg	 61.44	11	 0.02048	fg/ul	 0.08192fg	 12.288	12	 4.096	ag/ul	 0.016384fg	 2.4576	
	
	
2.8	 	 Protein	Biochemistry		
2.8.1	 	 Cell	lysis	and	harvesting	After	drug	treatment	and/or	stimulation	SW48	cells	were	placed	on	a	metal	tray	on	ice	and	washed	3	times	with	ice-cold	1	x	PBS.	Depending	on	the	dish	size,	an	appropriate	 amount	 of	 RIPA	 buffer	 containing	mammalian	 Protease	 Inhibitor	Cocktail	and	1	PhosStop	Phosphatase	Inhibitor	Cocktail	tablet	(#04906837001,	Roche)	was	added	on	 the	cells	 (for	amount	of	 lysis	buffer	used	per	dish	–	 see	Table	2.2).	Cells	were	lysed	for	30	mins	on	ice	with	gentle	shaking.	Cell	lysis	was	assessed	under	a	microscope	(Invertoscope	ID	03,	Zeiss)	with	phase–contrast	to	determine	 the	 extent	 of	 cell	 membrane	 disruption	 and	 cellular	 debris.	 The	lysates	 were	 then	 transferred	 to	 Eppendorf	 microcentrifuge	 tubes	 and	centrifuged	at	18,000	x	g	for	15	mins	at	4˚C.	The	supernatants	were	transferred	to	fresh	eppendorf	tubes	and	vortexed	before	measuring	protein	concentration	using	the	BCA	assay	(section	2.8.3)	and	storage	at	-20	˚C.	
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2.8.2		 	 	 Protein	purification		To	 extract	protein	 from	mouse	 tissues	or	 cell	 lines,	 the	 flow-through	 retained	from	the	Norgen	RNA	extraction	step	(section	2.7.8)	was	processed	according	to	the	manufacturer’s	 instructions	 for	 RNA/Protein	 Purification	 Kit	 in	 a	 96-well	plate	format	(#37900,	Norgen;	Geneflow	code:	P4-0085,	cat	#582782)	or	using	spin	 columns	 (#23000,	 Norgen;	 Geneflow	 lot	 no	 #581790).	 When	 using	columns,	 up	 to	100	µl	 of	 flow-through	was	 adjusted	 to	575	µl	with	Molecular	Biology	Grade	Water	(#W4502)	and	24	µl	of	pH	Binding	Buffer	was	added	and	mixed.		600	µl	of	the	pH-adjusted	protein	sample	was	applied	at	a	time	onto	the	column	and	centrifuged	for	2	mins	at	5,200	x	g.	The	column	was	washed	with	500	µl	of	Protein	Wash	Buffer	by	centrifuging	for	2	mins	at	5,200	x	g.	Then	9.3	µl	of	Neutralizer	(containing	45	mM	citric	acid	and	45	mM	phosphoric	acid)	was	added	to	a	fresh	1.7	ml	elution	tube	and	protein	was	eluted	in	100	µl	of	Protein	Elution	Buffer	(10	mM	sodium	phosphate,	pH	12.5)	by	centrifuging	for	2	mins	at	5,200	x	g.	Purified	protein	samples	were	stored	at	-80˚C.	
For	 the	 96-well	 format,	 100	 µl	 of	 flow	 through	 was	 adjusted	 to	 400	 µl	 with	Molecular	Biology	Grade	Water	and	16	µl	of	pH	Binding	Buffer	was	added	and	mixed.	The	pH-adjusted	protein	samples	were	applied	into	the	wells	of	the	96-Well	Filter	Plate	and	centrifuged	for	2	mins	at	3,000	x	g.	The	plate	was	washed	with	400	µl	of	Protein	Wash	Buffer	by	centrifuging	for	2	mins	at	3,000	x	g.	Then	9.3	µl	of	Neutralizer	was	added	per	well	 into	a	new	96-Well	Elution	Plate	and	protein	was	eluted	in	100	µl	of	Protein	Elution	Buffer	by	centrifuging	for	2	mins	at	3,000	x	g.			
	
2.8.3	 	 Bicinchoninic	acid	(BCA)	protein	assay			The	 Pierce®	 BCA	 Protein	 Assay	 Kit	 (#23225,	 Thermo	 Scientific)	 was	 used	 to	measure	protein	concentration	in	cell	(section	2.8.1)	and	tissue	lysates	(section	2.8.2).	2	mg/ml	bovine	IgG	solution	(#I5506)	was	used	to	generate	a	standard	curve	for	calculating	absolute	protein	concentrations	up	to	2,000	µg/ml.	1-5	µl	of	 protein	 sample	 was	 assayed	 in	 duplicate.	 A	 Multiskan	 Spectrum	 plate	spectrophotometer	 (Thermo	Labsystems)	was	used	 to	measure	absorbance	at	
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595	nm.	The	background	absorbance	was	subtracted	from	the	raw	data	prior	to	calculation	of	sample	protein	concentrations.			
2.8.4	 	 Sodium	dodecyl	sulfate-polyacrylamide	gel	
electrophoresis	(SDS-PAGE)		Lysates	were	prepared	in	1	x	Laemmli	sample	buffer	(2%	SDS,	10%	glycerol,	5%	2-mercaptoethanol,	 0.002%	 bromphenol	 blue	 and	 62.5	mM	 Tris	 HCl,	 pH	 6.8)	and	 boiled	 at	 98˚C	 for	 5	 mins.	 Lysate	 concentrations	 were	 adjusted	 to	 allow	loading	of	equal	volumes	and	protein	amounts	per	lane.	10-25	µg	of	lysate	was	loaded	per	well	on	a	10%	polyacrylamide	gel	(National	Diagnostics)	or	a	precast	4-12%	 Bis-Tris	 NuPAGE	 gel	 (Novex®,	 Life	 Technologies).	 The	 recipes	 for	 the	10%	resolving	and	4%	stacking	gel	solutions	are	shown	in	Table	2.18.	Standard	SDS-PAGE	gels	were	run	in	BioRad	tanks	in	1x	running	buffer	(1%	SDS,	24.8	mM	Tris	 Base,	 192	 mM	 glycine),	 whereas	 NuPAGE	 gradient	 gels	 were	 run	 in	Invitrogen	 tanks	 in	1	x	MES	 (2-(N-morpholino)ethanesulfonic	acid)	buffer	 (50	mM	 MES,	 50	 mM	 Tris	 Base,	 0.1%	 SDS,	 1	 mM	 EDTA,	 pH	 7.3,	 #NP0002-02,	NuPAGE,	Invitrogen).	The	gels	were	run	first	at	100	V	for	10	mins	and	then	at	150-180	V	until	the	dye	front	reached	the	bottom	of	the	gel.	Full-range	rainbow	marker	 (#RPN800E,	 GE	 Healthcare	 Life	 Sciences)	 was	 used	 to	 determine	 the	protein	sizes.	
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Table	 2.18	Recipes	 for	 10%	 resolving	 and	 4%	 stacking	 gel	 solutions	 for	
SDS-PAGE.	 ProtoGel	 (#EC-890;	 30%	 (w/v)	 acrylamide:	 0.8%	 (w/v)	 Bis-Acrylamide	Stock	solution	(37:5:1)),	ProtoGel	Stacking	Buffer	(#EC-893;	0.5	M	Tris-HCl,	0.4%	SDS	pH	6.8)	and	ProtoGel	Resolving	Buffer	(#EC-892;	4x:	1.5	M	Tris-HCl,	0.4%	SDS	pH	8.8)	were	 from	National	Diagnostics.	APS	 -	 ammonium	persulfate.	
	 Volume	per	
Resolving	gel	
Volume	per	
Stacking	gel	ProtoGel	 3.35	ml	 0.65	ml	Resolving/Stacking	buffer	 2.6	ml	 1.25	ml	Deionised	water	 3.95	ml	 3.05	ml	10%	APS	 75	µl	 25	µl	TEMED	 7.5	µl	 5	µl	Total	 10	ml	 5	ml			
	
2.8.5	 	 Western	Blotting			Following	 SDS-PAGE,	 the	 gel	 was	 removed	 from	 plates,	 trimmed	 and	 briefly	rinsed	 in	 transfer	buffer	 (25	mM	Tris,	 192	mM	glycine,	20%	(v/v)	methanol).	Next,	the	gel	was	transferred	into	a	Genie	blotter	tank,	which	was	assembled	in	the	 following	 order:	 2	 grids	 ridged	 side	 up,	 cathode	 plate,	 1	 grid	 ridged	 side	down,	 pad,	 Whatman	 paper,	 gel,	 nitrocellulose	 membrane	 (#10600001,	 GE	Healthcare	 Life	 Sciences,	 Amersham	 Protran,	 0.2	 µm	 pore	 size),	 Whatman	paper,	pads	up	to	top	(3-4),	grid	ridged	side	up,	anode	plate,	plastic	cover.	The	pads,	 paper	 and	membrane	were	 previously	 immersed	 in	 transfer	 buffer	 and	care	was	 taken	 to	 remove	 all	 bubbles	 as	 transfer	 buffer	was	 poured	 into	 the	assembly.	 The	 container	 was	 then	 put	 into	 Genie	 blotter	 tank	 and	 the	 whole	assembly	 was	 run	 for	 1	 hour	 at	 constant	 current	 of	 0.5	 A	 (around	 30	 V)	(Burnette,	1981).			
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The	 Genie	 blotter	was	 disassembled	 and	 the	membrane	was	 briefly	 rinsed	 in	Ponceau-S	to	stain	the	transferred	proteins.	If	necessary,	the	membrane	was	cut	with	 a	 stainless	 steel	 surgical	 blade	 (Sterile	 Blade	No.	 11,	 Swann-Morton)	 for	blotting	 of	 differently	 sized	 proteins	 with	 more	 than	 one	 antibody.	 The	membrane	was	washed	in	1	x	TBST	(Tris	buffered	saline	plus	Tween-20;	12	mM	Tris,	137	mM	NaCl,	pH	7.6,	0.1%	w/v	Tween-20)	to	de-stain	Ponceau-S	and	then	incubated	 for	 1	 hr	 at	 room	 temperature	 in	 the	 appropriate	 blocking	 buffer	(Table	2.19),	 corresponding	 to	 the	primary	antibody,	using	gentle	 rocking.	All	blocking	buffers	and	primary	antibodies	were	prepared	in	1	x	TBST.	Following	blocking,	 the	membrane	was	 transferred	 to	 the	 appropriate	primary	 antibody	solution	 and	 incubated	 overnight	 at	 4˚C	 with	 gentle	 rocking.	 Following	incubation,	the	membrane	was	washed	3	times	for	5-10	mins	in	1	x	TBST	before	incubating	in	the	appropriate	secondary	antibody	(Table	2.20)	for	1	hr	at	room	temperature.	 All	 incubations	were	 in	 the	 same	blocking	 buffer	 as	 for	 primary	antibody	incubations	(Table	2.19).		The	membrane	was	again	washed	3	times	in	1	 x	 TBST	 and	placed	 on	 the	 LICOR	Odyssey	 for	 scanning	 at	 84	 µm	 resolution	with	high	intensity.	The	bands	were	quantified	using	ImageJ	(1.47v).		
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Table	2.20	Secondary	antibody	list	for	Western	blotting.			
Secondary	antibody	
name	
Manufacturer	(code)	 Dilution	Donkey	anti-mouse	IRDye	800CW	 LICOR	Biosciences	(926-32212)	 1/15000	Donkey	anti-mouse	IRDye	680CW	 LICOR	Biosciences	(926-32222)	 1/15000	Donkey	anti-rabbit	IRDye	800CW	 LICOR	Biosciences	(926-32213)	 1/15000	Donkey	anti-goat	IRDye	800CW	 LICOR	Biosciences	(926-32214)	 1/15000				
2.9	 	 Proteomics		
2.9.1	 	 Ras	standards		The	 Ras	 standards	 were	 kindly	 provided	 by	 Dr	 Craig	 Mageean	 (Prior	Laboratory,	 University	 of	 Liverpool,	 UK)	 (Mageean	 et	 al.,	 2015).	 In	 brief,	 the	standards	were	27kDa,	his-tagged,	full-length	Ras	proteins,	labelled	with	Arg10	and	Lys8	and	grown	in	auxotrophic	AT713	E.	coli	bacteria	that	do	not	generate	their	own	arginine	or	lysine	(obtained	from	The	Coli	Genetic	Stock	Center,	Yale).	The	 standards	were	 purified	 through	 his-tag	 pull	 down	 using	 a	metal-affinity	column	 and	 then	 gel	 filtration	 through	 Superdex	 200(GE	 Healthcare).	 The	standards	were	over	98%	 labelled	with	heavy	 isotopes	of	 arginine	and	 lysine.	To	measure	the	concentration	of	the	standards,	a	known	quantity	of	light	KRasB	reference	protein	was	used	in	a	mix	with	heavy	labelled	Ras	proteins.	The	light	KRasB	protein	was	accurately	quantified	using	BCA	assay,	as	well	as	Nanodrop	1000,	using	an	absorbance	at	280	nm	(Mageean	et	al.,	2015).	For	quality	control,	standards	were	run	on	a	12-4%	Bis-Tris	NuPAGE	gel	and	stained	using	Colloidal	Blue	 Staining	 Kit	 (#LC6025,	 Invitrogen)	 according	 to	 manufacturer’s	instructions,	which	showed	minimal	contamination	with	non-specific	proteins.	
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	The	 standards	were	 stored	 in	 standard	 buffer	 (20mM	Tris	 (pH	 7.4),	 150	mM	NaCl,	2mM	DTT,	5mM	MgCl2)	 in	1.5	ml	Protein	LoBind	tubes	(#0030	108.116,	Eppendorf)	that	were	pre-treated	with	2%	BSA	for	2	hours	at	RT,	before	all	the	BSA	was	removed	and	any	remaining	liquid	was	allowed	to	evaporate	in	a	tissue	culture	hood	for	over	3	hours.	All	dilutions	of	the	standards	were	performed	in	standard	buffer	plus	0.1%	BSA.	Stock	 solutions	were	 stored	at	 -80˚C	and	 final	standard	 concentrations	 were	 freshly	 prepared	 for	 use	 in	 quantitative	proteomics	experiments.	The	standards	were	always	thawed	on	ice	and	flicked	gently	to	mix.	They	were	stored	at	-80˚C	and	flash-frozen	in	liquid	nitrogen	after	use	 (up	 to	 3	 times).	 10	 ng	 of	 KRas-4B	 and	 5	 ng	 of	 each	 H-Ras	 and	 N-Ras	standards	were	used	per	50	µg	of	protein	lysate.		
	
	
2.9.2	 	 In-gel	digest	protocol		The	 Ras-specific	 in-gel	 digest	 protocol	 was	 optimised	 by	 Dr	 Craig	 Mageean	(Prior	 Laboratory,	 University	 of	 Liverpool,	 UK).	 In	 brief,	 45-50	 µg	 of	 protein	lysates	 in	 Laemmli	 sample	 buffer	 (section	 2.8.4)	 were	 spiked	 with	 Ras	standards	and	run	on	10-well,	1.5mm,	12-4%	Bis-Tris	NuPAGE	gel	 in	1	x	MES	buffer	 at	 50V	 for	 10	 mins	 and	 then	 at	 150V	 until	 the	 samples	 had	 migrated	halfway	down	the	gel.	The	gel	was	 fixed	 in	10%	acetic	acid,	40%	HPLC	water,	50%	HPLC	methanol	 for	15	mins	using	gentle	shaking	and	 then	washed	 twice	with	HPLC	grade	water	(#	97063-722,	VWR	Chemicals).			The	 gel	 was	 transferred	 to	 a	 laminar	 flow	 cabinet	 and	 placed	 in	 non-tissue	culture	 treated	15	 cm	polystyrene	Petri	 dish	 (#P5981-100EA).	 The	 gel	 pieces	were	excised	between	the	31	kDa	and	17	kDa	markers.	The	gel	pieces	were	then	diced	 into	 cubes	 1	 mm	 in	 diameter,	 carefully	 transferred	 to	 1.5	 ml	 LoBind	Eppendorf	tubes	in	their	entirety	and	then	briefly	centrifuged	for	15	sec.		150	µl	of	50	mM	ammonium	bicarbonate/	50%	(w/w)	acetonitrile	was	added	to	the	gel	pieces	and	incubated	at	37°C	for	15	mins	in	a	thermoshaker	at	900	rpm.	
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The	supernatant	was	discarded	using	a	gel	 loading	tip	and	the	gel	pieces	were	washed	again	in	the	same	solution	and	the	solution	was	discarded.		150	 µl	 of	 10	 mM	 dithiothreitol	 (DTT)	 was	 added	 and	 the	 gel	 pieces	 were	incubated	at	37°C	for	30	mins	in	a	thermoshaker	at	900	rpm.	The	supernatant	was	discarded	and	the	gel	pieces	were	cooled	for	5	mins	at	room	temperature.	150	 µl	 of	 55	 mM	 iodoacetamide	 (IAA)	 was	 added	 and	 incubated	 at	 room	temperature	 in	 the	 dark	 for	 30	mins.	 The	 solution	was	 discarded	 and	 the	 gel	pieces	 were	 washed	 twice	 in	 the	 following	 order:	 with	 200	 µl	 of	 100%	acetonitrile	in	a	thermoshaker	at	37°C	for	10	minutes	and	then	with	HPLC	water	in	 thermoshaker	 for	 5	 minutes.	 Water	 was	 removed,	 the	 gel	 pieces	 were	dehydrated	 with	 200	 µL	 of	 100%	 acetonitrile	 at	 37°C	 for	 15	 min	 in	 a	thermoshaker	 and	 then	 left	 at	 room	 temperature	 for	 10	 mins	 to	 allow	 the	solvent	to	evaporate.		250	µl	of	Dilute	Trypsin	Gold	(Promega)	in	reaction	buffer	(40	mM	ammonium	bicarbonate,	 9%	 (v/v)	 acetonitrile)	 was	 added	 to	 gel	 pieces,	 using	 200	 ng	 of	trypsin	per	every	50	µg	of	lysate.	The	reaction	was	incubated	overnight	at	37˚C	(>16	hours).		The	supernatant	obtained	from	the	overnight	reaction	was	transferred	to	fresh	LoBind	 tubes	 and	 0.1%	 of	 formic	 acid	 was	 added.	 200	 µl	 of	 acetonitrile	 was	added	to	 the	gel	pieces	and	 incubated	 for	10	min	at	room	temperature	at	900	rpm.	 The	 supernatant	 was	 transferred	 again	 to	 the	 same	 LoBind	 tubes	containing	 formic	 acid	 and	 centrifuged	 for	 15	min	 at	 13,000	 x	 g.	Most	 of	 the	supernatant	was	 transferred	 to	 fresh	 LoBind	 eppendorf	 tubes,	 leaving	 behind	around	3-5	µl	to	avoid	gel	debris.	The	samples	were	dried	in	SpeedDry	vaccum	concentrator	 (RVC	 2-25,	 CHRIST	with	 cooling	 trap	 CT02-50)	 at	 60°C	 until	 all	liquid	had	evaporated	and	the	protein	pellets	were	stored	at	-20˚C.			
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2.9.3	 	 Mass	spectrometry		The	 protein	 pellets	 were	 re-suspended	 with	 25	 µl	 0.1%	 trifluoroacetic	 acid	(TFA),	vortexed	thoroughly	and	centrifuged	at	18,000	x	g	for	15	mins	at	4	˚C	in	a	bench-top	centrifuge.	25	µl	was	transferred	into	a	glass	vial	and	5	µl	was	loaded	onto	 the	 5500	 QTRAP	 (AB	 SCIEX)	 to	 measure	 diagnostic	 peptides	 and	transitions	 (Mageean,	 2014)	 in	 Pharmacology	 Mass	 Spectrometry	 Facility,	University	of	Liverpool	(measured	by	Dr	Rosalind	Jenkins).	
	
	
2.10	 	 Bioinformatics	and	statistical	analysis		The	 following	 software	 packages	were	 used	 in	 this	 study:	NetPrimer	 Premier	Biosoft	v1.10	and	Primer-BLAST	(Ye	et	al.,	2012)	was	used	 for	primer	design;	Basic	Local	Alignment	Search	Tool	 (BLAST)	 (Altschul	 et	 al.,	 1990)	 to	 compare	nucleotide	 and	 protein	 sequences;	 MultiExperiment	 Viewer	 MeV	 v4.8.1	 for	generation	of	heat	maps;	VECTOR	NTI	Advance	v11.5.2	for	dendrograms	of	Ras	family	and	Ras	isoforms;	SerialCloner	2-5	for	generating	plasmid	vector	maps.		The	mean,	 standard	deviation	(SD)	and	 the	standard	error	of	 the	mean	(SEM)	were	calculated	for	triplicate	biological	experiments.	For	statistical	analysis,	the	data	was	analysed	by	unpaired	student	t-test	and	one	or	two-way	ANOVA	with	Fisher’s	 LSD	 or	 Tukey’s	 post-hoc	 test	 using	 PRISM	 v6.0c.	 Means	 were	considered	to	be	significantly	different	if	p<0.05	(two-tailed	P	value).	EC50	and	IC50	values	were	calculated	for	the	normalised	response	also	using	PRISM	v6.0c.		When	curating	data	from	literature	to	compare	relative	Ras	isoform	abundance,	data	was	 normalised	 to	 the	 highest	 value	within	 a	 study	 (100%),	 and	 all	 Ras	isoform	 abundance	 values	 were	 assigned	 a	 number	 1-4,	 depending	 on	 the	quartile	 into	which	 they	 fell:	 1	 –	0	 -	 25%,	2	 –	25%<	 -	 50%,	3	 –	50%<	 -	 75%,		4	–	75%<	-	100%.	
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Chapter	3	
Establishing	Reagents	for	qRT-PCR	
	
3.1	 	 	 Introduction	This	chapter	describes	the	design,	optimisation	and	performance	of	quantitative	reverse	 transcription-polymerase	 chain	 reaction	 (qRT-PCR)	 assays	 used	 to	investigate	the	abundance	of	Ras	isoforms	at	transcripts	by	SYBR®	Green	assays	in	mouse	embryonic	stem	cell	line	and	in	mouse	tissues.	As	described	in	detail	below,	 many	 variables	 must	 be	 taken	 into	 account	 to	 design	 specific	 and	sensitive	assays.	
PCR	primers	were	individually	designed	that	were	specific	for	each	Ras	isoform	using	 the	 BLAST	 online	 tool	 (Altschul	 et	 al.,	 1990,	 Ye	 et	 al.,	 2012)	 and	 Net	primer	software	(PREMIER	Biosoft	International).	As	different	assays	would	be	run	on	the	same	plates,	a	common	optimal	annealing	temperature	was	chosen.	The	 primers	were	 then	 tested	 for	 specificity	 between	 Ras	 isoforms	 and	 their	efficiency	in	product	amplification.	The	Ras	primers	described	in	this	thesis	met	all	 the	 criteria	 for	 primer	 design	 and	 RT-PCR	 reaction	 optimisation	 (Bio-Rad	Laboratories,	2006,	Degen	et	al.,	2006).		
Different	 quantification	 methods	 were	 also	 evaluated.	 Plasmids	 encoding	 the	Ras	 isoforms	 were	 subcloned	 and	 linearised	 to	 generate	 standard	 curves	 for	absolute	quantification	of	Ras	transcripts	in	qRT-PCR	reactions.	In	addition,	the	use	of	a	reference	transcript	that	might	be	applicable	across	tissues	and	through	development	was	considered	for	relative	quantification.	
	
3.1.1	 qRT-PCR	 as	 a	 method	 for	 accurate	 quantification	 of	
transcript	abundance	In	 qRT-PCR	 the	 amount	 of	 amplified	 product	 is	measured	 in	 real	 time	 as	 the	reaction	 proceeds	 (Higuchi	 et	 al.,	 1992,	 VanGuilder	 et	 al.,	 2008).	 qRT-PCR	requires	 a	 set	 of	 target-specific	 primers,	 a	 template	 DNA,	 a	 heat-stable	 Taq	
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polymerase	(Chien	et	al.,	1976,	Saiki	et	al.,	1988,	Eckert	and	Kunkel,	1990)	and	a	fluorescent	dye	to	monitor	the	product	accumulation	(Kubista	et	al.,	2006).	qRT-PCR	 has	 many	 advantages	 over	 other	 nucleic	 acid	 quantitative	 techniques,	including	 wide	 dynamic	 range,	 high	 accuracy	 and	 cost	 effectiveness	 of	 the	detection	 of	 defined	 sets	 of	 transcripts	 (Schmittgen	 et	 al.,	 2000,	 Heid	 et	 al.,	1996).	A	variety	of	qRT-PCR	strategies	are	available,	including	the	use	of	FRET	probes	 such	as	Taqman,	or	 sequence-independent	 intercalators,	 such	as	 SYBR	green	(Kubista	et	al.,	2006,	McPherson	and	Møller,	2006).	
A	 common	 feature	 of	 qRT-PCR	 assay	 is	 that	 accumulation	 of	 the	PCR	product	with	 each	 PCR	 cycle	 is	 directly	 proportional	 to	 detection	 of	 a	 fluorescent	 dye	(Nolan	 et	 al.,	 2006,	 VanGuilder	 et	 al.,	 2008).	 These	 raw	 data	 are	 used	 to	determine	the	cycle	threshold	(CT)	value	for	each	reaction,	that	is	the	number	of	cycles	required	to	achieve	a	defined	fluorescence	signal	above	noise.	Thresholds	are	 set	 in	 the	 exponential	 phase	 of	 the	 PCR	 reaction,	 where	 product	 doubles	with	 each	 cycle,	 so	 there	 is	 linear	 relationship	 between	 the	 CT	 value	 and	 the	logarithm	(base	2)	of	the	initial	amount	of	template	(Higuchi	et	al.,	1993).		
In	 this	 study,	 qRT-PCR	was	 based	 on	 SYBR®	 Green	 I	 (Ponchel	 et	 al.,	 2003),	 a	fluorescent	dye	that	binds	to	the	double-stranded	DNA	(dsDNA)	(Vitzthum	et	al.,	1999,	Morrison	et	al.,	1998,	Bengtsson	et	al.,	2003).	Interaction	of	SYBR	Green	I	with	single-stranded	DNA	(ssDNA)	is	about	11-fold	weaker	than	intercalation	to	dsDNA	(Zipper	et	al.,	2004),	which	enhances	its	fluorescence	more	than	1,000-fold	 (Dragan	 et	 al.,	 2012).	 This	 fluorescence	 is	 recorded	 by	 qRT-PCR	thermocyclers	 after	 each	 cycle	 as	 the	 when	 double-stranded	 amplicons	 are	generated.	Overall,	SYBR	Green	I	is	a	very	good	DNA	intercalating	dye,	which	is	routinely	used	in	RT-PCR	experiments,	due	to	its	thermal	stability	and	ability	to	detect	any	dsDNA	sequence.	Because	of	this,	however,	 there	are	some	caveats.	SYBR	 Green	 I	 binds	 to	 non-specific	 amplification	 products	 and	 to	 primer-dimers,	 which	 can	 lead	 to	 false	 positive	 signals	 in	 non-optimal	 qRT-PCR	reactions	(McPherson	and	Møller,	2006).		For	 this	 reason,	 qPCR	 instruments	 can	 characterise	 the	 final	 PCR	 reaction	components	 by	melt	 curve	 analysis	 (Ririe	 et	 al.,	 1997,	Wilhelm	 and	 Pingoud,	
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2003).	The	DNA	is	slowly	denatured,	by	incremental	temperature	increases	and	the	loss	of	fluorescence	signal	is	monitored.	When	the	temperature	reaches	the	melting	 temperature	(Tm)	of	an	amplicon,	 the	 fluorescence	decreases	abruptly	as	 the	 dsDNA	 melts	 (Nygren	 et	 al.,	 1998,	 Kubista	 et	 al.,	 2006).	 This	 shift	 in	fluorescence	can	be	plotted	as	a	peak	on	a	negative	derivative	melt	curve	graph.	As	 specific	 and	 non-specific	 amplicons	 such	 as	 primer-dimers	 have		distinct	 Tm	 they	 are	 easily	 distinguished	 as	 separate	 peaks	 on	 melt	 curves.		
	
3.1.2	 Considerations	 for	 the	 design	 and	 optimisation		
of	qRT-PCR		The	design	of	Ras	isoform-specific	primers	and	optimisation	of	qRT-PCR	assays	were	 based	 on	 generally	 accepted	 guidelines	 described	 in	 the	 Bio-Rad	 Real-Time	 PCR	 Applications	 Guide	 (Bio-Rad	 Laboratories,	 2006),	 Roche	 PCR	Applications	 Manual	 (Degen	 et	 al.,	 2006),	 PREMIER	 Biosoft	(http://www.premierbiosoft.com)	and	key	reviews	(Kubista	et	al.,	2006,	Bustin,	2000,	Lutfalla	and	Uze,	2006,	McPherson	and	Møller,	2006,	Kramer	and	Coen,	2006).		
3.1.2.1	 	 						Primer	design	The	efficiency	of	the	amplification	reaction	depends	on	the	amplicon	size,	which	should	 be	 between	 75	 to	 200	 base	 pairs	 (bp).	 Longer	 amplicons	 lead	 to	 less	efficient	reactions	and	potentially	saturating	fluorescence	signal.	However,	very	short	 amplicons	 may	 not	 be	 distinguishable	 from	 primer-dimers.	 It	 is	 also	important	to	consider	the	properties	of	primer	pairs	(Williams,	1989,	Wu	et	al.,	1991).	The	length	of	primer	pairs	should	be	similar	and	within	the	range	of	18-30	bases,	which	 is	sufficient	 for	 target	specificity,	even	within	complex	human	genomic	 DNA.	 Primers	 that	 are	 too	 short	 may	 bind	 non-specifically,	 whereas	longer	primers	can	reduce	PCR	efficiency	 through	slow	hybridisation	rate	and	hence	decrease	the	yield.		The	balance	of	nucleotides	within	a	primer	is	also	important.	For	a	given	primer	pair,	the	Tm	should	be	similar	and	allow	annealing	to	the	template	at	55	to	65˚C.	The	 Tm	 is	 defined	 as	 the	 temperature	 at	 which	 50%	 of	 the	 primer-template	duplexes	melts	and	becomes	single-stranded.	The	Tm	reflects	the	stability	of	the	
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primer-template	 complex	 and	 is	 dependent	 on	 the	 percentage	 of	 G	 and	 C	nucleotides	(GC%).	As	G-C	hydrogen	bonding	provides	higher	stability	than	A-T	bonding,	it	contributes	to	a	higher	Tm	(Wu	et	al.,	1991).	Ideally,	the	overall	%GC	for	each	primer	should	be	40-60%.	Primer	should	also	be	designed	with	a	G	or	C	at	the	3’	end,	referred	to	as	a	GC	clamp,	to	aid	in	the	correct	priming	from	the	template.	However,	GC	runs	exceeding	three	bases	should	be	avoided	at	the	3’	end,	 as	 this	 can	 lead	 to	 mispriming	 of	 GC-rich	 regions	 and	 can	 contribute	 to	primer-dimer	formation.	Long	GC	runs	can	also	lead	to	non-Watson-Crick	base	pairing	within	a	primer,	which	can	impede	primer-template	binding	or	result	in	mispriming.	 Di-nucleotide	 repeats	 should	 also	 be	 avoided,	 as	 repeats	 of	more	than	four	(e.g.	TATATATA),	can	also	cause	mispriming.		Primer	 design	 should	 avoid	 sequences	 that	 may	 form	 stable	 secondary	structures,	 as	 these	 hinder	 primer	 annealing	 to	 the	 template	 and	 lead	 to	 low	product	 yield	 (Wang	 and	 Seed,	 2003,	 Hoebeeck	 et	 al.,	 2005).	 Intramolecular	hybridisation	occurs	due	to	 internal	complementarity	within	a	primer	and	can	lead	to	stable	formation	of	a	hairpin.	Predicted	3’	end	hairpins	with	Gibbs	free	energy	G	(ΔG)	of	 -2	kcal/mol	and	 internal	hairpins	with	ΔG	of	 -3	kcal/mol	are	generally	acceptable.		Secondary	structure	can	also	arise	from	intermolecular	interactions	that	lead	to	the	 formation	 of	 primer-dimers:	 either	 homo-dimers	 due	 to	 self-complementarity,	or	hetero-	dimers	that	can	form	by	complementarity	between	forward	and	reverse	primers.	3’	end	primer-dimers	with	ΔG	=	-5	kcal/mol	and	internal	primer-dimers	with	ΔG	=	 -6	kcal/mol	are	generally	accepted.	Primer-dimer	 formation	often	 leads	 to	misquantification	 in	qRT-PCR	experiments	and	therefore	any	base-pairing	at	the	3’	ends	of	primer	sequences	should	be	avoided	(Wang	 and	 Seed,	 2003).	 Primer-dimer	 formation	 can	 be	 monitored	 by	 melt	curve	analysis	as	described	in	section	3.1.1.		
3.1.2.2	 	 						Annealing	temperature	
	The	annealing	temperature	(Ta)	used	during	the	PCR	reaction	is	critical	for	the	specificity	 and	 efficiency,	 as	 primer-template	 hybridisation	 is	 temperature-
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dependent	(Williams,	1989,	Rychlik	et	al.,	1990).	If	the	Ta	is	too	high,	this	causes	dissociation	 of	 the	 template	 and	 the	 primers,	 leading	 to	 reduced	 yield	 of	 PCR	product	 (Don	et	 al.,	 1991).	On	 the	other	hand,	 if	 the	Ta	 is	 too	 low,	 this	 allows	partial	hybridisation	decreasing	the	specificity	of	priming.	Therefore,	an	optimal	Ta	should	yield	minimal	amount	of	non-specific	PCR	products	and	maximise	the	correct	amplicon.			For	 optimal	 stringency,	 the	 Ta	 should	 be	 within	 5°C	 of	 the	 Tm	 of	 primers	(Rychlik	et	al.,	1990).	Sufficient	annealing	of	the	primers	to	the	template	already	occurs	at	the	primer	Tm	(von	Ahsen	et	al.,	2001),	but	the	maximum	specificity	of	the	 PCR	 assay	 is	 achieved	 using	 the	 highest	 Ta,	 at	 which	 amplification	 of	 the	correct	 PCR	 product	 still	 occurs	 (Wu	 et	 al.,	 1991).	 Although	 theoretical	calculation	 of	 optimal	 Ta	 is	 possible	 (Rychlik	 et	 al.,	 1990),	 each	 primer	 pair	should	be	tested	empirically	using	a	range	of	Ta	to	optimise	product	specificity	and	reaction	efficiency	.			
3.1.2.3		 	 Primer	efficiency	
	The	final	aspect	to	consider	in	PCR	optimisation	is	the	reaction	efficiency	for	a	given	primer	set.	During	the	exponential	phase	of	amplification,	the	reaction	is	100%	efficient	if	the	amount	of	the	amplicon	doubles	every	cycle	(Higuchi	et	al.,	1993).	 However,	 reaction	 efficiency	 is	 often	 limited	 by	 a	 number	 of	 factors,	including	 primer	 secondary	 structures,	 self-complementarity	 of	 the	 DNA	template	sequences	(Wang	and	Seed,	2003)	and	non-optimal	Ta	(Rychlik	et	al.,	1990,	Chou	et	al.,	1992).	Therefore,	it	is	important	to	empirically	determine	the	reaction	efficiency	for	each	primer	pair.	The	equation	Q	=	q02n	denotes	how	the	amount	of	PCR	product	Q	 correlates	 to	 the	number	of	 cycles	n	with	a	 starting	amount	of	DNA	template	q0	if	the	reaction	is	100%	efficient.	
		Typically	 serial	 dilution	 of	 a	 DNA	 template	 is	 used	 to	 determine	 reaction	efficiency.	Recorded	CT	values	are	plotted	against	 the	 logarithm	(base	dilution	factor)	 of	 starting	 quantity	 of	 the	 template	 for	 regression	 analysis.	 Accurate	calculation	of	reaction	efficiency	depends	on	the	number	of	dilution	points	and	the	 dilution	 factor	 used	 (Hellemans	 et	 al.,	 2007).	 Based	 on	 the	 previous	
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equation,	calculation	of	efficiency	of	the	reaction	E	uses	the	formula	E	=	2(m1/m2),	where	m1	denotes	the	perfect	gradient	and	m2	–	the	gradient	of	the	regression	line.	In	case	of	a	2-fold	dilution	series,	the	perfect	gradient	m1	would	be	-1	and	the	reaction	efficiency	would	be	2.	To	calculate	the	percentage	efficiency	of	the	reaction	%E,	 the	 equation	%E	 =	 (E-1)	 ·	 100%	 is	 used.	 Ideally,	%E	 should	 be	between	 90-105%,	 as	 low	 values	 indicate	 poor	 optimisation	 of	 the	 reaction	conditions	 or	 primer	 design.	 Values	 that	 are	 too	 high	 usually	 imply	 pipetting	errors	or	amplification	of	primer-dimers.			
3.1.2.4		 	 Quantification	of	qRT-PCR	In	 general,	 there	 are	 two	methods	 that	 can	be	 employed	 to	quantify	 the	qRT-PCR	 results:	 the	 absolute	 quantification	 method	 using	 a	 template	 standard	curve	and	the	relative	quantitation	using	a	reference	gene.			For	 absolute	 quantitation,	 CT	 values	 obtained	 from	 the	 qRT-PCR	 data	 are	converted	to	copy	number	using	standard	curves	generated	by	a	serial	dilution	of	the	template,	for	example	cloned	into	a	plasmid.	However,	the	CT	values	of	the	chosen	 dilutions	 must	 reflect	 the	 range	 of	 CT	 values	 obtained	 from	 the	 test	samples,	 so	 that	 any	 calculated	 data	 could	 be	 interpolated,	 not	 extrapolated,	from	the	standard	curve.	The	calculated	data	can	be	normalised	to	unit	mass,	for	example	data	may	be	expressed	as	copy	number	per	pg	of	RNA.		The	alternative	method	of	quantifying	transcripts	by	qRT-PCR	relies	on	relative	quantification.	In	essence,	this	is	a	method	of	normalising	the	expression	level	of	a	 target	gene	 to	 those	of	a	 reference	gene	 (Karge	et	al.,	1998).	 In	brief,	 the	CT	values	of	a	target	gene	are	subtracted	from	the	CT	values	of	a	reference	gene	in	each	 test	 sample,	 using	 the	 equation	 ∆CT	 (relative	 expression)	 =	 2CT(reference)	 -	CT(target)	 to	determine	the	target/reference	gene	expression	ratio.	Thus,	relative	expression	of	the	target	gene	can	be	compared	to	across	samples.	The	data	may	be	 further	 normalised	 to	 a	 calibrator,	 e.g.	 a	 control	 sample	 within	 the	experiment.			One	benefit	of	such	∆CT	method	that	normalised	expression	of	a	target	gene	to	a	reference	 gene	 is	 reduction	 of	 experimental	 noise	 arising	 from	 technical	
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variations	 between	 test	 samples,	 such	 as	 differences	 in	 input	 RNA	 amount	 or	reverse	 transcription	 efficiency	 (Karge	 et	 al.,	 1998,	 Derveaux	 et	 al.,	 2010).	However,	 choosing	 a	 reliable	 reference	 gene	 is	 crucial.	 	 First,	 the	 efficiency	of	amplification	for	the	reference	gene	and	target	gene	should	be	similar	to	ensure	that	the	∆CT	equation	is	valid	(Kozera	and	Rapacz,	2013).	Secondly,	a	reference	gene	must	be	ubiquitously	and	stably	expressed	across	all	test	samples.		
3.1.2.5		 	 Selection	 of	 reference	 genes	 for	 relative	 quantitation	 in	
qRT-PCR	
To	enable	relative	quantitation,	the	expression	levels	of	a	reference	gene	must	be	 constant	 across	 all	 test	 samples,	 regardless	 of	 developmental	 stage,	 tissue	type	 or	 treatment	 method.	 In	 some	 cases	 it	 is	 not	 possible	 to	 find	 a	 single	candidate	 gene	 that	 would	 fulfil	 these	 criteria	 (Carnahan	 et	 al.,	 2013),	 as	expression	 levels	 of	 all	 genes	 are	 tightly	 regulated	 and	 depend	 on	 different	physiological	 states	 (Kraemer	 et	 al.,	 2012).	 Hence,	 several	 reference	 genes	should	be	independently	assessed	for	any	given	experimental	context.	Although	it	is	recommend	to	normalise	qRT-PCR	data	to	more	than	one	reference	gene	to	achieve	better	accuracy	(Kozera	and	Rapacz,	2013,	Nicot	et	al.,	2005),	the	use	of	a	 single	 optimised	 reference	 gene	 might	 be	 sufficient	 (Willems	 et	 al.,	 2006,	Thellin	et	al.,	1999).		
Among	 the	 most	 commonly	 used	 reference	 genes	 in	 qRT-PCR	 are	 so-called	housekeeping	 genes.	 These	 are	 essential	 metabolic	 or	 structural	 genes,	 and	were	the	first	to	be	considered	as	reference	genes	(Thellin	et	al.,	1999,	Kozera	and	Rapacz,	 2013).	One	 example	 is	 cytoskeletal	 β–actin,	 for	which	 expression	levels	 have	 been	 shown	 to	 be	 stable	 in	 various	 samples	 under	 different	treatments	(Giulietti	et	al.,	2001).	However,	certain	conditions	can	affect	β–actin	mRNA	 levels,	 e.g.	 hypoxia	 (Suzuki	 et	 al.,	 2000).	 Another	 housekeeping	 gene,	glyceraldehyde-3-phosphate	 dehydrogenase	 (GAPDH),	 is	 also	 widely	 used	 for	normalisation	of	qRT-PCR	data	(McPherson	and	Møller,	2006).	It	 is	an	enzyme	primarily	 involved	 in	 glycolysis,	 but	 also	 in	 a	 number	 of	 non-metabolic	processes.	Although	its	expression	is	ubiquitous	and	generally	stable	across	cell	
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types,	 levels	 can	 be	 affected	 by	 certain	 treatments,	 such	 as	 programmed	neuronal	cell	death	(Suzuki	et	al.,	2000,	Ke	et	al.,	2000).		An	alternative	reference	gene	commonly	used	in	qRT-PCR	is	the	ribosomal	RNA	(rRNA)	 subunit	 18S	 (Kozera	 and	 Rapacz,	 2013).	 There	 are,	 however,	 several	pitfalls	associated	with	its	use	for	normalisation.	First,	this	iRNA	is	synthesised	by	RNA	polymerase	I,	independently	to	mRNA	synthesis	by	RNA	polymerase	II	(Radonic	et	al.,	2004).	The	18S	expression	level	is	also	much	higher	than	that	of	many	 mRNAs	 (Paolacci	 et	 al.,	 2009),	 and	 the	 rRNA:mRNA	 ratios	 can	 also	significantly	 differ	 between	 test	 samples	 (Vandesompele	 et	 al.,	 2002),	making	18S	rRNA	unsuitable	for	normalisation	of	lower	abundance	transcripts.	What	is	more,	 rRNA	 is	 more	 stable	 than	 mRNA	 (Paolacci	 et	 al.,	 2009),	 meaning	 that	normalisation	to	18S	would	not	account	for	differences	in	mRNA	degradation	in	the	 test	 samples.	 18S	 rRNA	 expression	 can	 also	 be	 affected	 by	 certain	treatments	(Nicot	et	al.,	2005).	Overall,	18S	it	is	not	a	good	representation	of	the	mRNA	population	within	a	cell	(Suzuki	et	al.,	2000).	
Another	 reference	 gene	 to	 consider	 is	 RNA	 polymerase	 II	 (POL2RE).	 As	mentioned	above,	it	is	involved	in	the	transcription	of	all	mRNA	and	is	reported	to	 be	 the	 most	 stably	 expressed	 reference	 gene	 across	 different	 tissue	 types	(Radonic	et	al.,	2004).	POL2RE	levels	have	also	been	shown	to	remain	constant	throughout	 mouse	 ESCs	 differention	 (Kraemer	 et	 al.,	 2012).	 Taken	 together,	among	all	 reference	genes	 considered,	POL2RE	 is	most	 likely	 to	 reflect	mRNA	levels	in	murine	test	samples	examined	in	this	study.	
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3.2	 	 	 Results	
3.2.1	 	 						Primer	design	
 Based	on	the	general	recommendations	for	primer	design	(section	3.1.2.1),	Ras	primers	were	designed	to	generate	amplicons	of	approximately	200	bp	that	met	the	GC	content	criteria.	The	Ras	isoform	primers,	together	with	their	properties,	are	 listed	 in	 Table	 3.1.	 Primer	 sequence	 positions	 within	 the	 Ras	 isoform	transcripts	 are	 illustrated	 in	 Fig.	 3.1	 –	 3.4,	 based	 on	 AceView	 sequence	representation	 (http://www.ncbi.nlm.nih.gov/IEB/Research/Acembly/)	(Thierry-Mieg	 and	 Thierry-Mieg,	 2006,	 Durbin	 and	 Thierry-Mieg,	 1994)	 and	BLAST	(Altschul	et	al.,	1990).		To	 avoid	 the	 detection	 and	 amplification	 of	 any	 contaminating	 genomic	 DNA,	primers	 that	 span	 exon-exon	 boundaries	 or	 flank	 introns	 were	 designed	(McPherson	and	Møller,	2006,	Degen	et	al.,	2006,	Huang	et	al.,	1996,	Wang	and	Seed,	2003).	For	the	former,	at	least	one	primer	within	each	pair	was	designed	to	 span	 an	 intron,	 so	 that	 it	 would	 partially	 hybridise	 to	 the	 first	 exon	 and	partially	 to	 the	 following	 exon.	 Hence,	 such	 primers	 would	 not	 amplify	 any	contaminating	genomic	DNA,	which	contains	the	intron.	This	method	of	primer	design	was	used	for	primer	pairs	that	specifically	amplify	KRas-4B	(Fig.	3.3)	and	NRas	 (Fig.	 3.4)	 transcripts.	 	 The	 design	 of	 primers	 on	 exon-exon	 boundaries	aided	 in	 the	 specific	 amplification	 of	 alternatively	 spliced	 KRas	 isoforms	 (Fig.	3.3).		The	other	option	was	to	design	primers	that	flank	introns,	so	that	the	forward	and	reverse	primer	anneal	entirely	to	different	exons	separated	by	at	least	one	intron.	 Thus,	 genomic	 DNA	 templates	would	 be	 longer	 than	 intron-less	 cDNA	templates	 and	 unlikely	 to	 be	 amplified	 during	 the	 qRT-PCR	 reaction	 cycles.	 If	genomic	amplicons	were	produced,	these	could	be	distinguished	by	melt	curve	analysis	(section	3.2.2)	or	by	performing	an	end-point	PCR	reaction	and	running	the	 PCR	 products	 on	 an	 agarose	 gel.	 Primer	 pairs	 flanking	 an	 intron	 were	designed	for	specific	amplification	of	ERas	(Fig.	3.1),	HRas	(Fig.	3.2)	and	KRas-
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4A	 (Fig.	 3.3)	 transcripts.	 For	 ERas,	 the	 forward	 primer	 annealed	 to	 the	 non-coding	exon	0,	comprising	the	5’	untranslated	region	(UTR).				These	methods	of	primer	design	were	an	extra	precaution,	as	all	RNA	samples	were	treated	with	DNase	to	remove	genomic	DNA.	Also,	representative	samples	were	compared	along	with	their	“-RT”	controls	(RNA	samples	without	reverse	transcriptase	 in	 the	 reverse	 transcription	 reaction)	 using	 end-point	 PCR	 and	qRT-PCR	to	exclude	any	false	positives	due	to	genomic	DNA	amplification.		Each	primer	pair	was	tested	 in	silico	using	NetPrimer	v1.10	(PREMIER	Biosoft	International)	for	the	formation	of	any	secondary	structures,	including	hairpins	and	primer-dimers,	GC	content	and	Tm.	Primers	with	GC	content	of	50-65%,	and	with	 free	 energy	 higher	 than	 ΔG	 =	 -0.7kcal/mol	 for	 hairpin	 formation,	 ΔG	 =	 -5kcal/mol	for	self-dimer	and	ΔG	=	-5.5kcal/mol	for	cross-dimer,	as	well	as	with	a	Tm	of	around	60˚C	were	chosen	and	further	verified	by	Primer-BLAST	(Ye	et	al.,	2012)	for	gene	specificity.	Several	to	dozens	of	primer	pairs	were	tested	for	each	 Ras	 isoform	 in	 silico	 before	 the	 most	 optimal	 primers	 were	 chosen	 for	laboratory	evaluation.			
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A.	Gene	overview		
 	
B.	Transcript	NM_181548.2													
	
 
 
C.	qRT-PCR	primer	positions	in	mRNA	sequence	of	NM_181548.2	
 
ggtcagatccgcctactgcccctcatcagactgctactcctgggagcacagcacctgct
ctttacacctcttccttgagctgctggggaATGGCTTTGCCTACAAAGTCTAGCATCTT
GGACCTGAGCTCCGGCACCCCATGCACCAGATCTCCAGAGGAAAGTCACGAGGCTTGGG
CACAGTGCAAAGATGCTGGCAGGCAGCTACCCGAGTACAAGGCAGTGGTGGTGGGTGCA
AGTGGTGTTGGTAAAAGTGCTCTCACCATCCAGATGACTCACCAATGCTTCGTGAAAGA
CCATGACCCCACTATCCAAGATTCCTACTGGAAGGAAGTGGCCAGGGACAACGGAGGCT
ACATTCTAAATGTTCTGGATACATCTGGGCAGGATATTCACCGGGCTCTGCGTGACCAG
TGCTTGGCATCTGGTGATGGTGTGCTGGGCGTCTTTGCTCTTGACGACCCCTCGTCTCT
GGACCAGTTGCAGCAGATATGGTCCACCTGGACCCCTCACCACAAGCAGCCTCTGGTAC
TAGTGGGCAACAAGTGTGACCTGGTGACCACTGCTGGAGATGCTCATGCTGCCGCAGCC
CTCCTTGCTCACAAGTTGGGGGCCCCCTTGGTGAAGACCTCAGCCAAGACGCGGCAAGG
TGTGGAGGAAGCCTTTGCCCTGCTTGTCCATGAGATTCAGAGGGCCCAGGAGGCTGTGG
CCGAATCAAGCAAGAAGACCCGACACCAGAAAGCCGTGTGTAGCTGTGGCTGCTCTGTA
GCCTGAagatctttgtctagcaaattgacccttgtctcatgtcaaggtgacaattctct
tgtaataagatttccctctccgaccaagttaccacagacatctttttattgtcatttgg
tgagaagttacgtggtaacatgggacatccctcattgactgtgttttatgaaactctat
gcaaaattaaataaatgttctcaggattcaaagcttcctttatac 
 
Fig.	 3.1	 ERas	 sequence	 and	 position	 of	 qRT-PCR	 primers.	A	 A	 schematic	gene	 overview	with	 exons	 (boxes)	 and	 introns	 (lines)	 and	 the	 corresponding	lengths	in	base	pairs	(bp).	B.	Transcript	variant	showing	coding	(blue)	and	non-coding	 sequence	 (black)	 in	 exons	with	 aligned	 qRT-PCR	 primers	 (arrows).	C.	mRNA	 coding	 sequence	 with	 primer	 positions	 (red	 arrows	 and	 underlined	sequences).	Non-coding	sequence	is	depicted	in	lower	case,	coding	sequence	is	depicted	in	blue.	
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A.	Gene	overview		
		
 
B.	Transcript	variants	
	NM_008284.2				 	NM_001130444.1				 	NM_001130443.1		 
	
 
C.	qRT-PCR	primer	positions	in	mRNA	sequence	of	NM_008284.2			
 
gctgtagaagctATGACAGAATACAAGCTTGTGGTGGTGGGCGCTGGAGGCGTGGGAAAGAG
TGCCCTGACCATCCAGCTGATCCAGAACCACTTTGTGGACGAGTATGATCCCACTATAGAGG
ACTCCTACCGGAAACAGGTGGTCATTGATGGGGAGACATGTCTACTGGACATCTTAGACACA
GCAGGTCAAGAAGAGTATAGTGCCATGCGGGACCAGTACATGCGCACAGGGGAGGGCTTCCT
CTGTGTATTTGCCATCAACAACACCAAGTCCTTCGAGGACATCCATCAGTACAGGGAGCAGA
TCAAGCGGGTGAAAGATTCAGATGATGTGCCAATGGTGCTGGTGGGCAACAAGTGTGACCTG
GCTGCTCGCACTGTTGAGTCTCGGCAGGCCCAGGACCTTGCTCGCAGCTATGGCATCCCCTA
CATTGAAACATCAGCCAAGACCCGGCAGGGCGTGGAGGATGCCTTCTATACACTAGTCCGTG
AGATTCGGCAGCATAAATTGCGGAAACTGAACCCACCCGATGAGAGTGGTCCTGGCTGCATG
AGCTGCAAATGTGTGCTGTCCTGAcaccaggctcaggacatgg 
	
Fig.	 3.2	 HRas	 sequence	 and	 position	 of	 qRT-PCR	 primers.	A	 A	 schematic	gene	 overview	with	 exons	 (boxes)	 and	 introns	 (lines)	 and	 the	 corresponding	lengths	 in	 base	 pairs	 (bp).	B.	 Transcript	 variants	 showing	 coding	 (alternating	blue	and	green;	alternative	exon	in	orange)	and	non-coding	sequences	(black)	in	exons	with	aligned	qRT-PCR	primers	(arrows).	C.	mRNA	sequence	with	primer	positions	 (red	 arrows	 and	 underlined	 sequences).	 Non-coding	 sequence	 is	depicted	in	lower	case,	coding	exons	in	alternating	blue	and	green.		
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A.	Gene	overview	
 
 
 
B.	Transcript	variants	
				BC119495.1		KRasA		
				NM_021284.6		KRasB		 
C.		qRT-PCR	primer	positions	in	KRasA	mRNA	BC119495.1		 
ATGACTGAGTATAAACTTGTGGTGGTTGGAGCTGGTGGCGTAGGCAAGAGCGCCTTGACGATACAGCT
AATTCAGAATCACTTTGTGGATGAGTATGACCCTACGATAGAGGACTCCTACAGGAAACAAGTAGTAA
TTGATGGAGAAACCTGTCTCTTGGATATTCTCGACACAGCAGGTCAAGAGGAGTACAGTGCAATGAGG
GACCAGTACATGAGAACTGGGGAGGGCTTTCTTTGTGTATTTGCCATAAATAATACTAAATCATTTGA
AGATATTCACCATTATAGAGAACAAATTAAAAGAGTAAAGGACTCTGAAGATGTGCCTATGGTCCTGG
TAGGGAATAAGTGTGATTTGCCTTCTAGAACAGTAGACACGAAACAGGCTCAGGAGTTAGCAAGGAGT
TACGGGATTCCGTTCATTGAGACCTCAGCAAAGACAAGACAGAGAGTGGAGGATGCTTTTTATACATT
GGTGAGAGAGATCCGACAGTACAGATTGAAAAAAATCAGCAAAGAAGAAAAGACTCCTGGCTGTGTGA
AAATTAAAAAATGCGTTATAATGTAAtctgggtgttgacgatg 
	
D.		qRT-PCR	primer	positions	in	KRasB	mRNA	NM_021284.6				 
ATGACTGAGTATAAACTTGTGGTGGTTGGAGCTGGTGGCGTAGGCAAGAGCGCCTTGACGATACAGCT
AATTCAGAATCACTTTGTGGATGAGTATGACCCTACGATAGAGGACTCCTACAGGAAACAAGTAGTAA
TTGATGGAGAAACCTGTCTCTTGGATATTCTCGACACAGCAGGTCAAGAGGAGTACAGTGCAATGAGG
GACCAGTACATGAGAACTGGGGAGGGCTTTCTTTGTGTATTTGCCATAAATAATACTAAATCATTTGA
AGATATTCACCATTATAGAGAACAAATTAAAAGAGTAAAGGACTCTGAAGATGTGCCTATGGTCCTGG
TAGGGAATAAGTGTGATTTGCCTTCTAGAACAGTAGACACGAAACAGGCTCAGGAGTTAGCAAGGAGT
TACGGGATTCCGTTCATTGAGACCTCAGCAAAGACAAGACAGGGTGTTGACGATGCCTTCTATACATT
AGTCCGAGAAATTCGAAAACATAAAGAAAAGATGAGCAAAGATGGGAAGAAGAAGAAGAAGAAGTCAA
GGACAAGGTGTACAGTTATGTGA 
	
Fig.	 3.3	 KRas	 sequence	 and	 position	 of	 qRT-PCR	 primers.	A	 A	 schematic	gene	 overview	with	 exons	 (boxes)	 and	 introns	 (lines)	 and	 the	 corresponding	lengths	 in	 base	 pairs	 (bp).	B.	 Transcript	 variants	 showing	 coding	 (alternating	blue	and	green;	alternative	exon	in	orange)	and	non-coding	sequences	(black)	in	exons	with	aligned	qRT-PCR	primers	(arrows).	C.	and	D.	mRNA	sequence	with	primer	positions	(red	arrows	and	underlined	sequences).	Non-coding	sequence	is	 depicted	 in	 lower	 case,	 coding	 exons	 in	 alternating	 blue	 and	 green	 and	alternative	exon	in	orange.	
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A.	Gene	overview			
	
 
 
 
B.	Transcript			NM_010937													
  
 
C.	qRT-PCR	primer	positions	in	mRNA	sequence	of	NM_010937	
 
ATGACTGAGTACAAACTGGTGGTGGTTGGAGCAGGTGGTGTTGGGAAAAGCGCCTTGAC
GATCCAGCTAATCCAGAACCACTTTGTGGATGAATATGATCCCACCATAGAGGATTCTT
ACCGAAAGCAAGTGGTGATTGATGGTGAGACCTGCCTGCTGGACATACTGGACACAGCT
GGACAAGAGGAGTACAGTGCCATGAGAGACCAGTACATGAGGACAGGCGAAGGGTTCCT
CTGTGTATTTGCCATCAATAATAGCAAATCATTTGCAGATATTAACCTCTACAGGGAGC
AAATTAAGCGTGTGAAAGATTCTGATGATGTCCCCATGGTGCTGGTAGGCAACAAGTGT
GACTTGCCAACAAGGACAGTTGACACAAAGCAAGCCCACGAACTGGCCAAGAGTTACGG
AATTCCATTCATTGAGACCTCAGCCAAGACCCGACAGGGTGTGGAGGATGCCTTTTACA
CACTGGTAAGGGAGATACGCCAGTACCGAATGAAAAAGCTCAACAGCAGTGACGATGGC
ACTCAAGGTTGTATGGGGCTGCCCTGTGTGCTGATGTAGtaagaca 
 
 
Fig.	 3.4	 NRas	 sequence	 and	 position	 of	 qRT-PCR	 primers.	A	 A	 schematic	gene	 overview	with	 exons	 (boxes)	 and	 introns	 (lines)	 and	 the	 corresponding	lengths	 in	 base	 pairs	 (bp).	B.	 Transcript	 variant	 showing	 coding	 (alternating	blue	and	green)	and	non-coding	sequences	(black)	 in	exons	with	aligned	qRT-PCR	 primers	 (arrows).	 C.	 mRNA	 coding	 sequence	 with	 primer	 positions	 (red	arrows	 and	underlined	 sequences).	Non-coding	 sequence	 is	 depicted	 in	 lower	case,	coding	exons	are	depicted	in	alternating	blue	and	green.		
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3.2.2	 	 	Optimisation	of	qRT-PCR	
	Each	 step	 of	 the	 RT-PCR	 reaction	 (extension,	 denaturation	 and	 annealing)	utilising	 SYBR	 Green	 I,	 as	 well	 as	 primers	 used	 in	 the	 assay,	 require	 further	optimisation	 (McPherson	 and	Møller,	 2006,	 Bio-Rad	 Laboratories,	 2006).	 The	qRT-PCR	reaction	cycles	were	based	on	previous	assays	established	 in	 the	 lab	and	 are	 described	 in	 Chapter	 2.	 The	 primers	 selected	 in	 section	 3.2.1	 were	tested	 empirically.	 Subsequent	 sections	 will	 describe	 annealing	 temperature	optimisation	(section	3.2.2.2),	testing	of	primer	specificity	(section	3.2.2.3)	and	efficiency	 (section	 3.2.2.4),	 as	well	 as	 generation	 of	 standard	 curves	 to	 assess	RT-PCR	 reaction	 performance	 (section	 3.2.2.5).	 Section	 3.2.2.1	 describes	 the	generation	of	Ras	isoform-specific	plasmids	for	use	as	control	templates	and	the	final	 section	 3.2.2.6	 addresses	 selection	 of	 a	 reference	 gene	 for	 qRT-PCR	data	normalisation.	
 	
3.2.2.1	 	 	 Generation	of	plasmids		Plasmids	 encoding	 murine	 Ras	 isoforms	 were	 used	 to	 test	 the	 Ras	 primer	specificity	 (section	 3.2.2.3)	 and	 to	 generate	 standard	 curves	 for	 absolute	quantification	 of	 Ras	 isoforms	 in	 qRT-PCR	 reactions	 (section	 3.2.2.5).	 Mouse	ERas,	 KRasA	 and	 KRasB	 plasmids	 were	 purchased	 from	 Source	 Bioscience.	Mouse	HRas	and	NRas	fragments	were	cloned	from	undifferentiated	R1	mouse	ESCs	 cDNA	 for	 TOPO	 cloning	 (vector	maps	 are	 shown	 in	 Appendix	 Fig.	 A3.1-A3.2).		For	HRas,	the	whole	coding	DNA	sequence	(CDS),	as	well	as	a	small	non-coding	DNA	 fragment	 from	 exon	 1	 (Fig.	 3.2),	 were	 amplified	 from	 the	 cDNA	 using	previously	 designed	 HRas	 forward	 primer	 (Table	 3.1,		F:	 5’	 GCTGTAGAAGCTATGACAGAATAC	 3’)	 and	 a	 cloning	 reverse	 primer		(R:	 5’	 ACCTCGAGATCAGGACAGCAC	 3’)	 that	 recognised	 the	 3’	 end	 of	 the	 CDS	(exon	4B	of	all	transcript	variants,	Fig.	3.2).	The	properties	of	the	forward	and	reverse	primers	are	summarised	in	Table	3.2.	Although	NetPrimer	predicted	the	formation	 of	 a	 cross-dimer	 and	 a	 self-dimer	 for	 the	 reverse	 primer	 (∆G	 was	lower	than	6	kcal/mol),	any	non-specific	products	would	be	unlikely	to	prevent	
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amplification	of	the	required	product.	Primer-BLAST	confirmed	that	the	specific	amplicon	 would	 be	 582	 bp	 long,	 whereas	 any	 amplification	 of	 genomic	 DNA	would	 yield	 an	 amplicon	 longer	 than	 3,000	 bp,	 which	 would	 be	 easily	distinguished	on	an	agarose	gel.	Primer-BLAST	also	predicted	amplification	of	additional	sequences,	which	included	a	664	bp	product	from	HRas	transcript	1	variant	X4	(XM_006536160.1).			
	
Table	 3.2	 Properties	 of	 HRas	 cloning	 primers.	 Primers	 were	 used	 for	amplifying	 mouse	 HRas	 transcript	 1	 coding	 DNA	 sequence	 and	 a	 short	 non-coding	 fragment	 for	 subsequent	TOPO	 cloning.	Nt	 –	 nucleotides,	 Tm	 –	melting	temperature,	GC%	-	percentage	of	G	and	C	bases,	∆G	–	Gibbs	free	energy.	
	 Primer	 Length	(nt)	 Tm	(˚C)	 GC%	 ∆G	(kcal/mol)	Hairpin	 Self-dimer	 Cross-dimer	Forward	 24	 53.23	 41.67	 -0.59	 -4.89	 -9.03	Reverse	 21	 58.84	 57.14	 -0.57	 -9.96			The	PCR	reactions	were	performed	using	annealing	 temperature	gradient	and	PfuUltra	Hotstart	 polymerase	 that	 has	 a	 proofreading	 ability	 (Lundberg	 et	 al.,	1991)	 (section	 2.7.12).	 PCR	 products	 were	 run	 on	 a	 2%	 agarose	 gel	 and	visualised	by	UV	transilluminator	(Fig.	3.5).	The	reaction	revealed	an	additional	band	at	 a	molecular	weight	 (MW)	above	600	bp	 (Fig	3.5,	 red	asterisk),	which	might	have	been	the	predicted	HRas	transcript	1	amplicon.		For	NRas	cloning,	the	PCR	primers	designed	for	RT-PCR	(Table	3.1)	were	used	to	amplify	a	213	bp	 fragment	 from	 the	CDS	and	3’UTR	of	NRas	 (Fig.	3.4).	The	PCR	products	were	run	on	a	2%	agarose	gel	(Fig.	3.5).	The	Ras	sequences	were	gel-purified	and	subcloned	into	pCR4-TOPO	and	transformed	into	competent	E.	
coli	 TOPO	bacteria.	 Glycerol	 stocks	 and	minipreps	were	made	 from	overnight	bacterial	cultures	and	minipreps	were	tested	for	the	correct	fragment	insertion	by	EcoRI	restriction	digest	and	sequencing.			
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Fig.	 3.5	 Generation	 of	 mouse	 isoform-specific	 Ras	 fragments	 for	
subcloning	 into	 pCR4-TOPO	 plasmid.	 End-point	 PCR	 reactions	 were	performed	with	40	ng	of	cDNA	from	undifferentiated	R1	ESCs	p.19	using	mouse	HRas-	 or	 NRas-specific	 primers,	 including	 blanks	with	water	 instead	 of	 cDNA	used	 as	 a	 negative	 control.	 PCR	 reactions	 were	 using	 proofreading	 Pfu	polymerase	 and	 annealing	 temperature	 (Ta)	 gradient.	 The	PCR	products	were	run	on	2	%	agarose	gels	(Ta	=	52.1˚C,	 for	HRas;	Ta	=	52.3˚C,	 for	NRas)	and	the	correct	 amplified	 gene	 fragments	 (shown	 by	 arrows	with	 length	 in	 bp)	 were	excised	 and	 purified	 for	 subsequent	 subcloning	 into	 the	 pCR4-TOPO	 plasmid.	Red	 asterisk	 corresponds	 to	 an	 unspecific	 amplification	 product	 for	 HRAS	primers.	MW	–	molecular	weight	marker,	bp	–	base	pair.			
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3.2.2.2		 	 Annealing	temperature	optimisation	
	First,	 all	 Ras-isoform	 primer	 pairs	 were	 amplified	 at	 Ta	 =	 60˚C	 for	 40	 cycles	using	cDNA	from	undifferentiated	R1	ESCs	as	a	 template	(Fig.	3.6	A).	Negative	controls	with	“-RT”	and	with	nuclease-free	water	were	included	in	each	primer	set.	 The	PCR	products	 of	 all	 reactions	were	 run	 on	2%	agarose	 gels	 to	 reveal	correct	amplification	products	for	each	Ras	isoform-specific	primers.	However,	primer-dimer	product	 formation	was	present	 in	 all	 negative	 control	 reactions	for	 all	 primer	 pairs	 and	 in	 reactions	 with	 cDNA	 for	 ERAS,	 HRAS	 and	 KRASA	primers.	 Although	 no	 other	 unspecific	 amplicons	 were	 present,	 formation	 of	primer-dimer	 products	 alone	 meant	 that	 the	 PCR	 conditions	 were	 not	 fully	optimised.		Next,	an	annealing	temperature	gradient	was	used	in	end-point	PCR	for	a	series	of	 PCR	 assays	 with	 Ta	 below	 and	 above	 the	 Tm	 of	 each	 Ras	 isoform-specific	primer	 pair.	 A	 negative	 control	 (blank)	 with	 nuclease-free	 water	 instead	 of	cDNA	was	included	for	each	primer	set	and	the	PCR	products	were	run	on	2%	agarose	 gels	 (Fig.	 3.6B).	 For	 HRas,	 two	 different	 primer	 pairs	 were	 tested	initially	–	HRAS1,	specific	only	for	HRAS	transcript	1,	and	HRAS,	specific	for	all	HRAS	transcripts.	Both	primer	pairs	amplified	the	desired	PCR	products	of	171	bp	 and	188	bp	 for	 the	HRAS1	 and	HRAS	primer	 pairs,	 respectively.	However,	PCR	 reactions	 with	 the	 HRAS1	 primer	 pair	 led	 to	 primer-dimer	 products	 at	lower	 annealing	 temperatures	 (55.1-57.8˚C)	 and	 in	 the	 reaction	 with	 no	template	 cDNA	 (blank).	 Thus,	 this	 primer	 set	 was	 not	 ideal	 for	 qRT-PCR	 as	primer-dimer	 formation	 depletes	 primers	 from	 binding	 to	 the	 DNA	 template	and	 reduces	 reaction	 efficiency	 (Chou	 et	 al.,	 1992).	 No	 non-specific	 product	formation	was	seen	for	HRAS	primer	pair,	hence,	these	were	chosen	for	further	optimisation.	
	For	 the	 remaining	Ras	 isoform-specific	primer	pairs,	 all	PCR	reactions	yielded	products	 of	 the	 desired	 length,	 suggesting	 correct	 amplification	 of	 the	 PCR	product	within	the	range	of	tested	Ta	(Fig.	3.6B).	However,	higher	Ta	during	the	PCR	resulted	 in	 less	PCR	product.	For	KRASB	primer	pair	at	Ta	=	56.7˚C	 there		
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A														
	
	
B		
	
	
Fig.	 3.6	Optimising	 annealing	 temperature	 (Ta)	 for	 Ras	 isoform	primers.	Ras	 isoform-specific	 primers	 were	 used	 to	 amplify	 20	 ng	 of	 cDNA	 from	undifferentiated	R1	ESCs.	“-RT”	and	nuclease-free	water	were	used	in	reactions	as	 negative	 controls.	 Reaction	 products	were	 run	 on	 2%	 agarose	 gels.	A	 PCR	conditions:	95˚C	for	5	mins,	94˚C	for	30sec,	60˚C	for	30	sec,	72˚C	for	30	sec,	40	cycles;	blank	–	no	reaction.	B	PCR	conditions:	95˚C	for	5	min,	94˚C	for	30	sec,	Ta	(gradient	55-65˚C)	for	30	sec,	72˚C	for	20	sec;	35	cycles.	Blanks	represent	PCR	with	no	 cDNA	 (Ta	=	60.9˚C	 for	KRASB,	Ta	=	59.0˚C	 for	other	primers).	 Specific	amplicons	 for	Ras	 isoforms:	ERAS	–	230bp,	HRAS	transcript	1	–	171	bp,	HRAS	(all	transcripts)	–	188	bp,	KRASA	–	184	bp,	KRASB	–	142	bp,	NRAS	–	213	bp.	Red	asterisks	indicate	primer-dimer.		
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was	 no	 PCR	 product,	 possibly	 because	 of	 mispipetting	 of	 one	 of	 the	 PCR	constituents.	 Negative	 controls	 (blanks)	 did	 not	 show	 formation	 of	 primer-dimer	 products.	 Representative	 bands	 from	 each	 primer	 pair	 reaction	 were	excised,	 purified	 and	 sequence-verified	 (Dundee	 Sequencing	 Services).	 As	higher	 Ta	 contributes	 to	 better	 primer-template	 specificity,	 a	 Ta	 of	 62˚C	 was	chosen	for	the	subsequent	PCR	reactions	for	all	primer	pairs.			
3.2.2.3		 	 Primer	specificity	
	Primer	 specificity	 depends	 on	 the	 Ta	 (Wu	 et	 al.,	 1991,	 Don	 et	 al.,	 1991),	 as	discussed	in	section	3.1.2,	and	is	also	highly	sensitive	to	other	PCR	parameters	(Wang	and	Seed,	2003).	Ras	isoform-specific	primers	were	shown	to	amplify	the	correct	PCR	products	(Fig.	3.6),	which	complemented	in	silico	primer	specificity	testing	by	Primer-BLAST	(section	3.2.1).	However,	 the	specificity	between	Ras	isoforms	under	the	selected	PCR	condition	also	needs	to	be	verified	empirically.			Ras	 isoform	 plasmids	 (Section	 3.2.2.1)	 were	 used	 as	 DNA	 templates	 in	 PCR	reactions	for	each	Ras	isoform	primer	pair	(Fig.	3.7).	All	primers	revealed	high	specificity	for	the	correct	Ras	isoform	by	amplifying	the	desired	DNA	fragments	only	 in	 the	 reactions	with	 the	 corresponding	Ras	 plasmids.	Most	 importantly,	Ras	primers	did	not	cross-amplify	from	the	other	Ras	isoform	plasmids.		
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Fig.	 3.7	 Ras	 isoform	 primer	 specificity.	 Ras	 isoform-specific	 primers	 were	used	in	end-point	PCR	reactions	with	10	pg	of	each	Ras	isoform	plasmid	as	DNA	template.	Nuclease-free	water	 instead	of	 cDNA	was	used	as	a	negative	control	for	 each	 primer	 set.	 The	 PCR	 products	 were	 run	 on	 2%	 agarose	 gels;	 PCR	conditions:	95˚C	for	5	mins,	94˚C	for	30	sec,	62˚C	for	30	sec,	72˚C	for	30	sec,	40	cycles.	PCR	specific	products	had	the	following	lengths:	ERAS	–	230bp,	HRAS	–	188,	KRASA	–	184bp,	KRASB	–	142bp,	NRAS	–	213bp.		
	
	
3.2.2.4			 	 Primer	efficiency	Relative	quantification	in	qRT-PCR	relies	on	the	assumption	that	the	amount	of	DNA	 product	 doubles	 during	 each	 PCR	 cycle,	 which	 means	 the	 reactions	 are	100%	efficient.	To	test	this	assumption,	cDNA	from	undifferentiated	mouse	R1	ESCs	was	used	to	generate	a	2-fold	dilution	series	(Fig.	3.8)	to	measure	reaction	efficiency,	as	described	 in	section	3.1.2.3.	Fig.	3.8	summarises	the	 linear	graph	equations,	as	well	as	the	calculated	percent	efficiency	of	qRT-PCR	reactions	for	each	 Ras	 isoform	 primer	 set.	 Overall,	 Ras	 isoform-specific	 primers	demonstrated	good	reaction	efficiency.	Only	the	HRAS	primer	pair	had	>105%	efficiency,	 although	 no	 non-specific	 amplification	 products	 were	 detected	 by	melt	curve	analysis	that	might	account	for	this	over	amplification.	Moreover,	all	experimental	data	fit	well	with	the	regression	line,	which	was	represented	by	a	
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high	 coefficient	 of	 determination	R2	(above	 0.980,	 Fig.	 3.8).	 In	 summary,	 qRT-PCR	 optimisation	 for	 each	 Ras	 isoform	 primer	 pair	 gave	 good	 results	 both	 in	
silico	 and	 by	 empirical	 testing,	 which	 included	 optimisation	 of	 the	 Ta,	 primer	specificity	 and	 reaction	 efficiency.	 The	 next	 sections	 will	 describe	 the	quantitation	methods	used	for	qRT-PCR.		
	
A.	
	
	
B.	
Primers	 Ct	value	range	 Equation	 !!	 %E	ERas	 24-30	 y	=	-1.0047x	+	38.586	 0.99946	 99	HRas	 28-34	 y	=	-0.8907x	+	40.798	 0.99659	 118	KRasA	 28-34	 y	=	-0.9934x	+	41.582	 0.98435	 101	KRasB	 24-30	 y	=	-1.0389x	+	37.734	 0.99494	 95	NRas	 24-30	 y	=	-1.0236x	+	38.134	 0.99921	 97	
	
Fig.	 3.8	 Mouse	 Ras	 isoform	 primer	 amplification	 efficiencies.	 Standard	curves	 were	 generated	 on	 the	 basis	 of	 a	 2-fold	 dilution	 series	 of	 a	 cDNA	template	from	undifferentiated	R1	ESCs	p.26	with	each	Ras	isoform	primer	set.	The	initial	(neat)	cDNA	amount	was	10	ng.	After	qRT-PCR,	the	average	Ct	values	of	 two	 technical	 replicates	 were	 calculated	 for	 each	 dilution.	 A.	 An	 example	standard	 curve	 graph	 for	 ERas	 primer	 set.	 B.	 A	 summary	 table	 for	 all	 Ras	isoform	 primers	 that	 includes	 the	 CT	 value	 range	 for	 all	 dilution	 points,	 the	linear	 regression	 line	 equations,	 the	 coefficients	 of	 determination	 R2	 and	 the	calculated	percentage	efficiencies	%E	of	amplification.	PCR	conditions:	95˚C	for	5	mins,	94˚C	for	30	sec,	62˚C	for	30	sec,	72˚C	for	30	sec,	40	cycles.		
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3.2.2.5	 	 	Quantification	of	qRT-PCR	results		To	absolutely	quantify	Ras	 transcript	expression,	mouse	Ras	 isoform	plasmids	(section	3.2.2.1)	were	used	in	5-fold	serial	dilutions	to	generate	standard	curves	specific	 for	 each	 Ras	 primer	 set	 (Table	 3.3).	 Assuming	 that	 one	 base	 pair	 is	about	 675	Da	 (the	 average	 of	 the	 calculated	 unified	 atomic	mass	 unit	 for	A-T	and	C-G	base	pairs),	and	knowing	 that	1	Da	=	1.660538921(73)	 ·	10-27	kg,	 the	mass	of	a	given	plasmid	molecule	and,	hence,	the	plasmid	copy	number	can	be	calculated.	To	generate	a	standard	curve,	qRT-PCR	is	performed	for	template	at	each	dilution	and	the	obtained	CT	values	are	plotted	against	the	logarithm	(base	=	 dilution	 factor)	 of	 the	 starting	 plasmid	 quantity	 as	 illustrated	 for	 a	 2-fold	dilution	series	in	Fig.	3.8.	The	best	fit	line	through	the	data	points	gives	a	linear	graph	equation	(Ong	and	Irvine,	2002,	Higuchi	et	al.,	1993).	 In	the	case	of	a	5-fold	 dilution	 series,	 as	 applied	 for	 the	mouse	 Ras	 plasmids	 in	 this	 study,	 the	expected	CT	interval	between	each	dilution	point	is	2.32	cycles,	i.e.	the	slope	of	the	linear	equation	would	be	-2.32,	indicating	100%	reaction	efficiency.			In	this	study,	the	efficiency	of	each	standard	curve	was	assessed	separately	and	is	discussed	in	subsequent	chapters.	To	absolutely	quantify	Ras	isoforms	in	the	test	samples,	the	Ras	isoform	standards	were	run	on	each	qRT-PCR	plate	along	with	 the	 tested	 samples.	 The	 CT	 values	 obtained	 from	 the	 test	 samples	 were	then	 compared	 to	 CT	 values	 of	 the	 standards	 and	 the	 absolute	 copy	 numbers	were	 calculated	based	on	 the	 standard	 curve	 equation	 (the	best	 fit	 line)	 (Ong	and	Irvine,	2002).				
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3.2.2.6	 	 Reference	genes	for	relative	quantitation	in	qRT-PCR	
	Based	 on	 the	 available	 literature	 (discussed	 in	 section	 3.1.2.5),	 amongst	 the	various	reference	genes	available,	RNA	polymerase	II	(POL2RE)	was	considered	most	 likely	to	reflect	stable	mRNA	levels	across	the	murine	samples	examined	in	this	study.		To	 test	 whether	 POL2RE	 would	 be	 a	 good	 reference	 gene,	 mouse	 POL2RE	primers	were	kindly	provided	by	Dr	Aleksandra	Rak-Raszewska	(University	of	Liverpool)	and	tested	both	 in	silico	and	experimentally,	as	in	previous	sections	for	Ras	primer	pairs.	Primer-BLAST	and	end-point	PCR	revealed	no	non-specific	amplification	 products	 or	 primer-dimers	 for	 POL2RE	 primers	 (Fig.	 3.9).	 Ta	optimisation	 using	 temperature	 gradient	 showed	 specific	 amplification	 at	 all	tested	temperatures,	with	very	good	amplification	at	Ta	around	62˚C,	which	was	previously	chosen	to	be	used	for	qRT-PCR	with	Ras	primer	pairs.	Furthermore,	reaction	efficiency	was	acceptable	and	the	expression	level	(CT	value	range)	of	POL2RE	was	similar	to	that	for	the	more	abundant	Ras	isoforms	in	cDNA	from	undifferentiated	ESCs	(Fig.	3.10).		A	 POL2RE-specific	 plasmid	 was	 generated	 to	 use	 as	 a	 standard	 for	 absolute	quantification	of	POL2RE	levels	in	test	samples.	As	before,	the	proofreading	Pfu	polymerase	 together	 with	 POL2RE	 qRT-PCR	 primers	 that	 amplify	 a	 278	 bp	fragment	was	 used	 in	 end-point	 PCR	with	 cDNA	 from	undifferentiated	mouse	R1	 ESCs	 (Fig.	 3.11).	 The	 correct	 size	 product	 was	 excised,	 purified	 and	subcloned	 into	 pCR4-TOPO	 vector,	which	was	 then	 sequence-verified.	 Finally,	the	POL2RE-specific	plasmid	was	used	 in	5-fold	dilution	 series	 to	generate	an	absolute	standard	curve	for	copy	number	quantification	(Table	3.4).						
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Fig.	3.9	Ta	optimisation	and	primer	specificity	for	mouse	POL2RE	primers.	20	 ng	 of	 template	 cDNA	 from	mouse	 undifferentiated	 R1	 ESCs,	 together	with	POL2RE	primers	were	used	in	end-point	PCR	with	a	Ta	gradient	of	55-65˚C	(left	panel).	Nuclease-free	water	instead	of	cDNA	was	used	as	a	blank	(Ta	=	59.0˚C).	To	further	confirm	primer	specificity,	end-point	PCR	was	run	at	Ta	=	62˚C	with	additional	negative	control	“-RT”	(right	panel).	PCR	products	were	run	on	a	2%	agarose	 gel	 and	visualised	with	 ethidium	bromide.	PCR	 conditions:	 95˚C	 for	5	mins,	94˚C	for	30sec,	Ta	for	30	sec,	72˚C	for	30	sec,	40	cycles.	Arrow	denotes	PCR	product	size.	MW	–	molecular	weight	markers,	POL2RE	–	RNA	polymerase	II,	bp	–	base	pair.															
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A.	
		
B.	
Primers	 Ct	value	range	 Equation	 !!	 %E	POL2RE	 22-28	 y	=	-0.9524x	+	35.24	 0.99202	 107	
	
Fig.	 3.10	 POL2RE	 primer	 amplification	 efficiency.	 A	 standard	 curve	 was	generated	 on	 the	 basis	 of	 2-fold	 dilution	 series	 of	 a	 cDNA	 template	 from	undifferentiated	R1	ESCs	p.26	with	POL2RE	primer	set	(neat	cDNA	amount	was	10	ng).	The	average	Ct	value	of	two	technical	replicates	was	calculated	at	each	dilution.	A.	A	standard	curve	graph	for	POL2RE	primer	set.	B.	A	summary	table	for	POL2RE	reference	gene	that	includes	the	linear	regression	line	equation,	the	coefficient	of	determination	R2	 and	 the	 calculated	percentage	efficiency	%E	of	amplification.	qRT-PCR	conditions:	95˚C	for	5	mins,	94˚C	for	30	sec,	62˚C	for	30	sec,	72˚C	for	30	sec,	40	cycles.							
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Fig.	 3.11	 Generation	 of	 mouse	 POL2RE	 reference	 gene	 fragment	 for	
subsequent	 subcloning	 into	 pCR4-TOPO	 plasmid.	 40	 ng	 of	 cDNA	 from	undifferentiated	R1	ESCs	was	used	in	end-point	PCR	with	POL2RE	primers	and	proofreading	Pfu	polymerase.	Annealing	 temperature	gradient	of	55-65˚C	was	used.	 PCR	 products	 were	 run	 on	 2%	 agarose	 gel	 and	 excised,	 purified	 and	subcloned	 into	 pCR4-TOPO.	 PCR	 conditions:	 95˚C	 for	 5	 mins,	 94˚C	 for	 30sec,	54.3˚C	for	30	sec,	72˚C	for	30	sec,	40	cycles.	POL2RE	–	RNA	polymerase	II,	MW	–	molecular	weight	marker,	bp	–	base	pair.			
Table	3.4	5-fold	dilution	 series	of	mouse	POL2RE	plasmid	 standards.	0.2	ng/µl	 of	 pCR4-TOPO-POL2RE	 plasmid	 was	 used	 in	 5-fold	 dilution	 series	containing	12	dilution	points	 (standard	number).	The	 standards	were	used	 in	qRT-PCR	 assays	 to	 generate	 RNA	 polymerase	 II	 (POL2RE)	 standard	 curve,	which	 was	 used	 to	 absolutely	 quantify	 POL2RE	 expression	 in	 test	 samples.	Plasmid	copy	numbers	were	calculated	based	on	plasmid	size	in	daltons	(Da).		
	 Standard	number	 Plasmid	concentration	(fg/µl)	 Plasmid	amount	per	assay/4	µl	(fg)	 Plasmid	copy	number	1	 200000	 800000	 1.69	·	108	2	 40000	 160000	 3.37	·	107	3	 8000	 32000	 6.74	·	106	4	 1600	 6400	 1.35	·	106	5	 320	 1280	 2.70	·	105	6	 64	 256	 5.39	·	104	7	 12.8	 51.2	 1.08	·	104	8	 2.56	 10.24	 2.16	·	103	9	 0.512	 2.048	 4.32	·	102	10	 0.1024	 0.4096	 86.3	11	 0.02048	 0.08192	 17.3	12	 0.004096	 0.016384	 3.45		
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3.3	 	 Summary	and	conclusions	
	In	 this	 chapter	 I	 have	 highlighted	 the	 careful	 design	 and	 the	 empirical	optimisation	 of	 qRT-PCR	 primer	 pairs	 required	 to	 enable	 quantitative	evaluation	of	Ras	isoform	expression	at	the	transcript	level.			The	design	of	primer	pairs	that	span	or	flank	exon	boundaries	allowed	cDNA	to	be	 selectively	 amplified	 without	 amplification	 of	 any	 genomic	 DNA	 that	 may	contaminate	 sample	 preparations.	 The	 primer	 design	 has	 also	 enabled	transcripts	 for	 each	 of	 the	Ras	 isoforms	 to	 be	 clearly	 discriminated,	 including	the	 closely	 related	 KRasA	 and	 KRasB	 transcripts.	 	 This	 was	 demonstrated	 in	reactions	 that	 tested	 for	 cross-amplification	 by	 primers	 from	 the	 alternative	cloned	 Ras	 templates.	 The	 expected	 CT	 values	 for	 each	 Ras	 isoform	 from	 ESC	mRNA	were	also	determined.				The	efficiency	of	amplification	with	each	of	the	Ras	primer	pairs	was	within	an	acceptable	 range	 to	 allow	 quantitative	 analysis.	 For	 absolute	 quantitation,	linearised	 plasmid	 dilution	 series	 were	 validated	 for	 use	 as	 standard	 curves.		For	 relative	 quantification,	 POL2RE	 was	 evaluated	 as	 a	 potentially	 suitable	reference	gene.			The	primers	and	protocols	that	were	optimised	in	this	chapter	will	now	be	used	to	evaluate	Ras	 isoform	expression	during	mouse	ESC	differentiation	(Chapter	4)	and	between	organ	systems	during	mouse	development	(Chapter	5).	
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Chapter	4	
Ras	isoform	expression	in	mouse	embryonic	stem	cells	
	
4.1	 	 Introduction	
4.1.1		 	 Embryonic	stem	cells	(ESCs)	and	embryoid	body	(EB)	model	
of	early	embryogenesis		
	Embryonic	 stem	 cells	 (ESCs)	 are	 pluripotent	 stem	 cells	 derived	 from	 the	undifferentiated	 inner	 cell	mass	 (ICM)	 of	 a	 blastocyst,	 at	 day	 4	 to	 5	 of	 a	 pre-implantation	 embryo.	 ESCs	 that	 could	 be	 cultured	 in	 vitro	 were	 first	 isolated	from	 the	mouse	 embryo	 (mESC)	 in	 1981	 (Evans	 and	 Kaufman,	 1981,	Martin,	1981).	The	isolation	of	human	ESCs	(hESC)	followed	almost	two	decades	later	in	1998	(Thomson	et	al.,	1998).	Both	mouse	and	human	ESC	are	able	to	self-renew	and	 show	 no	 signs	 of	 senescence	 after	 long-term	 culture;	 hence,	 ESCs	 are	considered	 to	 be	 “immortal”	 (Evans	 and	 Kaufman,	 1981,	 Suda	 et	 al.,	 1987,	Brimble	et	al.,	2004,	Zalzman	et	al.,	2010).		There	 is	 evidence	 that	 hESC	 might	 be	 at	 a	 higher	 developmental	 stage	 than	mESC,	as	their	expression	profile	more	closely	resembles	mouse	epiblast	stem	cells	(mEpiSC),	which	are	derived	from	the	post-implantation	embryo	(Nichols	et	al.,	2009,	Tesar	et	al.,	2007).	Developmental	stage	differences	are	reinforced	by	distinct	culturing	conditions	for	mESC	and	hESC.	The	former	are	maintained	in	the	undifferentiated	state	by	co-culture	on	a	feeder	layer	of	mouse	embryonic	fibroblasts	(mEFs)	and/or	by	using	mouse	cytokine	leukaemia	inhibitory	factor	(LIF)	 in	 the	medium	(Koestenbauer	et	 al.,	 2006,	Williams	et	 al.,	 1988).	On	 the	other	hand,	hESC	require	basic	fibroblast	growth	factor	(bFGF)	(Xu	et	al.,	2005)	and	maintenance	on	mEFs	(Humphrey	et	al.,	2004)	or	on	either	human-serum	matrix	or	Matrigel	with	or	without	a	conditioned	medium	(Koestenbauer	et	al.,	2006,	 Schatten	 et	 al.,	 2005,	 Stojkovic	 et	 al.,	 2005).	 By	 contrast,	 bFGF	 causes	differentiation	of	mESC	(Stavridis	and	Smith,	2003).			
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Both	mESC	and	hESC	are	pluripotent	cells	that	are	able	to	differentiate	into	any	cell	type	of	the	three	germ	layers:	ectoderm,	endoderm	and	mesoderm.	In	vivo,	following	 transplantation	 into	 blastocysts,	 mESC	 can	 support	 foetal	development	and	produce	viable,	completely	cell	culture-derived	mice	(Nagy	et	al.,	1990,	Nagy	et	al.,	1993).	In	vitro,	mESC	and	hESC	differentiate	into	embryoid	bodies	 (EBs),	 which	 are	 cell	 aggregates	 that	 resemble	 the	 developing	 early	embryo	(Arnold	and	Robertson,	2009,	Doetschman	et	al.,	1985,	Itskovitz-Eldor	et	 al.,	 2000).	 EBs	 have	 been	 extensively	 used	 as	 a	 model	 to	 study	 normal	embryonic	development	and	early	stages	of	cell	 lineage	specifications	(O'Shea,	2004,	Robertson,	1987).		To	induce	spontaneous	EB	formation,	mESC	are	cultured	in	suspension	in	non-adherent	 dishes	 in	 the	 absence	 of	 LIF	 (Doetschman	 et	 al.,	 1985,	 Leahy	 et	 al.,	1999,	 Murray	 and	 Edgar,	 2004).	 Following	 cell	 aggregation	 after	 2	 days	 of	culture	 (Murray	 and	Edgar,	 2001),	 the	 peripheral	 cells	 of	 the	 EB	 differentiate	into	 extraembryonic	 primitive	 endoderm	 cells,	 which	 recapitulate	 primitive	endoderm	(hypoblast)	formation	in	vivo	from	the	ICM	of	a	blastocyst	(Nadijcka	and	 Hillman,	 1974).	 Fig.	 4.1	 illustrates	 the	 morphology	 of	 the	 EB	 during	 the	initial	 steps	 of	 spontaneous	 differentiation	 (endoderm	protocol),	 employed	 in	this	study.	Around	day	4	of	suspension	culture,	the	primitive	endoderm	cells	of	the	 EB	 start	 to	 deposit	 extracellular	matrix	 (ECM)	 in	 the	 form	 of	 a	 basement	membrane	(BM)	that	separates	them	from	the	underlying	undifferentiated	cells	(Leahy	 et	 al.,	 1999).	 This	 parallels	 the	 Reichert’s	 membrane,	 a	 thick	 BM	 that	develops	 in	 vivo	 in	 the	 peri-implantation	 embryo	 from	 the	 trophoblast	 cells	(that	 give	 rise	 to	 the	 placenta)	 and	 primitive	 endoderm	 cells	 (Salamat	 et	 al.,	1995).		In	 the	EB,	 the	cells	underlying	the	BM	become	polarised	and	differentiate	 into	primitive	 ectoderm	 epithelium	 (Li	 et	 al.,	 2001,	Murray	 and	Edgar,	 2000).	 The	unpolarised	cells	 that	do	not	make	contact	with	 the	BM	undergo	programmed	cell	 death,	 which	 is	 coordinated	 by	 the	 BM	 itself.	 This	 process	 leads	 to	 the	formation	of	central	cavity,	which	resembles	the	proamniotic	cavity	as	seen	 in	the	 developing	 embryo	 (Coucouvanis	 and	Martin,	 1995).	 By	 day	 8	 of	 in	 vitro	culture	 the	 EBs	 enlarge	 and	 the	 majority	 of	 them	 transition	 to	 cystic	 EBs	
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(Doetschman	et	al.,	1985).	Continued	culture	of	EBs	leads	to	the	differentiation	of	 primitive	 ectoderm	 cells	 into	mesoderm	 that	 delaminate	 the	 BM	 and	 grow	outside	the	EB	(Fujiwara	et	al.,	2007),	which	mimics	gastrulation	in	vivo	(Smyth	et	 al.,	 1999,	 Tam	 and	 Behringer,	 1997).	 Finally,	 derivatives	 of	 all	 three	 germ	layers	 appear	 in	 differentiating	 EBs	 (Leahy	 et	 al.,	 1999),	 but	 any	 further	development	ceases	after	around	20	days	of	culture	(Doetschman	et	al.,	1985).	As	opposed	to	spontaneous	differentiation	of	EBs,	in	which	primitive	endoderm	differentiation	 occurs	 as	 a	 first	 step,	 other	 protocols	 have	 been	 developed	 to	specifically	 induce	mesoderm	differentiation,	 in	 order	 to	 study	 this	 particular	germ	line	(Fehling	et	al.,	2003,	Notarianni	and	Evans,	2006,	Rak-Raszewska	et	al.,	2012).	The	highest	number	of	mesodermal	cells	was	obtained	in	a	protocol	using	 high	 concentrations	 of	 FCS	 in	 IMDM	 medium	 (Rak-Raszewska	 et	 al.,	2012),	which	was	also	employed	 in	 this	 study	 (section	2.4)	 (Fig.	1,	mesoderm	protocol).	Mesodermal	differentiation	starts	after	2	days	 in	suspension	culture	and	after	4-5	days	of	differentiation	mesodermal	cells	grow	outside	of	the	EB,	in	which	the	BM	is	not	visible.	The	absence	of	the	BM	has	been	shown	to	accelerate	mesoderm	 differentiation	 in	 suspension	 culture	 (Fujiwara	 et	 al.,	 2007).	 From	day	 7	 of	 mesoderm	 differentiation,	 primitive	 endoderm	 and	 the	 BM	 start	 to	form,	 which	 further	 leads	 to	 differentiation	 of	 EBs	 into	 all	 three	 germ	 layers	(Rak-Raszewska	et	al.,	2012).	Taken	 together,	 this	 study	 examines	 self-renewing	 R1	 mESCs	 using	 the	undifferentiation	protocol	with	LIF	 supplementation	 and	mEF	 feeder	 layer,	 as	well	 as	 the	 above-described	 differentiation	 protocols.	 Both	 endoderm	differentiation	 (spontaneous	EB	differentiation)	 and	mesoderm	differentiation	protocols	 eventually	 give	 rise	 to	 all	 3	 germ	 layers	 and	 are	 summarised	 in		Fig.	4.1.	
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Fig.	 4.1	 Morphological	 changes	 of	 embryoid	 bodies	 (EBs)	 during	
differentiation	 of	 mouse	 embryonic	 stem	 cells	 (ESCs).	 After	 2	 days	 of	suspension	 culture	 using	 endoderm	 or	 mesoderm	 differentiation	 protocols,	ESCs	 form	 aggregates	 of	 undifferentiated,	 pluripotent	 cells.	 Around	 day	 4	 of	endoderm	 differentiation	 protocol	 (spontaneous	 EB	 differentiation	 after	withdrawal	of	LIF	from	the	medium),	primitive	endoderm	differentiates	 in	the	periphery	of	 the	EB	and	deposits	a	 thick	basement	membrane	(BM).	After	3-4	days	 of	 culture	 using	 the	mesoderm	differentiation	 protocol,	mesodermal	 cell	differentiate	 and	 migrate	 outside	 the	 EB	 (blue	 arrow)	 and	 no	 visible	 BM	 is	present.	 Both	 protocols	 lead	 to	 differentiation	 of	 EB	 into	 three	 germ	 layers,	including	ectoderm,	and	cavity	formation.		
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4.1.2			 Functions	of	Ras	isoforms	in	ESCs		Based	on	a	limited	number	of	studies,	distinct	Ras	isoforms	play	different	roles	during	 cellular	differentiation.	Dominant	negative	HRas	mutant	was	 shown	 to	inhibit	 nerve-growth	 factor	 (NGF)-induced	 neuronal	 differentiation	 of	 PC12	cells	 (Szeberenyi	 et	 al.,	 1990).	 Subsequently,	 active	 HRas	 was	 shown	 to	 be	crucial	 for	 induction	 of	 extraembryonic	 endoderm	 differentiation	 in	 mouse	ESCs,	 through	 signalling	 via	 the	 Raf-MEK-ERK	 pathway	 (Yoshida-Koide	 et	 al.,	2004),	whereas	constitutively	active	K-Ras	was	 found	 to	enhance	self-renewal	and	proliferation	of	mouse	ESCs	in	an	undifferentiated	state	(Luo	et	al.,	2007).	Also,	 signalling	 of	 activated	 KRas	was	 shown	 to	 be	 associated	with	 cancer	 in	endodermal	 stem	 cells,	 whereas	 activated	 HRas	 was	 shown	 to	 contribute	 to	endoderm	differentiation	and	growth	arrest	(Quinlan	et	al.,	2008,	Quinlan	and	Settleman,	2008).	However,	these	studies	generally	involved	overexpression	of	Ras	isoforms	rather	than	studying	endogenous	protein	function.	Besides,	little	is	known	 about	 isoform-specific	Ras	 effector	 pathways	 involved	 in	 regulation	 of	stemness/differentiation.		
	It	has	been	recently	discovered	that	a	new	Ras	isoform,	ERas,	is	solely	expressed	in	mESCs	and	is	responsible	for	their	transforming	potential	(Takahashi	et	al.,	2003).	ERas	 is	 constitutively	 active	 without	 mutation	 and	 it	 binds	 preferentially	 to	downstream	 PI3K,	 but	 not	 to	 Raf.	 ERas-null	 mESCs	 maintain	 pluripotency,	 but	display	reduced	tumourigenicity	and	growth.	These	findings	may	substantiate	the	importance	of	Ras	isoform-specific	signalling,	especially	in	early	development.	The	human	ERAS	 homologue,	 however,	 contains	 a	premature	polyadenylation	 signal	and	is	not	expressed	at	protein	level	in	hESCs	(Kameda	and	Thomson,	2005).	The	Ras	isoform-specific	differences	in	affecting	self-renewal	and	differentiation	of	SCs	might	be	attributed	to	either	distinct	functions	of	individual	isoforms	or	to	 disparity	 of	 timing	 and/or	 level	 of	 their	 gene	 expression	 in	 particular	 cell	types	(Castellano	and	Santos,	2011).	To	investigate	the	possibility	of	the	latter,	this	study	aimed	to	determine	endogenous	expression	levels	of	Ras	isoforms	in	undifferentiated	 and	 differentiating	 R1	 mESCs	 using	 qRT-PCR	 to	 calculate	mRNA	copy	number	per	cell.		
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4.2		 	 	 Results	
4.2.1	 	 	 Establishing	ESC	culture	protocols	
	Undifferentiated	R1	ESCs	were	cultured	on	an	STO	cell	feeder	layer	from	which	they	 need	 to	 be	 separated	 before	 harvesting	 for	 subsequent	RNA	 and	protein	extraction,	as	described	 in	section	2.3.6	and	 illustrated	 in	Fig.	4.2	A.	To	assess	whether	 the	 separated	 ESCs	 were	 contaminated	 with	 STOs,	 media	 with	suspended	 ESCs	 was	 plated	 on	 a	 separate	 gelatin-coated	 dish	 and	 examined	under	the	microscope	the	following	day.	Most	fields	of	view	showed	no	or	only	occasional	 contaminating	 STOs	 (Fig.	 4.2	 B),	 which	 indicated	 that	 the	 cell	separation	method	was	successful.				In	 order	 to	 investigate	 the	 expression	 profiles	 of	 Ras	 isoforms	 during	 ESC	differentiation,	 R1	 mESCs	 were	 cultured	 in	 suspension	 using	 endoderm	 and	mesoderm	 differentiation	 protocols	 (section	 2.4).	 Embryoid	 bodies	 (EBs)	formed	 aggregates	 at	 day	 2	 of	 differentiation	 (Fig.	 4.3).	 Depending	 on	 the	protocol,	the	morphology	of	EBs	had	distinct	features.	By	day	4	of	the	endoderm	differentiation	 protocol,	 primitive	 endodermal	 cells	 differentiated	 outside	 of	visible	 basement	membrane	 (BM)	 (Reichert’s	membrane).	After	 this	 time,	 cell	polarisation	 and	 differentiation	 of	 primitive	 ectoderm	 under	 the	 BM	 occurs	(Murray	 and	 Edgar,	 2000),	 but	 this	 was	 not	 visible	 in	 the	 bright	 field	micrographs	(Fig.	4.3,	day	6	onwards).	On	day	8,	 the	size	of	 the	EBs	 increased	and	the	cells	inside	the	EB	underwent	programmed	cell	death	leading	to	cavity	formation	 (Doetschman	 et	 al.,	 1985),	 which	 could	 be	 represented	 by	 darker	areas	 in	 the	 centre	 of	 the	EB	 (Fig.	 4.3,	 day	8	 onwards).	At	 day	12,	 visible	 cell	outgrowth	appeared	in	the	EB	(Fig.4.3,	day	12,	MESO),	indicating	differentiation	of	primitive	ectoderm	cells	into	mesoderm	(Fujiwara	et	al.,	2007).		During	 the	mesoderm	differentiation	protocol,	 extraembryonic	 endoderm	and	BM	 structures	 did	 not	 appear.	 Instead,	 mesoderm	 differentiating	 EBs	 were	larger	 than	 those	 undergoing	 endoderm	 differentiation	 for	 the	 first	 6	 days	 of	suspension	culture	(Fig.	4.3).	From	day	6,	EBs	became	less	round	and	regular	in		
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		STO	+	ESCs	 	 	 					STO		 	 	 			ESCs	
		
Fig.	 4.2	 Separation	 of	 undifferentiated	 R1	 embryonic	 stem	 cells	 (ESCs)	
from	STO	feeder	layer	cells	for	cell	harvesting.	A	A	schematic	representation	of	a	protocol	for	R1	ESCs	separation	from	STO	feeder	layer.	Trypsinised	R1	ESCs	grown	 on	 STO	 feeder	 layer	 were	 transferred	 in	 R1	 medium	 onto	 a	 gelatin-coated	 dish	 and	 incubated	 at	 37˚C.	 After	 about	 20	 mins	 the	 majority	 of	 STO	fibroblasts	adhered	 to	 the	dish	and	 the	R1	medium	with	ESCs	 in	solution	was	transferred	to	a	Falcon	tube	for	subsequent	cell	counting	and	RNA	and	protein	extraction.	B	 Micrographs	 showing	 the	 efficiency	 of	 separation	 of	 ESCs	 from	STO	feeder	layer.	STO	+	ESCs	represents	STO	feeder	layer	with	undifferentiated	R1	ESCs.	Red	arrow	indicates	an	ESC	colony.	STO	 indicates	STO	on	gelatinised	plate	after	R1	ESCs	were	removed.	Red	arrow	 indicates	a	 large	STO	cell.	ESCs	micrograph	depicts	R1	 cells	 after	 separation	 from	STO	 feeder	 layer,	plated	on	gelatinised	 dish.	 Red	 arrow	 indicates	 a	 contaminating	 STO	 cell.		Scale	bar	=	100	µm	
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Fig.	4.3	Morphology	of	mouse	embryoid	bodies	(EB)	during	differentiation.	Representative	 bright	 field	 micrographs	 for	 endoderm	 and	 mesoderm	differentiation	 protocols	 of	 R1	 mouse	 embryonic	 stem	 cells	 (ESCs).	 During	endoderm	 differentiation,	 basement	 membrane	 (BM)	 and	 endodermal	 cells	(ENDO)	 outside	 the	 EB	 were	 visible	 (red	 arrows).	 Mesodermal	 cells	 (MESO)	appeared	 outside	 the	 EB	 during	 mesoderm	 differentiation	 and	 later	 during	endoderm	differentiation	(red	arrows).	Scale	bar	=	200	µm.	
DAY$2$
DAY$4$ BM$
ENDO$
DAY$6$
MESO$
ENDO$
DAY$8$
DAY$10$
DAY$12$ MESO$
	 102	
shape,	as	mesodermal	cells	started	to	differentiate	and	migrate	outside	the	EB		(Fig.	 4.3,	 day	 6,	 MESO).	 EBs	 became	 also	 more	 complex,	 as	 during	 this	 time	primitive	 endoderm	 and	 the	 central	 cavity	 start	 to	 form,	 leading	 to	differentiation	of	all	three	germ	layers	(Rak-Raszewska	et	al.,	2012).		Overall,	 the	 micrographs	 of	 differentiating	 EBs	 depicted	 the	 formation	 of	distinct	morphological	features	specific	for	each	differentiation	protocol.	These	methods	were	used	for	studying	early	endoderm	and	mesoderm	differentiation	to	measure	Ras	isoform	transcript	levels.									
4.2.2	 	 Quality	control	of	RNA	from	ESCs		To	accurately	determine	the	abundance	of	Ras	isoforms	at	the	transcript	level	in	undifferentiated	 and	 differentiating	 R1	 ESCs,	 extracted	 RNA	 was	 quality	checked	by	Nanodrop	and	agarose	gel	electrophoresis.	Only	samples	with	good	yields	 and	 absorbance	 ratio	 A260/280	 nm	 between	 1.8	 and	 2.0,	 as	 well	 as	showing	distinct	18S	and	28S	rRNA	bands	on	agarose	gels	(Becker	et	al.,	2010)	were	 subsequently	 used	 in	 qRT-PCR	 experiments.	 Fig.	 4.4	 presents	 the	 RNA	agarose	gels	for	all	ESCs	samples	discussed	in	this	chapter,	which	fulfilled	these	quality	control	criteria.	For	all	samples	the	28S	rRNA	band	was	approximately	twice	 as	 abundant	 as	 the	 18S	 band,	 which	 indicated	 high	 integrity	 of	 the	extracted	 RNA	 (Becker	 et	 al.,	 2010).	 Moreover,	 there	 was	 no	 evidence	 of	genomic	DNA	or	of	degraded	RNA.						
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Fig.	 4.4	 Assessment	 of	 RNA	 quality	 by	 agarose	 gel	 electrophoresis	 of	
mouse	 R1	 ESCs	 samples.	 RNA	 was	 extracted	 using	 Norgen	 RNA/protein	extraction	 kit	 and	 1µg	 of	 RNA	 was	 run	 per	 lane	 on	 1.2%	 agarose	 gel.	 Two	distinct	 28S	 and	 18S	 rRNA	 bands	 were	 visible	 in	 each	 sample,	 indicated	 by	arrows.	A	 RNA	 from	undifferentiated	 ESCs.	 #1-3	 indicate	 biological	 replicates	(see	 text).	 B	 RNA	 from	 ESCs	 undergoing	 endoderm	 and	 mesoderm	differentiation,	 as	 well	 as	 from	 mouse	 liver	 (E11.5).	 C	 RNA	 from	undifferentiated	 and	 mesoderm	 differentiating	 ESCs.	 bp	 –	 base	 pairs	 of	 DNA	ladder,	undiff.	–	undifferentiated	sample	R1	#4	(see	text),	diff.	–	differentiation,	d	–	day	of	differentiation,	(m)	–	pre-differentiation	medium,	28S	and	18S	–	rRNA	subunits.	
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4.2.3	 	 	 Ras	 isoform	 transcript	 expression	 in	 undifferentiated		
R1	mESC		RNA	 extracted	 from	 4	 biological	 replicates	 (#1-4)	 of	 undifferentiated	 ESCs	(Section	 4.2.2)	was	 analysed	 by	 qRT-PCR	 to	 quantify	 Ras	 isoform	 transcripts.	The	 expression	 levels	 of	 POL2RE	 reference	 transcript,	 determined	 from	 the	plasmid	standard	curve,	averaged	around	6	copies	per	pg	of	RNA.	However,	 in	one	of	the	biological	replicates	(#4,	used	along	with	differentiation	experiment	in	Fig.	4.7)	less	than	1	copy	per	pg	of	RNA	was	detected,	which	was	significantly	lower	than	in	the	remaining	samples	(7-8	copies/pg)	(Table	4.1,	Fig.	4.5	B).	As	the	quality	of	RNA	was	good	in	all	samples	(Fig.	4.4	A	and	C)	and	the	expression	levels	 and	 percentage	 contribution	 of	 Ras	 isoforms	 across	 the	 four	 biological	replicates	did	not	vary	significantly	(Fig.	4.5	A),	the	downregulation	of	POL2RE	expression	in	only	one	sample	was	unexpected	and	may	be	due	to	either	sample	handling	 error	 or	 to	 fluctuating	 expression	 of	 POL2RE	 in	 ESCs	 colonies.	Moreover,	 percentage	 amplification	 efficiency	 as	 determined	 by	 POL2RE	standard	curves	remained	consistent	 for	all	 replicates	at	around	77-78%	with	
R2	values	>0.99	(Appendix,	Fig.	A4.1	and	A4.2).	Due	to	this	uncertainty,	the	Ras	isoform	transcript	levels	were	not	normalised	to	POL2RE	reference	gene	using	the	∆CT	method,	as	this	could	introduce	a	bias	into	the	final	results.			Instead,	 the	 abundance	 of	 Ras	 isoform	 transcripts	 was	 calculated	 using	 Ras	isoform-specific	plasmid	standard	curves.	Table	4.1	and	Fig.	4.5	summarise	the	expression	levels	of	the	tested	genes	in	4	biological	replicates	of	R1	ESCs	(#1-4).	Transcripts	 for	 all	 Ras	 isoforms	were	 expressed	 and	 are	 represented	 as	 copy	number	 per	 pg	 of	 RNA	 and	 copy	 number	 per	 cell.	 To	 estimate	 Ras	 transcript	abundance	per	undifferentiated	ESC,	the	average	total	RNA	content	per	cell	was	calculated	based	on	 the	number	of	 cells	used	 for	RNA	extraction	and	 the	RNA	yields,	 and	 was	 approximately	 20	 pg.	 This	 value	 corresponds	 to	 previous	findings	in	mouse	ESCs	(Calabrese	et	al.,	2007).			The	most	abundant	Ras	 isoform	was	KRasB	with	about	3	transcripts	per	pg	of	RNA	(57	copies	per	cell),	followed	by	NRas	with	almost	1.5	copies/pg	(29	copies	
	 105	
per	cell)	and	ERas	with	about	1	copy/pg	(20	copies	per	cell).	The	least	abundant	Ras	 isoforms	were	HRas	 and	KRasA,	with	 0.1	 and	 0.04	 copies	 per	 pg	 of	 RNA,	respectively,	equivalent	to	just	over	2	copies	per	cell	and	less	than	1	copy/cell.	Total	Ras	transcripts	(pan	Ras)	levels	added	up	to	around	5.5	transcript	copies	per	pg	of	RNA,	which	was	equal	to	109	copies	per	cell.			
	
Table	 4.1	 Ras	 isoform	 and	 reference	 gene	 RNA	 polymerase	 II	 (POL2RE)	
transcript	 levels	 in	 undifferentiated	 mouse	 R1	 ESCs.	 qRT-PCR	 was	performed	on	4	biological	replicates	of	cDNA	from	undifferentiated	R1	ESCs	(R1	#1	–	4).	Absolute	expression	 levels	were	obtained	by	 interpolation	of	plasmid	standard	curves,	which	were	specific	for	each	tested	transcript	and	the	average	and	 standard	deviation	 (SD)	were	 calculated.	The	estimated	 copy	number	per	cell	 (shown	 in	parentheses)	was	based	on	 the	 total	RNA	 content	per	 cell.	 Pan	Ras	–	the	sum	of	all	Ras	isoforms.	
	
	
Copy	number	per	pg	RNA	
(Estimated	copy	number	per	cell)	
Sample	
number	
ERas	 HRas	 KRasA	 KRasB	 NRas	 Pan	Ras	 POL2RE	
R1	#1	 1.152	(23.0)	 0.091	(1.8)	 0.024	(0.5)	 2.284	(45.7)	 1.496	(29.9)	 5.047	(100.9)	 7.880	(157.6)	
R1	#2	 1.249	(25.0)	 0.111	(2.2)	 0.026	(0.5)	 3.900	(78.0)	 1.579	(31.6)	 6.865	(137.3)	 8.168	(163.4)	R1	#3	 0.975	(19.5)	 0.089	(1.8)	 0.019	(0.4)	 2.863	(57.3)	 1.763	(35.3)	 5.709	(114.2)	 7.821	(156.4)	R1	#4	 0.604	(12.1)	 0.185	(3.7)	 0.073	(1.5)	 2.436	(48.7)	 0.956	(19.1)	 4.254	(85.1)	 0.712	(14.2)	
average	 	0.995	(19.9)	 0.119	(2.4)	 0.036	(0.7)	 2.871	(57.4)	 1.448	(29.0)	 5.469	(109.4)	 6.145	(122.9)	SD	 0.284	(5.7)	 0.045	(0.9)	 0.025	(0.5)	 0.729	(14.6)	 0.347	(6.9)	 1.104	(22.1)	 3.625	(72.5)	
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A		
	
B	
	
	
C																																																																	D	
								
	
									
E	 –	ERas,	H	 –	HRas,	KA	 –	KRasA,		
KB	 –	 KRasB,	N	 –	 NRas,	 NS	 –	 not	significant,	*	p	≤	0.05,	**	p	≤	0.01,		***	p	≤	0.001,	****	p	≤	0.0001				
Fig.	 4.5	 Ras	 isoform	 transcript	 abundance	 in	 undifferentiated	 R1	 ESCs.	qRT-PCR	using	Ras	isoform-specific	primers	or	reference	gene	POL2RE	primers	was	 performed	 on	 cDNA	 obtained	 from	 undifferentiated	 mouse	 R1	 ESCs.	Absolute	 copy	numbers	were	 calculated	by	 interpolation	of	 transcript-specific	plasmid	standard	curves.	A	Ras	isoform	and	B	reference	gene	RNA	polymerase	II	(POL2RE)	transcript	levels	in	each	of	4	biological	replicates	of	R1	ESCs	(#1-4).	
C	Average	expression	levels	±	SD	(n	=	4)	of	Ras	isoforms	in	undifferentiated	R1	ESCs.	Data	in	C	was	analysed	by	one-way	ANOVA	with	Tukey’s	post	hoc	test	and	summarised	in	D.		
0"
2"
4"
6"
8"
R1"1" R1"2" R1"3" R1"4"
co
py
"n
um
be
r"p
er
"1
pg
"R
N
A" POL2RE"
0"
1"
2"
3"
4"
5"
6"
7"
R1"#1" R1"#2" R1"#3" R1"#4"c
op
y"
nu
m
be
r"p
er
"1
pg
"R
N
A"
KRasB" KRasA" NRas" HRas" ERas"
0%#
20%#
40%#
60%#
80%#
100%#
R1##1# R1##2# R1##3# R1##4#
pe
rc
en
ta
ge
#c
on
tr
ib
u8
on
#
0"
1"
2"
3"
4"
5"
6"
7"
R1"#1" R1"#2" R1"#3" R1"#4"c
op
y"
nu
m
be
r"p
er
"1
pg
"R
N
A"
KRasB" KRasA" NRas" HRas" ERas"
0.0#
0.5#
1.0#
1.5#
2.0#
2.5#
3.0#
3.5#
4.0#
ERas# HRas# KRasA# KRasB# NRas#
co
py
#n
um
be
r#p
er
#1
pg
#R
N
A#
	 107	
4.2.4	 	 Ras	 isoform	 transcript	 expression	 in	 differentiating		
R1	mESCs	
	In	an	initial	experiment,	embryoid	bodies	were	harvested	every	two	days	until	day	12	of	differentiation.	RNA	from	samples	harvested	at	day	12	and	before	day	8	 for	 mesoderm	 and	 endoderm	 differentiation,	 respectively,	 had	 ethanol	contamination	 and	 gave	 poor	 RNA	 yields,	 hence,	 was	 not	 used	 for	 qRT-PCR	analysis.	The	remaining	samples	from	differentiating	ESCs	were	quality	checked	using	 agarose	 gel	 electrophoresis	 (Fig.	 4.4	 B).	 RNA	 from	 mouse	 liver	 at	embryonic	day	E11.5	was	used	as	a	reference	of	a	tissue	of	endodermal	origin	(Friedman	 and	 Kaestner,	 2011)	 to	 compare	 Ras	 isoform	 expression	 during	endoderm	differentiation.		Overall,	 during	 mesoderm	 differentiation	 this	 representation	 of	 the	 data	suggests	a	decline	in	expression	of	all	Ras	isoforms,	except	for	NRas,	the	levels	of	 which	 were	 fluctuating	 (Fig.	 4.6).	 As	 ERas	 isoform	 is	 only	 expressed	 in	undifferentiated	ESCs	(Takahashi	et	al.,	2003),	its	diminishing	expression	levels	over	time	during	mesoderm	differentiation	indicated	a	decrease	in	the	number	of	such	cells	within	the	EB.	This	could	further	confirm	that	EBs	were	becoming	more	differentiated	and	the	differentiation	protocol	was	working	successfully.		Ras	isoform	copies	per	pg	of	RNA	were	similar	to	Ras	isoform	expression	levels	in	undifferentiated	ESCs	(biological	replicates	#1-3)	(Fig.	4.5,	4.6).	However,	the	least	abundant	Ras	isoforms	HRas	and	KRasA	appeared	to	increase	(2-	and	10-fold,	 respectively)	 their	 expression	 levels	 early	 in	 mesoderm	 differentiation	(Fig.	4.6,	day	2)	as	compared	to	the	levels	in	undifferentiated	cells	(day	0).		Over	time,	 however,	 expression	 levels	 returned	 to	 those	 of	 undifferentiated	 ESCs	(day	10).			
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Fig.	 4.6	 Ras	 isoform	 transcript	 expression	 during	 endoderm	 and	
mesoderm	differentiation	of	mouse	ESCs.	Copy	number	of	Ras	isoforms	ERas,	HRas,	 KRasA,	 KRasB,	 NRas,	 as	 well	 as	 reference	 gene	 RNA	 polymerase	 II	(POL2RE)	were	calculated	based	on	qRT-PCR	using	standard	curves.	cDNA	was	derived	 from	 undifferentiated	 (day	 0	 of	 differentiation,	 in	 triplicate)	 and	differentiating	(days	2-12,	single	experiment)	R1	mouse	ESCs	and	from	mouse	embryonic	 liver	 (E11.5).	 Differentiating	 cells	 were	 obtained	 from	 embryoid	bodies	following	either	mesoderm	or	endoderm	differentiation	protocols.	Error	bars	for	day	0	represent	SD.		
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In	 contrast,	 due	 to	 the	 fact	 that	 the	 endoderm	differentiation	 experiment	 had	only	 three	 time	points,	 it	was	difficult	 to	 identify	 any	 robust	 trends	 (Fig.	 4.6).	Interestingly,	however,	 in	embryonic	 liver,	 there	was	no	detectable	expression	of	 ERas,	 which	 further	 confirmed	 that	 its	 expression	 is	 restricted	 to	 mESCs	(Takahashi	et	al.,	2003).				To	 replicate	 this	 initial	 experiment	 and	 investigate	 the	 expression	 profiles	 of	Ras	isoforms	later	in	mesoderm	differentiation,	EBs	were	harvested	from	day	1	until	 day	 18	 of	 differentiation.	 Absolute	 quantification	 by	 qRT-PCR	 suggested	that	 the	 expression	 of	 all	 Ras	 isoforms	 increased	 on	 day	 1	 of	 mesoderm	differentiation	 as	 compared	 to	 undifferentiated	 cells	 (biological	 replicate	 #4)	and	showed	large	fluctuations	in	transcript	levels	throughout	the	course	of	the	experiment	 (Fig.	 4.7).	 Reference	 gene	 expression	 was	 fluctuating	 over	 time	during	 differentiation	 (Fig.	 4.6	 and	 4.7)	 and,	 hence,	 it	 was	 impossible	 to	normalise	the	data	using	the	∆CT	method	(section	3.1.2.4).	Thus,	fluctuations	in	expression	levels	may	imply	varying	amounts	of	input	RNA.			To	control	for	this	possibility,	the	results	were	“internally	normalised“	to	show	the	 percentage	 contribution	 of	 Ras	 isoform	 transcripts	 to	 the	 total	 Ras	expression	 (Fig.	 4.8).	 This	 way	 of	 representing	 the	 data	 now	 revealed		a	 consistent	 pattern	 of	 Ras	 isoform	 contribution	 throughout	 mesoderm	differentiation	 in	 both	 experiments.	 During	 endoderm	 differentiation	 relative	isoform	 contribution	 was	 markedly	 different	 compared	 to	 mesoderm	differentiation	protocol,	as	the	abundance	of	ERas	was	proportionally	higher	at	the	expense	of	KRasB	levels.										
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Fig.	4.7	Ras	isoform	expression	during	mesoderm	differentiation	of	mouse	
ESCs.	Copy	numbers	of	Ras	isoforms	ERas,	HRas,	KRasA,	KRasB,	NRas,	as	well	as	a	reference	gene	RNA	polymerase	 II	 (POL2RE)	were	calculated	based	on	qRT-PCR	 using	 plasmid	 standard	 curves.	 cDNA	was	 derived	 from	 undifferentiated	(day	0,	R1	#4)	and	differentiating	 (days	1-18)	R1	mouse	ESCs.	Differentiating	cells	were	obtained	from	embryoid	bodies	 following	mesoderm	differentiation	protocol.			
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During	 mesoderm	 differentiation,	 the	 percentage	 contribution	 of	 ERas	 was	steadily	 decreasing	 over	 time	until	 day	10	 (Fig.	 4.8).	 This	 again	 confirms	 that	ERas	is	expressed	exclusively	in	undifferentiated	mESC	(Takahashi	et	al.,	2003),	which	diminish	 in	number	as	 the	EB	matures.	 Interestingly,	during	mesoderm	differentiation	there	was	a	peak	in	contribution	of	KRasA	abundance	at	days	2	and	4	in	both	experiments.		To	sum	up,	the	expression	pattern	of	Ras	isoform	transcripts	during	endoderm	differentiation	was	different	 than	that	during	mesoderm	differentiation	and	 in	undifferentiated	R1	mESCs.	During	endoderm	differentiation,	KRasB,	NRas	and	ERas	 contribution	 to	 total	 Ras	 was	 similar	 at	 around	 30%	 of	 total	 Ras	expression.	 In	 contrast,	 during	 mesoderm	 differentiation	 and	 in	undifferentiated	mESC,	the	most	abundant	isoform	was	KRasB,	with	over	50%	contribution	to	total	Ras	expression	levels,	 followed	by	NRas	(about	30%)	and	ERas	 (up	 to	18%).	KRasA	and	HRas	were	 the	 least	abundant	 isoforms	 in	both	protocols,	comprising	only	up	to	4%	of	all	Ras	isoform	levels.		
 	
4.3		 	 	 Discussion	In	this	chapter	the	ESC	and	EB	mouse	models	of	self-renewal	and	differentiation	(Evans	and	Kaufman,	1981,	Leahy	et	al.,	1999,	Martin,	1981,	Rak-Raszewska	et	al.,	2012)	were	used	to	study	abundance	of	Ras	isoforms	during	early	stages	of	mouse	 development.	 Methods	 for	 extracting	 RNA	 from	 undifferentiated	 and	differentiating	R1	ESCs	and	performing	qRT-PCR	were	 successfully	 optimised.	Four	biological	 replicates	were	analysed	 from	undifferentiated	ESCs,	however,	due	 to	 time	 constraints,	 only	 one	 or	 two	biological	 replicates	 of	 endoderm	or	mesoderm	differentiation	 protocols	were	 examined.	 Bearing	 this	 in	mind,	 the	results	 of	 these	 experiments	 remain	 inconclusive,	 and	 require	 further	 repeats	and	validation.	
The	 EB	 model	 of	 differentiation	 is	 a	 complex	 system	 that	 resembles	 early	embryonic	 differentiation	 (Doetschman	 et	 al.,	 1985,	 Robertson,	 1987)	 and		
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comprises	cells	of	all	three	germ	layers	(Leahy	et	al.,	1999).	Thus,	the	extracted	RNA	from	the	differentiating	EBs	is	not	specific	for	a	given	germ	layer,	but	it	is	only	enriched	in	one	of	them	and	is	generally	heterogeneous.	Therefore,	future	work	 on	 this	model	 should	 include	 separation	 of	 germ	 layers	 before	 the	RNA	extraction	 step.	 One	 of	 the	 techniques	 to	 employ	 would	 be	 fluorescence	activated	cell	sorting	(FACS)	that	would	enable	separation	of	cells	expressing	a	certain	 lineage	 marker,	 as	 previously	 done	 for	 mesodermal,	 Brachyury-expressing	 cells	 (Fehling	 et	 al.,	 2003,	 Rak-Raszewska	 et	 al.,	 2012).	 For	 this	purpose,	however,	a	specifically	labelled	cell	line	should	be	used,	e.g.	Bra-GFP,	in	which	 the	Brachyury	 locus	also	expresses	 the	green	 fluorescent	protein	(GFP).	Similarly,	to	select	neural	cells	and	primitive	neurons	that	derive	from	ectoderm	germ	layer,	GFP	may	be	expressed	from	the	Tau	and	nestin	enhancer	loci	(Lenka	et	al.,	2002,	Tucker	et	al.,	2001).	Definite	endoderm	(DE)	cells,	however,	can	be	separated	from	differentiating	mESC	using	DE-specific	surface	marker	Cxcr4	by	FACS	(Li	et	al.,	2011,	Mfopou	et	al.,	2014).		
Another	aspect	of	EB	heterogeneity	is	that	a	population	of	undifferentiated	cells	is	usually	present,	possibly	because	differentiated	cells	produce	LIF	(Rathjen	et	al.,	 1990),	 which	 supports	 self-renewal	 of	 ESC	 (Koestenbauer	 et	 al.,	 2006,	Williams	 et	 al.,	 1988).	 On	 the	 other	 hand,	 ESC	maintained	 in	 undifferentiated	state	may	spontaneously	differentiate	in	culture	(Smith,	2001),	again	leading	to	heterogeneous	 cell	 populations.	 Such	 effect	 could	 be	 controlled	 by	 separating	undifferentiated	 cells	 using	 FACS	 sorting	 based	 on	 GFP	 expressed	 from	 Oct4	locus,	 a	 transcription	 factor	 that	 controls	 self-renewal	 (Ensenat-Waser	 et	 al.,	2006).	Moreover,	the	STO	feeder	layer	that	maintains	self-renewing	ESCs,	could	be	 efficiently	 removed	 by	 magnetic	 separation	 using	 MACS	 technology	 and	 a	fibroblast-specific	 marker	 mEF-SK4,	 leaving	 behind	 less	 than	 0.15%	 of	contaminating	 mEFs	 (Knoebel	 et	 al.,	 2010).	 These	 methods	 could	 also	 be	employed	in	obtaining	pure	cell	populations	in	future	studies	on	Ras	abundance	in	ESC.	
Despite	 these	 limitations,	 some	 preliminary	 conclusions	 may	 be	 drawn	 from	this	study.	Undifferentiated	mESC	express	all	Ras	isoforms,	where	KRasB	is	the	most	abundant	 transcript,	with	over	50%	contribution	 to	 total	Ras	expression	
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levels,	 followed	 by	 NRas	 (about	 30%)	 and	 ERas	 (up	 to	 18%)	 (Fig.	 4.5	 C).	 A	similar	 trend	 is	 also	 reflected	 throughout	 mesoderm	 differentiation.	Interestingly,	 ERas	 expression	 decreases	 over	 time	 in	 differentiating	 EBs,	suggesting	a	gradual	 loss	of	self-renewal	and	stemness	potential	(Takahashi	et	al.,	2003).	During	endoderm	differentiation,	the	distribution	of	KRasB,	NRas	and	ERas	 is	 approximately	 equal	 and	 comprises	 around	 30%	 of	 total	 Ras	 isoform	transcripts.	 KRasA	 and	HRas	 are	 the	 least	 abundant	 isoforms	 in	 all	 protocols,	comprising	only	up	to	4%	of	all	Ras	isoform	levels.		
The	 total	Ras	 isoform	 transcript	 levels	 sum	up	 to	 around	109	 copies	per	ESC,	which	places	Ras	isoforms	among	~6%	of	the	most	abundant	transcripts,	based	on	 expression	 data	 from	 NIH3T3	 mouse	 fibroblasts	 (Schwanhausser	 et	 al.,	2011).		According	to	the	same	study,	which	used	metabolic	pulse	labelling,	NRas	transcripts	comprise	around	23	copies	per	cell,	 close	 to	 the	median	 transcript	level	 of	 17	 copies	 per	 cell.	 In	 the	 current	 study,	 NRas	 abundance	 in	undifferentiated	ESC	was	similar	and	around	29	copies	per	cell,	which	supports	previous	 findings.	 However,	 the	 abundance	 of	 other	 Ras	 isoforms	 was	 not	quantified	in	the	afore-mentioned	study	and	the	data	was	only	available	for	fully	differentiated	fibroblasts,	which	may	not	be	directly	comparable	to	pluripotent	and	differentiating	ESC	used	in	the	current	study.	
More	relevant	data	may	arise	from	the	analysis	of	the	transcriptional	profile	in	single	mouse	blastomeres	derived	from	2-	and	4-cell	stage	embryos	(Tang	et	al.,	2011).	 In	 that	 study,	 TaqMan	 RT-PCR	 detected	 all	 Ras	 isoforms	 at	 both	developmental	stages,	apart	from	ERas,	which	was	only	detected	in	2-cell	stage	embryo.	 That	 data,	 however,	 does	 not	 provide	 any	 quantitative	 information	about	relative	transcript	abundance,	as	it	was	not	normalised	and	presented	as	CT	values	only.		
Unfortunately,	 no	 previous	 findings	 present	 Ras	 isoform	 abundance	 in	 ESC	 in	absolute	transcript	copy	numbers.	Therefore,	to	validate	the	data	in	this	study,	more	biological	 replicates	of	undifferentiated	and	differentiating	mESC	should	be	analysed.	As	a	further	confirmation	of	the	results,	a	panRas	primer	pair	could	be	 designed	 for	 qRT-PCR.	However,	 one	 crucial	 finding	 of	 this	work	was	 that	
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KRasB	was	 the	most	 abundant	 isoform	 in	 almost	 all	 analysed	mESC	 samples,	apart	 from	 endoderm	 differentiating	 EBs,	 in	 which	 it	 was	 equally	 expressed	with	NRas	 and	ERas.	This	 is	 particularly	 interesting,	 as	KRasB	 is	 the	only	Ras	isoform	essential	 for	mouse	development	 (Koera	et	al.,	1997,	Nakamura	et	al.,	2008,	 Plowman	 et	 al.,	 2003).	 This	 could	 indicate	 that	 functional	 differences	between	 Ras	 isoforms	 arise	 from	 differences	 in	 their	 expression	 levels	 and	possibly	different	sites	of	expression.	A	previous	study	demonstrated	that	HRas	can	 substitute	 essential	 functions	 of	 KRas,	when	 expressed	 from	 its	 locus,	 i.e.	HRas	knock	in	(KI)	mice	are	viable,	but	develop	cardiovascular	problems	later	in	adulthood	(Potenza	et	al.,	2005).	This	gives	further	evidence	that	Ras	isoform	functional	 difference	 could	 be	 due	 to	 differences	 in	 the	 control	 of	 gene	expression	and,	hence,	also	different	transcript	abundance.		
However,	 current	 data	 on	 Ras	 expression	 pattern	 in	mESC	 does	 not	 consider	Ras	 isoform	 protein	 levels,	 which	 may	 not	 directly	 correlate	 with	 trends	 of	transcript	abundance.		According	to	NIH3T3	data	(Schwanhausser	et	al.,	2011),	NRas	protein	levels	were	9	times	higher	than	KRasB	protein	levels,	showing	that	KRasB	 was	 not	 the	 most	 abundant	 Ras	 isoform	 in	 this	 cell	 type.	 Therefore,	future	 experiments	 on	 Ras	 isoform	 abundance	 in	 mESCs	 should	 include	proteomics	data,	for	which	the	timescale	of	the	current	study	did	not	allow.	
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Chapter	5	
Ras	isoform	expression	in	mouse	tissues		
during	development	
	
5.1	 	 	 Introduction	
5.1.1	 Ras	 isoform-specific	 mutation	 frequency	 and	 role	 in	
development	
HRAS,	KRAS	 and	NRAS,	 the	 genes	 of	 the	Ras	 subfamily,	 represent	 some	of	 the	most	frequently	mutated	proto-oncogenes.	The	incidence	of	Ras	mutations	in	all	human	 cancers	 ranges	 between	 9	 to	 30%,	 depending	 on	 the	 database	 used:	COSMIC (v72)	 (Forbes	et	 al.,	 2015),	 cBioPortal	 (Cerami	et	 al.,	 2012,	Gao	et	 al.,	2013),	TumorPortal	(Lawrence	et	al.,	2014),	ICGCDataPortal	(v3.8.2.1	-	API	v1	-	d21bce2)	(International	Cancer	Genome	et	al.,	2010),	which	were	sumarised	in	two	 recent	 reviews	 (Prior	 et	 al.,	 2012,	 Cox	 et	 al.,	 2014).	Although	KRas	 is	 the	most	commonly	mutated	Ras	isoform	across	all	tested	human	tumour	samples	(86%),	 the	 mutation	 frequency	 of	 each	 Ras	 isoform	 is	 not	 uniform	 across	different	 cancer	 types.	 KRas	mutations	 constitute	 almost	 all	 Ras	mutations	 in	pancreatic	and	lung	cancers	and	are	predominant	in	multiple	myeloma	as	well	as	in	endometrial,	stomach	and	colorectal	cancers	(Cox	et	al.,	2014,	Forbes	et	al.,	2015).	 NRas	 mutations	 are	 prevalent	 in	 cutaneous	 melanoma,	 acute	myelogenous	 leukaemia	 (AML)	 and	 thyroid	 cancer.	 HRas	 mutations	 are	infrequent	overall	(3%),	but	they	are	the	most	common	Ras	mutations	in	head	and	neck	squamous	cell	carcinoma	(HNSCC)	as	well	as	in	bladder	cancer.			The	reason	why	KRas	mutations	are	prevalent	 in	tissues	of	endodermal	origin	(pancreas,	colon	and	lung)	might	be	due	to	the	fact	that	mutated	KRas	promotes	proliferation	 and	 maintenance	 of	 stem-like	 properties	 of	 endodermal	progenitors,	 therefore	 leading	 to	 expansion	 of	 cell	 populations	 that	 carry	 the	mutation	 (Quinlan	 et	 al.,	 2008,	 Quinlan	 and	 Settleman,	 2008).	 On	 the	 other	hand,	 mutated	 HRas	 or	 NRas	 causes	 either	 differentiation	 of	 or	 no	 effect	 on	endodermal	 progenitor	 cells,	 respectively.	 An	 alternative	 explanation	 for	 the	
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abundance	 of	 KRas	 mutations	 was	 suggested	 recently	 based	 on	 the	 high	frequency	of	rare	codons	in	KRas	(Lampson	et	al.,	2013).	This	was	suggested	to	result	 in	 impaired	 expression	 of	 KRas.	 Since	 high	 expression	 of	 Ras	 protein	leads	 to	 senescence	 rather	 than	 proliferation,	 the	 authors	 suggested	 that	 the	lower	expression	of	KRas	versus	 the	other	 isoforms	might	be	advantageous	 in	avoiding	 this	 non-productive	 phenotype	when	KRas	 is	 oncogenically	mutated.		Hence,	more	work	 is	 necessary	 to	 better	 understand	 Ras	 isoform	 coupling	 to	different	human	cancers.	
	The	 importance	 of	 KRas	 is	 also	 highlighted	 during	 development,	 as	 its	 KRasB	splice	variant	 is	 the	only	Ras	 isoform	essential	 for	normal	development	 in	 the	mouse	 (Koera	 et	 al.,	 1997,	 Johnson	 et	 al.,	 1997,	 Plowman	 et	 al.,	 2003).	 KRas	knock	 out	 (KO)	 mice	 die	 prenatally	 between	 E12.5	 and	 birth	 due	 to	 thin	ventricular	walls	of	the	heart,	motoneuron	death	in	the	medulla	and	the	spinal	cord	 and	 liver	 defects.	 However,	 KO	 of	 KRasA-specific	 exon	 in	 inbred	 and	crossbred	mice	has	no	effect	on	growth	and	development.	 Interestingly,	HRas-	or	NRas-deficient	mice	separately	exhibit	a	normal	phenotype	(Ise	et	al.,	2000,	Umanoff	et	al.,	1995).	A	double	knockout	of	both	HRas	and	NRas	loci	also	yields	normal	 viable	 mice,	 further	 suggesting	 that	 both	 of	 these	 Ras	 isoforms	 are	dispensable	for	normal	mouse	growth,	development	and	fertility	(Esteban	et	al.,	2001,	Nakamura	et	al.,	2008).	However,	double	knockout	mice	are	born	at	lower	than	 expected	 Mendelian	 frequency.	 This	 finding	 may	 suggest	 a	 partial	functional	 overlap	 of	 Ras	 isoforms.	 Furthermore,	 although	 KRas+/-	 mice	(heterozygous	 for	 KRas	 deletion)	 are	 viable,	 KRas+/-;	 NRas-/-	 mice	 die	 during	embryonic	 development	 or	 perinatally	 due	 to	 severe	 anaemia	 (Johnson	 et	 al.,	1997).	Also,	double	homozygous	mutant	KRas-/-;	NRas-/-	or	KRas-/-;	HRas-/-	mice	die	before	E9.5	or	between	E9.5	and	E11.5,	respectively,	suggesting	that	 these	phenotypes	 are	 more	 severe	 than	 single	 KRas	 deletion	 (Johnson	 et	 al.,	 1997,	Nakamura	 et	 al.,	 2008).	 Altogether,	 current	 studies	 imply	 that	 KRas	 alone	 is	both	 crucial	 and	 sufficient	 for	 normal	 growth	 and	 development	 in	 mice,	 but	partial	functional	overlap	of	other	Ras	isoforms	also	exists.	HRas	knock	in	(KI)	mice,	which	 express	HRas	 from	KRas	 locus	 and	 have	 no	 detectable	 KRas,	 are	viable	 and	 born	 at	 predicted	Mendelian	 ratios,	 hence	 showing	 that	 HRas	 can	functionally	 replace	 KRas	 during	 mouse	 development	 (Potenza	 et	 al.,	 2005).	
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However,	 KRas-/-	 phenotype	 is	 only	 rescued	 until	 adulthood,	 as	 HRasKI	 mice	develop	 later	 cardiovascular	 problems,	 suggesting	 a	 KRas-specific	 role	 in	cardiovascular	 homeostasis.	 Similarly,	 KRas-/-	 phenotype	 can	 be	 rescued	 by	 a	HRas	human	transgene,	which	encodes	human	HRas	protein	identical	to	that	of		mouse	 protein	 (Nakamura	 et	 al.,	 2008).	 The	 transgene	 is	 also	 able	 to	functionally	 substitute	 all	 three	Ras	 genes	 in	Ras	 triple	mutant	mice	 (KRas-/-;	NRas-/-;	HRas-/-).	
	
5.1.2	 Ras	isoform-specific	abundance	in	normal	tissues	Whether	Ras	isoform	functional	redundancy	seen	in	the	above-described	mouse	models	 is	 due	 to	 the	 pattern	 and	 timing	 of	 Ras	 isoform	 expression,	 could	 be	better	understood	by	measuring	Ras	transcript	and	protein	levels	in	a	range	of	normal	mouse	 tissues	and	at	different	developmental	 stages.	Such	work	could	also	 aid	 in	 delineating	 why	 KRasB	 is	 the	 key	 Ras	 isoform	 for	 mouse	development	 (Koera	 et	 al.,	 1997,	 Plowman	 et	 al.,	 2003)	 and	may	 explain	why	certain	 Ras	 isoforms	 couple	 to	 specific	 cancer	 types	 (Castellano	 and	 Santos,	2011).		
	Current	 data	 from	 a	 limited	 number	 of	 studies	 from	 both	 human	 and	mouse	suggests	 that	 distinct	 Ras	 isoforms	 are	 not	 equally	 abundant	 across	 different	tissues	 and	 cell	 lines	 (Fig.	 5.13).	 To	 compare	 Ras	 isoform	 expression	 at	transcript	 level,	 a	 range	 of	 semi-quantitative	 techniques	 has	 been	 used	 in	previous	studies.	For	example,	Northern	blotting	of	mouse	mRNA	(Leon	et	al.,	1987)	allowed	for	relative	comparison	of	 isoform	expression	across	a	panel	of	tissues,	derived	from	both	adult	and	postnatal	animals.	However,	comparison	of	mRNA	levels	between	the	different	Ras	isoforms	was	not	possible	and	the	study	did	not	account	for	the	two	KRas	splice	variants.	On	the	other	hand,	studies	that	aimed	 at	 comparing	 transcript	 expression	 levels	 of	 KRas	 splicing	 isoforms	(using	 Northern	 blotting	 and	 semi-quantitative	 RT-PCR),	 did	 not	 include	 the	remaining	Ras	 isoforms	 in	their	work	(Pells	et	al.,	1997,	Plowman	et	al.,	2006,	Plowman	et	al.,	2003,	Wang	et	al.,	2001).		
	Current	data	on	Ras	isoform	abundance	at	protein	level	in	different	tissue/cell	types	 is	also	derived	mainly	 from	semi-quantitative	methods,	such	as	Western	
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blotting.	 Most	 studies	 are	 not	 comprehensive	 and	 only	 focus	 on	 some	 Ras	isoforms	or	only	certain	tissues	(Nunez	Rodriguez	et	al.,	2006,	Sithanandam	et	al.,	1998).	Our	laboratory	previously	found	that	Ras	isoform-specific	antibodies	are	 not	 very	 accurate	 and	 difficult	 to	 work	 with,	 and	 instead,	 used	 a	 panRas	antibody	 and	 siRNA	 approach	 to	 estimate	 Ras	 isoform	 abundance	 in	 Ras	isoform	knock	 down	 (KD)	 human	 cancer	 cell	 lines	 (Omerovic	 et	 al.,	 2008).	 In	that	study,	KRas	was	observed	to	be	the	most	abundant	isoform	across	a	panel	of	cancer	cell	lines.		A	more	quantitative	method	to	measure	Ras	protein	levels	is	quantitative	mass	spectrometry,	which	was	used	 in	previous	 studies	utilising	peptide	 standards.	Up-to-date	results	mostly	show	conflicting	data,	 in	which	 total	Ras	abundance	ranges	over	5	orders	of	magnitude	(<100	to	>5,000,000	copies/cell)	(Halvey	et	al.,	2012,	Nagaraj	et	al.,	2011,	Ruppen-Canas	et	al.,	2012,	Schwanhausser	et	al.,	2011,	 Wang	 et	 al.,	 2011).	 However,	 these	 methods	 did	 not	 account	 for	 the	inefficiencies	 linked	 to	 antibody-based	 enrichment,	 sample	 handling	 or	proteolysis.	 Together,	 these	 studies	 do	 not	 give	 a	 fully	 comprehensive	comparison	of	all	Ras	isoforms	and	use	mainly	semi-quantitative	methods,	often	leading	 to	 contradicting	 results	 (Fig.	 5.13).	Moreover,	most	 of	 the	 data	 comes	from	 adult	 tissues	 or	 cell	 lines,	 missing	 the	 developmental	 outlook	 on	 Ras	isoform	 expression	 during	 embryogenesis	 and	 postnatal	 development.	Therefore,	 the	 aim	of	 the	 current	 study	 is	 to	 provide	 a	 complete	 comparative	map	 of	 all	 four	 major	 Ras	 isoform	 expression	 profiles	 across	 different	 tissue	types	 as	 well	 as	 between	 the	 isoforms.	 The	 expression	 profiles	 are	 to	 be	measured	at	different	developmental	time	points	using	a	mouse	model.	Also,	as	transcript	 expression	 levels	 do	 not	 necessarily	 reflect	 protein	 abundance	(Schwanhausser	 et	 al.,	 2011),	 it	 is	 important	 to	 measure	 both	 mRNA	 and	peptide	levels.	The	quantitative	methods	used	in	this	study	comprise	qRT-PCR	(Chapter	3	describes	method	development),	 for	measuring	absolute	 transcript	copy	 number,	 and	 mass	 spectrometry	 (MS)	 with	 protein	 standard	 absolute	quantification	(Mageean	et	al.,	2015)	to	estimate	protein	copy	number	in	SW48	colorectal	cancer	cell	lines	isogenic	for	Ras.	In	combination,	they	will	allow	the	
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first	 comparative	 analysis	 of	 absolute	 transcript	 and	 protein	 abundance	between	Ras	isoforms.	
	
5.2		 	 	 Results		
5.2.1	 Expression	studies	using	a	mouse	model	
A	 model	 of	 normal	 mouse	 development	 (Fig.	 5.1)	 was	 used	 to	 obtain	 three	biological	 replicates	 of	 a	 range	 of	 tissues:	 brain,	 liver,	 lungs,	 heart,	 stomach,	intestine,	kidneys,	skin	and	skeletal	muscle.	A	widely	used	outbred	strain	of	CD1	mice	 was	 chosen	 due	 to	 a	 good	 breeding	 performance	 and	 to	 reflect	 the	heterogeneity	 found	 in	 the	wild	mice	 (Aldinger	 et	 al.,	 2009,	Chia	 et	 al.,	 2005).	Hence,	CD1	strain	was	likely	to	reflect	a	generic	mouse	Ras	expression	profile.			During	 mouse	 embryonic	 development	 and	 at	 birth,	 tissues	 were	 harvested	from	separate	litters	at	embryonic	days	(E)	11.5,	13.5,	16.5	and	at	postnatal	day	(P)	 0	 (birth).	 During	 postnatal	 development,	 pups	 were	 sacrificed	 from	 the	same	 litters	at	P5,	P10,	P15,	P20,	P25	and	P30,	as	well	as	 their	corresponding	mothers.	 Therefore,	 biological	 replicates	 for	 the	 embryonic	 tissues	 represent	pools	of	individuals	from	a	single	litter.	Whereas	the	biological	replicates	for	the	postnatal	 samples	 represent	 separate	 litters	where	 littermates	 represent	 each	time-point.	 The	 adult	 sample	 is	 the	mother	 from	 the	 cognate	post-natal	 litter.	Three	biological	replicates	representing	litters	and	mothers	for	each	tissue	type	were	 analysed	 in	 this	 study	 to	measure	 Ras	 isoform	 transcript	 abundance.	 In	total,	 there	were	27	 individual	mouse	adult	 tissue	samples	and	240	pooled	or	individual	 tissue	 samples	 collected	 throughout	 mouse	 development.	 Pooled	samples	 always	 represented	 distinct	 litters	 and	 were	 only	 collected	 when	individual	tissue	samples	were	lighter	than	10	mg	(section	2.6).	Mouse	protein	samples	 were	 first	 collected	 alongside	 RNA	 using	 the	 Norgen	 kit	 for	simultaneous	extraction	of	RNA	and	protein	(section	2.7.8	and	2.8.2).			The	 rationale	 behind	 choosing	 11	 developmental	 stages	 in	 the	mouse	 in	 this	study,	 was	 to	 represent	 the	 best	 possible	 range	 of	 developmental	 changes,	starting	from	the	earliest	time	point,	from	which	accurate	manual	collection	of	
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distinct	 tissues/organs	 was	 possible.	 The	 first	 developmental	 stage	 of	 mouse	development	chosen	for	this	study	was	E11.5,	at	which	the	mouse	embryo	has	43-48	 pairs	 of	 somites	 and	 the	 buds	 of	 most	 major	 organs	 have	 already	developed	 (brain,	 heart,	 liver,	 lungs,	 stomach)	 and	 are	 distinguishable	(Kaufman,	1992).	The	developmental	changes	during	mouse	embryogenesis	and	postnatal	period	are	described	in	detail	in	the	introduction	(section	1.1.4.2.1). 	Most	 importantly,	 it	 has	 been	 known	 that	 KRas-deficient	 mice	 die	 prenatally	between	E12.5	and	birth	(Koera	et	al.,	1997).	Hence,	in	this	study,	tissues	were	collected	 from	 developmental	 time	 points	 before,	 during	 and	 after	 this	 lethal	stage	 (time	 points:	 E11.5,	 E13.5,	 E16.5,	 P0	 and	 P5,	 Fig.	 5.1).	 Also,	 abnormally	thin	ventricular	walls	of	the	heart	were	observed	in	KRas-/-	mouse	embryos	at	E15.5,	 but	 not	 at	 E13.5	 (Koera	 et	 al.,	 1997).	 Therefore,	 it	 was	 of	 interest	 to	measure	Ras	isoform	expression	in	the	embryonic	heart.	Skeletal	muscle	tissue	was	 used	 to	 compare	 Ras	 levels	 to	 those	 in	 cardiac	 muscle.	 The	 remaining	tissues	 were	 chosen	 in	 order	 of	 Ras	 isoform	 mutation	 frequency:	 lungs,	stomach,	 intestine	 and	 kidneys	 are	 the	 sites	 of	 cancers	 with	 frequent	 KRas	mutations,	 while	 brain	 and	 skin	 are	 the	 equivalent	 sites	 for	 NRas	 and	NRas/HRas	mutations,	respectively.	
		
5.2.2	 Extraction	 and	 quality	 control	 of	 RNA	 from	 mouse	
tissues	Mouse	 tissues	were	 collected	 at	 11	 developmental	 time	 points	 (section	 5.2.1)	and	 RNA	was	 extracted	 using	 Norgen	 extraction	 kit	 (section	 2.7.8).	 RNA	was	then	quality	checked	by	Nanodrop	and	agarose	gel	electrophoresis	(Fig.	5.2	and	Fig.	5.3).	Almost	all	samples	fulfilled	quality	control	criteria	by	showing	distinct	18S	rRNA	bands	on	agarose	gels	(Palmer	and	Prediger,	2014)	and	no	genomic	DNA	or	 other	 contaminants	 (adult	 intestine	 and	P5	 liver	 in	 Fig.	 5.2	 and	 adult	skeletal	muscle	in	Fig.	5.3	have	very	faint	18S	rRNA	band).	RNA	from	each	tissue	from	three	biological	replicates	representing	distinct	 litters	and	mothers	were	subsequently	 used	 in	 cDNA	 synthesis	 and	 qRT-PCR	 to	 determine	Ras	 isoform	transcript	copy	number.			
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Fig.	 5.2	 Assessment	 of	 RNA	 quality	 by	 agarose	 gel	 electrophoresis	 of	
mouse	 tissues:	 intestine,	 stomach,	 liver	 and	 kidneys,	 throughout	
development.	RNA	was	extracted	using	Norgen	RNA/protein	extraction	kit	and	1µg	 of	 RNA	was	 run	 per	 lane	 on	 1.2%	agarose	 gel.	 Two	distinct	 28S	 and	 18S	rRNA	bands	are	indicated	by	arrows.	The	figure	is	a	representative	example	of	three	 biological	 replicates	 of	 tissues	 harvested	 from	 the	 same	 litter	 and	 the	corresponding	adult	mothers.	E	–	embryonic	day,	P	–	postnatal	day,	bp	–	base	pairs,	28S	and	18S	–	rRNA	subunits.				
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Fig.	 5.3	 Assessment	 of	 RNA	 quality	 by	 agarose	 gel	 electrophoresis	 of	
mouse	 tissues:	 heart,	 limb/muscle,	 brain	 and	 lungs,	 throughout	
development.	RNA	was	extracted	using	Norgen	RNA/protein	extraction	kit	and	1µg	 of	 RNA	was	 run	 per	 lane	 on	 1.2%	agarose	 gel.	 Two	distinct	 28S	 and	 18S	rRNA	bands	are	indicated	by	arrows.	The	figure	is	a	representative	example	of	three	 biological	 replicates	 of	 tissues	 harvested	 from	 the	 same	 litter	 and	 the	corresponding	 adult	mothers.	 Limb/muscle	 denotes	 either	 limb	 harvested	 on	E11.3	and	E13.5	or	skeletal	muscle	harvested	on	the	remaining	developmental	time	points.	E	–	embryonic	day,	P	–	postnatal	day,	bp	–	base	pairs,	28S	and	18S	–	rRNA	subunits.	
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5.2.3	 Absolute	 transcript	 copy	 number	 of	 Ras	 isoforms	 in	
mouse	adult	tissues	and	during	development	
Ras	 isoform	 transcript	 levels	 were	 quantified	 by	 qRT-PCR	 in	 three	 biological	replicates	 (representing	 distinct	 litters	 and	mothers)	 of	 RNA	 from	 a	 panel	 of	mouse	 adult	 tissues:	 brain,	 thymus,	 oesophagus,	 lung,	 heart,	 skeletal	 muscle,	skin,	intestine,	stomach,	liver,	spleen,	kidney,	adrenal	gland,	bladder,	uterus	and	ovary.	 The	 copy	 number	 of	 individual	 Ras	 isoforms	was	 calculated	 across	 all	biological	 replicates	 using	 a	 single	 standard	 curve	with	 the	 best	 amplification	efficiency	 (Appendix	 Fig.	 A5.1).	 This	 was	 done	 to	 normalise	 for	 on-plate	differences	 where	 some	 plate-based	 standard	 curves	 exhibited	 poor	 PCR	efficiency.	The	total	Ras	abundance	(panRas)	was	calculated	from	the	sum	of	all	Ras	 isoform	 transcripts	 and	 was	 represented	 as	 copy	 number	 per	 pg	 of	extracted	 RNA	 (Fig.	 5.4	 A).	 Overall,	 panRas	 transcript	 abundance	 across	 all	tested	 tissue	 types	 ranged	 between	 5-110	 copies	 per	 pg	 RNA	 (average	 26	copies/pg).	 Since	 a	 typical	 mammalian	 cell	 contains	 around	 20	 pg	 of	 RNA	(Alberts	 et	 al.,	 1994,	 Copois	 et	 al.,	 2003,	 Ramskold	 et	 al.,	 2012),	 panRas	transcript	levels	can	be	estimated	to	average	approximately	520	copies	per	cell.	The	 highest	 Ras	 transcript	 levels	 were	 found	 in	 the	 murine	 thymus	 (around	2200	copies	per	cell),	whereas	in	the	muscle	Ras	transcript	abundance	was	the	lowest	(around	110	copies	per	cell).			The	 individual	 Ras	 isoform	 contribution	 to	 total	 Ras	 transcript	 levels	 varies	across	 adult	 tissues	 (Fig.	 5.4	 B).	 Together,	 both	KRasA	 and	KRasB	 transcripts	are	the	most	abundant	typically	comprising	>80%	of	total	Ras,	where	KRasB	is	by	 far	 the	 major	 isoform.	 Interestingly,	 the	 contribution	 of	 KRasA	 transcript	levels	 to	 total	 Ras	 exhibits	 the	 highest	 variation	 across	 different	 tissue	 types,	from	<1%	in	8	of	the	16	adult	tissues	to	9-20%	in	the	kidney,	liver,	intestine	and	stomach.	NRas	represents	on	average	15%	of	total	Ras	transcript	levels	(range		6–30%),	 whilst	 HRas	 is	 in	 general	 the	 least	 abundant	 isoform	 in	 all	 tested	tissues	 with	 an	 average	 1.9%	 contribution	 to	 total	 Ras	 transcript	 levels.	 In	summary,	 KRas	 dominates	 transcript	 abundance	 across	 all	 adult	 tissues	 with	KRasB	being	typically	5-40-fold	more	abundant	than	NRas	or	HRas.		
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A	
B	
	
Fig.	5.4	Ras	 isoform	transcript	expression	 in	adult	mouse	tissues.	A	Total	Ras	 transcript	 copy	 number	 per	 pg	 of	 RNA	 based	 on	 summation	 of	 qRT-PCR	data	for	Ras	isoforms	in	adult	mouse	tissues,	representing	means	±	SEM	(n	=	3).	Data	was	analysed	by	one-way	ANOVA	with	Fisher’s	LSD	post	hoc	test	(inset).		
B	Percentage	contribution	of	Ras	isoforms	to	total	Ras	transcript	copy	number	per	pg	of	RNA	in	adult	mouse	tissues	(n	=3).	
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To	 measure	 Ras	 isoform	 abundance	 during	 mouse	 development,	 a	 restricted	panel	 of	 tissues	 used	 for	 the	 adult	 investigation	 was	 chosen.	 The	 analysis	consisted	 of	 10	 developmental	 time	 points	 using	 three	 biological	 replicates	representing	 distinct	 litters.	 Data	was	 collated	with	 that	 for	 adult	 tissue	 from	the	corresponding	mothers	 (Fig.	5.5	and	Fig.	5.6).	Overall,	 as	observed	 for	 the	adult	 tissues,	 KRasB	 was	 the	 most	 abundant	 transcript	 in	 all	 tested	 tissues.	Generally,	expression	levels	of	each	Ras	isoform	remained	constant	throughout	mouse	development;	the	two	notable	exceptions	were	for	NRas	and	KRasA,	for	which	statistical	analysis	was	performed	and	summarised	in	Fig.	5.7.			NRas	 transcript	 levels	 showed	 a	 progressive	 decrease	 during	 embryonic	development	across	many	tissues.	This	can	be	most	clearly	seen	in	the	brain	and	liver,	where	NRas	exhibits	a	10-fold	decrease	between	day	E11.5	and	post-natal	day	30	(Fig.	5.5	and	Fig.	5.6).	Intriguingly,	the	slope	of	these	decreases	differs;	in	liver	the	reduction	in	NRas	transcript	abundance	ceases	by	post-natal	day	5.	In	contrast,	 the	 brain	 exhibits	 a	 constant	 decrease	 over	 the	 entire	 time	 course;	although	 the	 values	 for	 post-natal	 day	 30	 are	 equivalent	 to	 the	 adult	 brain	levels,	suggesting	that	further	decreases	are	unlikely.		On	 the	 other	 hand,	 KRasA	 was	 the	 most	 dynamically	 regulated	 isoform.	 It	showed	a	marked	≥10-fold	increase	in	transcript	levels	in	the	intestine,	stomach	and	kidney	(Fig.	5.5)	during	embryonic	development,	which	stabilised	at	adult	levels	 just	 after	 birth	 (P0).	 Also,	 to	 a	 lesser	 extent,	 KRasA	 expression	 was	increasing	until	around	P25	in	the	liver	(Fig.	5.5).	Remarkably,	given	that	KRasA	has	not	previously	been	detected	in	the	heart	(Plowman	et	al.,	2003),	a	transient	peak	reaching	10-fold	baseline	levels	was	observed	just	before	and	at	birth	(Fig.	5.6,	E16.5	and	P0).	In	contrast,	KRasA	transcript	expression	was	continually	low	during	development	in	skeletal	muscle,	lung	and	brain	(Fig.	5.6).						
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Intestine	 	 	 	 Stomach		
	
Liver	 	 	 	 	 Kidney	
	 	
	
Fig.	5.5	Ras	isoform	transcript	expression	throughout	mouse	development	
in	 intestine,	 stomach,	 liver	 and	kidney.	Transcript	 levels	were	measured	at	11	 developmental	 time	 points	 by	 qRT-PCR	 and	 converted	 to	 copy	 number	values	using	Ras	isoform-specific	standard	curves	(n	=	3).	The	data	represents	means	±	 SEM	 (n=3),	which	was	plotted	on	a	 logarithmic	 scale.	 E	 –	 embryonic	day,	 P	 –	 postnatal	 day.	 Statistical	 analysis	 of	 trends	 depicted	 in	 text	 is	summarised	in	Fig.	5.7.					
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Heart	 	 	 	 	 Skeletal	muscle	
	
	
Lung	 	 	 	 	 Brain	
		 	
	
Fig.	5.6	Ras	isoform	transcript	expression	throughout	mouse	development	
in	 heart,	 muscle,	 brain	 and	 lung.	 Transcript	 levels	 were	 measured	 at	 11	developmental	 time	points	by	qRT-PCR	and	converted	 to	 copy	number	values	using	Ras	isoform-specific	standard	curves	(n	=	3).	The	data	represents	means	±	SEM	 (n=3),	which	was	 plotted	 on	 a	 logarithmic	 scale.	 E	 –	 embryonic	 day,	 P	 –	postnatal	 day.	 Statistical	 analysis	 of	 trends	 depicted	 in	 text	 is	 summarised	 in		Fig.	5.7.				
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Fig.	 5.7	 Statistical	 significance	 of	 Ras	 isoform	 transcript	 expression	 data	
obtained	 by	 qRT-PCR	 throughout	 normal	 mouse	 development.	 Statistical	significance	of	data	from	Fig.	5.5	and	Fig.	5.6	was	analysed	by	one-way	ANOVA	with	 Fisher’s	 LSD	 post	 hoc	 test	 and	 represented	 as	 heat	 maps	 using	MultiExperiment	Viewer	(MeV	v4.8.1).		
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To	 better	 illustrate	 a	 full	 mouse	 developmental	 profile	 for	 each	 Ras	 isoform	across	all	tested	tissues,	hierarchical	clustering	was	performed	on	the	qRT-PCR	data	from	this	study	(Fig.	5.8,	Fig.	5.9).	This	representation	of	the	data	revealed	that	 panRas	 expression	 levels	 decrease	 during	 development	 in	 all	 tissues	examined	(Fig.	5.8).	The	same	trend	was	also	seen	in	the	majority	of	tissues	for	most	Ras	 isoforms,	except	 for	KRasA	(Fig.	5.9).	The	 tissues	co-clustered	based	on	trends	in	transcript	levels,	highlighting	similar	upregulation	of	KRasA	in	the	kidney,	 stomach,	 intestine	 and	 liver.	 Strikingly,	 intestine,	 kidney	 and	 stomach	cluster	was	also	evident	in	the	KRasB	and	NRas	expression	profiles.	In	contrast	to	 KRasA,	 however,	 KRasB	 and	 NRas	 transcript	 levels	 decreased	 during	postnatal	 development	 in	 these	 tissues.	 HRas,	 on	 the	 other	 hand,	 showed	 a	distinct	expression	pattern	 from	other	 isoforms,	with	a	 less	clear	clustering	of	the	kidney,	stomach	and	intestine.																		
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Fig.	 5.8	 Heat	 map	 representing	 relative	 total	 Ras	 (panRas)	 transcript	
expression	 throughout	mouse	development	across	different	 tissue	 types.	Total	 Ras	 (panRas)	 transcript	 levels	were	 calculated	 as	 a	 sum	 of	 Ras	 isoform	transcript	 levels	 (KRasA,	 KRasB,	 NRas,	 HRas)	 obtained	 by	 qRT-PCR	 and	represented	 as	 copies	 per	 pg	 of	 RNA	 by	 (n	 =	 3).	 Heat	map	was	 generated	 by	MultiExperiment	 Viewer	 (MeV	 v4.8.1)	 and	 hierarchically	 clustered	 using	Pearson	correlation.	E	–	embryonic	day,	P	–	postnatal	day.		
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Fig.	5.9	Heat	maps	representing	relative	Ras	isoform	transcript	expression	
throughout	mouse	 development	 across	 different	 tissue	 types.	 Heat	maps	show	absolute	Ras	transcript	levels	per	pg	of	RNA	calculated	by	qRT-PCR	(n	=	3)	and	 were	 generated	 by	 hierarchical	 clustering	 using	 Pearson	 correlation	(MultiExperiment	Viewer	MeV	v4.8.1).	E	–	embryonic	day,	P	–	postnatal	day.	
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5.2.4		 Absolute	abundance	of	Ras	isoform	proteins	in	mouse	
adult	tissues		
To	investigate	whether	the	Ras	transcript	expression	profiles	were	indicative	of	expression	 at	 the	 protein	 level,	 absolute	 quantification	 of	 Ras	 isoforms	 using	mass	 spectrometry	 was	 employed.	 First,	 isotopically	 labelled	 Ras	 protein	standards	 were	 quality	 checked	 by	 gel	 electrophoresis	 and	 Colloidal	 Blue	staining	(Fig.	5.10).	The	gel	revealed	distinct	~30	kDa	bands	of	equal	densities	representing	 purified	 Ras	 standards	 of	 equal	 abundance.	 The	 NRas	 standard	showed	a	high-density	bovine	serum	albumin	(BSA)	band,	which	was	used	as	a	quenching	solution	to	stop	protein	standards	from	attaching	to	the	surface	of	a	tube.	 The	 standards,	 apart	 from	 KRasA,	 were	 subsequently	 spiked	 at	 known	concentrations	 into	 protein	 samples	 extracted	 from	 mouse	 tissues	 for	 Ras	isoform	quantification.	
	
	
Fig.	 5.10	 Assessment	 of	 protein	 quality	 of	 Ras	 standards	 labelled	 with	
heavy	 arginine	 (Arg10)	 and	 lysine	 (Lys8)	 for	 proteomics	 by	 gel	
electrophoresis.	50	ng	of	each	His-tagged	Ras	standard	(supplied	by	Dr	Craig	Mageean,	 University	 of	 Liverpool,	 UK)	 and	 a	 BSA	 control	were	 run	 on	 4-12%	Bis-Tris	 NuPAGE	 gel	 and	 stained	with	 the	 Colloidal	 Blue	 Staining	 Kit.	 All	 Ras	standards	showed	a	distinct	band	of	around	30	kDa	(denoted	by	arrow	“Ras”)	of	similar	abundance.	50	ng	of	bovine	serum	albumin	(BSA)	was	run	alongside	as	a	quantity	 control	 (denoted	 by	 arrow	 “BSA”).	 The	 BSA	 in	 the	 NRas	 standard	 is	from	the	BSA-coated	tube	that	was	used	to	reduce	adsorption	of	the	standard.	
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Due	to	a	 limited	amount	of	 time	 for	 this	part	of	 the	study,	only	5	adult	mouse	tissues	 were	 analysed	 by	 mass	 spectrometry	 in	 a	 pilot	 experiment:	 brain,	intestine,	liver,	lung	and	pancreas.	The	latter	tissue	was	not	previously	analysed	by	qRT-PCR	due	to	poor	RNA	recovery.	The	choice	of	tissues	was	based	on	the	transcript	level	results	(brain	and	liver	were	initially	representing	tissues	with	high	and	low	total	Ras	abundance,	respectively)	and	previously	known	data	on	Ras	 contribution	 to	 human	 cancers	 (KRas	 is	 often	mutated	 in	 colon,	 lung	 and	pancreatic	cancers	(Cox	et	al.,	2014)).	The	mass	spectrometry	data	revealed	that	there	 was	 a	 significant	 variation	 between	 the	 three	 biological	 replicates	 and,	hence,	 one	 set	 of	 samples	 was	 randomly	 chosen	 to	 generate	 three	 technical	replicates,	which	are	summarised	in	Fig.	5.11.		Total	Ras	protein	levels	were	estimated	by	measuring	a	panRas	peptide	(amino	acids	 6-16)	 common	 to	 all	 Ras	 isoforms	 and	 revealed	 the	 highest	 panRas	abundance	in	the	brain,	followed	by	lung,	intestine,	liver	and	pancreas,	ranging	from	45	to	770	ng	panRas	protein	per	mg	total	protein	(Fig.	5.11	A,	Appendix	Table	A5.1).	Using	the	proteomics	approach	described	in	this	chapter,	Dr	Craig	Mageean	 (Prior	Laboratory,	University	of	Liverpool,	UK)	has	observed	90-220	ng	 of	 endogenous	 panRas	 per	mg	 of	 total	 protein	 in	 SW48	 colon	 cancer	 cells,	which	 was	 estimated	 to	 be	 around	 ~250,000-540,000	 copies	 of	 Ras	 per	 cell	(Mageean	et	al.,	2015).		The	use	of	Ras	protein	standards	allows	each	isoform	to	be	precisely	quantified.	Unfortunately,	 KRasA	 analysis	 has	 not	 been	 optimised	 whilst	 NRas	 peptides	were	 not	 detected	 due	 to	 an	 error	 with	 the	 settings	 used	 on	 the	 mass	spectrometer.	Nonetheless,	NRas	and	KRasA	protein	abundance	was	estimated	by	 subtracting	 the	 other	 isoforms	 abundance	 from	 panRas	 expression	 levels.	Intriguingly,	 whilst	 KRas4B	 transcripts	 were	 18-80-fold	 more	 abundant	 than	HRas	transcripts	in	these	tissues,	the	protein	abundance	of	these	two	isoforms	is	far	more	similar	(Fig.	5.6	and	Fig.	5.11).	However,	KRasB	was	not	detected	in	the	liver	and	had	a	low	abundance	in	pancreas,	where	KRasA	and/or	NRas	were	estimated	to	be	the	dominant	isoforms.				
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B	 																	
	
	
	
	
	
	
	
	
	
Fig.	 5.11	 Ras	 isoform	 protein	 levels	 in	 adult	 mouse	 tissues.	 A	 Total	 Ras	(panRas)	 as	well	 as	 individual	Ras	 isoform	protein	 levels	 per	 50µg	 of	 protein	based	 on	 absolute	 quantification	 by	 mass	 spectrometry	 (MS)	 of	 adult	 mouse	tissues	are	represented	as	means	±	SD	(n	=	3	technical	replicates)	on	a	log	scale.		
B	Percentage	contribution	of	Ras	isoform	protein	levels	to	total	measured	Ras	in	mouse	 adult	 tissues	 (n	 =	 3	 technical	 replicates).	 KRasA	 and	 NRas	 percentage	contribution	 (KRasA+NRas)	 was	 estimated	 by	 subtracting	 KRasB	 and	 HRas	contributions	from	total	Ras.	MS	analysis	was	performed	by	Dr	Rosalind	Jenkins	(University	of	Liverpool,	UK).	
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In	 summary,	 proteomics	 data	 from	 this	 study	 shows	 a	 similar	 order	 of	decreasing	 expression	 level	 of	 total	 Ras	 as	 compared	 to	 mRNA	 levels	 in	 the	following	 tissues:	 brain,	 lung,	 intestine	 and	 liver	 (Fig.	 5.4	 A	 and	 Fig.	 5.11	 A).	However,	 the	 relative	 isoform	 contributions	 to	 total	 Ras	 abundance	 are	 not	equivalent	at	the	transcript	versus	protein	level.	For	example,	HRas	represented	only	2.4%	of	total	Ras	transcripts	in	the	brain	versus	the	KRasB	contribution	of	~90%,	yet	>50%	of	total	Ras	protein	abundance	measured	by	quantitative	mass	spectrometry	was	HRas.	Fig.	5.12	summarises	the	correlation	between	panRas	abundance	at	 transcript	 and	protein	 level	 in	 the	 four	mouse	organs	 for	which	both	transcript	and	protein	data	was	obtained.	Yet,	it	is	important	to	emphasise	that	this	proteomics	study	should	be	interpreted	with	some	caution	as	it	is	only	preliminary	and	represents	technical,	not	biological	repeats.						
5.3	 Discussion	
This	study	aimed	to	quantitatively	measure	Ras	isoform	transcript	and	protein	expression	 levels	 in	 various	normal	mouse	 tissues.	 Previous	 investigations	 on	Ras	 expression	 pattern	 often	 show	 contradictory	 results	 (Fig.	 5.13)	 due	 to	differences	 in	 methods	 and	 the	 examined	 samples	 as	 well	 as	 non-comprehensive	and	semi-quantitative	approach.	The	experimental	strategy	for	the	study	of	this	thesis	was	designed	to	provide	a	more	comprehensive	analysis	of	 Ras	 isoform	 expression	 compared	 to	 previous	 studies	 (Leon	 et	 al.,	 1987,	Plowman	 et	 al.,	 2006,	 Plowman	 et	 al.,	 2003,	 Shyamsundar	 et	 al.,	 2005).	Transcript	levels	were	analysed	in	sixteen	major	adult	mouse	tissues,	as	well	as	at	10	time	points	during	embryonic	and	postnatal	development	in	eight	tissues.	This	study	used	more	quantitative	methods	that	also	allowed	cross	comparison	between	isoforms	in	contrast	to	previous	analyses.	Transcript	copy	number	per	pg	 of	 RNA	 and	 per	 cell	 were	 calculated	 based	 on	 qRT-PCR,	 giving	 the	 first	quantitative	data	across	all	four	main	Ras	isoforms	(Fig.	5.13).	Proteomics	data,	although	 preliminary,	 gave	 the	 first	 insight	 into	 Ras	 isoform	 protein	 copy	number	in	normal	mouse	tissues.		
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Fig.	 5.12	 Protein	 and	 transcript	 levels	 of	 Ras	 isoforms	 in	 normal	 adult	
mouse	 tissues.	 A	 Protein/RNA	 correspondence	 plot	 for	 panRas	 expression.	panRas	peptide	abundance	was	obtained	from	quantitative	mass	spectrometry	(section	2.9)	and	panRas	transcript	abundance	from	qRT-PCR	(section	2.7.12),	both	 from	normal	mouse	adult	 tissues	(brain,	 lung,	 intestine	and	 liver).	 	Mean	panRas	 peptide	 abundance	 ±	 SEM	 (n	 =	 3	 technical	 replicates)	 was	 plotted	against	 mean	 panRas	 transcript	 copy	 number	 ±	 SEM	 (n	 =	 3	 biological	replicates).	B	Percentage	contribution	of	Ras	isoforms	to	total	Ras	at	transcript	and	 protein	 level	 (a	 summary	 of	 Fig.	 5.4	 B	 and	 Fig.	 5.11B).	 KRasA	 and	 NRas	percentage	contribution	at	protein	level	were	estimated	on	the	basis	of	panRas	abundance.	
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5.3.1		 	 	 Comparison	with	previous	studies	
In	 general,	 transcript	 abundance	 results	 of	 the	 current	 study	 on	 adult	mouse	tissues	 showed	 little	 similarity	 with	 previous	 Northern	 blotting	 data,	 when	compared	 across	 tissues	 per	Ras	 isoform	 (Fig.	 5.13)	 (Leon	 et	 al.,	 1987).	HRas	transcript	abundance	was	 found	to	be	high	 in	 the	adult	mouse	skin,	brain	and	skeletal	 muscle	 and	 lowly	 abundant	 in	 the	 spleen.	 However,	 the	 earlier	 data	identified	the	liver	and	ovary	as	sites	with	the	least	HRas	expression,	whereas	in	this	 chapter	 they	were	 close	 to	median	values	 for	HRas	expression	across	 the	tissue	studied.	In	the	current	study,	NRas	transcripts	were	most	abundant	in	the	thymus,	ovary	and	uterus.	The	thymus	was	also	identified	as	a	site	of	high	NRas	expression	 in	 the	 Leon	 study	 and	 similarly	 to	 this	 earlier	 work,	 this	 study	showed	 that	 NRas	 abundance	 is	 lowest	 in	 the	 liver.	 Finally,	 there	 is	 some	similarity	with	previous	data	that	found	high	expression	of	KRas	in	the	thymus	and	low	in	the	skeletal	muscle	and	liver.	
A	further	 improvement	compared	to	previous	published	work	is	that	the	qRT-PCR	data	has	scored	Ras	isoform	transcript	abundance	in	absolute	terms,	which	allowed	for	direct	comparison	between	the	isoforms.	In	contrast,	the	Northern	blotting	 data	 only	 measured	 relative	 expression	 levels	 per	 isoform.	 Thus,	according	 to	 Northern	 blotting	 data,	 Ras	 isoform	 transcript	 expression	 may	appear	to	be	relatively	low	or	high	in	certain	tissues,	but	this	does	not	account	for	 total	 Ras	 expression.	 For	 example,	 although	 HRas	 transcript	 abundance	appears	 to	 be	 high	 in	 the	 brain	 (Fig.	 5.13,	 study	 2),	 in	 reality	 it	 is	 low	when	compared	 to	 other	 Ras	 isoforms	 (Fig.	 5.4).	 The	 same	 is	 true	 for	 the	 relative	expression	 of	 KRas	 and	 NRas,	 which	 cannot	 be	 directly	 compared	 in	 the	Northern	 blotting	 results.	 On	 the	 other	 hand,	 this	 study	 showed	 that	 during	gestation	 both	 KRas	 isoforms	 and	 NRas	 generally	 decrease	 in	 transcript	expression	 levels	 over	 time	 (Fig.	 5.7),	 which	 also	 agrees	 with	 the	 Northern	blotting	data	(Leon	et	al.,	1987).		
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Transcript	 expression	 of	 KRasA	 and	 KRasB	 splice	 isoforms	 in	 adult	 mouse	tissues	 in	the	current	study	(Fig.	5.4)	 is	similar	to	the	results	of	a	more	recent	work	 that	 investigated	 transcript	 levels	 of	 both	 these	 splice	 variants	by	 semi-quantitative	RT-PCR	in	adult	mice	(Plowman	et	al.,	2003).	It	showed	that	KRasA	was	highly	abundant	in	the	intestine,	kidneys	and	liver	and	was	also	expressed	in	the	stomach	and	lungs,	but	not	present	in	the	adult	heart	and	brain	and	that	KRasB	was	the	dominant	splice	variant	expressed	at	high	levels	in	all	tissues.	A	similar	 transcript	 expression	 pattern	 of	 KRasA	 and	 KRasB	 isoforms	 was	 also	previously	 shown	 in	 normal	 adult	 human	 tissues	 (Plowman	 et	 al.,	 2006,	Plowman	et	al.,	2003).		
According	to	the	current	work,	 transcript	expression	 levels	of	all	Ras	 isoforms	(panRas)	averaged	around	26	copies	per	pg	RNA	across	all	 the	normal	 tissues	examined	in	adult	mice.	Based	on	the	estimated	RNA	amount	per	cell	(Alberts	et	al.,	1994,	Copois	et	al.,	2003,	Ramskold	et	al.,	2012),	this	value	is	equivalent	to	around	520	Ras	transcripts	per	cell.	
After	 internal	 normalisation	 to	 total	 Ras	 transcript	 levels,	 both	 KRas	 splice	variants	 constituted	 the	most	 abundant	 Ras	 isoforms	 across	 all	 tested	mouse	adult	 tissues.	 One	 way	 to	 compare	 the	 tissues	 is	 to	 divide	 them	 into	 groups	based	 on	 their	 germ	 layer	 origin.	 The	 liver,	 lungs	 and	 the	 epithelium	 of	 the	gastrointestinal	 tract	 (including	 intestine	 and	 stomach)	 are	 of	 endodermal	origin	 (Gilbert,	2010).	Whilst	 the	pattern	of	Ras	 isoform	 transcript	expression	across	all	 these	 tissues	 is	varying,	 it	 is	notable	 that	 these	are	all	of	 the	 tissues	where	 KRasA	 is	 expressed	 at	 high	 levels,	 apart	 from	 the	 lungs	 (Fig.	 5.4	 B).	Another	exception	to	this	is	the	kidney,	which	harbours	high	KRasA	levels,	but	is	of	mesodermal	origin	(Gilbert,	2010).	Other	mesoderm-derived	tissues,	cardiac	and	skeletal	muscles,	have	very	low	KRasA	levels	(Fig.	5.4	B).	Finally,	the	skin,	which	is	both	of	mesodermal	and	ectodermal	origin	(Gilbert,	2010),	shows	low	levels	of	KRasA,	whereas	the	brain,	which	is	derived	from	the	ectoderm	(Gilbert,	2010),	 is	 the	 site	where	 Ras	 expression	 almost	 exclusively	 consists	 of	 KRasB.	Therefore, whilst	 it	 is	 difficult	 to	 identify	 clear	 correlations	 between	 tissue	origin	 and	 Ras	 expression,	 the	 link	 between	 endoderm-derived	 tissues	 and	KRasA	expression	may	be	of	interest.	
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5.3.2		 	 	 Dynamic	KRasA	expression	
Very	low	KRasA	abundance	detected	by	qRT-PCR	in	mouse	adult	heart,	skeletal	muscle	and	brain,	among	the	others,	may	actually	indicate	no	KRasA	expression	(Fig.	5.4	B	and	Fig.	5.6).	The	obtained	CT	values	 for	 these	 tissues	were	around	31,	which	was	within	 the	 range	 of	 the	 CT	 values	 for	 plasmid	 standard	 curves	and,	 hence,	 KRasA	 transcript	 abundance	 was	 calculated	 by	 interpolation.	However,	 the	 analysed	 tissues	 might	 have	 had	 some	 contaminants	 of	neighbouring	 tissues,	 e.g.	 connective	 tissues	 and	 blood,	 which	 could	 contain	higher	 amounts	 of	 KRasA,	 giving	 a	 positive	 signal	 for	 the	 tested	 tissue.	 This	could	be	 further	 investigated	by	measuring	KRasA	abundance	 in	mouse	 tissue	samples	obtained	by	microdissection.	
KRasA	was	the	most	dynamically	regulated	Ras	isoform	over	time	during	mouse	development.	Its	transcript	levels	increased	by	10-fold	in	the	intestine,	stomach	and	 kidneys	 during	 gestation	 (Fig.	 5.5).	 Also,	 in	 this	 study,	 KRasA	 transcripts	were	 detected	 for	 the	 first	 time	 in	 the	 mouse	 heart,	 appearing	 transiently	between	E16.5	and	P0	(Fig.	5.6).	During	this	phase	of	development,	the	murine	heart	grows	in	size	and	its	axis	becomes	more	oblique	(Savolainen	et	al.,	2009).	The	only	major	changes	occur	in	the	atrioventricular	valve	leaflets	and	coronary	arteries.	 Whether	 KRasA	 plays	 a	 role	 at	 this	 stage	 of	 heart	 development	 is	unknown;	however,	previous	work	using	KRas	and	KRasA	KO	mice	has	shown	that	KRasB	has	an	essential	function	in	cardiovascular	homeostasis,	but	KRasA	is	dispensable	(Potenza	et	al.,	2005,	Koera	et	al.,	1997).	KRas-deficient	mice	die	between	E12.5	and	term	due	to,	among	the	others,	thin	ventricular	walls	of	the	heart.	To	further	examine	the	role	of	KRasA	in	heart	development,	 it	would	be	useful	to	check	whether	its	expression	is	restricted	only	to	specific	sites	in	the	developing	 heart.	 For	 instance,	 this	 could	 be	 done	 by	 microdissecting	 the	atrioventricular	valve	leaflets	and	ventricular	walls	and	performing	qRT-PCR.	
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5.3.3	 Correlation	 between	 Ras	 isoform	 expression	 and	
cancer	
Based	 on	 the	 current	 results,	 it	 was	 of	 interest	 whether	 Ras	 isoform	 tissue-specific	 expression	 pattern	 related	 to	 the	 incidence	 of	 Ras	 isoform-specific	mutations	in	tumours	derived	from	particular	tissues	type.	For	example,	 it	has	been	 previously	 shown	 that	 higher	 transcript	 levels	 of	 KRasA	 in	 mouse	 lung	tissue	 correlate	 with	 increased	 risk	 of	 developing	 lung	 tumour	 (Wang	 et	 al.,	2001).	Among	murine	tissues	examined	in	the	current	study,	stomach,	intestine,	lungs	and	kidneys	are	the	sites	of	predominantly	KRas-driven	tumours,	namely	gastric,	colorectal	and	lung	adenocarcinomas	and	renal	papillary	cell	carcinoma	(Cox	et	al.,	2014).	All	these	tissues	have	high	transcript	expression	of	KRasA	and	KRasB	isoforms,	which	contribute	to	over	68%	of	total	Ras	(Fig.	5.4	B).		More	 generally,	 it	 is	 difficult	 to	 identify	 any	 link	 between	 expression	 and	Ras	mutation	 incidence	 in	 cancer	 due	 to	 the	 high	 abundance	 of	 KRas	 transcripts	across	all	tissues	(Fig.	5.4	B	and	Fig.	5.13).	For	example,	in	the	liver,	which	is	the	origin	 of	 hepatocellular	 carcinoma,	 the	 majority	 of	 Ras	 mutations	 are	 due	 to	activation	 of	 NRas	 (60%	 of	 total	 Ras),	 followed	 by	 KRas	 (40%	 of	 total	 Ras)	(Forbes	 et	 al.,	 2015).	 In	 this	 tissue,	NRas	 transcript	 expression	 contributes	 to	12%	of	total	Ras,	whereas	both	KRas	splice	variants	constitute	83%.		Several	 studies	 suggested	 that	 there	 is	 a	 positive	 correlation	 between	 gene	expression	 level	 and	 mutation	 frequency	 (Comeron,	 2004,	 Majewski,	 2003),	especially	 for	ubiquitously	expressed	genes	 (Cui	et	al.,	2012a,	Ramskold	et	al.,	2009),	both	 in	 somatic	 cells	 (Cui	 et	 al.,	 2012a)	and	 in	 the	germline	 (Cui	 et	 al.,	2012b,	Park	et	al.,	2012).	The	underlying	reason	for	such	observation	is	thought	to	 be	 the	 imbalance	 between	 transcription-associated	 mutagenesis	 (TAM)	(Hendriks	 et	 al.,	 2010,	 Herman	 and	 Dworkin,	 1971,	 Savic	 and	 Kanazir,	 1972)	and	 transcription-coupled-repair	 (TCR)	 (Green	 et	 al.,	 2003,	 Hanawalt,	 1994,	Svejstrup,	 2002),	 resulting	 in	 the	 increased	 density	 of	 single	 nucleotide	polymorphisms	(SNP)	(Cui	et	al.,	2012a,	Cui	et	al.,	2012b,	Park	et	al.,	2012).	This	thesis	 shows,	 however,	 that	 Ras	 transcript	 expression	 pattern	 in	 different	mouse	 adult	 tissues	 does	 not	 appear	 to	 correlate	 with	 the	 incidence	 of	 Ras	
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isoform	mutations	 in	 human	 cancers.	 There	might	 be	 a	 few	 reasons	why	 this	correlation	is	not	as	expected,	based	on	the	TAM-TCR	hypothesis.	First,	the	tested	tissues	were	derived	from	mouse,	not	human	samples,	and	the	genetics	 and	 tumour	 incidence	 in	both	 species	varies	 and	may	not	be	directly	comparable	(Anisimov	et	al.,	2005).	Hence,	to	better	understand	the	association	between	 gene	 expression	 and	 mutation	 frequency,	 normal	 human	 tissues	should	 be	 studied	 instead.	 Second,	 each	 cancer	 type	 derives	 only	 from	 a	particular	 cell	 type	 or	 a	 cancer	 stem	 cell	 (Lobo	 et	 al.,	 2007)	 and	 it	 would	 be	more	appropriate	 to	examine	Ras	expression	patterns	only	 in	 these	particular	cell	 types.	The	whole	organs,	as	examined	in	this	study,	comprise	a	mixture	of	tissues,	which	may	each	have	a	distinct	Ras	isoform	expression	profile.	Finally,	the	 incidence	of	Ras	 isoform-specific	mutations	 in	different	tissues	may	rather	arise	 from	 the	 predisposition	 of	 Ras	 isoform	 loci	 to	 particular	 carcinogens,	which	 usually	 affects	 particular	 tissue	 types.	 For	 instance,	 tobacco	 smoke	carcinogens	 affect	 the	 lungs	 and	 the	 mutational	 hotspot	 caused	 by	 these	carcinogens	 is	 codon	12	of	KRas,	but	not	of	NRas	or	HRas	 (Feng	et	 al.,	 2002).	This	 preferential	mutation	 in	 one	 of	 the	 three	Ras	 loci	might	 be	 explained	 by	preferential	 DNA-carcinogen	 adduct	 formation	 and	 poor	 repair	mechanism	 at	this	 particular	 site.	 Further	 research	 suggested	 that	 such	 preferential	mechanisms	 at	 codon	 12	 of	 KRas	 might	 be	 due	 to	 an	 unknown	 epigenetic	modification	(Hu	et	al.,	2003).		Curiously,	 another	 study	 depicted	 that	 differential	 susceptibility	 for	 certain	mutations	 in	 different	 Ras	 genes	 might	 be	 due	 to	 distinct	 sequences	surrounding	 each	 Ras	 gene.	 It	 showed	 that	HrasKI	 mice,	 which	 express	 HRas	under	 the	 regulation	 of	 KRas	 promoter	 and	 completely	 lack	 KRas	 expression,	still	develop	 lung	 tumours	due	 to	mutation	 in	HrasKI	allele	when	treated	with	urethane,	which	normally	causes	only	KRas	mutations	in	wild	type	mice	(To	et	al.,	 2008).	 On	 the	 other	 hand,	 induced	 skin	 tumours	 develop	 as	 a	 result	 of	mutation	 of	 endogenous	 Hras	 allele,	 not	 the	 “knock-in”	 HrasKI.	 Hence,	 the	predisposition	of	KRas	mutations	to	induce	lung	tumour	and	HRas	mutations	to	induce	 skin	 tumour,	 may	 likely	 be	 due	 to	 both	 Ras	 genes	 having	 unique	 cis-acting	 regulatory	 elements	 (CRE).	 CREs	 are	 non-coding	 DNA	 sites	 found	 near	
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the	 gene,	 which	 are	 usually	 binding	 sites	 for	 transcription	 factors.	 Taken	together,	 the	reason	why	specific	cancers	and	mutations	couple	 to	certain	Ras	isoforms	appears	to	be	complex	and	it	is	possible	that	a	mixture	of	factors	could	affect	 it,	 including	 gene	 regulatory	 elements,	 expression	 levels	 and	 epigenetic	regulation.			
5.3.4	 Transcript	versus	protein	abundance	
To	 examine	 whether	 Ras	 isoform	 expression	 profiles	 at	 transcript	 level	 hold	true	also	at	protein	 level,	 the	 study	of	 this	 thesis	used	proteomics	analysis	on	samples	 derived	 from	 the	 same	 mouse	 tissues	 previously	 used	 for	 qRT-PCR	analysis	(section	5.2.2	and	5.2.3).	An	earlier	study	in	NIH3T3	mouse	fibroblasts	showed	 that	 41%	 genes	 correlated	 in	 relative	 abundance	 at	 the	 protein	 and	transcript	 level	 and	 that	 the	 protein	 abundance	 per	 cell	 is	 about	 900	 times	higher	than	that	of	the	corresponding	mRNA	(Schwanhausser	et	al.,	2011).	The	study	of	this	thesis	generated	preliminary	data	on	absolute	quantification	of	Ras	isoform	protein	expression	in	adult	mouse	tissues	(Fig.	5.11).		However,	the	contribution	of	individual	Ras	isoforms	to	total	Ras	abundance	at	protein	 level	did	not	parallel	 the	Ras	 transcript	profiles	 in	 this	 study	(Fig.	5.4,	Fig.	 5.12	 B).	 Specifically,	 KRas	 protein	 contributed	 far	 less	 to	 total	 Ras	abundance	 than	predicted	 from	the	 transcript	data.	The	 findings	 in	 this	 thesis	contrast	with	mass	 spectrometry	 analysis	 in	 NIH3T3	 cells	 (Schwanhausser	 et	al.,	 2011),	 which	 found	 that	 NRas	 is	 a	 dominant	 Ras	 isoform	 contributing	 to	around	85%	of	 total	Ras,	while	KRas	and	HRas	are	 lowly	abundant	with	10%	and	5%	contribution,	 respectively.	However,	 the	proteome	data	was	generally	consistent	 with	 previous	 findings	 across	 different	 human	 cancer	 cell	 lines,	 in	which	Western	 blotting	 revealed	 that	 typically	 KRas	 is	 the	 dominant	 isoform,	whereas	HRas	contributes	to	less	than	10%	of	total	Ras	(Omerovic	et	al.,	2008).		The	 method	 used	 in	 this	 thesis	 to	 quantitatively	 determine	 Ras	 protein	abundance	 at	 endogenous	 levels	 utilised	 full-length	 Ras	 standards	 that	 were	spiked	 into	 the	 lysate	 prior	 to	 any	 further	 sample	 processing,	 which	 allowed	
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avoiding	 inefficiencies	 associated	 with	 gel	 extraction	 and	 Ras	 proteolysis	(Mageean	et	al.,	2015).	This	was	in	contrast	to	previous	studies,	which	spiked	in	the	standards	just	prior	to	the	analysis	by	the	mass	spectrometer	and	resulted	in	 a	 wide	 spread	 of	 the	 data	 (Halvey	 et	 al.,	 2012,	 Ruppen-Canas	 et	 al.,	 2012,	Wang	et	al.,	2011).		The	 preliminary	 results	 presented	 in	 this	 thesis	 showed	 that	 panRas	 protein	levels	ranged	between	44-770	ng	of	panRas	per	mg	of	total	protein,	depending	on	 tissue	 type	 (Appendix	 Table	 A5.1).	 This	 value	 is	 similar	 to	 90-220	 ng	 of	endogenous	panRas	per	mg	of	total	protein	found	in	SW48	colorectal	cancer	cell	line	using	the	same	method	(Mageean	et	al.,	2015)	and	 it	 is	especially	striking	that	intestinal	tissue	examined	in	this	thesis	had	93	ng	of	panRas	per	mg	of	total	protein.	It	is	difficult	to	estimate	the	absolute	number	of	Ras	protein	molecules	per	 cell,	 as	 total	 protein	 content	 per	 cell	 is	 approximate	 and	 may	 vary	depending	on	cell	type	(Lodish	et	al.,	2000).	Unfortunately,	the	measurement	of	cell	 number	 in	 heterogeneous	 tissues	 was	 beyond	 the	 scope	 of	 this	 study.	Nevertheless,	 it	might	 be	 accurate	 to	 estimate	 the	 total	 Ras	 abundance	 in	 the	intestine	to	around	250,000	molecules	per	cell,	as	this	was	the	calculated	value	based	 on	 90	 ng	 of	 panRas	 per	 mg	 protein	 in	 SW48	 cell	 line	 (Mageean	 et	 al.,	2015).		
	The	discrepancy	between	relative	transcript	versus	protein	abundance	of	each	Ras	isoform	(Fig.	5.12	B)	might	be	explained	by	a	recent	finding,	which	showed	that	KRAS	is	poorly	translated	as	compared	to	HRAS	due	to	the	presence	of	rare	codons	 in	 the	genomic	 sequence	of	KRAS	 (Lampson	et	 al.,	 2013).	Rare	 codons	appear	infrequently	in	the	genomic	sequence	as	compared	to	other	degenerate	codons	 that	 encode	 for	 the	 same	 amino	 acid.	As	 a	 result,	 rare	 codons	 impede	translation	 and	 cause	 ribosome	 stalling,	 thus	 leading	 to	 lower	 than	 expected	protein	 levels.	 Interestingly,	 rare	 codon	 bias	 in	 the	 KRAS	 gene	 in	 conserved	across	mammalian	species	and,	hence,	is	relevant	to	the	to	mouse	KRas	protein	levels	investigated	in	this	thesis.		
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Rare	 codons	 found	 in	 KRAS	 not	 only	 affect	 KRas	 protein	 levels,	 but	 are	 also	suggested	to	influence	its	tumourigenic	potential,	making	it	a	weaker	oncogene	than	 HRas	 (Lampson	 et	 al.,	 2013).	 This	 result	 seems	 in	 contrary	 to	 the	prevalence	 of	 KRas	 mutation	 in	 human	 cancer	 (Cox	 et	 al.,	 2014,	 Prior	 et	 al.,	2012).	 However,	 rare	 codon	 bias	 and	 low	 expression	 are	 suggested	 to	predispose	KRas	to	initiate	tumourigenesis	in	untransformed	cells,	which	would	otherwise	 undergo	 senescence	 due	 to	 oncogenic	 stress	 caused	 by	 high	expression	of	the	mutated	protein.	Yet,	the	data	in	this	thesis	argues	against	this	model	 since	 KRas	 protein	 abundance	 was	 generally	 similar	 to	 the	 other	isoforms.	Therefore,	the	high	transcript	abundance	of	KRas	isoforms	appears	to	be	 a	 compensatory	 mechanism	 for	 inefficient	 protein	 translation	 to	 ensure	similar	protein	abundance	to	the	other	Ras	isoforms.		Overall,	the	data	from	this	study	suggests	that	KRas,	and	especially	KRasB,	is	the	most	 abundant	Ras	 isoform	 in	 all	mouse	 tissues	 and	developmental	 stages,	 at	least	at	transcript	level.	This	result	may	partially	explain	why	KRas	is	the	most	frequently	mutated	Ras	isoform	in	human	cancers	(Cox	et	al.,	2014,	Prior	et	al.,	2012)	and	why	KRasB	is	the	only	developmentally	essential	Ras	isoform	in	the	mouse	(Koera	et	al.,	1997,	Plowman	et	al.,	2003).	Future	studies	should	focus	on	Ras	 expression	 pattern	 in	 particular	 cell	 types	 and	 ideally	 should	 include	samples	from	human	biopsies.	There	still	remain	tissues,	such	as	the	pancreas,	which	should	be	examined,	but	for	which	the	scope	of	this	study	and	technical	problems	did	not	allow.	Moreover,	proteomics	data	from	this	study	represented	technical	 repeats	 and,	 hence,	 further	 confirmation	 of	 expression	 patterns	 is	required	using	biological	replicates.	Nonetheless,	 this	work	generated	the	 first	comprehensive	 developmental	 map	 of	 Ras	 isoform	 transcript	 abundance	 in	normal	mouse	tissues	and	gave	the	insight	into	the	differential	regulation	of	Ras	isoform	 expression.	 Establishing	 baseline	 expression	 levels	 in	 normal	 tissues	could	 be	 key	 to	 better	 understanding	 of	 isoform-specific	 Ras	 coupling	 to	different	cancers,	as	well	as	better	interpretation	of	current	and	future	data	on	Ras	levels	and	signalling	in	malignant	tissues.	
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Chapter	6	
Isoform-specific	Ras	signalling		
6.1	 	 Introduction	All	 cells	 express	 three	 almost	 identical	Ras	proteins	 (HRas,	KRasB	 and	NRas).		Mouse	knockout	data	demonstrates	that	KRasB	is	uniquely	required	for	normal	development,	 whereas	 HRas	 and	 NRas	 are	 dispensable,	 suggesting	 isoform-specific	 functions	of	 the	Ras	proteins	 (Koera	et	 al.,	 1997,	 Johnson	et	 al.,	 1997,	Plowman	et	al.,	2003,	Umanoff	et	al.,	1995,	Esteban	et	al.,	2001).	Similarly,	KRas	is	 far	 more	 frequently	 mutated	 in	 cancer	 implying	 a	 particular	 oncogenic	potency	that	is	not	yet	fully	understood	(Cox	et	al.,	2014,	Quinlan	and	Settleman,	2008).	
Current	 research	 suggests	 that	 stimulation	 of	 downstream	 signalling	 is	 Ras	isoform-specific,	 due	 to	 differential	 coupling	 of	 isoforms	 to	 effector	 proteins	(Voice	et	al.,	1999,	Yan	et	al.,	1998)	and	feedback	loops	(Eser	et	al.,	2014,	Fivaz	et	 al.,	 2008,	 Thevathasan	 et	 al.,	 2013).	 Early	 studies	 based	 on	 ectopic	overexpression	 of	 Ras	 isoforms	 revealed	 that	 HRas	 and	 NRas	 are	 better	activators	 of	 PI3K	whilst	 KRasA	 and	KRasB	were	 better	 activators	 of	 Raf	 and	Rac	 than	 the	 other	 Ras	 isoforms	 (Voice	 et	 al.,	 1999,	 Yan	 et	 al.,	 1998).	 A	 key	drawback	with	this	approach	is	that	overexpression	of	Ras	can	lead	to	signalling	perturbation	and	profound	phenotypic	outputs	such	as	senescence	that	are	not	seen	with	oncogenic	Ras	 signalling	 from	 the	endogenous	 locus	 (Serrano	et	al.,	1997,	Tuveson	et	al.,	2004).	More	recent	work	utilised	in	vivo	approaches,	such	as	 knock-in	 (KI)	mice	 (Di	Nicolantonio	 and	Bardelli,	 2013,	Haigis	 et	 al.,	 2008,	Tuveson	et	al.,	2006),	as	well	as	methods	to	examine	endogenous	Ras	signalling	in	 various	 cell	 lines,	 using	 siRNA	 (Fleming	 et	 al.,	 2005,	Omerovic	 et	 al.,	 2008)	and	gene	KI	(isogenic	cell	lines	–	(Arena	et	al.,	2007,	Vartanian	et	al.,	2013)).	
Unfortunately,	most	of	these	techniques	analysed	only	one	or	two	Ras	isoforms	in	 an	 endogenous	 context	 or	 likely	 showed	 compensation	 effects	 of	 other	isoforms,	as	in	case	of	siRNA	(Omerovic	et	al.,	2008).	Therefore,	the	aim	of	this	
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chapter	is	to	present	a	method,	in	which	the	signalling	of	all	three	Ras	isoforms	is	compared	 in	a	normal	physiological	environment.	The	use	of	mouse	models	bearing	specific	KI	of	a	mutation	for	each	Ras	isoform	would	be	costly	and	time-consuming.	 Thus,	 a	 panel	 of	 cell	 lines	 isogenic	 with	 an	 endogenous	heterozygous	 codon	 mutation	 for	 each	 Ras	 isoform	 represents	 a	 plausible	higher-throughput	 alternative	 allowing	 endogenous	 isoform-specific	 Ras	signalling	to	be	compared	against	the	same	genetic	background.	
Isogenic	cells	harbouring	oncogenic	KRas	variants	have	already	been	generated	and	extensively	characterised.	These	comprise	colorectal	HCT-116	(G13D)	and	DLD-1	(G13D)	and	HEC1A	(G12D)	endometrial	cells	where	the	indicated	mutant	KRas	allele	was	deleted	(Kim	et	al.,	2004,	Shirasawa	et	al.,	1993)	and	MCF10a	breast	 cancer	 cells	 where	 a	 G12V	mutation	 was	 introduced	 into	 a	 KRas	 wild	type	 allele	 (Konishi	 et	 al.,	 2007).	 There	 are	 two	 specific	 problems	with	 these	models.	The	 first	 is	 that	 for	HCT-116,	DLD-1	and	HEC1A	 the	parental	 cell	 line	has	 only	 one	 wild	 type	 KRas	 allele,	 potentially	 reducing	 endogenous	 KRas	protein	expression	compared	to	the	mutant	isogenic	cell	line.	The	second	is	that	for	all	of	the	isogenic	models	there	has	been	a	focus	on	KRas	effectors	and	there	are	 no	 corresponding	 mutations	 in	 the	 other	 Ras	 isoforms	 that	 have	 been	generated.	
More	 recently	 a	 panel	 of	 isogenic	 colorectal	 SW48	 cells	 harbouring	 different	KRas	point	mutations	has	been	generated	using	adeno-associated	virus	 (AAV)	gene	editing	technology	(De	Roock	et	al.,	2010).	These	have	been	supplemented	by	Horizon	Discovery,	 so	 that	 now	 there	 is	 a	 panel	 of	 14	 Ras	mutant	 variant	isogenic	SW48	cells.	These	include	cells	harbouring	G12V	mutations	in	HRas	or	KRas	that	have	now	been	complemented	by	NRas	G12V	SW48	cells	produced	by	the	Prior	laboratory.	
Colorectal	cancer	(CRC)	 is	 the	third	most	common	human	cancer	(Hamilton	et	al.,	 2010)	 and	 colorectal	 adenocarcinoma	 is	 its	most	 prevalent	 type,	 which	 is	derived	from	epithelial	cells	of	the	colorectal	mucosa	(Fleming	et	al.,	2012).	Ras	mutations	occur	in	over	50%	of	colorectal	adenocarcinoma	cases,	making	it	the	second	 cancer	 type	 with	 most	 prevalent	 Ras	 mutations	 (Forbes	 et	 al.,	 2015,	
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Prior	 et	 al.,	 2012).	 85%	 of	 these	 mutations	 are	 in	 the	 KRAS	 gene,	 with	 the	remaining	ones	occurring	in	the	NRAS	gene	and	no	mutations	in	HRAS.		
Although	 the	 most	 common	 KRas	 mutation	 in	 colorectal	 cancers	 is	 G12D	(Forbes	et	al.,	2015),	substitution	of	the	same	codon	with	valine	residue	(G12V)	leads	 to	 more	 aggressive	 cancer	 phenotypes	 and	 is	 associated	 with	 lower	survival	rates	in	patients,	compared	to	other	KRas	mutations,	as	well	as	the	wild	type	 protein	 (Winder	 et	 al.,	 2009).	 Indeed,	 G12V	mutation	 of	 Ras	 is	 generally	associated	with	greater	transforming	efficiency	than	G12D	and	other	mutations	(Fasano	et	al.,	1984,	Seeburg	et	al.,	1984).	In	a	mouse	colorectal	cancer	model,	KRasG12V	 also	 shows	 higher	 metastatic	 efficiency	 and	 lower	 apoptosis	 than	another	common	mutant	KRasG13D	(Alamo	et	al.,	2015).	Consistent	with	 this,	different	activating	oncogenic	mutations	of	KRas	exhibit	distinct	proteome	and	phosphoproteome	signatures	(Hammond	et	al.,	2015,	Miller	and	Miller,	2011).	This	 also	 has	 therapeutic	 implications	 since	 colorectal	 cancer	 tumours	 with	codon	12	mutations	 of	KRas	 are	 resistant	 to	 the	EGFR	 inhibitor	 cetuximab	 as	opposed	 to	 tumours	 with	 wild	 type	 KRas	 or	 bearing	 other	 KRas	 mutations	(Amado	et	 al.,	 2008,	Karapetis	 et	 al.,	 2008). Therefore,	when	 investigating	 the	differences	in	isoform-specific	oncogenic	Ras	signalling,	it	is	important	that	each	isoform	harbours	the	same	oncogenic	mutation.	
In	 this	 chapter,	 SW48	 cell	 lines	 that	 are	 isogenic	 except	 for	 the	 potent	 G12V	mutation	 in	 each	 of	 the	 three	 Ras	 isoforms	 (cell	 lines	 harbouring	 HRasG12V,	KRasG12V	 or	 NRasG12V),	 as	 well	 as	 wild	 type	 parental	 cell	 line,	 were	 used	 to	further	 delineate	 the	 subtleties	 of	 isoform-specific	 signal	 transduction	 in	 an	endogenous	context.	The	differences	in	downstream	signalling	between	the	cell	lines	were	 examined	by	 comparing	 the	 two	 canonical	 signalling	 cascades	 that	stem	from	activated	Ras	–	MAPK	and	PI3K	pathways	(Karnoub	and	Weinberg,	2008,	Moodie	et	al.,	1993,	Rodriguez-Viciana	et	al.,	1994)	(Fig.	6.1).	The	levels	of	activation	 of	 downstream	 effectors	 by	 phosphorylation	 were	 measured	 by	Western	 blotting	 using	 phospho-specific	 antibodies:	 pMEK,	 pERK,	 pAkt	 and	pp70S6K.	 Finally,	 this	 chapter	 describes	 preliminary	 optimisation	 of	 reagents	for	 a	 network	 biology	 study,	 where	 differences	 in	 Ras	 isoform-dependent	signalling	networks	will	be	determined	by	utilising	effector-specific	 inhibitors,	as	well	as	distinct	GFs	that	activate	the	various	RTKs	upstream	of	Ras.		
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Fig.	6.1	A	schematic	 representation	of	Ras-dependent	 signalling	network	
measured	 by	 effector-specific	 inhibitors	 and	 receptor	 agonists.	 The	 two	canonical	 signalling	 cascades	 downstream	 of	 Ras	 comprise	 the	 mitogen-activated	 protein	 kinase	 (MAPK)	 Raf-Mek-ERK	 and	 the	 phosphoinositide	 3-kinase	 (PI3K)	 pathways.	 Effector-specific	 inhibitors	 used	 in	 this	 study	 are	depicted	 in	 red	 and	 their	 targets	 are	 shown	 in	 red	 boxes.	 The	 growth	 factors	(GFs)	 used	 to	 stimulate	 receptor	 tyrosine	 kinases	 (RTK)	 upstream	 of	 Ras	 are	shown	in	blue	circles	adjacent	to	the	receptors.	
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6.2	 	 Results	
6.2.1	 	 Cell	growth	kinetics	of	SW48	isogenic	cell	lines	To	 compare	 cell	 growth	 kinetics	 between	 SW48	 cell	 lines	 isogenic	 for	 Ras	isoform	mutations,	CellTiter-Glo®	Luminescent	Cell	Viability	Assay	was	used	to	measure	 the	 number	 of	 viable	 cells	 during	 cell	 culture.	 The	 assay	 measures	cellular	ATP	and	therefore	is	a	read-out	of	cellular	metabolism,	which	at	least	in	part	will	correlate	with	the	growth	kinetics	of	the	cells.		Parental	SW48	cell	line	was	empirically	observed	 to	be	 the	 fastest	growing	of	all	SW48	 isogenics	and,	hence,	was	chosen	to	optimise	 the	seeding	density	(Fig.	6.1).	The	cell	 line	was	seeded	 on	 a	 96-well	 plate	 at	 the	 following	 densities,	 each	 in	 5	 technical	replicates:	 0,	 250,	 500,	 750,	 1000,	 1250,	 1500,	 2000,	 2500,	 3000,	 4000	 and	5000	cells	per	well.	The	luminescence	was	measured	after	5	days	of	continuous	cell	 culture	 and	 background	 luminescence	 from	wells	 with	medium	 only	was	subtracted.	
Based	on	the	results	(Fig.	6.2),	SW48	parental	cell	line	showed	a	linear	growth	at	cell	densities	up	to	around	1000	cells	per	well,	from	which	the	growth	curve	started	to	plateau.	To	make	sure	that	the	cell	growth	is	within	the	linear	range	after	5	days	of	culture,	750	cells	per	well	were	chosen	as	a	starting	density	for	the	next	experiment,	in	which	the	growth	kinetics	of	all	SW48	isogenic	cell	lines	was	measured	(Fig.	6.3).	
The	growth	kinetics	of	all	Ras	isogenic	cell	lines	was	measured	every	day	for	5	days	inclusive.	The	luminescence	data	was	then	normalised	to	day	1	to	account	for	the	possible	seeding	differences	at	day	0.	According	to	the	results	(Fig.	6.3),	the	 slowest	 growth	 rate	 was	 seen	 in	 the	 SW48	 cell	 line	 bearing	 NRasG12V	mutation	whereas	 the	 remaining	Ras	mutant	 cell	 lines	were	 equivalent	 to	 the	parental	 SW48	 cells.	 The	 growth	 rate	 is	 slower	 at	 the	 beginning,	 then	accelerates	 from	 day	 3,	 and	 here	 again	 the	 acceleration	 is	 more	 rapid	 for	parental,	KRas	G12V	and	HRas	G12V	cell	 lines,	as	compared	to	NRas	G12V.	On	day	5	the	 basal	 difference	 between	 normalised	 luminescence	 is	 around	 40%	 higher	for	 parental	 compared	 to	 NRasG12V	 isogenic	 cell	 line.	 In	 conclusion,	 G12V			
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Fig.	6.2	Optimisation	of	seeding	density	of	SW48	parental	cell	line	for	cell	
viability	assay.	Parental	cells	seeded	at	the	indicated	densities	were	measured	after	 5	 days	 of	 cell	 culture	 using	 the	 CellTiter-Glo	 viability	 assay.	 Data	represents	means	±	SD	(n	=	5	technical	repeats).	RLU	–	relative	light	units.	
	
	
	
Fig.	6.3	Cell	growth	differences	between	Ras	isogenic	cell	 lines	measured	
by	cell	viability	assay.	750	SW48	cells	per	well	were	seeded	and	grown	for	the	indicated	number	of	days	before	cell	viability	was	measured	using	CellTiter-Glo.	Luminescence	 was	 normalised	 to	 day	 1.	 Data	 represents	 means	 ±	 SD	 (n	 =	 3	independent	biological	repeats).	RLU	–	relative	light	units,	PAR	–	parental,	H	–	HRasG12V,	N	–	NRasG12V,	K	–	KRasG12V	SW48	cell	lines.	
0.0E+00%
5.0E+05%
1.0E+06%
1.5E+06%
2.0E+06%
2.5E+06%
3.0E+06%
0% 1000% 2000% 3000% 4000% 5000%
lu
m
in
es
ce
nc
e)
(R
LU
))
seeding)density)(cell)number))
0"
2"
4"
6"
8"
10"
1" 2" 3" 4" 5"
no
rm
al
is
ed
"lu
m
in
es
ce
nc
e"
(R
LU
)"
;me"(days)"
PAR$
H$
N$
K$
	 154	
mutation	seems	 to	negatively	affect	 the	growth	of	SW48	colorectal	 cancer	cell		line	when	present	in	NRas,	but	not	in	other	Ras	isoforms.	However,	such	effect	might	be	clone-specific	and,	hence	more	clones	bearing	Ras	mutations	should	be	tested.	
To	 investigate	 whether	 the	 G12V	 mutation	 affects	 Ras	 isoform	 abundance,	Western	 blotting	 was	 performed	 on	 lysates	 from	 all	 isogenic	 SW48	 cell	 lines	using	 isoform-specific	 antibodies	 (Fig.	 6.4).	 When	 compared	 to	 actin	 loading	control,	 the	 expression	 of	 Ras	 isoforms	 and	 total	 Ras	 was	 slightly	 variable	across	 the	different	 isogenic	 cell	 lines,	 both	when	cultured	 in	normal	medium	(10%	FBS)	or	starved.	This	experiment,	however,	represents	only	one	biological	repeat.	
	
6.2.2	 	Differential	activation	of	PI3K	and	MAPK	pathways		
 To	compare	 the	effect	of	EGF	 stimulation	on	SW48	Ras	 isogenic	 cell	 lines,	 the	activation	 of	 two	 canonical	 pathways	 –	 MAPK	 and	 PI3K	 pathways	 –	 was	measured	by	Western	blotting	(Fig.	6.5A	and	Fig.	6.6A).	To	check	the	potency	of	activation	 at	 different	 EGF	 concentrations	 and	 to	 calculate	 the	 EC50	 (effective	concentration	 needed	 to	 result	 in	 50%	 of	 activation),	 a	 range	 of	 EGF	concentrations	was	chosen:	0.1,	0.25,	0.5,	1,	1.5,	2,	5,	10,	20,	30	and	50	ng/ml.	Cell	were	starved	for	16	hours	and	then	stimulated	for	5	minutes,	apart	from	a	control.	To	measure	the	activation	of	PI3K	pathway,	pAkt	levels	were	quantified	using	pAkt-specific	antibody	and	densitometry	software.	Similarly,	 to	measure	activation	 of	 MAPK	 pathway,	 pMEK	 levels	 were	 quantified.	 The	 data	 was	normalised	 to	 actin	 loading	 control,	 total	 Akt	 or	 MEK	 protein,	 and	 to	 3	maximum	EGF	stimulations	(Fig,	6.5B	and	Fig.	6.6B).		
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Fig.	 6.4	 Ras	 isoform	 protein	 levels	 in	 SW48	 isogenic	 cell	 lines.	 SW48	isogenic	 cell	 lines	 were	 grown	 in	 either	 normal	 medium	 (10%	 FBS)	 or	 were	starved	for	24	hours.	After	cell	 lysis,	samples	were	run	on	SDS-PAGE,	followed	by	Western	blotting.	A	Each	sample	was	immunoblotted	with	panRas	antibody	and	with	Ras	isoform	specific	antibodies.	Representative	actin	is	showed	for	Ras	isoforms	 and	 panRas.	B	 The	 immunoblots	were	 quantified	 and	 normalised	 to	actin	 (n=1).	 P	 –	 parental,	 H	 –	HRasG12V,	 N	 –	NRasG12V,	 K	 –	 KRasG12V	 SW48	 cell	lines.		
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For	both	pAkt	and	pMEK,	HRasG12V	displayed	the	most	sensitive	response	with	an	EC50	of	0.44	and	1.07	ng/ml	respectively.	In	comparison,	the	EC50	of	Parental	and	NRasG12V	were	in	the	1.30	–	2.36	ng/ml	range	whilst	KRasG12V	was	the	most	resistant	 to	 EGF	 stimulation	 with	 EC50	 of	 2.71	 and	 3.40	 ng/ml	 for	 pAkt	 and	pMEK	 respectively	 (Fig.	 6.5B	 and	 Fig.	 6.6B).	 Therefore,	 HRasG12V	 isogenic	 cell	line	responds	at	least	two	times	more	potently	to	EGF	stimulation	in	activating	PI3K	and	MAPK	signalling	as	compared	to	parental	and	the	other	mutated	Ras	isoform	 cell	 lines.	 Whilst	 EC50	 values	 have	 been	 determined	 based	 on	 the	maximal	 signal	 observed,	 it	 looks	 like	 some	 of	 the	 stimulations	may	not	 have	plateaued.	 This	 is	 most	 evident	 for	 Parental	 and	 KRasG12V	 cells.	 Therefore,	further	work	could	be	done	to	extend	the	upper	range	of	EGF	concentrations	to	confirm	the	saturating	doses.		One	potential	confounding	factor	with	directly	comparing	the	cells	lines	is	that	the	Western	blot	membrane	of	each	cell	 line	was	developed	at	different	times.	Therefore,	whilst	the	dose	response	can	be	fairly	compared,	it	is	not	possible	to	know	whether	 the	absolute	 intensities	observed	were	equivalent	between	cell	lines,	 i.e.	 are	 there	 quantitative	 differences	 in	 the	 relative	 output	 of	 the	 Ras	isoforms	in	response	to	a	given	stimulation?	To	address	this,	the	samples	from	all	 isogenic	 cell	 lines	 stimulated	 with	 1.5	 and	 30ng/ml	 EGF	 concentrations,	representing	 sub-saturating	 and	 approximately	 saturating	 doses,	 were	 re-run	altogether	 on	 one	 blot	 (Fig.	 6.7).	 The	 results	 recapitulated	 the	 data	 seen	 in	Figures	 6.4	 and	 6.5	 in	 showing	 that	 HRasG12V	 cells	 were	 more	 sensitive	 to	stimulation	 by	 the	 sub-saturating	 dose	 of	 EGF	 compared	 to	 the	 other	 Ras	isoforms.	 Importantly,	 at	 the	 higher	 concentration	 of	 EGF,	 HRasG12V	 cells	exhibit	significantly	higher	pAKT	and	pMEK	responses	than	the	other	cell	lines.	The	 attenuated	 response	 of	 KRasG12V	 cells	 in	 particular	 may	 mean	 that	KRasG12V	is	uncoupled	from	the	signalling	cascades	or	that	there	has	been	an	upregulation	of	negative	feedback.		
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Fig.	6.5	Activation	of	downstream	PI3K	signalling	pathway	in	Ras	isogenic	
SW48	cell	lines	depending	on	stimulation	with	different	concentrations	of	
EGF.	 A	 A	 representative	 immunoblotting	 of	 Akt-pS457	 (pAkt)	 and	 one	 actin	blot.	B	Relative	quantitation	of	Akt-pS457	activation	normalised	 to	actin,	 total	Akt	 and	 maximum	 GF	 responses,	 where	 100%	 =	 the	 mean	 of	 the	 3	 highest	concentrations	 of	 GF	 stimulations.	 Data	 represents	 means	 ±	 SD	 (n	 =	 3	independent	biological	 repeats).	 P	 –	 parental,	H	 –	HRasG12V,	N	 –	NRasG12V,	K	 –	KRasG12V	SW48	cell	lines.			
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Fig.	 6.6	 Activation	 of	 downstream	 MAPK	 signalling	 pathway	 in	 Ras	
isogenic	 SW48	 cell	 lines	 depending	 on	 stimulation	 with	 different	
concentrations	 of	 EGF.	 A	 A	 representative	 immunoblotting	 of	 MEK-pS217/pS221	 (pMEK)	 and	 one	 actin	 blot.	 B	 Relative	 quantitation	 of	 MEK-	pS217/pS221	 activation	 normalised	 to	 actin,	 total	 MEK	 and	 maximal	 GF	responses	 where	 100%	 =	 the	 mean	 of	 the	 3	 highest	 concentrations	 of	 GF	stimulations.	 Data	 represents	 means	 ±	 SD	 (n	 =	 3	 independent	 biological	repeats).	P	–	parental,	H	–	HRasG12V,	N	–	NRasG12V,	K	–	KRasG12V	SW48	cell	lines.	
	
	
	
0.01$
0.1$
1$
0.1$ 1$ 10$
lo
g$
(r
el
a,
ve
$a
bu
nd
an
ce
)$
log([EGF])$
P" H" K" N"
0	
50	
100	
150	
0.1	 1	 10	
log(ng/ml	EGF)	
0	
50	
100	
150	
0.1	 1	 10	
log(ng/ml	EGF)	
0	
50	
100	
150	
0.1	 1	 10	
log(ng/ml	EGF)	
0	
50	
100	
150	
0.1	 1	 10	
log(ng/ml	EGF)	
%	relat
ive	abu
ndance
	
%	relat
ive	abu
ndance
	
EC50	=	1.07	EC50	=	2.36	
EC50	=	3.40	 EC50	=	1.65	
	 159	
	
A	
	
	
	
B	
	
	
	
	
	
Fig.	 6.7	 Activation	 of	 MAPK	 and	 PI3K	 pathways	 in	 Ras	 isoform	 SW48	
isogenic	 cell	 lines	 by	 EGF	 stimulation.	 A	 A	 representative	 blot	 (n	 =	 3	biological	replicates)	–	a	re-run	of	samples	from	EGF	gradient	in	Fig.	6.5	and	Fig.	6.6	 now	 in	 one	 blot.	 B	 Relative	 quantification	 of	 Akt-pS473	 (pAkt)	 and	MEK-	pS217/pS221	(pMEK)	from	A	normalised	to	actin	and	total	Akt	or	MEK	protein.		SW48	cell	lines:	P	–	parental,	H	–	HRasG12V,	K	–	KRasG12V,	N	–	NRasG12V.	Data	was	analysed	by	one-way	ANOVA	with	Fisher's	LSD	post-hoc	test.	*	p	≤	0.05,	**	p	≤	0.01	
	To	complement	 these	data,	a	 separate	experiment	was	carried	out,	where	Ras	isogenic	cell	lines	were	cultured	in	normal	(10%	FBS)	medium	or	were	starved		for	16	hours	and	stimulated	for	5	minutes	with	either	0.5	or	30ng/ml	EGF	(Fig.	6.8).		When	normalised	to	actin	loading	control	and	total	Akt	or	MEK,	the	results	also	 indicated	 that	 pAkt	 and	 pMEK	 are	 activated	 more	 potently	 by	 HRasG12V.	Moreover,	ERK	activation	downstream	of	MEK	was	measured	and	revealed	that	at	a	higher	EGF	concentration	HRasG12V	is	slightly	less	potent	than	wild	type	Ras.	For	KRasG12V	 the	pattern	of	activating	Akt	and	MEK	was	similar	as	 in	previous			
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Fig.	 6.8	 Differential	 response	 to	 EGF	 in	 Ras	 isoform	 SW48	 isogenic	 cell	
lines.	Cells	were	cultured	either	in	normal	medium	(10%	FBS)	or	were	starved	and	 stimulated	 with	 different	 EGF	 concentrations.	A	 Immunoblotting	 of	 Akt-pS473	 (pAkt),	 MEK-pS217/pS221	 (pMEK),	 ERK-pT202/pY204	 (pERK)	 and	representative	actin	(n	=	1).	B	Relative	quantification	of	A	normalised	to	actin	and	total	Akt,	MEK	or	ERK	protein.	SW48	cell	lines:	P	–	parental,	H	–	HRasG12V,	K	–	KRasG12V,	N	–	NRasG12V.	
pAkt	 pMEK	
pERK	
0.0#
0.1#
0.2#
0.3#
0.4#
0.5#
0.6#
0.7#
0.8#
,# 0# 0.5# 30#
re
la
1v
e#
ab
un
da
nc
e#
[EGF#ng/ml]#
P"
H"
K"
N"
0.0	
0.5	
1.0	
1.5	
2.0	
-	 0	 0.5	 30	
re
la
-v
e	
ab
un
da
nc
e	
[EGF	ng/ml]	
P	
H	
K	
N	
0.0	
0.2	
0.4	
0.6	
0.8	
1.0	
1.2	
1.4	
-	 0	 0.5	 30	
re
la
0v
e	
ab
un
da
nc
e	
[EGF	ng/ml]	
P	
H	
K	
N	
0.0	
0.1	
0.2	
0.3	
0.4	
0.5	
0.6	
0.7	
0.8	
-	 0	 0.5	 30	
re
la
1v
e	
ab
un
da
nc
e	
[EGF	ng/ml]	
P	
H	
K	
N	
	 161	
experiments	 and	 it	 was	 also	 present	 for	 downstream	 ERK.	 However,	 these	results	were	only	based	on	one	biological	repeat	and,	hence,	more	experiments	are	needed	to	determine	phosphorylation	status	of	ERK.	
All	 in	 all,	 Western	 blotting	 of	 Ras	 isogenic	 cell	 lines	 suggests	 that	 there	 are	different	 signalling	 strengths	 downstream	 of	 Ras	 depending	 on	 the	 isoform	mutated	 and	 they	 all	 respond	 differently	 to	 EGF	 stimulation	 in	 activating	canonical	pathways	PI3K	and	MAPK.	These	differences	may	arise	from	varying	sensitivity	 of	 Ras	 isoforms	 to	 stimulation	 and	 negative	 feedback	 loops	within	pathways,	which	will	be	further	discussed	in	the	next	sections.	
	
6.2.3	 	Isoform-specific	Ras	networks		The	following	sections	describe	outcomes	of	stimulation	and	inhibition	of	Ras-dependent	pathways.	For	each	experiment,	a	concentration	gradient	of	either	a	GF	 or	 an	 inhibitor	 was	 used	 to	 measure	 the	 differences	 in	 signalling	 and	phosphorylation	 status	 of	 proteins	 either	 upstream	 or	 downstream	 of	 Ras	 by	Western	blotting.	
6.2.3.1	 Stimulation	of	Ras	upstream	signalling	To	 check	 the	 phosphorylation	 status	 of	 receptors	 upstream	 of	 Ras,	 SW48	isogenic	cell	lines	were	starved	for	24	hours	and	stimulated	for	20	minutes	with	gradients	of	the	following	GFs:	EGF,	HGF	and	IGF	–	to	stimulate	EGFR,	Met	and	IGFR1β	 receptors,	 respectively	 (Fig.	 6.9-6.11).	 Both	 phosphorylated	 and	 total	protein	were	measured	and	normalised	to	actin	loading	control.	For	EGFR,	the	Y1068	site	was	monitored	 for	phosphorylation,	as	 it	 is	one	of	 the	 three	major	autophosphorylation	 sites	of	EGFR,	 the	other	being	Y1148	and	Y1173	 (Abe	et	al.,	2006,	Downward	et	al.,	1984).	The	phosphorylation	status	of	EGFR	may	be	altered	 in	 cell	 lines	 bearing	 the	 oncogenic	 G12V	 mutation	 in	 Ras,	 due	 to	feedback	 loops	 from	 downstream	 ERK	 back	 to	 the	 receptor	 (Klinger	 et	 al.,	2013).	The	most	EGFR	stimulation	was	achieved	 in	KRasG12V	 isogenic	cell	 line,		implying	 that	 mutated	 KRas	 positively	 regulates	 upstream	 EGFR	 activation			
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Fig.	 6.9	 Phosphorylation	 status	 of	 EGFR	 in	 SW48	 Ras	 isogenic	 cell	 lines.	Cells	 were	 starved	 and	 stimulated	 with	 different	 EGF	 concentrations.	 A	Immunoblot	 of	 EGFR,	 EGFR-pY1068	 (pEGFR)	 and	 representative	 actin.	 B	Relative	quantification	of	EGFR-pY1068	normalised	to	actin	and	C	 to	actin	and	total	EGFR	protein.	Arrow	indicates	the	size	of	the	blotted	protein.		
	(Fig.	6.9).	On	the	other	hand,	NRasG12V	trends	towards	the	lowest	activation	of	EGFR,	whilst	HRasG12V	 is	 similar	 to	 that	of	wild	 type	Ras.	There	may	also	be	subtle	differences	in	receptor	abundance	that	are	investigated	further	later	(Fig.	6.12).	
For	Met	 receptor,	 the	 highest	 phosphorylation	 status	 is	 present	 in	 KRasG12V	cell	 line,	whereas	 the	 remaining	 cell	 lines	 show	similar	 amounts	of	pMet	 (Fig.	6.10).	Phosphorylation	of	Met	has	still	not	plateaued	in	the	KRasG12V	cell	line,	whereas	 for	all	of	 the	other	cell	 lines	≤25	ng/ml	HGF	is	saturating.	The	higher	pMet	 seen	 in	 the	 KRasG12V	 cell	 line	 may	 be	 due	 to	 the	 fact	 that	 these	 cells	express	significantly	more	Met	receptor	than	the	others	(Fig.	6.12).	
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Fig.	6.10	Phosphorylation	status	of	Met	receptor	in	SW48	Ras	isogenic	cell	
lines.	Cells	were	starved	and	stimulated	with	different	HGF	concentrations..	A	Immunoblot	 of	 Met,	 Met-pS217/S221	 (pMet)	 and	 representative	 actin.	 B	Relative	 quantification	 of	 Met-pS217/S221	 normalised	 to	 actin	 and	 C	normalised	to	actin	and	total	Met	protein.	Arrows	indicate	the	size	of	the	blotted	protein.			 	The	amount	of	pIGFR1β	in	IGF-stimulated	Ras	isogenic	cell	lines	is	also	variable	between	 cell	 lines	 when	 normalised	 to	 actin	 loading	 control	 only	 with	HRasG12V	cells	showing	the	highest	responses	(Fig.	6.11B).	However,	when	the	IGFR1β	data	are	also	normalised	to	total	IGFR1β	protein,	the	relative	amount	of	IGFR1β	phosphorylation	 is	 the	 highest	 in	KRasG12V	 and	 lowest	 in	HRasG12V	cell	line	(Fig.	6.11C).		
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Fig.	6.11	Phosphorylation	status	of	IGFR1β	in	SW48	Ras	isogenic	cell	lines.	Cells	 were	 starved	 and	 stimulated	 with	 different	 IGF	 concentrations.	 A	Immunoblot	of	IGFR1β,	pIGFR1β	(IGFR1β-pY1135/Y1136	and	Insulin	Receptor	β-pY1150/Y1151)	 and	 representative	 actin.	 B	 Relative	 quantification	 of	pIGFR1β	 normalised	 to	 actin	 and	 C	 normalised	 to	 actin	 and	 total	 IGFR1β	protein.		The	 abundance	 of	 receptors	 measured	 in	 previous	 figures	 (Fig.	 6.9-6.11)	without	 GF	 stimulation	 (0ng/ml)	 and	 normalised	 to	 actin	was	 collated	 in	 Fig.	6.12	across	all	Ras	isogenic	cell	lines.	Based	on	the	results,	there	was	a	trend	for	higher	 EGFR	 expression	 in	 the	 SW48	 cell	 lines	 with	 mutant	 Ras	 isoforms	compared	to	wild	type	(parental).	The	highest	EGFR	abundance	is	for	HRasG12V	cell	line	(40%	more	than	parental).	In	contrast,	Met	receptor	is	the	most	highly	expressed	 in	 KRasG12V	 cell	 line,	 whereas	 its	 expression	 is	 similar	 in	 the	remaining	cell	lines. This	is	consistent	with	previous	work	that	found	increased	Met	 receptor	expression	 in	 isogenic	 cell	 lines	expressing	oncogenic	KRas	with	
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																																							EGFR	 	 	 	 									Met	
								 		 	 			IGFR1β								
Fig.	 6.12	 Differential	 expression	 of	 cell	 membrane	 receptors	 in	 SW48	
isogenic	cell	 lines.	The	data	was	collated	from	Fig.	6.9-6.11	for	no	stimulation	with	GF	 (starved	 state)	 normalised	 to	 actin	 and	 represented	 as	 percentage	 of	maximum	 expression.	 P	 –	 parental,	 H	 –	 HRasG12V,	 N	 –	 NRasG12V,	 K	 –	 KRasG12V	SW48	cell	lines.	
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G12	 mutations	 (Hammond	 et	 al.,	 2015).	 Whilst	 IGFR1β	 levels	 are	 equivalent	across	 most	 of	 the	 cell	 lines,	 there	 is	 a	 trend	 for	 reduced	 expression	 in	 the	KRasG12V	cell	line.		
In	summary,	both	upstream	and	downstream	components	of	the	Ras	signalling	pathway	exhibit	clear	differences	in	abundance	or	phosphorylation	in	each	Ras	isoform	mutant	cell	 line.	Further	work	 is	required	to	reproduce	some	of	 these	data	and	to	determine	the	extent	to	which	these	changes	are	dependent	on	the	presence	of	the	mutant	Ras	protein.			
		
6.2.3.2	 Inhibition	of	Ras	downstream	signalling	 				Network	biology	analysis	requires	measurement	of	both	the	activation	of	nodes	within	a	network	and	the	network	responses	to	inhibition	of	nodes.	The	use	of	inhibitors	 helps	 to	 reveal	 the	 extent	 to	 which	 negative	 feedback	 loops	 are	engaged	 within	 the	 network.	 To	 optimise	 the	 conditions	 for	 future	 network	biology	analysis,	concentration	gradients	of	a	range	of	 inhibitors	were	used	to	measure	 attenuation	 of	 signalling	 downstream	 of	 the	 target.	 Inhibition	 was	performed	 for	 1	 hour,	 followed	 by	 stimulation	 for	 20	minutes	with	 20%	 FBS	containing	the	inhibitor.	LY294002	was	used	to	reversibly	inhibit	PI3K	(Mena	et	al.,	 2014,	Wu	 et	 al.,	 2014)	 and	 the	 level	 of	 inhibition	 of	 downstream	Akt	was	measured	 by	 Western	 blotting	 for	 pAkt	 (Fig.	 6.13).	 An	 almost	 complete	attenuation	 of	 phosphorylation	 of	 Akt	 was	 seen	 at	 around	 20µM	 drug	concentration	 and	 the	 IC50	 across	 all	 Ras	 isoforms	 were	 similar	 (0.01-0.02).		Total	Akt	protein	levels	were	equivalent	across	all	cell	lines.	
The	next	 inhibitor	used	was	AZD6244	(Selumetinib),	which	reversibly	 inhibits	MEK1/2	 (Garon	 et	 al.,	 2010,	 Huynh	 et	 al.,	 2007).	 Complete	 attenuation	 of	downstream	 pERK	 signal	was	 seen	 at	 10µM	 concentration	 in	 all	 Ras	 isogenic	cell	lines.	Again,	the	IC50	values	were	similar	across	the	cell	lines	(0.004-0.005)	(Fig.	6.14).	Total	protein	levels	of	ERK	were	similar	across	all	isogenic	cell	lines.	
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Fig.	6.13	Inhibition	of	PI3K	in	SW48	Ras	 isogenic	cell	 lines	with	different	
LY294002	 concentrations.	A	 Immunoblotting	 of	 Akt,	 Akt-pS473	 (pAkt)	 and	representative	actin.	B	Relative	quantification	of	Akt-pS473	(pAkt)	to	actin	and	
C	to	actin	and	total	Akt	protein. Isogenic	cells	were	serum	starved	for	24	hours	before	 addition	of	LY294002	 for	1	hour	and	 then	addition	of	20%	FBS	 for	20	minutes.	n=1.	P	–	parental,	H	–	HRasG12V,	N	–	NRasG12V,	K	–	KRasG12V	SW48	cell	lines.	
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Fig.	 6.14	 Inhibition	 of	 MEK1/2	 in	 SW48	 Ras	 isogenic	 cell	 lines	 with	
different	 AZD6244	 concentrations.	 A	 Immunoblotting	 of	 ERK,	 ERK-pT202/pY204	 (pERK)	 and	 representative	 actin.	 B	 Relative	 quantification	 of	ERK-pT202/pY204	 (pERK)	 to	 actin	 and	 C	 to	 actin	 and	 total	 ERK	 protein. Isogenic	cells	were	serum	starved	for	24	hours	before	addition	of	AZD6244	for	1	 hour	 and	 then	 addition	 of	 20%	 FBS	 for	 20	minutes.	 n=1.	 P	 –	 parental,	 H	 –	HRasG12V,	N	–	NRasG12V,	K	–	KRasG12V	SW48	cell	lines.	
		To	 specifically	 inhibit	 mTOR	 signalling,	 a	 gradient	 of	 concentrations	 of	 a	reversible	inhibitor	Rapamycin	(Edwards	and	Wandless,	2007)	was	used	in	Ras	isogenic	 cell	 lines.	 	 The	 level	 of	 phosphorylation	 of	 the	 downstream	 mTOR	target	 p70S6K	 was	 measured	 by	 Western	 blotting	 (Fig.	 6.15)	 and	 showed	
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varying	 levels	 of	 inhibition	 depending	 on	 the	 Ras	 isoform	 that	 was	 mutated.	First	 of	 all,	 Parental	 and	 NRasG12V	 cells	 display	 only	 low	 pp70S6K	 levels	compared	 to	 the	 other	 Ras	mutant	 cell	 lines.	 This	means	 that	 it	 is	 difficult	 to	distinguish	responses	to	treatment	with	different	concentrations	of	Rapamycin	(Fig.	6.15B).	The	most	striking	observation	is	that	the	HRasG12V	and	KRasG12V	cell	 lines	 display	 reciprocal	 responses	 to	Rapamycin	 treatment	with	 pp70S6K	almost	completely	reduced	at	around	0.2	µM	in	HRasG12V	cells.	In	contrast,	the	KRasG12V cell	 line	 showed	 an	 initial	 reduction	 of	 pp70S6K	before	 it	went	 up	again	 and	 exceeded	 basal	 level	 straight	 at	 doses	 greater	 than	 0.2	 µM	 of	Rapamycin.	This	may	suggest	relief	of	a	negative	feedback	loop.	
The	final	inhibitor	used	was	Sorafenib,	which	inhibits	Raf	kinase	(Wilhelm	et	al.,	2004).	 However,	 it	 also	 inhibits	 tyrosine	 kinase	 receptors	 involved	 in	angiogenesis	 at	 higher	 doses.	 To	 measure	 its	 inhibition	 effectiveness	 at	inhibiting	Ras	in	Ras	isogenic	cell	lines,	phosphorylation	of	the	Raf	effector	MEK	was	measured	(Fig.	6.16).	Unfortunately,	pMEK	levels	did	not	seem	to	decrease	with	 higher	 Sorafenib	 concentrations	 in	 neither	 of	 the	 cell	 lines.	 This	observation	 could	 not	 be	 explained	 by	 the	 sensitivity	 of	 pMEK	 antibody,	 as	 it	was	 working	 in	 previous	 experiments	 (Fig.	 6.5,	 Fig.	 6.6,	 Fig.	 6.7).	 It	 seemed	plausible	at	first	to	check	Sorafenib	inhibition	potency	at	higher	concentrations	and/or	 longer	 inhibition	 times.	 Hence,	 optimisation	 of	 Raf	 inhibition	 by	Sorafenib	is	shown	in	the	next	section.	
Importantly,	 the	 above	 data	 represents	 only	 single	 biological	 replicates	 and	more	repeats	are	needed	to	ascertain	the	true	differences	between	Ras	isoform-dependent	signalling.		
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Fig.	6.15	Inhibition	of	mTOR	in	SW48	Ras	isogenic	cell	lines	with	different	
Rapamycin	 concentrations.	 A	 Immunoblotting	 of	 p70S6K,	 p70S6K-pT389	(pp70S6K)	and	representative	actin.	B	Relative	quantification	of	p70S6K-pT389	(pp70S6K)	to	actin	and	C	to	actin	and	total	p70S6K	protein.	Isogenic	cells	were	serum	starved	for	24	hours	before	addition	of	Rapamycin	for	1	hour	and	then	addition	of	20%	FBS	for	20	minutes.	n=1.	Arrows	indicate	the	size	of	the	blotted	protein.	P	–	parental,	H	–	HRasG12V,	N	–	NRasG12V,	K	–	KRasG12V	SW48	cell	lines.	
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Fig.	 6.16	 Inhibition	 of	 Raf	 in	 SW48	Ras	 isogenic	 cell	 lines	with	 different	
Sorafenib	concentrations.	A	Immunoblot	of	MEK,	MEK-pS217/pS221	(pMEK),	and	 representative	 actin.	 B	 Relative	 quantification	 of	 MEK-pS217/pS221	(pMEK),	to	actin	and	C	to	actin	and	total	MEK	protein.	Isogenic	cells	were	serum	starved	for	24	hours	before	addition	of	Sorafenib	for	1	hour	and	then	addition	of	20%	 FBS	 for	 20	minutes.	 n=1.	 P	 –	 parental,	 H	 –	 HRasG12V,	 N	 –	 NRasG12V,	 K	 –	KRasG12V	SW48	cell	lines.	
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6.2.3.3						 	 Optimisation	of	Raf	inhibition	in	Ras	isogenic	cell	lines	
	To	optimise	Raf	inhibition	in	Ras	isogenic	cell	lines,	Sorafenib	concentration	was	increased	to	100	µM	and	incubation	time	to	either	2	or	16	hours.	Parental	SW48	cell	 line	 was	 treated	 as	 a	 representative.	 To	 check	 whether	 Sorafenib	 was	working	properly,	a	control	sample	treated	with	the	same	inhibitor,	but	from	a	different	 supplier	 (Santa	 Cruz),	was	 used	 alongside	 the	 old	 one	 on	 a	Western	blot	(Fig.	6.17).		Moreover,	pERK	levels	were	measured	together	with	pMEK	and	the	corresponding	non-phosphorylated	protein.		
According	 to	 the	 results,	 the	 inhibitor	 seemed	 to	 have	 a	 bigger	 effect	 on	 cell	lines	which	were	starved	and	then	stimulated	with	20%	FBS,	rather	than	grown	in	normal	10%	FBS	medium.	Surprisingly,	in	non-starved	samples	the	longer	the	inhibition	 and	 the	 higher	 the	 dose,	 the	more	 activation	 of	MEK	 and	 ERK	was	achieved,	which	was	also	true	for	the	control	sample	with	the	drug	from	another	supplier.	 	For	serum-starved	and	stimulated	cell	 lines,	 the	 inhibitor	seemed	to	inhibit	downstream	Raf	signalling,	when	compared	to	non-treated	control.	After	2	 hours	 of	 inhibition,	 the	 levels	 of	 both	 pMEK	 and	 pERK	 decreased,	with	 the	higher	response	seen	with	100µM	Sorafenib.	After	16	hours,	however,	the	levels	of	phosphorylation	decreased	dramatically,	especially	 for	pERK	and	 the	upper	band	of	pMEK,	which	may	represent	different	phosphorylation	status	of	MEK	or	one	of	 the	MEK	 isoforms.	At	 the	 same	 time,	 the	 levels	of	 total	protein	of	MEK	and	 ERK	 also	 seemed	 to	 decrease.	 Nevertheless,	 30µM	 or	 100µM	 Sorafenib	appeared	 to	 potently	 inhibit	 Raf	 kinase	 when	 pre-incubated	 for	 16	 hours	(Figure	6.17).	
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Fig.	6.17	Inhibition	of	Raf	in	SW48	parental	cell	line	with	Sorafenib	for	16	
hours.	Cells	were	grown	either	in	normal	(10%	FBS)	medium	(non-starved)	or	were	serum-starved	and	stimulated	with	20%	FBS	 for	20	min.	 	 Sorafenib	was	added	for	the	indicated	amounts	of	time	before	stimulation	and	cell	harvesting.	The	 figure	 represents	 immunoblotting	 of	 MEK,	 MEK-pS217/pS221	 (pMEK),	ERK,	 ERK-pT202/pY204	 (pERK)	 and	 representative	 actin.	 Soraf.	 inc.	 t	 [h]	 –	Sorafenib	incubation	time	in	hours.			
Complete	 response	 to	 inhibition	 by	 Sorafenib	 was	 achieved	 already	 at	 30µM	after	16	hours	of	incubation	for	the	parental	cell	line.	Hence,	this	concentration	was	used	as	a	maximum	in	the	concentration	gradient	to	measure	the	response	to	 inhibition	 in	 the	remaining	 isogenic	cell	 lines	 (Fig.	6.18).	Unfortunately,	 the	previously	observed	response	in	the	parental	cell	line	was	not	reproduced.	After	16	 hours	 of	 inhibition,	 pMEK	 levels	 seemed	 to	 increase	 with	 higher	concentrations	of	Sorafenib.	Such	increase	in	phosphorylation	was	also	seen	for	KRasG12V	 cell	 line.	 However,	 for	 NRasG12V	 and	 HRasG12V	 cell	 lines,	 the	increase	in	pMEK	levels	was	followed	by	a	rapid	decrease	in	phosphorylation	at	30µM	and	20µM	of	Sorafenib,	 respectively.	For	HRasG12V	very	 few	cells	were	recovered	 from	 the	 treatment	 with	 Sorafenib	 at	 30µM	 and	 therefore	 the	corresponding	lane	on	the	Western	blot	was	left	blank	(Fig.	6.18).	It	seemed	that	
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both	 HRasG12V	 and	 NRasG12V	 cell	 lines	 were	 more	 responsive	 to	 Sorafenib	treatment	 than	 the	 parental	 and	 KRasG12V	 cell	 lines.	 Nonetheless,	 the	inhibitory	 effect	 seemed	 also	 to	 contribute	 to	 cellular	 toxicity,	 at	 least	 in	HRasG12V	cell	line.		
To	 investigate	 whether	 inhibition	 with	 Sorafenib	 leads	 to	 apoptosis	 in	 Ras	isogenic	 cell	 lines,	Western	 blotting	 was	 used	 to	 detect	 cleaved	 PARP,	 which	signals	 undergoing	 programed	 cell	 death	 due	 to	DNA	 damage	 and/or	 cellular	stress.	 Interestingly,	higher	amounts	of	cleaved	PARP	(Fig.	6.18,	 lower	band	of	PARP)	 were	 present	 in	 samples	 treated	 with	 more	 inhibitor	 (10-30µM),	concluding	that	Sorafenib	exerted	a	toxic	effect	on	the	cells.	
	
	
	
Fig.	 6.18	 Inhibition	 of	 Raf	 with	 Sorafenib	 for	 16	 hours	 in	 SW48	 Ras	
isogenic	 cell	 lines	 and	 apoptotic	 effect.	 Cells	 were	 grown	 in	 serum-free	medium	 for	 24	 hours	 and	 then	 incubated	 with	 different	 concentrations	 of	Sorafenib	(30µM,	20µM,	10µM,	5µM,	2.5µM)	 for	16	hours	and	stimulated	with	20%	FBS	for	20	minutes.	Protein	lysates	were	immunoblotted	for	cleaved	PARP,	MEK,	MEK-pS217/pS221	 (pMEK)	 and	 actin	 	 (representative	 blot	 shown).	 P	 –	parental,	H	–	HRasG12V,	K	–	KRasG12V,	N-	NRasG12V	SW48	isogenic	cell	lines.		To	further	examine	the	response	of	cells	to	the	treatment	with	Sorafenib,	visible	changes	 to	 cell	 appearance	 were	 observed	 using	 phase	 contrast	 microscopy	(Fig.	 6.19).	 The	 experiment	 was	 a	 blind	 study,	 as	 the	 pictures	 were	 taken	randomly	without	knowing	which	cell	line	they	represent.		
	 175	
	
			 			 					
Fig.	 6.19	 Micrographs	 of	 SW48	 Ras	 isogenic	 cell	 lines	 treated	 with	 Raf	
inhibitor	 Sorafenib.	 Cells	 were	 grown	 in	 full	 medium	 (10%	 FBS)	 or	 were	serum	 starved	 (0%	 FBS)	 for	 24	 hours,	 followed	 by	 incubation	 with	 30µM	Sorafenib	 for	 16	 or	 4	 hours.	 Cells	were	 then	 stimulated	with	20%	FBS	 for	 20	minutes	and	visualised	by	contrast	microscopy.	Scale	bar	=	100	μm.		
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When	grown	in	full	medium	(10%	FBS),	the	cell	size	for	SW48	HRasG12V	was	bigger	than	for	the	remaining	SW48	cell	lines	(Fig.	6.19).	The	cell	size	difference	was	even	more	striking	 for	 serum-starved	cell	 lines.	When	 treated	with	30µM	Sorafenib	 for	 16	 hours,	 in	 non-starved	 cell	 lines,	 cell	 size	 decreased	substantially	 as	 compared	 to	 non-treated	 cells,	 as	 if	 the	 cells	 were	 shrinking,	perhaps	 due	 to	 apoptosis	 or	 the	 loss	 of	 adhesion.	 Remarkably,	 cell	 density	seemed	to	be	constant,	regardless	of	Sorafenib	treatment.		
In	starved	cells	incubated	with	Sorafenib,	the	cells	also	looked	apoptotic,	but	the	density	dramatically	decreased,	especially	in	KRasG12V	cell	line,	as	compared	to	non-starved	cells.	In	SW48	HRasG12V	cell	line,	clumps	of	cells	detached	from	the	plate	 surface	 were	 floating	 in	 the	 medium,	 suggesting	 that	 the	 reduction	 in	density	may	be	due	to	dysfunctional	adhesion.	
The	shrinking/apoptotic	effect	of	Sorafenib	treatment	was	also	apparent	in	cells	which	 were	 starved	 and	 stimulated	 with	 20%	 FBS	 for	 20	 minutes.	 SW48	parental	 cell	 line	 seemed	 to	 maintain	 higher	 density	 than	 its	 Ras	 isogenic	derivative	cell	 lines.	This	might	be	due	to	a	 lower	number	of	apoptotic	cells	 in	SW48	 parental	 cell	 line	 and	 may	 indicate	 better	 resistance	 to	 Sorafenib	treatment.	For	HRasG12V	cell	line,	a	cluster	of	floating	cells	was	present	again,	which	could	explain	why	a	low	number	of	cells	were	recovered	in	the	previous	experiment	 (Fig.	 6.18).	 Finally,	when	 treated	with	 Sorafenib	 for	 only	 4	 hours,	the	 shrinking	 effect	 was	 still	 preserved	 in	 parental	 cell	 line,	 but	 not	 in	 the	remaining	 cell	 line.	 Cell	 densities	 also	 appeared	 to	 be	 higher,	 as	 compared	 to	treatment	for	16	hours.		
To	conclude,	Sorafenib	is	toxic	for	SW48	cell	lines	isogenic	for	G12V	mutation	in	Ras	isoforms,	as	it	negatively	affects	cell	density,	suggesting	a	loss	in	viable	cells.	For	parental	cell	line,	the	changes	in	density	are	not	clearly	visible,	implying	that	these	cells	are	more	resistant	 to	 treatment	with	Sorafenib. Inhibition	of	pMEK	or	pERK	responses	could	not	be	reproducibly	achieved	in	any	of	the	cell	lines.	
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6.3		 	 	 Discussion	This	 chapter	 focused	 on	 endogenous	 Ras	 isoform-dependent	 signalling	 in	 a	context	 of	 a	 human	 colorectal	 cancer	 cell	 line.	 Fully	 diploid	 SW48	 cell	 lines	isogenic	 for	 a	 heterozygous	 G12V	 mutation	 in	 each	 of	 the	 three	 RAS	 genes	allowed	 to	 directly	 compare	 Ras	 isoform	 signalling	 outcomes	 by	 providing	identical	genetic	background	for	each	cell	line	and	endogenous	protein	levels.		
The	limitations	of	this	study	included	the	use	of	only	single	cell	clones,	i.e.	only	one	 of	 each	 NRas,	 KRas	 and	 HRas	 cell	 line	 clone	 with	 G12V	 mutation	 was	compared.	The	lack	of	comparison	of	cell	lines	derived	from	other	clones	of	the	parental	SW48	cell	line	raises	the	possibility	of	unnoticed	clonal	artefacts,	which	may	have	been	taken	as	true	isoform-specific	responses.	Cells	derived	from	the	parental	 cell	 line	 by	 clonal	 selection	 (limited	 dilution	method	 –	 (Dexter	 et	 al.,	1978))	 can	 show	 different	 phenotypical	 properties,	 such	 as	 doubling	 time,	colony	formation	 in	soft	agar	and	metastatic	potential	(Li	et	al.,	2001,	Ware	et	al.,	 2007).	 Hence,	 it	 is	 important	 to	 compare	 at	 least	 2-3	 different	 clones	 to	assure	the	accuracy	of	the	results.	
Nevertheless,	these	preliminary	results	suggested	marked	differences	between	the	 signalling	 of	 distinct	 Ras	 isoforms	 and	 the	 phenotypic	 changes	 of	 the	isogenic	 cell	 lines.	 G12V	 mutation	 seemed	 to	 decrease	 the	 cell	 growth	 when	present	in	NRas,	but	not	in	other	Ras	isoforms	(Fig.	6.3).	A	previous	study	in	a	colon	 cancer	 mouse	 model	 expressing	 the	 G12D	 mutation	 in	 either	 KRas	 or	NRas	has	shown	that	only	oncogenic	KRas	can	contribute	to	hyperplasia	in	the	colon	(Haigis	et	al.,	2008),	hence,	higher	growth	rate	could	also	be	expected	for	the	SW48	cell	line	with	oncogenic	KRas.	However,	this	does	not	explain	why	the	NRasG12V	cell	 line	 is	 actually	 growing	 slower	 than	all	 remaining	 isogenic	 cell	lines,	 including	 the	 parental.	 Another	 reason	 could	 be	 that	 cells	 with	 mutant	NRas	undergo	differentiation	at	higher	densities	(Fig.	6.3,	day	3)	(Roberts	et	al.,	2006b,	 Zweibaum	 et	 al.,	 1983).	 SW48	 cells	 are	 actually	 poorly	 to	moderately	differentiated	 (Huschtscha	 et	 al.,	 1991,	 MacKay	 et	 al.,	 1995),	 so	 there	 is	 a	possibility	that	under	certain	environmental	or	endogenous	stimuli	 they	could	differentiate	 further	 and,	 hence,	 cease	 proliferating	 (Jogi	 et	 al.,	 2012).	 Yet	
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another	 explanation	 for	 slower	 growth	 rate	 of	 NRasG12V	 cell	 line	 would	 be	induction	 of	 apoptosis.	 Previous	 research	demonstrated	 that	 oncogenic	Ras	 is	capable	 of	 stimulating	 pro-apoptotic	 signals	 via	 RASSF1-mediated	 or	 even	MAPK-mediated	cascades	(Vos	et	al.,	2000,	Cox	and	Der,	2003).	These	findings	pose	 a	 chance	 that	 in	 case	 of	 SW48	 cell	 line	 such	 apoptotic	 event	 would	 be	plausible.	 Either	 way,	 to	 confirm	whether	 differentiation	 or	 programmed	 cell	death	 actually	 occurred,	 further	 experiments	 would	 have	 to	 validate	 the	presence	of	specific	markers	–	e.g.	CDX1	as	a	marker	of	intestinal	differentiation	(Bonner	 et	 al.,	 1995,	 Chan	 et	 al.,	 2009,	 Mallo	 et	 al.,	 1997)	 or	 Bax	 as	 a	 pro-apoptotic	marker	(Paradiso	et	al.,	2001).	What	is	also	interesting	to	note,	G12V	mutation	 did	 not	 accelerate	 proliferation	 of	 SW48	 cell	 line	 when	 present	 in	KRas	or	HRas,	 implying	 that	 these	 isoforms	may	not	 further	 contribute	 to	 the	transforming	potential	of	these	cells.		
Another	 striking	 difference	 between	 Ras	 isogenic	 cell	 lines	 were	 the	 distinct	levels	of	activation	of	downstream	signalling,	as	measured	by	phosphorylation	of	Akt,	MEK	and	ERK	(Fig.	6.5-6.8).	Based	on	Western	blotting,	after	stimulation	with	EGF,	human	HRas	protein	seemed	to	provide	better	pAkt	and	pMEK	signals	than	 other	 Ras	 isoforms.	 Interestingly,	 pERK	 appeared	 to	 be	 less	 affected	 by	activate	 HRas,	 at	 least	when	 compared	with	wild	 type	 protein	 (Fig.	 6.8).	 It	 is	important	 to	 take	 into	account	 the	mutations	already	existing	 in	wt	SW48	cell	line,	which	are	G719S	in	EGFR,	S33Y	in	CTNNB1	and	S668fs*39	(frame	shift)	in	FBXW7	(Forbes	et	al.,	2015,	Ahmed	et	al.,	2013).	The	mutation	present	in	EGFR	is	 hyperactivating	 and	 resutls	 in	 around	 10-fold	more	 active	 protein	 than	wt	(Yun	 et	 al.,	 2007).	Mutations	 in	 EGFR	 are	 generally	 not	 frequent	 in	 colorectal	cancer	(Barber	et	al.,	2004,	Lynch	et	al.,	2004,	Moroni	et	al.,	2005,	Nagahara	et	al.,	 2005,	Yunxia	et	 al.,	 2010,	Oh	et	 al.,	 2011)	and	 their	 significance	 in	disease	prognosis	and	treatment	has	not	been	established.	On	the	other	hand,	mutations	of	the	S33	codon	of	beta-catenin	(CTNNB1	gene)	are	common	in	various	human	cancers,	 including	 hereditary	 non-polyposis	 colorectal	 cancer	 (Akiyama	 et	 al.,	2000,	 Johnson	 et	 al.,	 2005,	 Kim	 et	 al.,	 2003,	 Saegusa	 and	 Okayasu,	 2001).	Mutations	 in	 beta-catenin	 may	 confer	 resistance	 to	 PI3K	 and	 Akt	 inhibitors	(Tenbaum	 et	 al.,	 2012).	 Finally,	 F-box	 and	 WD	 repeat	 domain-containing	 7	
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(FBXW7)	 is	a	part	of	an	E3	ubiquitin	 ligase	complex	and	a	 tumour	suppressor	often	mutated	 in	colorectal	cancer	 (Markowitz	and	Bertagnolli,	2009,	Wang	et	al.,	2012).	Mutations	in	FBXW7	may	also	sensitise	cells	to	treatment	with	mTOR	inhibitors	(Jardim	et	al.,	2014,	Mao	et	al.,	2008,	Wang	et	al.,	2013).				Notably,	 these	 endogenous	 mutations	 in	 SW48	 cell	 line	 could	 affect	 Ras-dependent	 signalling,	 especially	 the	 changes	 in	 upstream	RTK	 receptor	 EGFR.	Although	these	mutations	uniformly	affect	all	Ras	isogenic	cell	lines,	they	could	have	a	greater	impact	on	a	particular	isoform	which	participates	in	a	feedback	loop.	Earlier	 studies	demonstrated	 that	Ras	 is	 involved	 in	a	negative	 feedback	loop	from	MEK	to	upstream	ERBB,	EGFR	or	IGFR	receptors,	which	is	relieved	by	MEK	or	BRAF	inhibition	that	leads	to	activation	of	ERK	or	PI3K	and	Akt	(Ebi	et	al.,	 2011,	 Klinger	 et	 al.,	 2013,	 Lamba	 et	 al.,	 2014,	Misale	 et	 al.,	 2014,	Molina-Arcas	et	al.,	2013,	Prahallad	et	al.,	2012,	Sun	et	al.,	2014,	Turke	et	al.,	2012,	Van	Schaeybroeck	et	al.,	2014).	This	negative	regulation	was	seen	in	studies	focused	on	KRas	signalling	and	whether	this	is	a	generic	or	an	isoform-specific	signalling	mechanism	remains	to	be	revealed.	In	this	context,	the	increased	stimulation	in	PI3K	 and	 MAPK	 pathways	 seen	 in	 the	 HRasG12V	 mutant	 cell	 line	 could	 be	explained	 by	 the	 fact	 that	 HRas	 may	 not	 take	 part	 in	 negative	 feedback	regulation,	as	opposed	to	the	other	Ras	isoforms.	Rather,	KRas	and	NRas	mutant	cell	 lines	 may	 show	 decreased	 levels	 of	 pAkt	 and	 pMEK	 due	 to	 feedback	inhibition	 of	 upstream	 signalling	 receptors.	 Interestingly,	 pERK	 levels	 do	 not	seem	to	be	affected	by	these	feedback	loops,	as	ERK	might	be	the	final	node	in	these	negative	regulation	loops	and	its	high	levels	of	activation	may	aid	in	their	propagation.	
To	 further	 investigate	 the	 differences	 in	 network	 biology	 in	 a	 Ras	 isoform-dependent	background,	each	isogenic	cell	line	was	treated	with	specific	GFs	and	pathway	component	inhibitors	(Fig.	6.9	–	6.16).	The	data	of	this	study	provided	some	preliminary	 results,	which	 can	be	used	 for	 studying	 relative	 coupling	of	isoforms	to	downstream	effectors	and	involvement	in	feedback	loops.	Previous	work	 utilised	 a	 combined	 empirical	 and	 theoretical	 means	 of	 modelling	signalling	networks	in	an	EGFR-dependent	context	(Klinger	et	al.,	2013).	In	that	
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study,	 the	 phosphorylation	 status	 of	 cell	 lines	 prior	 and	 after	 treatment	 was	measured	 using	 multiplex	 proteomics	 and	 the	 data	 was	 examined	 using	 a	modular	 response	 analysis	 (MDA),	 which	 allows	 to	 quantitatively	 measure	negative	and	positive	feedback	loops,	as	well	as	cross	talks	between	pathways.	This	 is	 important	 as	 such	 signal	 transduction	 subtleties	may	 exert	 significant	effects	 on	 the	 pharmacologic	 action	 of	 drugs	 (Cirit	 et	 al.,	 2010,	 Friday	 et	 al.,	2008,	Fritsche-Guenther	et	al.,	2011,	Sturm	et	al.,	2010).	This	chapter	aimed	to	optimise	 the	 necessary	 reagents,	 both	 receptor	 agonists	 (GFs)	 and	 inhibitors,	for	the	experimental	part	of	such	network	biology	approach.	The	data	obtained	for	saturating	and	sub-saturating	levels	of	these	reagents	will	be	used	in	future	work,	 which	 combines	 inhibition	 and	 stimulation	 to	 delineate	 differences	 in	phosphorylation	 status	 and,	 hence	 variations	 in	 the	 regulation	 of	 signalling	networks.	
The	 results	 of	 this	 chapter	 suggest	 that	 stimulation	 with	 EGF	 exerts	 a	differential	effect	on	Ras	isoform	signal	propagation	(Fig.	6.9).	Highest	levels	of	phosphorylated	 EGFR	 were	 present	 in	 KRasG12V	 cell	 line,	 followed	 by	HRasG12V,	however,	 total	 receptor	 levels	were	higher	 in	 the	 latter	 (Fig.	6.12).		Activation	of	EGFR	requires	dimerisation,	which	can	be	driven	by	either	ligand-binding	 or	 increased	 receptor	 expression	 (Yarden	 and	 Schlessinger,	 1987a,	Yarden	and	Schlessinger,	1987b).	A	crucial	step	in	EGFR	activation	is	the	release	of	 the	 intrinsic	 autoinhibition	 of	 its	 kinase	 domain	 by	 the	 formation	 of	 an	asymmetric	dimer	between	 the	kinase	domains	of	 the	 receptor	 (Kovacs	 et	 al.,	2015,	 Zhang	 et	 al.,	 2006).	 The	 C	 lobe	 of	 one	 kinase	 domain	 (activator)	allosterically	 binds	 to	 the	 N	 lobe	 of	 the	 other	 kinase	 domain	 (receiver)	 and	switches	 it	 on.	 Such	 asymmetry	 of	 EGFR	 dimer	 may	 lead	 to	 different	phosphorylation	 of	 the	 activator	 and	 receiver	 tyrosine	 residues	 in	 the	intracellular	tail	(Kovacs	et	al.,	2015).	
The	 observed	 increase	 in	RTK	 abundance	 in	 the	 study	 of	 this	 thesis	might	 be	linked	with	a	positive	 feedback	 loop	 in	HRasG12V	mutant	 cell	 line,	 e.g.	due	 to	increased	 transcription	 of	 EGFR	 downstream	 of	 Ras.	 Egfr	 gene	 expression	 is	regulated	by	Sp1,	ETF	and	c-jun	transcription	 factors	(Kageyama	et	al.,	1988a,	Kageyama	 et	 al.,	 1988b,	Mialon	 et	 al.,	 2005),	 whereas	 Ras	 signalling	 affects	 a	
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myriad	 of	 downstream	 TFs,	 including	 c-jun	 (Chang	 et	 al.,	 2003,	 Chen	 et	 al.,	2001).	Hence,	 it	 is	possible	that	Ras	also	regulates	Egfr	transcription	via	c-jun.	On	 the	other	hand,	 receptor	abundance	on	 the	cell	membrane	depends	on	 the	subtle	equilibrium	between	receptor	degradation	and	recycling	(Chi	et	al.,	2011,	Doherty	and	McMahon,	2009,	 Jones	et	 al.,	 2006,	Maxfield	and	McGraw,	2004).	Thus,	 such	 increase	 in	 EGFR	 levels	 may	 be	 a	 result	 of	 either	 a	 decrease	 in	protein	 degradation	 due	 to	 reduction	 in	 receptor	 phosphorylation	 and	subsequent	ubiquitination	(Roepstorff	et	al.,	2009),	or	an	elevated	recycling	of	the	 receptor	 back	 to	 the	 cell	 membrane,	 which	 could	 be	 especially	 affecting	HRasG12V	 cell	 line.	 To	 examine	 whether	 EGFR	 protein	 levels	 increased	 as	 a	result	of	one	of	these	mechanisms,	transcript	levels	could	be	measured	by	qPCR	and	ubiquitination	status	checked	by	pull	down	assay.	Also,	EGFR	 levels	could	be	quantified	after	shorter	stimulation	times	with	EGF,	e.g.	after	5	min	instead	of	20	min,	 which	would	 allow	 for	 looking	 at	 the	 receptor	 before	 internalisation	(Henriksen	et	al.,	2013).		
On	 the	 other	 hand,	 Met	 receptor	 abundance	 was	 observed	 to	 be	 highest	 in	KRasG12V	cell	line,	whereas	the	remaining	cell	lines	did	not	seem	to	have	any	of	the	 receptor	expressed	 (Fig.	6.10	and	6.12).	This	 is	particularly	 interesting,	as	increased	Met	 abundance	was	 observed	 before	 in	 SW48	 cell	 line	 bearing	G12	codon	mutations	(including	G12V)	in	KRas,	but	not	G13D	mutation	or	parental	cell	 line	 (Hammond	 et	 al.,	 2015).	 This	 increased	 receptor	 abundance	 was	correlated	 with	 increased	 levels	 of	 doublecortin-like	 kinase-1	 (DCLK1),	 A-kinase	anchor	protein	12	(AKAP12)	and	Caveolin-1.	 In	contrary,	 tight	 junction	protein	 ZO-2	 and	 the	 aldehyde	 dehydrogenase	 ALDH3A1	 showed	 concerted	decrease	 in	 protein	 abundance	 in	 KRasG12V	 cell	 line,	 compared	 to	 parental.	Remarkably,	 caveolin-1	 has	 been	 shown	 to	 be	 regulated	 by	 KRas	 in	 colon	tumourigenesis	(Basu	Roy	et	al.,	2013),	whereas	DCLK1	has	been	shown	to	be	an	 intestinal	 tumour	stem	cell-specific	marker	(Nakanishi	et	al.,	2013).	DCLK1	protein	expression	pattern	correlates	well	with	Met	expression	in	KRas	mutant	SW48	 cell	 lines,	 suggesting	 regulatory	 mechanism	 for	 gene	 expression	(Hammond	et	 al.,	 2015).	 It	would	be	useful	 to	 examine	whether	DCLK1	 levels	
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also	correspond	to	Met	abundance	in	the	remaining	Ras	isogenic	cell	lines	using	Western	blotting	or	proteomics.	
Finally,	 IGF1Rβ	 stimulation	 with	 IGF	 revealed	 that	 KRasG12V	 cell	 line	 had	relatively	 highest	 phosphorylation	 status	 of	 this	 RTK,	 although	 total	 receptor	levels	were	lowest,	as	compared	to	other	isogenic	cell	lines	(Fig.	6.11	and	6.12).	This	 preliminary	 data	 suggests	 that	 oncogenic	 KRas	 may	 mediate	 a	 positive	feedback	 loop	 back	 to	 IGF1Rβ,	 which	 finally	 may	 lead	 to	 downregulation	 of	receptor	 abundance.	 This,	 however,	 will	 require	 further	 confirmation.	 In	conclusion,	 the	RTKs	examined	 in	 this	study	 in	context	of	Ras	signalling	 imply	tangible	differences	between	Ras	isoforms	and	should	be	studied	further	using	more	biological	replicates.	Similarly	 to	 stimulation	 data	 shown	 in	 this	 chapter,	 experiments	 involving	inhibition	 of	 Ras	 pathway	 components	 were	 briefly	 examined	 using	 single	biological	 replicates	 and,	 hence,	 provide	 initial	 optimisations	 for	 the	 drugs	chosen	 (Fig.	 6.13-6.16).	While	 PI3K	 inhibitor	 LY94002	 and	MEK1/2	 inhibitor	AZD6244	 seem	 to	 potently	 inhibit	 their	 targets	 in	 all	 isogenic	 cell	 lines	 (Fig.	6.13-6.14),	 mTOR	 inhibitor	 rapamycin	 appears	 to	 only	 suppress	 signalling	 in	the	HRasG12V	cell	 line	(Fig.	6.15).	Both	NRasG12V	and	parental	cell	 lines	may	not	have	any	basal	phosphorylated	p70S6K,	which	may	mean	that	their	mTOR	signalling	to	downstream	effectors	is	somehow	suppressed.	This	may	be	further	reflected	by	the	fact	that	SW48	cells	with	HRasG12V	mutation	appear	to	be	the	largest	when	 grown	 in	 normal	 or	 starved	 culture	media	 (Fig.	 6.19),	 as	mTOR	signalling,	which	 is	 potently	 active	 in	 this	 cell	 line,	 is	 associated	with	 protein	synthesis	 and	 cell	 growth	via	 its	downstream	substrate	p70S6K	 (Fingar	 et	 al.,	2004,	Laplante	and	Sabatini,	2009).	Moreover,	rapamycin	 inhibits	signalling	 in	KRasG12V	 cell	 line	 only	 at	 lower	 drug	 concentrations	 and	 further	 titration	reverses	this	inhibitory	effect.	It	seems	that	there	might	be	a	negative	feedback	loop	in	KRasG12V	cell	line,	which	might	be	relieved	upon	mTOR	inhibition.	This	assumption	 could	 be	 tested	 using	 the	 network	 biology	 approach	 described	above	(Klinger	et	al.,	2013).			
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Lastly,	 inhibition	 of	 Raf	 with	 sorafenib	 requires	 further	 optimisation,	 as	 its	inhibitory	effect	on	parental	SW48	cell	line	(Fig.	6.17)	could	not	be	replicated	in	later	 experiments	 and	 in	 KRasG12V	 isogenic	 cell	 line	 (Fig.	 6.18).	 Sorafenib	appears	 to	 be	 toxic,	 especially	 in	 HRasG12V	 cell	 line,	 and	 it	 may	 induce	apoptosis	in	the	tested	cell	lines	(Fig.	6.18-6.19).	Previous	studies	demonstrated	that	Raf	 inhibitors,	 including	sorafenib,	paradoxically	activate	MAPK	signalling	in	 cell	 lines	 with	 wt	 BRAF	 and	 oncogenic	 Ras	 (Hall-Jackson	 et	 al.,	 1999,	Holderfield	et	al.,	2014,	Poulikakos	et	al.,	2010).	This	is	due	to	Raf	kinases	taking	part	in	negative	feedback	regulation	via	MEK-dependent	mechanism,	e.g.	active	ERK	 phosphorylates	 and	 inhibits	 both	 BRAF	 and	 CRAF,	 which	 impedes	 their	heterodimerisation	and,	hence,	coupling	with	Ras	(Dougherty	et	al.,	2005,	Ritt	et	al.,	2010).	Use	of	Raf	inhibitors	relieves	this	negative	regulation	and	contributes	to	 activation	 of	 downstream	MEK.	 Furthermore,	 Raf	 itself	 suppresses	 its	 own	activation:	BRAF	has	been	shown	to	inhibit	the	activity	of	CRAF	(Garnett	et	al.,	2005)	 and	 Raf	 dimers	 inhibit	 each	 other	 via	 trans-autophosphorylation.	Interestingly,	oncogenic	KRas	has	been	demonstrated	to	reinforce	the	activation	of	CRAF	in	cells	treated	with	Raf	inhibitors	(Hatzivassiliou	et	al.,	2010,	Heidorn	et	 al.,	 2010).	 Taken	 together,	 these	means	 of	Raf	 self-regulation	 and	 feedback	loops	suggest	that	also	SW48	cell	line,	especially	with	mutant	KRasG12V,	could	support	the	paradox	of	Raf	activation	after	treatment	with	sorafenib	inhibitor.	In	 summary,	 this	 chapter	 demonstrated	 that	 Ras	 isoform	 signalling	 presents	subtle,	 but	 potentially	 significant	 differences	 in	 coupling	 MAPK	 and	 PI3K	pathways.	The	more	extensive	signalling	networks	examined	provided	the	first	insights	into	distinct	isoform-specific	features	of	Ras	in	an	endogenous	context,	However,	only	single	biological	repeats	were	examined	and	the	study	provides	only	 preliminary	 data.	 Future	 work	 with	 more	 biological	 replicates	 should	confirm	 the	 outcomes	 of	 this	 work	 and	 further	 investigation	 into	 network	biology	 using	 MDA	 approach	 should	 provide	 details	 of	 Ras	 isoform-specific	feedback	 loops,	 which	 may	 prove	 useful	 for	 the	 development	 of	 cancer	therapeutics.		
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Chapter	7	
Conclusions	and	Perspectives		The	three	founding	members	of	Ras	superfamily,	HRas,	KRas	(KRasA	and	KRasB	splice	 variants)	 and	 NRas,	 are	 the	 key	 signalling	 molecules	 involved	 in	 a	multitude	of	cellular	processes	and	are	some	of	the	most	common	human	proto-oncogenes.	 These	 highly	 homologous	 GTPases,	 however,	 exhibit	 isoform-specific	 coupling	 to	 different	 human	 cancers	 (Cox	 et	 al.,	 2014,	 Forbes	 et	 al.,	2015,	 Prior	 et	 al.,	 2012)	 and	 the	KRasB	 isoform	alone	 is	 sufficient	 for	 normal	mouse	 development	 (Koera	 et	 al.,	 1997,	 Johnson	 et	 al.,	 1997,	 Plowman	 et	 al.,	2003,	Umanoff	et	al.,	1995,	Esteban	et	al.,	2001).	These	discrepancies	may	be	the	result	of	Ras	isoform-specific	expression	across	tissues	and	during	development	and	the	differences	in	coupling	and	activation	of	Ras	downstream	effectors.		The	first	part	of	this	thesis	provided	the	first	measurement	of	the	absolute	copy	number	of	Ras	isoform	transcript	levels,	as	well	as	the	first	comprehensive	map	of	spatiotemporal	expression	of	Ras	across	all	four	isoforms	in	mouse	ESC	line	and	in	a	panel	of	mouse	tissues	throughout	development.	This	study	optimised	a	quantitative	method	based	on	real	time	RT-PCR,	which	allowed	estimating	Ras	isoform	transcript	 in	copy	number.	The	average	amount	of	 total	Ras	 (panRas)	was	around	5	copies/pg	RNA	in	ESCs	and	around	26	copies/pg	RNA	in	mouse	tissues.	 Mass	 spectrometry	 analysis	 provided	 the	 preliminary	 results	 on	 Ras	isoform	expression	at	protein	level,	with	an	estimated	44-770	ng	of	panRas/mg	of	total	protein.				At	 the	 transcript	 level,	 KRasB	was	 the	most	 abundant	 isoform,	whereas	HRas	was	 always	 lowly	 expressed.	 The	 expression	 of	 the	 ESC-specific	 Ras	 isoform	ERas	was	high	 in	undifferentiated	cells,	but	was	steadily	decreasing	over	 time	during	 cellular	 differentiation.	 In	 mouse	 tissues,	 KRasA	 was	 the	 most	dynamically	 regulated	 isoform,	 with	 increasing	 expression	 in	 the	 stomach,	intestine,	 kidney	 and	 liver	 over	 time	 during	 embryonic	 development.	Interestingly,	 KRasA	 was	 shown	 for	 the	 first	 time	 to	 be	 expressed	 in	 the	
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embryonic	 heart.	 At	 the	 protein	 level,	 the	 expression	 of	 KRasB	 and	 HRas	 in	murine	tissues	was	by	and	large	similar	and	it	did	not	parallel	transcript	levels.	However,	 these	proteomic	data	were	only	preliminary	 and	 represented	 single	biological	repeats.	Moreover,	the	protein	levels	of	NRas	could	not	be	measured	due	 to	 a	 technical	 error.	Therefore,	 future	work	 is	 necessary	 to	provide	more	biological	 replicates	 and	 to	 include	 the	 expression	 of	 the	 remaining	 Ras	isoforms.			Together,	 the	 expression	 studies	 reported	 in	 this	 thesis	 provide	 the	 most	comprehensive	and	quantitative	approach	for	studying	Ras	isoform	expression	to	date,	at	least	at	the	transcript	level.	Knowing	the	basal	expression	of	Ras	in	a	normal	 endogenous	 context	 provides	 the	 first	 insights	 into	understanding	 the	extent	of	Ras	isoform	functional	overlap	in	comparative	models.	The	differences	in	transcript	versus	protein	levels	obtained	in	this	study	may	be	explained	by	a	recent	 work,	 which	 showed	 that	 KRAS,	 as	 compared	 to	 HRAS,	 is	 poorly	translated	due	to	the	presence	of	rare	codons	in	its	genomic	sequence	(Lampson	et	 al.,	 2013).	 The	 study	 also	 argues	 that	 rare	 codons	 make	 KRas	 a	 weaker	oncogene	 than	 HRas.	 However,	 low	 protein	 levels	 of	 KRas	 may	 prompt	tumourigenesis,	 as	 high	 expression	 of	 the	 mutated	 protein	 may	 lead	 to	oncogenic	 stress	 and	 cellular	 senescence.	 The	 study	 of	 this	 thesis	 contradicts	this	model,	as	KRasB	protein	expression,	although	proportionally	lower	than	at	the	transcript	level,	is	similar	to	the	other	Ras	isoforms.		Finally,	the	first	hypothesis	of	this	thesis	(section	1.3)	can	be	rejected:	
	Hypothesis	 1:	 The	 expression	 levels	 can	 explain	 Ras	 isoform	 functional	 non-redundancy	during	development.	
	Expression	 levels	 do	 not	 justify	 the	 developmental	 requirement	 of	 KRasB	(Koera	 et	 al.,	 1997,	 Johnson	 et	 al.,	 1997,	 Plowman	et	 al.,	 2003,	Umanoff	 et	 al.,	1995,	 Esteban	 et	 al.,	 2001).	 Although	 KRasB	 is	 the	 major	 Ras	 isoform	 at	transcript	level,	 its	protein	expression	is	similar	to	the	levels	of	HRas,	which	is	dispensable	 for	 normal	 mouse	 development.	 Table	 7.1	 summarises	 the	
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milestones	 of	 this	 thesis	 that	 help	 us	 better	 understand	 the	 functional	differences	between	the	four	main	Ras	isoforms.		
	The	 second	 part	 of	 this	 study	 examined	 Ras	 isoform-specific	 signalling	 in	 an	endogenous	 context.	The	use	of	 fully	diploid	SW48	colorectal	 cancer	 cell	 lines	isogenic	for	a	heterozygous	oncogenic	G12V	mutation	in	each	of	the	RAS	genes	provided	a	comprehensive	approach	 for	studying	all	Ras	 isoforms	 in	 the	same	genetic	background.	HRas,	as	compared	to	other	Ras	 isoforms,	has	been	found	to	 couple	better	 to	both	downstream	MAPK	and	PI3K	pathways,	 by	providing	more	activating	phosphorylation	to	MEK,	ERK	and	Akt	(Table	7.1).			Moreover,	the	study	of	this	thesis	gave	the	first	preliminary	results	on	broader	Ras	 isoform	 signalling	 networks,	 enabling	 the	 investigation	 of	 negative	 or	positive	feedback	loops.	The	results	provided	the	initial	optimisation	of	GFs	and	inhibitors	 for	a	 future	modelling	 signalling	network	study,	based	on	multiplex	proteomics	 and	 modular	 response	 analysis	 used	 previously	 (Klinger	 et	 al.,	2013).	However,	this	preliminary	data	gave	evidence	that	oncogenic	KRas	may	relieve	 the	negative	 feedback	 loop	back	 to	 the	RTKs	(Table	7.1).	Nevertheless,	the	data	presented	in	this	thesis	are	from	a	single	experiment	and	will	require	further	work	 for	validation.	Also,	 single	clones	 for	each	 isogenic	cell	 line	were	used	in	this	study,	hence,	future	experiments	should	utilise	2-3	different	clones	for	 each	 cell	 line	 to	 exclude	 any	 potential	 clonal	 artefacts	 that	 may	 bias	 the	results.	However,	the	data	proves	the	second	hypothesis	of	this	thesis	(section	1.3):		Hypothesis	2:	Endogenous	Ras	isoforms	signal	differently	from	each	other.		Previously,	Ras	isoform	signalling	was	studied	in	overexpression	systems	(Voice	et	al.,	1999,	Yan	et	al.,	1998),	where	the	signalling	outcomes	could	be	the	result	of	 signal	 perturbation	 or	 senescence,	 which	 are	 not	 observed	 at	 endogenous	levels	of	Ras	(Serrano	et	al.,	1997,	Tuveson	et	al.,	2004).	These	studies	observed	that	 KRas	 is	 a	 better	 activator	 of	 Raf,	while	 HRas	 and	NRas	 are	more	 readily			
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Table	7.1	The	main	changes	in	the	understanding	of	Ras	isoform	cellular	
and	functional	differences	after	the	study	of	this	thesis.	For	references	please	refer	to	text.	PM	–	plasma	membrane.	
Property	
Ras	isoform	
HRas	 KRasB	 KRasA	 NRas	
Upstream	
activators	
	 Strongest	positive	feedback/relief	of	negative	feedback	to	EGFR,	Met	and	IGFR1β	
	
MAPK/PI3K	
association	
Strongest	activator	of	pMEK	and	pAkt	
Weakest	activator	of	pMEK	and	pAkt	 Moderate/weak	activator	of	pMEK	and	pAkt	Endogenous	signalling	distinct	from	exogenous	signalling	
mRNA	
expression	
Ubiquitous,	no	dynamic	expression	
Highly	abundant,	ubiquitous;		
Ubiquitously	expressed,	major	KRas	isoform	in	some	tissues,	expressed	in	mouse	embryonic	heart	
Moderately	abundant,	ubiquitous,	
Dynamic	expression	
Protein	
expression	
Highly	abundant;	 Similar	levels	to	HRas	 	 	Transcript	vs	proteins	levels	do	not	correlate	
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activating	PI3K.	This	 is	 in	 contrary	 to	 the	 results	of	 this	 thesis,	which	 showed		that	endogenous	HRas	 is	a	better	activator	of	both	MAPK	and	PI3K	pathways,	while	endogenous	KRas	is	the	weakest	activator	of	MAPK.		In	 summary,	 quantification	 of	 Ras	 isoform	 expression	 levels	 and	 signalling	outcomes	may	lead	to	better	understanding	of	normal	physiological	functions	of	endogenous	Ras.	The	methods	used	in	this	study	provide	the	best	quantitative	approaches	 for	 studying	 Ras	 isoforms	 to	 date.	 The	 results	 obtained	 are	imperative	 for	 future	 studies	 involving	 models	 of	 Ras	 isoform	 signalling	 and	may	 be	 key	 to	 delineating	 Ras	 isoform-specific	 coupling	 to	 different	 cancer	types,	contribution	to	normal	development	and	potential	future	therapeutics.	
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Appendix	
Name	of	construct:	 pCR4-TOPO-mouseHRas	cds+nc	Mouse	HRas	coding	sequences	and	12	bp	noncoding	fragment	
Origin	of	vector:	 pCR4-TOPO	
Origin	of	Insert:		 Library:	R1	Mouse	embryonic	stem	cells	cDNA;	Primers:	cmHRas	F	and	R;	Host:	DH10B	TonA	(E.	coli);	Restriction	sites:	5s:	TA	cloning,	3s:	TA	cloning		
Vector	size:	 3956	bp		
Insert	size:	 582	bp	(BC119495	–	HRas	mRNA)	
Date:	 	 	 23/05/2012		
Constructed	by:	 Anna	Newlaczyl	
Resistance:	 	 ampicillin	and	kanamycin	 	
Comments:		 Dundee	sequencing	with	M13	F	and	R	primers				
	
	
Fig.	 A3.1	 pCR4-TOPO-mHRas	 plasmid.	A	schematic	 representation	of	pCR4-TOPO	 plasmid	 with	 the	 mouse	 HRas	 fragment	 insert	 with	 annotation	 and	comments.	
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Name	of	construct:	 pCR4-TOPO-mouseNRas	cds+nc		 	 	 Mouse	NRas	coding	sequences	and	noncoding	fragment	
Origin	of	vector:	 pCR4-TOPO	
Origin	of	Insert:		 Library:	R1	Mouse	embryonic	stem	cells	cDNA;	Primers:	cmNRas	F	and	R;	Host:	DH10B	TonA	(E.	coli);	Restriction	sites:	5s:	TA	cloning,	3s:	TA	cloning		
Vector	size:	 3956bp		
Insert	size:	 213	bp	(NM_010937–	NRas	mRNA)	
Date:	 	 	 26/01/2012	
Constructed	by:	 Anna	Newlaczyl	
Resistance:	 	 ampicillin	and	kanamycin	 	
Comments:		 Dundee	sequencing	with	M13	F	and	R	primers			
	
	
	
Fig.	 A3.2	 pCR4-TOPO-mNRas	 plasmid.	 A	 schematic	 representation	of	pCR4-TOPO	 plasmid	 with	 the	 mouse	 NRas	 fragment	 insert	 with	 annotation	 and	comments.	
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ERas			 	 	 	 							HRas	
		
KRasA		 	 	 	 								KRasB	
		
NRas		 	 	 									 									POL2RE	
	
	
Plasmid	 Standard	curve	equation	 R2	 %E	ERas	 -2.661x+39.599	 0.99867	 83.00	HRas	 -2.5432x+38.549	 0.99851	 88.20	KRasA	 -2.4254x+37.152	 0.9994	 94.07	KRasB	 -2.5863x+39.671	 0.99549	 86.22	NRas	 -2.5293+38.202	 0.99836	 88.85	POL2RE	 -2.7848+43.324	 0.9905	 78.15	
	
Fig.	 A4.1	 Plasmid	 standard	 curves	 used	 in	 qRT-PCR	 for	 endoderm	 and	
mesoderm	 differentiation	 of	mouse	 embryonic	 stem	 cells	 (ESCs).	Graphs	for	 standard	 curve	 equations	 and	 a	 summary	 table	 including	 coefficient	 of	determination	R2	and	calculated	%	efficiency	(%E)	used	for	data	in	Fig.	4.5-4.6.	
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ERas			 	 	 	 							HRas	
		
KRasA		 	 	 	 								KRasB	
		
NRas		 	 	 									 									POL2RE	
	
	
Plasmid	 Standard	curve	equation	 R2	 %E	ERas	 -2.697x+42.129	 0.99672	 81.53	HRas	 -3.0946x+48.056	 0.98534	 68.14	KRasA	 -2.6449+43.885	 0.99843	 83.68	KRasB	 -3.0387x+45.065	 0.99659	 69.76	NRas	 -3.0288x+46.943	 0.99582	 70.05	POL2RE	 -2.8045x+42.673	 0.99448	 77.43	
	
Fig.	 A4.2	 Plasmid	 standard	 curves	 used	 in	 qRT-PCR	 for	 mesoderm	
differentiation	of	mouse	embryonic	stem	cells	 (ESCs).	Graphs	for	standard	curve	equations	and	a	summary	table	including	coefficient	of	determination	R2	and	calculated	%	efficiency	(%E)	used	for	data	in	Fig.	4.5	and	4.7.	
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A	
HRas	 	 	 	 	 						KRasA	
		
KRasB	 	 	 	 							NRas	
	
B	
Ras	isoform		 Standard	curve	equation	 R2	
	
%E	
	HRas	 -2.6679x+40.941	 0.99387	 82.81	KRasA	 -2.6092x+40.035	 0.99855	 85.30	KRasB	 -2.4924x+42.473	 0.99236	 90.74	NRas	 -2.4942+41.662	 0.99113	 90.65	
	
Fig.	 A5.1	 Ras	 isoform	 standard	 curves	 used	 for	 the	 qRT-PCR	 data	 from	
mouse	tissues.	Ras	standard	curves	were	based	on	isoform-specific	plasmids	in	5-fold	 serial	 dilutions	 for	 the	 calculation	 of	 transcript	 copy	 number.	 A	 Ras	isoform	 standard	 curve	 graphs.	 B	 A	 summary	 table	 for	 Ras	 standard	 curve	equations,	 the	 coefficient	 of	 determination	 R2	 and	 the	 calculated	 percentage	efficiency	%E	of	amplification.	qRT-PCR	conditions:	95˚C	for	5	mins,	94˚C	for	30	sec,	62˚C	for	30	sec,	72˚C	for	30	sec,	40	cycles.	
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Table	 A5.1	 Ras	 isoform	 protein	 abundance	 in	 adult	 mouse	 tissues.	 Ras	isoform	ng	protein	per	mg	of	total	protein	was	estimated	using	standard-based	mass	spectrometry.			
	
Ras	ng	protein/mg	total	protein	
Mouse tissue	 HRas	 KRasB	 KRasA+NRas	 panRas	brain	 424.00	 263.55	 83.07	 770.61	lung	 52.05	 65.28	 12.04	 129.37	intestine	 26.10	 37.39	 29.21	 92.70	liver	 13.79	 0.00	 58.64	 72.43	pancreas	 17.38	 3.47	 23.83	 44.67			
